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ABSTRACT

SYNTHESIS AND MOLECULAR MODELING STUDIES OF BICYCLIC
INHIBITORS OF DIHYDROFOLATE REDUCTASE,
RECEPTOR TYROSINE KINASES AND TUBULIN

By
Sudhir Raghavan
December 2013

Dissertation supervised by Dr. Aleem Gangjee
The results from this work are reported into two sections listed below:
Synthesis:
Following structural classes of compounds have been designed, synthesized and
studied as inhibitors of pjDHFR, RTKs and tubulin:
1. 2,4-Diamino-6-(substituted-arylmethyl)pyrido[2,3-d]pyrimidines
2. 4-((3-Bromophenyl)linked)-6-(substituted-benzyl)-7H-pyrrolo[2,3-d]pyrimidin-2amines
3. 6-Methyl-5-((substitutedphenyl)thio)-7H-pyrrolo[2,3-d]pyrimidin-2-amines
A total of 35 new compounds (excluding intermediates) were synthesized,
characterized and submitted for biological evaluation. Results from these studies will be
presented in due course. Bulk synthesis of the potent lead compound 170 was carried out
to facilitate in vivo evaluation.
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Docking Studies
Docking studies were performed using LeadIT, MOE, Sybyl or Flexx for target
compounds listed above and for other compounds reported by Gangjee et al. against the
following targets:
1. Dihydrofolate reductase: human, P. carinii, P. jirovecii (pjDHFR) and T. gondii
(tgDHFR)
2. Thymidylate synthase: human (hTS) and T. gondii (tgTS)
3. Receptor tyrosine kinases: VEGFR2, EGFR and PDGFR-
4. Colchicine binding site of tublulin.
Novel homology models were generated and validated for pjDHFR, tgDHFR, tgTS,
PDGFR-and the F36C L65P pjDHFR double mutant. The tgTS homology model
generated in this study and employed to design novel inhibitors shows remarkable
similarity with the recently published X-ray crystal structures. Docking studies were
performed to provide a molecular basis for the observed activity of target compounds
against DHFR, RTKs or tubulin. Results from these studies support structure-based and
ligand-based medicinal chemistry efforts in order to improve potency and/or selectivity of
analogs of the docked compounds against these targets.
Novel topomer CoMFA models were developed for tgTS and hTS using a set of 85
bicyclic inhibitors and for RTKs using a set of 60 inhibitors reported by Gangjee et al. The
resultant models could be used to explain the potency and/or selectivity differences for
selected molecules for tgTS over hTS. Topomer CoMFA maps show differences in steric
and/or electronic requirements among the three RTKs, and could be used, in conjuction
with other medicinal chemistry approaches, to modulate the selectivity and/or potency of

v

inhibitors with multiple RTK inhibitory potential. Drug design efforts that involve virtual
library screening using these topomer CoMFA models in conjunction with traditional
medicinal chemistry techniques and docking are currently underway.
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BIOCHEMICAL REVIEW
A. 1. ANTIFOLATES
A.1.1. The folate metabolism pathway:

Folic acid
Figure 1. Structure of folic acid
The term folate represents a group of water-soluble compounds composed of a
pteroic acid (pteridine ring linked to p-aminobenzoic acid) and one or more L-glutamate
residues. In nature, folate exists as a mixture of different forms that have variable
bioavailability and stability.2-5 The most common source of folates is folic acid (Figure 1),
an oxidized and chemically stable derivative. Folates play a vital role in cell proliferation
and amino acid metabolism. Folate deficiency leads to anemia, impaired growth and
dermatitis. Under normal conditions a high concentration of the folate pool is present in
the cell.6 Unlike mammalian cells, which get their folic acid from the diet, higher plants,
fungi and bacteria synthesize folates de novo.7
Derivatives of folic acid substituted at the N5- and N10-positions serve as
substrates for single-carbon transfer reactions in the production of nucleotides and
methionine (Figure 2). The reduced folate carrier (RFC) is the primary means for the
transport of folates into cells.8, 9 Another transporter of folates are the folate receptors (FR),
1

a cell membrane associated folate binding protein (FBP). 8,

10, 11

Additionally, proton-

coupled folate receptor (PCFT) was recently reported to contribute to folate absorption in
the duodenum.12 The tissue specificity and overall role of PCFT in folate transport and
homeostasis are currently being investigated.

Figure 2. Folate metabolism pathway. (modified from ref.13)Aminoimidazole carboxamide
formyltransferase, AICART; betaine-homocysteine methyltransferase, BHMT; dihydrofolate
reductase, DHFR; deoxythymidine monophosphate, dTMP; deoxyuridine monophosphate,
dUMP; dimethylglycine, DMG; folate receptor, FR; glycinamide ribonucleotide
formyltransferase, GART; methylenetetrahydrofolate reductase, MTHFR; methionine synthase,
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MTR; reduced folate carrier, RFC; S-adenosylhomocysteine, SAH; S-adenosylmethionine, SAM;
thymidylate synthase, TS.

The enzyme folylpoly-γ-glutamate synthetase (FPGS) sequentially adds up to
eight L-glutamic acid residues to the folate monoglutamate within the cell.14 This has the
following important consequences: (a) it greatly increases the affinity of the folates to
some folate-metabolizing enzymes, and (b) prevents efflux of the folates and increases
their intracellular retention.

Figure 3. Folic acid pathway

The various enzymes of the folate metabolism pathway (Figure 3) perform the
crucial role of utilizing the folate cofactors for the biosynthesis of DNA. Folate cofactors
and the folate metabolizing enzymes are also critical for amino acid metabolism.15-17 To
act as cofactors, folates have to be reduced to tetrahydrofolate (THF). This reduction
reaction is catalyzed by the enzyme dihydrofolate reductase (DHFR) and occurs from
dietary folates in two steps (Figure 3). The first step is the intracellular reduction of the
pyrazine portion of the pteridine ring of folic acid, in presence of reductant nicotinamide
adenine dinucleotide phosphate (NADPH) which leads to the formation of 7,8dihydrofolate (DHF) followed by the reduction of DHF to THF.18
The de novo synthesis of purines is described in Figure 4. In presence of the enzyme
3

glycinamide-ribonucleotide formyl transferase (GARFTase), another cofactor, 10formylTHF and glycinamide ribosyl-5-phosphate (GAR) are converted to THF and
formyl-glycinamide ribosyl-5-phosphate (fGAR) respectively. The fGAR formed is further
transformed to amino-imidazolecarboxamide ribosyl-5-phosphate (AICAR) in five steps.

Figure 4. De novo synthesis of purines.

The enzyme AICARFTase uses 10-formylTHF to convert AICAR to formylamino-imidazolecarboxamide ribosyl-5-phosphate (fAICAR) releasing THF in this
process. The fAICAR formed continues along the purine biosynthetic pathway leading to
the formation of inosine-5’-monophosphate (IMP), the precursor of adenosine-5’triphosphate (ATP) and guanosine-5’-triphosphate (GTP) necessary for ribonucleic acid
(RNA)

synthesis

and

of

2’-deoxyadenosine-5’-triphosphate

(dATP)

deoxyguanosine-5’-triphosphate (dGTP) essential for DNA synthesis.19, 20
4

and 2’-

Folates are key components for the formation of 2’-deoxythymidylate-5’monophosphate (dTMP) from 2’-deoxyuridylate-5’-monophosphate (dUMP) (Figure 5).
This process is catalyzed by thymidylate synthase (TS), and uses 5,10-methylene THF to
transfer a methylene to the 5-position of dUMP to form the 5-methyl group of dTMP. This
reaction is the sole de novo source of dTMP and is the rate-limiting step in mammalian
DNA synthesis.21 Hence inhibition of the folate pathway by targeting enzymes such as
DHFR or TS is a viable target for therapeutic intervention and has been successfully
employed in the clinic for the treatment of different cancers and pathogenic infections.

Figure 5. De novo synthesis of dTMP
A.1.2.Opportunistic infections

Figure 6: Structures of Trimethoprim (TMP), Trimetrexate (TMQ), Piritrexim (PTX) and
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Sulfamethoxazole (SMX)

Opportunistic infections caused by organisms such as Pneumocystis carinii (pc),
Pneumocystis jirovecii (pj), Toxoplasma gondii (tg), and Mycobacterium avium complex
(ma) often cause life threatening infections in immunocompromised patients such as HIV
patients and post-transplant patients on immunosuppressant drugs. 22-26 These infections
are a major cause of morbidity and severly decrease the quality of life of such patients.
While bacteria, fungi, yeasts and protozoa obtain dihydrofolate by de-novo synthesis
from simple precursors, humans obtain the required folates from diet, mostly as folic
acid, which is reduced sequentially to FH2 and FH4. Additionally, mammalian cells
contain active folate transport systems such as reduced folate carrier (RFC) while
pathogens lack such specialized transport systems. 27 This provides an excellent
opportunity to selectively target pathogen DHFR by means of lipophilic, non-classical
DHFR inhibitors such as trimethoprim (TMP), trimetrexate (TMQ), and piritrexim (PTX)
(Figure 6). These agents, which lack the glutamate chain of classical DHFR inhibitors, do
not require specialized transport systems for uptake into cells, passively diffuse across
cell membranes. Mammalian cells can be selectively protected from the resultant toxic
effects of such lipophilic agents by the co-administration of a folic acid precursor,
leucovorin, which is taken up by mammalian cells by active transport and provides the
necessary folate precursor for normal cellular function.28 Several excellent reviews that
detail the development of agents that target DHFR from opportunistic infections are
present in the literature.27, 29-32 X-ray crystal structures of human DHFR (hDHFR) and
pathogen DHFR have aided in drug development efforts and are discussed below.
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A.1.3.Structure of DHFR
A.1.3.1.Human DHFR
DHFR (EC 1.5.1.3) is one of the best studied enzymes in the folate metabolism
pathway.33-35 DHFR is found in all organisms except archaebacteria and few parasitic
protozoa. Currently the protein data bank (PDB)36 comprises of 323 DHFR structures
bound to cofactors as well as inhibitors. Bacterial DHFR shows lower homology (2540%) relative to vertebrate DHFR (75-90%). Homology at the N-terminal is much higher
than that at the C-terminal.37, 38 DHFR is a monomeric enzyme with a sequence of 159204 amino acid residues and a molecular weight in the range of 18000-22000 daltons.
The tertiary structure of DHFR, an α/β structure, contains a eight stranded β-sheet and
atleast four α-helices. The β-sheet consists of seven parallel strands, and one antiparallel
strand.

Figure 7: Stereoview. Folic acid (white) bound to the active site of hDHFR. (PDB: 1DRF 39)

The active site of the enzyme is located in a Hydrophobic pocket and shows the
presence of a conserved acid residue (Glu30 in vertebrate DHFR40 and Asp27 in
Escerichia coli (ec) DHFR).41 The Hydrophobic pocket acts as the binding site for the
7

substrate or the antifolates and nicotinamide portion of NADPH.40 The pteridine portion
and the glutamate side chain portions of folates interact with the polar side chains and
backbone carbonyls in the active site (Figure 7). Additionally, the binding site contains
hydrophobic flanking amino acids such as Phe31 and Phe34 which bind to the pteridine
scaffold of folic acid and other scaffolds of antifolates.40

A.1.3.2.Pneumocystis carinii DHFR (pcDHFR)
pcDHFR consists of 206 amino acid residues and is similar to rat liver (rl) DHFR
in size with a molecular weight of 26000 Dalton. The optimum pH for pcDHFR is 7.0
and its Km for FH2 is four-fold higher (17.6 ± 3.9 μM) than rat liver DHFR (4.0 ±
2.2μM).42
The size of the cavity of pcDHFR active site is smaller than that of hDHFR but
larger than that of bacteria such as E. coli DHFR.42 X-ray crystal structures42-44 have
shown that most residues of DHFR involved in catalysis and binding are conserved in
both hDHFR and pcDHFR with the exception of the polar Asn64 residue in hDHFR,
located just outside the binding site, being replaced by a nonpolar Phe69 in pcDHFR. The
more potent pcDHFR inhibitors like PTX (IC50 = 19.3 nM) and TMQ (IC50 = 42 nM)
lack selectivity.

A.1.3.3.Pneumocystis jiroveci (pjDHFR)
It was recently shown that P. jirovecii is the actual opportunistic pathogen that
infects humans, while P. carinii is the pathogen that is derived from and infects rats. 45, 46
It has recently been reported that patients with rheumatoid arthritis undergoing first line
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therapy with methotrexate (MTX) are at increased risk of contracting P. jirovecii
pneumonia (PCP).47 Cody et al48 reported that the recombinant human-derived pjDHFR
differs from rat-derived pcDHFR by 38% in amino acid sequences. There are no reported
crystal structures for DHFR from pjDHFR.

A.1.3.4.Toxoplasma gondii (tgDHFR)
T. gondii is a DHFR-TS bifunctional enzyme with the DHFR domain located at
the N-terminus and the TS domain is at the C-terminus.49 A junction polypeptide
separates the two domains. The protozoan parasite is a ubiquitous organism capable of
infecting a wide range of vertebrate hosts, including man. Toxoplasmosis is a leading
opportunistic pathogen associated with AIDS. 50, 51 Although the crystal structures of
tgDHFR are not yet available, the primary structure of the DHFR-TS gene from tg has
been reported by Roos.49
The Km for tgDHFR (IC50 = 4.6 ± 4.3 μM) is similar as that for rat liver (rl)
DHFR (IC50 = 20 μM). Several DHFR inhibitors such as TMQ (IC50 = 10 nM), PTX
(IC50 = 4.3 nM) and TMP (IC50 = 2.8 M) are active against isolated T. gondii enzyme
and against the growth of T. gondii cells in culture.27, 52
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A.1.4.DHFR inhibitors
DHFR inhibitors have been successfully used in the clinic in anticancer,
antibacterial and antiprotozoal treatment regimens. DHFR inhibitors commonly replace
the 2-amino-4-oxo system in folate with a 2,4-diamino system, which increases the
basicity of the nitrogen of the 1,3-diazine.53 This modification results in protonation at
N1 rather than N8 of the pteridine core. 39, 54-56 Resultantly, this intermediate cannot
accept a hydride ion and be converted to the product. Additionally, the intermediate is
commonly bound through a salt bridge to a conserved acidic residue (Glu or Asp) in the
DHFR active site.56

Figure 8. Interaction of Glu30 in the active site of human DHFR with (A) DHF (PDB: 1DRF39),
and (B) MTX (PDB: 1DLR57).

Analysis of various crystal structures indicates that MTX binds to DHFR such that
the para-aminobenzoyl group and the pteridine moiety are oriented perpendicular to each
other (Figure 8).39, 40 The N1 atom of MTX is protonated in its bound state (studied by
spectroscopic,54, 55 calorimetric,55 theoretical and NMR56 methods) and forms an ionic bond
with an ionized carboxylic acid of a conserved acidic residue (Glu or Asp; e.g. Asp26 in L.
casei, Glu30 in mammalian DHFR). In L. casei the Oδ2 of Asp26 is interacts with N1 and
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the Oδ1 is hydrogen bonded to the 2-amino group. This binding mode is found in a majority
of reported DHFR inhibitors and forms the basis for its activity against the enzyme.
Antifolates with a pteridine, pyridopyrimidine, or quinazoline core and a 2,4diamino moiety have been shown to bind to the active site of human DHFR (hDHFR)
similar to MTX. Additional interactions include a water mediated hydrogen bonding
network between the conserved residues of human DHFR – Thr136, Trp24 and the 2-NH2
and N8-nitrogen respectively.42, 58-60 The 4-NH2 group of MTX is the part of a hydrogen
bonding network between the conserved residues Ile7, Val115 and Tyr121. This
framework of hydrogen bonds is characteristic of all crystal structures reported for DHFR
complexes.61, 62 A comparison of the crystal structure of DHFR with folic acid and that
with the antifolate MTX indicates that they bind with their pteridine ring rotated 180°
from each other which is responsible for their different active site interactions.
The differences of the amino acid sequences in the active site of DHFR from
different species accounts for the differences in the binding affinity of inhibitors and has
been exploited to design inhibitors that are selective for pathogen DHFR over human
DHFR. Thus the binding affinity of TMP (Figure 6) is five orders of magnitude greater
than mammalian DHFR and hence TMP can function as a potent and selective
antibacterial agent.

A.1.4.1.Nonclassical DHFR inhibitors
Currently, different DHFR inhibitors including trimethoprim (TMP), trimetrexate
(TMQ) and piritrexim (PTX) (Figure 8) are used for treatment of opportunistic infections
caused by pc and tg.
A.1.4.1.Monocyclic DHFR inhibitors
11

The following section briefly summarizes selected important monocyclic DHFR
inhibitors and their analogs.
Trimethoprim
TMP (Figure 6) is a highly selective DHFR inhibitor ((IC50 = 7 nM for ecDHFR
compared to IC50 = 490000 nM for rat liver DHFR (rlDHFR)) and is approved for use as
an antibacterial and antipneumocysitis agent in combination with sulfamethoxazole
(SMX). SMX blocks the conversion of PABA to FH2 through the inhibition of
dihydropteroate synthase.22 Dapsone is often used in the prophylaxis of pneumocystis
pneumonia (PCP) in patients with AIDS who are unable to tolerate TMP/SMX. Severe
hematologic effects such as agranulocytosis, aplastic anemia, and hemolytic anemia have
been reported with the use of dapsone.63, 64 TMP lacks the glutamic acid side-chain,
which is the characteristic feature of the nonclassical antifolate.
Comparison of crystal structures of TMP in chicken liver (ch) DHFR and
ecDHFR was performed to explain the observed selectivity of TMP.41 TMP was observed
to bind deeper in chDHFR compared to ecDHFR. This binding led to the loss of two
hydrogen bonds. Additionally, the benzyl side chain of TMP is oriented towards the
NADPH binding site in ecDHFR, whereas in chDHFR the side chain of TMP points
away from the cofactor binding site. This difference in binding of TMP in ecDHFR and
chDHFR leads to a significant difference in the torsion angle about the C5-C7 and C7C1’ bonds for TMP.41 However, comparison of TMP bound to hDHFR, both in the crystal
and solution, showed no loss of hydrogen bonding. Crystal structures of aTMP analog
that contained a 3’-methoxy in the side chain phenyl ring indicated that the 3’-methoxy
substituent could form additional interactions with the -glutamate binding pocket of
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DHFR, thereby enhanced its inhibitory property.65
In contrast, the hydrophobic pocket of pcDHFR is larger than that of ecDHFR. 42
In the crystal structure of TMP bound to pcDHFR, the 4-amino group of TMP forms two
hydrogen bonds with the backbone carbonyls of Ile10 and Ile123. The benzyl group of
TMP occupies a hydrophobic pocket formed by Ile23, Leu25, Ile33, Phe36, Pro65, Ile66
and interacts with the nicotinamide ribose of the cofactor through hydrophobic
interactions.
TMQ and PTX (Figure 6) are potent and non-selective DHFR inhibitors and are
co-administered with leucovorin for host rescue66, 67 due to the high rate of
myelosupression associated with high doses of these agents.67, 68 However, the DHFR
inhibitor/leucovorin combination therapy also has several drawbacks including, the high
cost of leucovorin and the inconsistent effect of leucovorin under all clinical conditions. 69
Thus, there is a considerable interest to incorporate selectivity of TMP and potency of
TMX/PTX into a single agent that can be used alone to treat these infections and is the
target of several ongoing research endevours. An analysis of the literature indicates that
the issue of potency has been addressed in several studies, however selectivity over
hDHFR remains a significant challenge. The structural requirements for potential DHFR
inhibitors have been summarized in recent publications.31, 32, 53 The availability of high
resolution crystal structures of pcDHFR and human DHFR has aided rational drug design
in the development of highly potent and specific DHFR inhibitors. However, crystal
structures of pjDHFR, tgDHFR and maDHFR have not been solved yet. In these cases,
comparative modeling techniques have been used to generate models which have been
used in rational drug design efforts. Additionally, ligand based drug design efforts using
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3D-QSAR techniques, such as CoMFA, have been successfully applied in the design of
newer agents.53, 70, 71
The discovery of TMQ and pyrimethamine as potential antibacterial and
antimalarial agents stimulated the research for new nonclassical antifolates, which lack
the benzoylglutamate side chain of classical compounds such as MTX. These agents have
found utility in anti-infective therapy since bacteria and protozoa synthesize folic acid de
novo without using preformed folate. In addition, these compounds do not utilize the
folate active transport systems such as FR or RFC. They are taken up by passive and/or
facilitated diffusion and are not substrates for FPGS. Thus they overcome resistance
encountered with classical inhibitors like PTX, which are associated with a defect in
transport or FPGS activity. The main drawback of these new potent antifolates is their
lack of selectivity against DHFR derived from pathogens and hDHFR.

Figure 9. The structures of Pyrimethamine, DDMP and DAMP

Pyrimethamine (Figure 9) is a potent selective inhibitor of plasmodia DHFR used
in the treatment and prophylaxis of malarial. Two small structural changes to the
pyrimethamine: changing the 6-ethyl group to a methyl group and introducing an
additional chlorine on the phenyl ring, led to2,4-diamino-5-(3,4-dichlorophenyl)-6methylpyrimidine (DDMP, Figure 9), which is a potent vertebrate DHFR inhibitor and
was clinically used to treat MTX resistant tumors along with the structurally related
DAMP (Figure 9)169, 170
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Figure 10. The structures of MZPES and Methylbenzoprim

Analogs of pyrimethamine that vary in the 5-phenyl ring substitutions include
meta-azidopyrimethamine ethanesulphonate (MZPES, Figure 10), which completed
Phase I clinical trials as an antitumor agent. Methylbenzoprim is one of the most potent
nonclassical DHFR inhibitor (Ki = 9 pM against rat liver DHFR) reported in the
literature.172

A.1.4.2. 6,6-Fused Bicyclic DHFR Inhibitors
The following section deals with selected 6,6-fused bicyclic inhibitors of hDHFR and
pathogen DHFR.

Figure 11. Structures of TMQ and 1-3

Trimetrexate (TMQ) (Figure 11) is a potent inhibitor of hDHFR and pcDHFR and
displays better antitumor activity than MTX but its lack of selectivity for pcDHFR over
hDHFR limits its clinical applications. TMQ has been approved for the treatment of PCP.
Replacement of the nitrogen in the linker region of TMQ with a carbon affords 1 (Figure
15

11), which is a potent ecDHFR inhibitor. Tthe Z-isomer (2, cis) is more potent than the Eisomer (3).

Figure 12. Tetrahydroquinazoline analogues 4-6

Gangjee et al.72 reported a series of 6-substituted tetrahydroquinazoline analogues
of TMQ. Compounds 4-6 (Figure 12) showed nanomolar inhibition of tgDHFR with 5-11
fold selectivity ratios (IC50 rlDHFR/IC50 tgDHFR) as compared to rlDHFR.

Figure 13. The structure of PTX and 7 and 8

PTX is a potent 2,4-diaminopyrido[2,3-d]pyrimidine inhibitor of pcDHFR (IC50 = 31
nM, 40 – 1000 fold more potent than TMP73) but lacks selectivity. It is utilized as a
second-line therapy in the clinic for moderate to severe PCP. The 5-methyl group of PTX
was important for high potency. The removal of the 5-methyl group and/or the 2’,5’dimethoxy substituent both resulted in the decrease of activity.
Gangjee et al.74 reported 7 and 8 which replaced the methylene bridge of PTX with
CH2NCH3 (Figure 13). Compound 7 shows extremely potent inhibitory activity against
tgDHFR (IC50 = 0.58 nM) whereas 8 had excellent antitumor activity.
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Figure 14. Structures of 9 and 10

Suling et al.75 reported a series of 5-methyl-6-substituted pyrido[2,3d]pyrimidines as potential maDHFR inhibitors. The most potent compound in this series
was 9 (Figure 14, maDHFR IC50 = 0.84 nM) with excellent selectivity (2378-fold) over
hDHFR. Compound 10 exhbited the highest selectivity in this series (maDHFR IC50 = 1
nM, 7300-fold selective). Additional compouds that varied in the nature of the linker at
the 6-position of the pyrido[2,3-d]pyrimidine scaffold (-CH2-S- or –CH2-CH2- instead of
–CH2-NH-) were reported.75 These compounds displayed excellent selectivity (> 2500fold) for maDHFR over hDHFR.

Figure 15: Structures of 11 – 13.

PTX analogs 11 – 13 (Figure 15) were designed by Rosowski et al.76 as a part of a
series of compounds. While these compounds displayed fair selectivity, none were more
potent than PTX in targeting pathogen DHFR. Compound 11 was the most potent
inhibitor of tgDHFR (IC50 = 14 nM) and was modestly selective for tgDHFR (4-fold)
over rlDHFR. Compound 12 was the most selective inhibitor of tgDHFR (IC50 = 36 nM;
10.3-fold selective) as well as maDHFR (IC50 = 41 nM; 9-fold selective) over rlDHFR.
Compound 13 exhibited good potency and moderate selectivity against tgDHFR and
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maDHFR over rlDHFR. All the compounds of the series displayed submicromolar
inhibition of pcDHFR, displaying the importance of the 5-methyl group for activity.

Figure 16: Structures of 14 – 16

Gangjee et al.77 published 14 – 16 (Figure 16) as part of a series of compounds
that lack the 5-methyl group (from PTX and TMQ) and contains a reversed C9-N10
bridge leading to the transposition of the N9-nitrogen. Compound 14 was 304-fold
selective for tgDHFR versus hDHFR. Compound 14 was also a potent inhibitor of
pcDHFR (IC50 = 84 nM) and was 101-fold selective for pcDHFR over
hDHFR.Compound 15 was 192-fold selective for tgDHFR over hDHFR, but was much
less potent compared to PTX against all the DHFRs tested and exhibited an IC50 in
micromolar range. The corresponding N9-methyl analog 16 was a potent but nonselective
inhibitor of pcDHFR and tgDHFR.

Figure 17: Structures of 17 – 20

Gangjee et al.78 also designed 17 and 18 (Figure 17) in an attempt to explore the
effect of substitution at the N10-position on DHFR activity. Compounds 19 and 20 were
designed as analogs in which the N10-nitrogen was replaced with a carbon. Further, the
effect of conformational restriction was analyzed by 20. Compound 17 was an excellent
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inhibitor of tgDHFR (IC50 = 9 nM, 31-fold selective over rlDHFR). Compared to TMP,
compound 17 was only slightly less selective but displayed a vastly improved 300-fold
increased potentcy against tgDHFR. Compound 18 was a potent inhibitor of pcDHFR
and tgDHFR but lacked selectivity. Compounds 19 and 20 did not display potent DHFR
inhibition (M IC50s).

Figure 18: Structures of 21 – 23

Gangjee et al.79 further reported 21 – 23 (Figure 18) as a part of a series of
pyrido[2,3-d]pyrimidines designed to investigate the effect of variation in the substitution
and the size of the side chain on activity and/or selectivity for DHFR. Analog 21 was the
most selective inhibitor of both pcDHFR (IC50 = 440 nM; 15.7-fold selective) and
tgDHFR (IC50 = 300 nM; 23-fold selective) in this series. Compound 22 was the most
potent compound in this series against both pcDHFR (IC50 = 70 nM; 8.6-fold selective)
and tgDHFR (IC50 = 96 nM; 6.3-fold selective). The N10-methylated analog 23 displayed
a loss of potency against all three tested DHFRs.

Figure 19: Structures of 24 and 25

Gangjee et al.80 reported the synthesis of 24 and 25 (Figure 19) as a part of a
series of six 2,4-diaminopyrido[2,3-d]pyrimidines with a 6-methylthio bridge to an aryl
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group as inhibitors of pcDHFR and tgDHFR. Compound 24 showed the highest
selectivity ratios of 3.6 and 8.7 against pcDHFR and tgDHFR, respectively, against rat
liver (rl) DHFR. The -naphthyl analogue 25 exhibited the highest potency within the
series with an IC50 value of 0.17 and 0.09 M against pcDHFR and tgDHFR,
respectively. Compound 24 was evaluated for in vitro antimycobacterium activity and
was shown to inhibit the growth of M. tuberculosis H37Rv cells by 58% at a
concentration of 6.25 mg/mL.

A.1.5. Molecular modeling approaches employed for designing selective DHFR
inhibitors
This review summarizes modeling efforts for the design of selective DHFR
inhibitors against opportunistic agents and generation of homology models for pathogen
DHFR. These areas have been reviewed extensively in the literature by Tawari et al.53
Multiple high resolution (< 2.5 Å) X-ray crystal structures of DHFR from
pathogens such as P. carinii (17 structures), Cryptosporidium hominis (chDHFR, 5
structures), Leishmania major (3 structures) and T. cruzi (9 structures) among others can
be accessed in the protein data bank. Additionally, the presence of multiple hDHFR
crystal structures has aided in comparison of active sites, and aided in the design of
inhibitors selective for pathogen DHFR.81, 82 This review will cover modeling studies
with pcDHFR and tgDHFR.
A.1.5.1. Molecular Modeling studies with pcDHFR
pcDHFR is a 206 amino acid chain and shares 34% identity with human DHFR. 83
Table 1 provides a list of the 17 X-ray crystal structures of pcDHFR that can currently be
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accessed in the PDB.
Champness et al.42 described, 1.86 Å resolution crystal structure of ternary
complex of pc DHFR with TMP and NADP, similarly with PTX and NADP along with a
binary complex holoenzyme at 2.5 Å resolution. Cody et al.84 reported the crystal
structure (PDB: 1HFQ) of a classical furopyrimidine inhibitor, MOT (Figure 20,
pcDHFR IC50: 6.5 nM; hDHFR IC50: 2.7 nM), with pcDHFR and recombinant wild-type
human DHFR. These studies provided the first direct comparison of the binding
interactions of the same antifolate inhibitor in the active site for pcDHFR and human
DHFR.
Table 1: X-ray crystal structures of pcDHFR available in the PDB

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17

PDB
1DYR
3OAF
3L3R
1E26
1DAJ
1CD2
2CD2
3CD2
4CD2
1VJ3
1KLK
1S3Y
1LY3
1LY4
2FZH
2FZI
2FZJ

Resolution (Å)
1.86
1.70
2.00
2.00
2.30
2.20
1.90
2.50
2.00
2.10
2.30
2.25
1.90
2.10
2.10
1.60
2.00

Ligand
Reference
TMP, NDP 42
85
OAG
OAG, NDP 85
GPB, NAP 43
MOT, NDP 86
FOL, NAP 43
FOL, NAP 43
MTX, NAP 43
43
FOL
TAB, NDP 87
PMD, NDP 82
TQT, NAP 81
COG, NAP 82
COQ, NAP 82
DH1, NAP 44
DH3, NAP 44
DH3, NAP 44

Comparison of the pcDHFR crystal structure with folic acid and those of the apo
enzyme by Cody et al.86 revealed a >7 Å movement of the loop region near Asn23 that
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results in a “flap-open” position for the binary complex, and a “closed” position in the
ternary complexes, similar to that reported for ecDHFR complexes.
Cody et al.88 reported structural data for PT653 (Figure 20, PDB: 1KLK) with
pcDHFR. The crystal structure explained that the observed 21-fold selectivity of PT653
for pcDHFR over rlDHFR could be the result of a ligand-induced fit of the hydrophobic
dibenzazepine ring of PT653, which occupied regions of the enzyme active site not
occupied by other antifolates and due to conformational differences between the
structures of human and pcDHFR.

Figure 20: Structures of ligands cocrysallized with pcDHFR available in the PDB
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High resolution crystal structures of two ternary complexes of pcDHFR with the
cofactor NADPH and potent antifolates: the N9-10 reversed-bridge quinazoline inhibitor
COG (Figure 20) and its 3,5-dimethoxypyrido[2,3- d]pyrimidine analog, COQ (Figure
20) were reported by Cody et al.89 These studies revealed the first observation of an
unusual conformation for the reversed-bridge geometry (C5-C6-N9-C10 torsion angle) in
this antifolate. Structures of tetrahydroquinazoline antifolate 9 and its trimethoxy
analogue 10 (Figure 20) as inhibitor complexes with hDHFR and pcDHFR and
correlations between enzyme selectivity and stereochemistry have been described by
Cody et al.90 Structural analysis of these potent and selective DHFR inhibitor complexes
revealed preferential binding of the 6S-equatorial isomer in each structure. Cody et al.44
reported structural data for two highly potent antifolates, PY1011 (DH3, Figure 20), with
a 5000-fold selectivity for pcDHFR, relative to rlDHFR refined to 2.0 Å resolution and
PY957, (DH1, Figure 20) that has 80-fold selectivity for pcDHFR was refined to 2.2 Å
resolution. From these structures it was observed that carboxylate of the carboxyalkyloxy side chain of these inhibitors form ionic interactions with the conserved
Arg in the substrate binding pocket of DHFR. The structural data further revealed reasons
for differences in potency of two inhibitors.
Thus, the available crystal structures allow direct comparison of potent and
selective inhibitors of pathogen DHFR with human DHFR. Furthermore, some of the
structures indicate ligand induced specific conformational changes, which could be
exploited for the design of better inhibitors.
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A.1.5.2. Homology Modeling
There are no reported crystal structures of pjDHFR and tgDHFR. Thus, homology
models were required for these enzymes to aid structure based drug design of molecules
against these enzymes. Very recently Cody et al.91 described the generation of a
homology model of pjDHFR based on the crystal structure of pcDHFR complexed with
MTX.

Figure 21: Structure of ligand WR99210 in P. falciparum DHFR (PDB: 1J3I) 92

Cody et al.44 reported a model of the tgDHFR active site based on the crystal
structures of ecDHFR-MTX complexes and MtbDHFR-TMP ternary complex. The
homology model was generated using sequence alignments between the two crystal
structures. Popov et al.93 reported a homology model of the first 300 residues of tgDHFRTS sequence using the automated JIGSAW server and refined using Sybyl 7.0. Based on
the superimposition with crystal structure of P. falciparum DHFR (PDB ID: 1J3I92),
cofactor, NADPH and ligand, WR99210 (Figure 21), were added to the model. This
model was further used for correlating the docking scores from ensemble of poses for 11
docked inhibitors with their binding affinity. A correlation of 50.2% between docking
score and activity was obtained in these studies. Thus, in absence of experimentally
determined crystal structure, comparative modeling techniques provide an understanding
of DHFR inhibition.
A.1.5.3. Structure-based Approaches: Molecular Docking and Binding Affinity
Prediction
Availability of a large number of high resolution crystal structures of both
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pcDHFR and hDHFR has enabled structure-based design studies for potent and selective
DHFR inhibitors. Due to similarities in the binding pocket, inhibitors designed against
pcDHFR are usually screened against DHFR from other opportunistic agents such
maDHFR and tgDHFR. Molecular docking involves two steps: (a) initial placement of
the inhibitor in the active site, also known as pose prediction and (b) prediction of
binding affinity of the inhibitor based on the placement in the pocket. In general, majority
of docking algorithms show high accuracy (~ 2 Å root-mean-square deviation (RMSD) to
that of observed crystal structure) in pose prediction but lack similar accuracy in scoring
of poses in order to prioritize the docked poses. Ideally, a scoring function should be able
to reproduce binding energy and be able to rank the ligands according to their binding
affinity. However, the majority of scoring functions have been reported to often perform
poorly in reproduction of binding affinity; hence, use of these scoring functions is limited
to screening of databases of large number of ligand. 94, 95 Different postdocking methods
have been used in the literature to predict binding affinity of small molecule inhibitors.70,
94, 95

These methods range from simple consensus scoring to free energy perturbation.96, 97

This section of the review is limited to molecular modeling efforts reported for predicting
the binding affinity of opportunistic and hDHFR inhibitors. Graffner-Nordberg et al.88
calculated relative binding affinities from free energy perturbation simulations and
employed it for the selection of four esters with quinazoline and pteridine core as
inhibitors of human DHFR. Simulations were carried out using the protonation state of
the bound ligands with the free energy for protonation in water added as a correction to
account for the differences in protonation states of quinazoline and pteridine nuclei. The
results of the study demonstrated that the estimation of relative binding free energies by
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FEP simulations could be useful for the selection of target compounds to be synthesized
for biological evaluation against DHFR; it further revealed the importance and viability
of ester linkage in the MTX scaffold as potential DHFR inhibitors. Furthermore,
molecular dynamics (MD) simulations of three ligands in complex with pcDHFR and the
human DHFR enzyme were conducted to understand the molecular basis for the observed
selectivity. The LIE method98 was employed to predict the absolute binding free energies
of molecules against pcDHFR and human DHFR. The predicted binding affinity and the
selectivity ratio were well correlated with the experimental observations.
A series of compounds in which the methylenamino-bridge of non-classical
inhibitors was replaced with an ester function to provide potential inhibitors for
inhalation use against PCP was reported by Graffner-Nordberg et al.99 In this study, the
selection of the target compounds for synthesis was partly guided by an automated
docking and scoring procedure using AutoDock 3.0100 as well as MD simulations. Even
though, the AutoDock scores overestimated the magnitude of the binding free energies (16 to -11 kcal/mol), the relative comparison was possible. As predicted by their
AutoDock scores, the compounds were not selective versus human DHFR. Five of the
docked compounds were selected for studies using the more time consuming LIE
method. Compounds were again predicted to be non-selective by the LIE method. Thus,
this study provided compounds with only slight preference for the fungal enzyme;
furthermore, modest selectivity of the synthesized inhibitors was reasonably well
predicted using the employed computational methods, although a correct ranking of the
relative affinities was not successful in all cases.45
Gorse et al.101 reported MD simulations on hDHFR in order to determine the
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putative stable binding conformers of selected deazapterin analogs. Method based on
standard thermodynamics cycles and linear approximation of polar and non-polar free
energy contributions from MD averages was used to correlate the binding affinities of the
different ligands in each binding site with experimental dissociation constants. The study
provided insights into structure-activity-relationships (SAR) for use in the design of
modified inhibitors of DHFR. Pitts et al.66 reported interaction energy calculations for
various pcDHFR inhibitors including PTX, TMX, TMP and epiroprim using explicit
solvent model. Each inhibitor was divided into different substructural regions and the
minimized complexes were then used to calculate interaction energies for each intact
antifolate and its corresponding substructural regions with the pcDHFR binding site
residues. Substructural regions containing pteridyl, pyridopyrimidinyl and
diaminopyrimidinyl subregions contributed most to the stability of antifolate interactions,
while interaction energies for the hydrocarbon aromatic rings, methoxy and ethoxy
groups were much less stable.
Recently, Bag et al.22 described the design, synthesis and biological evaluation of
fourteen structurally diverse compounds. The top five docked poses using Glide-XP28
score were minimized using the local optimization feature in Prime28 and the energies
were calculated using the OPLSAA force field102 and the GBSA continuum model.63 The
docking scores from Glide-XP method and MM-GBSA predicted Gbind were able to
distinguish between the active and poorly active compounds. Furthermore, a good
correlation coefficient of 0.797 was obtained between the IC50 values and MM-GBSA
predicted Gbind.
Thus, a variety of methods ranging from simple docking scores, to
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computationally expensive and accurate methods like FEP, have been employed to rank
order DHFR inhibitors according to their binding energy, with varying success. However,
accurate prediction of binding affinity for a larger dataset of DHFR inhibitors still
remains a challenge.

A.1.5.4. Ligand Based Approaches - QSAR and Pharmacophore Modeling
Availability of large number of active and inactive ligands has aided rational
ligand based drug design. These methods vary from simple 2D descriptor based methods
to more complex and advanced receptor based 3D-QSAR methods. Furthermore, the
DHFR inhibitor dataset is often used to validate newly proposed ligand based
approaches. A survey of various ligand based models developed for inhibitors of
pcDHFR, tgDHFR and maDHFR is presented in this section.
Agrawal et al.64 reported development of QSAR models using a series of nineteen 2,6substituted 2,4-diaminopyrido[3,2-d]pyrimidine derivatives against pcDHFR using
topological indexes. Mattioni et al.67 used a data set of 345 diverse DHFR inhibitors to
build QSAR models using artificial neural networks to correlate chemical structure and
inhibition potency for pcDHFR, tgDHFR and rlDHFR. Classification models were also
built using linear discriminant analysis (LDA) to predict the selectivity for pcDHFR and
tgDHFR. A set of new nitrogen and oxygen-specific descriptors were developed to better
encode structural features. The developed neural network models were able to accurately
predict log IC50 values for the three types of DHFR to within ± 0.65 log units. The best
LDA models were able to correctly predict DHFR selectivity for approximately 70% of
the external prediction set compounds.
Gangjee et al.50, 103 reported 3D-QSAR model development using three methods,
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conventional CoMFA, all orientation search (AOS) CoMFA, and CoMSIA, using a
dataset of 179 structurally diverse compounds from their previous publications. Low
energy conformation of 5-((naphthalen-2-ylthio)methyl)furo[2,3-d]pyrimidine-2,4diamine (Figure 10), one of the most potent and selective inhibitor was used as template
for the flexible alignment using Molecular Operating Environment (MOE) suite. The
models were derived against pcDHFR, tgDHFR and rlDHFR. AOS CoMFA models gave
the best internal predictions (q2 = 0.604, 0.600, and 0.634 for pcDHFR, tgDHFR, and rl
DHFR respectively). CoMSIA models gave the best external predictions (predictive r 2 =
0.544, 0.648, and 0.488 for pcDHFR, tgDHFR, and rlDHFR respectively). Both AOS
CoMFA and CoMSIA analyses were used to construct stdev*coeff. contour maps which
provide an insight into SAR.
Jain et al.85 described QSAR analysis using 2D and 3D descriptors on a series of
DHFR analogs of 2,4-diaminopyrido[2,3-d]pyrimidines and 2,4-diaminopyrrolo[2,3d]pyrimidines. The QSAR model indicated importance of the hydrogen bond between
the hydroxyl group of Tyr129 and the cofactor NADPH. The major difference between
the earlier pharmacophore hypothesis developed using Catalyst and the one proposed in
this study was that the hydrogen bond acceptor feature corresponding to 3-nitrogen of
2,4-diaminodeazapteridin ring was missing in this pharmacophore. Also, one hydrogen
bond acceptor feature corresponding to 8-nitrogen was present in Catalyst
pharmacophore while in the one proposed in this study, hydrogen bond acceptor feature
corresponding to nitrogen at 1-position in 2,4-diaminodeazapteridin ring was present.
Moreover, the proposed new pharmacophore had two new donor features mapped to N-H
bonds of two amino groups of 2,4-diaminodeazapteridin ring system. The proposed
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pharmacophore was used to refine the earlier pharmacophore and was in agreement with
mechanism of the reaction catalyzed by the enzyme. The alignment from pharmacophore
model was used to develop CoMFA and CoMSIA models from 68 compounds taken from
a dataset of 90 compounds. Each model was further validated using a test set of 22
compounds not included in the training set. Of the various models evaluated CoMSIA
model with a combination of steric, electrostatic, hydrophobic, and H-bond fields
produced a statistically significant model with good correlation and predictive power.
Furthermore, analysis of various contours provided details about the SAR.
Gangjee et al.50 recently described CoMFA analysis of tgDHFR and rlDHFR
based on 80 antifolates with 6-5 fused ring system using the all-orientation search (AOS)
routine and a modified cross-validated r2-guided region selection (q2-GRS) routine. In
this study, two modifications of q2-GRS routine were suggested to improve the
predictability of models. In the first modification, the lowest corner of each modified
subregion was the lowest grid point of the conventional CoMFA grid enclosed by the
original q2-GRS subregion, and the highest corner of each modified subregion was the
highest grid point of the conventional CoMFA grid enclosed within the subregion of the
original q2-GRS routine. In the second modification, the region box was divided into 125
equal-sized subregions and the distance between the adjacent subregions was 1Å,
whereas in the original routine, the adjacent subregions touch each other. Among the
various generated models, the q2-GRS model using the second modification showed the
best external predictive r2 (0.499) along with a satisfactory internal cross-validated q2 at
0.647 (optimim number of components (ONC) = 3). On the basis of the steric contour
maps of the models, four new compounds were designed belonging to the 2,4-diamino-5-
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methyl-6-phenylsulfanyl-substituted pyrrolo[2,3-d]pyrimidine series. It was observed
that, as predicted, the new compounds were potent and selective inhibitors of tgDHFR.
One of them, 2,4-diamino-5-methyl-6-(2’,6’-dimethylphenylthio)pyrrolo[2,3d]pyrimidine, showed nanomolar tgDHFR inhibitory activity.
Thus, the QSAR models derived from the homologous series (e.g. 2,4diaminopyrido[3,2-d]pyrimidine, 2,4-diamino-5-methyl-6-[(substituted
anilino)methyl]pyrrido [2,3-d]pyrimidines, 2,4-diaminopyrido[2,3-d]pyrimidines and 2,4diaminopyrrolo[2,3-d]pyrimidines), for DHFR inhibition, have applicability domains
restricted to specific chemotypes. Furthermore, these models and even some of the
models derived from larger datasets, provide no information about the binding site. On
the other hand, the 3DQSAR models derived using methods such as, CoMFA and
CoMSIA, have distinct advantage of stdev*coeff. contour maps, which provides an
insight into SAR and generation of SAR in context of active site. However, these models
lack inherent ability to mine 3D databases in search of potent/selective DHFR inhibitors.
The models developed using receptor residue interaction energy, quantify the binding
contribution of active site residues. Pharmacophore models are reported for maDHFR,
however, there are no reports for development of pharmacophore models for pcDHFR
and tgDHFR.

A.1.6. Thymidylate synthase:
The enzyme TS (EC 2.1.1.45) is present in almost every living organism
including humans, bacteria and protozoa.104 Currently the protein data bank (PDB)105 lists
165 TS structures. The crystal structures depict the enzyme in different molecular states
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and reaction intermediates: apoprotein, binary and ternary complexes with one or both
substrates, dUMP and mTHF, products, dTMP and DHF, inhibitors or substrate analogs,
such as FdUMP, 2’-deoxyguanosine-5’-monophosphate (dGMP), 2’-deoxycytidine-5’monophosphate (dCMP) or classical or nonclassical antifolates. 106
The TS enzyme is active as a homodimer consisiting of two identical subunits
each having a molecular weight of 30-35 kDa.21, 107 It has two active sites, each formed
by residues from the monomers. In each monomer, there are two main domains: one
larger, conserved domain (residues 1-98 and 130-313 in human TS (hTS)) and one
smaller, variable domain (the small domain (SD), residues 99-129 hTS). Each monomer
shows an alpha and beta fold (α+β) with 8 β-strands and 5 α-helices in the large domain.
A five stranded β-sheet in each large domain forms the dimer interface. C195 in the
catalytic loop (CL, residues 184-199 hTS) is the catalytic amino acid that reacts with
carbon C6 of dUMP, forming the covalent complex. Other important regions that can be
recognized in the enzyme structure are the loop at the interface (HIL, residues 144-158
hTS), the loop around R50 and the C-terminal region (CT, residues 308-313 hTS).
The longest sequence of TS is found in Lactobacillus casei with 316 amino acids,
whereas the shortest sequence of TS is in E.coli with 264 amino acids. There are 6 major
insertions: Homo sapiens and Rattus norvegicus have an extended N-terminal with 24
and 18 residues, respectively. Bacillus subtilis has 10 amino acids inserted into the loop
around Arg50. P. carinii and Cryptosporidium hominis have a 6 and 1 residue insertion
respectively at residue 206. However, the most variable regions are the small domain and
the loop at the interface. The small domain varies in number from 20 to 70 residues from
E.coli to the L. casei sequence.
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The mechanism of catalysis by TS is well studied108 and is depicted in Figure 22.
Cys 195 (hTS) attacks C6 of dUMP to form an enolate which then abstracts a proton
from an unidentified basic residue of the protein to form an enol in step (A).

Figure 22. The mechanism of catalysis by TS (Modified from ref.109 )

The co-factor, 5,10-methyleneTHF is activated by iminium ion formation at N5.
The C5 position of dUMP, activated by enol formation, reacts with the methylene of the
activated co-factor in step (B). H5 of dUMP is abstracted and the enol is regenerated in
(C). Abstraction of a proton from O4 of the enol in (D) results in formation of an
exocyclic methylene and release of the catalytic Cys (Cys 195). The methylene is then
reduced by the modified cofactor to produce dTMP. The modified cofactor, which has
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served as methylene donor and reductant, is released from the active site of TS followed
by release of product, dTMP.

Figure 23. Structure of PDDF.

A 2.3 Å X-ray crystal structure of the ternary complex of E. coli
TS:FdUMP:PDDF was reported by Oatley et al.110 In this structure a covalent bond is
formed between Cys146 at C6 of the nucleotide analog FdUMP by a thioether bond.
Another key interaction of FdUMP is the charge-mediated interaction of the 5’-phosphate
group in the dianionic state with four conserved arginine residues (Arg21, Arg166,
Arg126, and Arg127), two from each subunit. In addition, the polar atoms in both the
pyrimidine and ribosyl moieties of FdUMP form hydrogen bonds with side chains of
binding pocket amino acid and ordered solvent molecules.
The cofactor analog PDDF binds in a partially folded conformation with its paraaminobenzoyl group inclined at a 65 ° angle to the heterocycle and the L-glutamate tail
exposed at the entrance to the active site cleft. Formation of the ternary complex induces
a large conformational change in which the active site is capped by four carboxylic acidterminal amino acids and the bound ligands are sequestered from the bulk solvent. PDDF
sits directly above the substrate analog FdUMP and the B-ring of PDDF forms a charge
transfer complex with the pyrimidine portion of FdUMP. The N1, N3 and the 2-NH2
groups of PDDF are involved in hydrogen bonds with side-chain residues of TS either via
direct hydrogen bonds or by water mediated hydrogen bonds. The C5 and C8 atoms of
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the quinazoline B-ring do not have hydrogen bond donor or acceptor side chain residues
within a distance of 5 Å. This could explain the improvement in inhibition produced by
quinazoline antifolates compared to pteridine antifolates, which require desolvation of the
polar N5 and N8 groups. The quinazoline ring also interacts via hydrophobic bonds with
Trp83 and Leu43. The hydrophobic interaction between the C6- methylene moiety of the
quinazoline and the conserved Trp80 is an important interaction. The 4-oxo group of
PDDF is not involved in hydrogen bonding interactions with side chain residues or
ordered water molecules of TS. In addition to the quinazoline backbone, the L-glutamate
moiety also contributes to binding by having interactions with Lys 50 and several
backbone residues including His53, Leu224 and Ile310 via the bridging of two conserved
water molecules.
A.1.6.1 TS Inhibitors
This review will cover bicyclic non-classical inhibitors of TS.
Table 2. Pyrrolo[2,3-d]pyrimidines as nonclassical inhibitors of TS

Non-classical compounds
IC50 in nM against
hTS

111

28 340
MTX 36
IC50 in µM against
hTS
29 0.13
30 0.15
PDDF 0.18
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Compound 31 exhibited 25%
inhibition of hTS at 23 µM

113

No inhibition of hTS at >10 µM

114

IC50 in µM against
hTS

115

33 >25 (20% inhibition)
PDDF 0.036

Inactive against TS
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A.2. RECEPTOR TYROSINE KINASE INHIBITORS
A.2.1. Angiogenesis:
The term angiogenesis is used to describe the physiological process of formation
of new blood vessels from pre-existing vasculature.117 Angiogenesis is critically
important for growth and development of the body and normally occurs only during
embryonic and post-embryonic development, reproductive cycle, and wound healing.
However, an upregulated angiogenesis has been observed as one of the hallmarks of
cancer, playing an essential role in tumor growth, invasion, and metastasis. 118
Furthermore, many other diseases – diabetic retinopathy, hemoangioma, arthritis,
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psoriasis and atherosclerosis among others – are also dependent on upregulated
angiogenesis.119, 120

Figure 24. Process of angiogenesis. (Modified from ref.119 )
(1) An activating, proangiogenic signal induces the switching on of the angiogenic phenotype of
resting endothelial cells, which become activated. (2) These activated cells acquire an invasive
potential, involving basal membrane degradation, (3) extracellular matrix remodeling,
proliferation, and migration. (4) Finally, morphogenesis contributes to the alignment of
endothelial cells forming a new microvessel, and (5) this microvessel is stabilized by eventual
recruitment of pericytes and acquisition of a new basal membrane.

The process of angiogenesis starts an angiogenic signal activates resting
endothelial cells. This initiates the release of degrading enzymes from endothelial cells
and initiates a sequence of migration, proliferation and cell differentiation to form new
vessels as depicted in Figure 1.119
Angiogenesis is critical for tumor growth beyond 1-2 mm and for tumor invasion
and metastasis.119 As a tumor grows in size, it becomes increasingly hypoxic, and triggers
the release of growth factors, particularly, vascular endothelial growth factor (VEGF),
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epidermal growth factor (EGF), and platelet derived growth factor (PDGF) among others,
which act as proangiogenic signals (Figure 24) and initiate angiogenesis. Leading from
this observation, Folkman, in 1971, proposed that inhibition of angiogenesis could serve
as a potential approach in cancer treatment. 117
Anti-angiogenic therapy, directed to activated endothelial cells presents a series of
advantages over therapies targeted to tumor cells. 119 First, due to the fact that endothelial
cells are homogeneous, diploid, genetically stable targets; spontaneous mutations rarely
occur in them relative to tumor cells. Second, the turnover of endothelial cells in tumoral
tissues is usually fifty-fold higher than that of quiescent endothelia in normal tissues. The
activated endothelium overexpresses specific markers – integrin αvβ3, E-selectin, Tie, and
vascular endothelial growth factor receptor (VEGFR) – that could be used as targets for
the development of specific therapies directed to these cells. In addition, the contact
between endothelial cells and blood makes this target easily accessible to systemically
administered drugs, therefore avoiding the problem of low penetration of antitumor
agents into the solid tumors.121 Finally, because a single vascular net may support the
growth of different populations of tumor cells, the inhibition of the vascular growth may
affect the survival of many tumor cells. 122
Any of the steps involved in angiogenesis may be a potential target for developing
novel anticancer agents.119 The present review will focus only on Receptor Tyrosine
Kinases (RTKs) as potential targets for the abrogation of cancer induced angiogenesis.

A.2.2. Receptor tyrosine kinases (RTKs):
Protein kinases are enzymes that transfer a phosphate group from ATP to the
hydroxyl group of serine, threonine, or tyrosine of specific proteins inside cells. 123 The
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phosphorylation by these enzymes achieves an important function of signal transduction
in eukaryotic cells, and controls the processes of cell proliferation metabolism, survival
and apoptosis. A misregulation of these tightly controlled processes results in the
overexpression of kinases and/or mutations and is associated with a variety of disease
states including cancer.124
For angiogenesis to occur, the pro-angiogenic growth factors have to bind to
transmembrane receptors of the protein kinase family identified as RTKs. At present, 58
RTKs are known, grouped into 20 subfamilies. 125 The structural composition of RTKs
consists of an extracellular ligand binding domain, a transmembrane hydrophobic
domain, and an intracellular catalytic domain. Following binding of the growth factor to
the extracellular domain, these receptors commonly undergo dimerization, resulting in
autophosphorylation of tyrosine residues within the catalytic domain. This triggers a
cascade of events through phosphorylation of intracellular proteins that ultimately
transmit the extracellular signal to the nucleus, causing changes in gene expression
eventually leading to angiogenesis.126
A number of RTKs have been recognized to be involved in tumor induced
angiogenesis. The key RTK families in cancer include the platelet derived growth factor
receptor (PDGFR), epidermal growth factor receptor (EGFR), and the VEGFR families
of RTKs.127
PDGFR. Members of the PDGFR family – PDGFRα and PDGFRβ have been
implicated, indirectly, in inducing VEGF secretion and hence in angiogenesis. 128
Although PDGFR plays a role in the development and maintenance of tumors due to its
role in blood vessel growth, the validity of PDGFR as a drug target itself is still unclear,
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as it is not usually the main factor in tumor development. However, there are several
cancers that exhibit an upregulation of PDGFR, namely, chronic myelomonocytic
leukemia (CMML), gastrointestinal stromal tumor (GIST), acute myeloid leukemia
(AML), chronic myeloproliferative disorders (CMPD), and dermatofibrosarcoma
protruberans (DFSP), a soft tissue sarcoma. 129, 130
EGFR. The ligand for EGFR, EGF, controls a pathway that is linked to cell
proliferation, migration, and differentiation. There are four subtypes of EGFR receptors:
EGFR-1 (later referred to as EGFR; also identified as erythroblastic leukemia viral
oncogene homologue 1, Erb-B1, or human EGF receptor HER-1), HER-2 (Erb-B2, or
neuroglioblastoma neu), HER-3 (Erb-B3), and HER-4 (Erb-B4). Among these, HER-2
lacks a known endogeneous ligand and HER-3 lacks kinase activity. Abnormal activity,
either by overexpression or constitutive action, has been linked to a number of cancers,
including lung, breast (especially HER-2/neu), and prostrate cancers.131 EGFR inhibitors
have been recommended as first line therapy for patients with advanced or metastatic
NSCLC.132
VEGFR. In the VEGFR family, VEGFR-2 (FlK-1/KDR) has been recognized as
the principal receptor that mediates VEGF stimulation in angiogenesis. VEGFRs are
almost exclusively expressed on endothelial cells. Targeted inhibition or disruption of
VEGFR-2 produces an abrogation of angiogenesis and tumor growth. 133, 134 In addition,
VEGFRs are overexpressed on many tumor types. 135-137 Reports suggest that VEGFR-1
(Flt-1) shows promise as a therapeutic target not only for tumor angiogenesis but also for
the inflammation associated with tumors.138
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A.2.3. RTK inhibitors approved for use in the U.S. and the importance of multi
kinase inhibition:
A list of kinase inhibitors approved (till 2012) for various cancer indications
within the U.S. is provided in Table 3. Imatinib mesylate (Figure 25) was the first RTK
inhibitor approved in the U.S. for Philadelphia chromosome (Ph)-positive chronic
myeloid leukemia (CML) patients130, 139. In addition, imatinib mesylate has been
approved for multiple cancers such as Gastrointestinal stromal tumors (GIST), Acute
lymphoblastic leukemia (ALL), myelodysplastic diseases associated with PDGFR gene
rearrangements, aggressive systemic mastocytosis (ASM), Dermatofibrosarcoma
protuberans (DFSP).
Early research suggests that imatinib has shown potential in the treatment of
plexiform neurofibromas.140 The use of imatinib has been associated with the
development of resistance mediated either by mutations within the kinase domain of
BCR-ABL or, to a lesser degree, amplification of the BCR-ABL genomic locus.141
Ruxolitinib was approved in 2011 for the treatment of intermediate or high-risk
myelofibrosis and is currently in clinical trials for the treatment of pancreatic cancer,
polycythemia vera and plaque soriasis.98 More recently, vemurafenib, which targets B-raf
kinase, was approved for the treatment of late stage melanoma in 2012. 100
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Table 3. RTK Inhibitors Approved for Use in the U.S.
Brand
Name

Iressa

2003

gefitinib

Tarceva

2004

erlotinib

Nexavar

2005

sorafenib
tosylate

Sutent

2006

sunitinib
malate

Sprycel

2006

dasatinib

Tasigna

2007

nilotinib

Tykerb

2007

lapatinib

US FDA Approved
Indications
chronic myeloid
leukemia (CML)
non-small-cell lung
cancer (NSCLC)
NSCLC, pancreatic
cancers
hepatocellular
carcinoma, renal cell
carcinoma (RCC)
GIST, renal cell
carcinoma
CML (especially
imatinib-resistant)
CML (imatinib resistant
and intolerant)
breast cancer

Votrient

2009

pazopanib

RCC, soft tissue sarcoma

Jakafi

2011

ruxolitinib

myelofibrosis
NSCLC with Alk
mutation
late stage melanoma

Gleevec

Xalkori
Zelboraf

Year
Generic
Approved Name
imatinib
2001
mesylate

2011
2012

crizotinib
vemurafenib

Target kinase(s)
Abl, c-Kit, PDGFRα,
PDGFRβ
EGFR
EGFR
Raf, VEGFR2, VEGFR3, cKit, PDGFRβ
c-Kit, VEGFR, PDGFR,
FLT3
Abl, c-Kit, PDGFR, Src
Abl, c-Kit, PDGFRβ, Src,
Ephthrin
EGFR, Her-2
VEGFR1, VEGFR2,
VEGFR3, PDGFRα,
PDGFRβ, c-Kit
JAK1, JAK2
Alk/Met
B-raf

Gefitinib and erlotinib (Figure 25), two inihibitors of EGFR kinase, were the
second and the third kinase inhibitors to be approved for clinical use. These drugs
showed remarkable effects in a subpopulation of patients with non-small-cell lung cancer
(NSCLC) harboring activating mutations. 142-149 Unfortunately, drug resistant tumors
were observed within a year or so of initating treatment. Lapatinib (Figure 2) was
approved in 2007 for use in breast cancer in combination with a cytotoxic agent.
Lapatinib is a dual inhibitor of both EGFR and human EGF receptor-2 (HER-2)
Although most of the early work in the area of RTK inhibitor discovery was
focused on producing inhibitors of single RTKs, recent data shows that tumors treated
with specific RTK inihibitors can develop resistance through an upregulation of alternate
42

kinase mediated pathways.150

Figure 25. Structures of RTK inhibitors currently marketed in the U.S.

There are a number of RTK mediated processes that can promote angiogenesis,
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thus inhibitors targeting a broader range of RTKs may lead to a more robust antitumor
response and prevent resistance by targeting two or more angiogenic pathways. 151, 152
This is underlined by the fact that the newly approved inhibitors of RTKs – sorafenib and
sunitinib (Figure 25) – target multiple RTKs. Sorafenib inhibits multiple vascular
endothelial growth factor receptor kinases, the mast-stem cell growth factor receptor (cKit) kinase, and the proto-oncogene c-Raf kinase. Sunitinib inhibits VEGF and PDGF
receptor kinases, in addition to c-Kit and FMS-like tyrosine kinase 3 (Flt3). These drugs
are expected to act by arresting the development of blood supplies to the growing tumors,
in addition to specifically blocking an oncogenic kinase within a tumor type (e.g., cKit).153-155
A.2.4. RTK activation relevant to the design of clinical inhibitors: DFG dynamics
and C-Helix dynamics:

Figure 26. Crystal structure an inhibitor dasatinib bound to Abelson tyrosine kinase (Abl) (PDB:
2GQG).156

All RTKs share a characteristic ATP binding structure as shown in Figure 26.157 The
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kinase or catalytic domain consists of an N-terminal lobe, which consists mainly of β
strands but contains one α helix, helix C. The C-terminal lobe is mainly α-helical in nature.
A short strand termed the hinge region connects the two lobes. The ATP binding site is
sandwiched between the two lobes. ATP forms critical hydrogen bonds with the hinge
region.
Early on, in the development of kinase inhibitors selectivity was identified as a
challenge when designing inhibitors that bound to the ATP pocket. This was a formidable
challenge because evolutionary pressure exerted to maintain a general common shape and
chemical similarity of the ATP binding site in different kinases. Hence, drug design efforts
have sought to exploit regions of the active site that are not directly involved in ATP
binding, or conformations of the kinase that show greater structural and chemical
heterogeneity.
The RTK active site is known to exist in multiple conformational states as a
consequence of the activation and inactivation mechanism of kinases. 157 The P-loop (or
phosphate-binding loop or glycine-rich loop) plays a key role in the dynamics of the kinase
domain where its conformation is a determining factor in the shape of the ATP-binding site
(Figure 26). In the active form of a kinase, a characteristic Asp-Phe-Gly motif (DFG motif),
located immediately above the activation loop, adopts a conformation with Asp and Phe
both oriented toward the binding site (DFG-in) (Figures 24 and 25a).
While the active form of the kinase catalytic domain is fairly homogeneous
structurally, the inactive forms are less so. The greater structural variations of the inactive
form exist because the inactive form of the kinase does not have to obey the requirement
of binding to the common substrate ATP. Hence numerous inactive states have been
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identified, which can be related to the mechanism of activation of the kinase. 158 One of
these states is called the “DFG-out” state and is associated with kinases that activate by
phosphorylation of residues on the activation loop. In the DFG-out state, the phenylalanine
of the DFG motif is positioned in the ATP-binding site so that it effectively blocks ATP
access to the binding site (Figure 27b). Phosphorylation of tyrosine, threonine, or serine
residues of the activation loop by another kinase is incompatible with this conformation
and consequently leads to activation of the kinase. Phosphorylation can occur as the
activation loop can act as a substrate for other kinases or can even be phosphorylated
autocatalytically. 158
Kinase inhibitors that bind to the active form of the kinase are called type I
inhibitors, and those that bind to the inactive form of the kinase are called type II
inhibitors.159 Imatinib, the first kinase inhibitor to make it to market, binds to the inactive
form of Abl, c-Kit, and PDGF kinases.160
A second inactive form of the kinase retains the general DFG-in form but rotation
and shifting of the C-helix out leads to inactivation of the kinase (Figure 27d-e).161, 162
This rotation of the C-helix can alter the nature of the ATP binding site. A number of
activation mechanisms have been associated with the helix-C-out inactive conformation.
In c-Src, activation of the kinase is effected by phosphorylation of a tyrosine in the
activation loop similar to the phosphorylation in Abl that destabilizes the DFG-out
inactive form. In CDK2, activation results from binding of the protein cyclin to the
kinase.
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Figure 27.157 Binding site comparisons of active and inactive forms of different kinases. (a) The
Abl active form in complex with dasatinib (PDB: 2GQG).The phenylalanine of the DFG motif
(green carbons) is shown to point away from the binding site and is buried in the interior of the
protein. (b)The Abl DFG-out inactive form in complex with imatinib (PDB: 1IEP). The
phenylalanine of the DFG motif points into the binding pocket. (c) Rotation of ∼90 degrees of (b)
to highlight the depth of the DFG-out pocket (surface representation). (d) Helix-C-out inactive form
of EGFR (PDB: 1XKK). The catalytic lysine (cyan carbons) is far removed from Helix C’s glutamic
acid (white carbons). (e) Helix-C movement from active (cyan helix) to inactive form (green helix)
from an overlay of the Abl (PDB: 2GQG, helix in) and EGFR (pdb code 1XKK, helix out). (a)-(c)
show the catalytic lysine (cyan carbons) and the salt bridge formed with the glutamic acid from
Helix C (white carbons).

In EGFR, formation of an asymmetric kinase domain homo- or heterodimer
following the extracellular binding of EGF results in kinase activation. 163, 164 Although the
EGFR kinases have a tyrosine in the activation loop that gets phosphorylated, this does not
appear to be necessary for activation.163 The C-helix-out form of the kinase has been shown
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to bind to lapatinib.162
The nature of the ATP binding site can be altered by the C-helix-out inactive form.
On rotation of helix C in EGFR, a conserved glutamic acid points towards solvent rather
than towards the ATP binding site (Figure 27d). Such a conformation disrupts the salt
bridge between glutamic acid and the conserved catalytic lysine residue. This salt bridge is
required to position the α and β phosphate groups of ATP and is therefore critical for
catalytic activity. The key structural changes associated with the movement from C-helixout inactive form to the active form are shown in Figure 27d and Figure 27e. Crystal
structures of EGFR bound to ATP analogs in the DFG-in/C-helix-out conformation have
been solved for EGFR.163 A crystal structure of the C-helix-out conformation of an inhibitor
bound to Abl has also been solved.165
Table 4. provides a list of approved inhibitors and the conformation of the RTKs
which these inhibitors target.166
Table 4. Small-molecule protein kinase inhibitors and their targets along with the target
conformation. [Modified from ref 166]
Inhibitor

Primary Targets

Targeted Conformation

Imatinib

Abl, Kit, PDGFR

Inactive (DFG-out and C-helix in)

Gefitinib

EGFR

Active (DFG-in and C-helix in)

Erlotinib

EGFR

Active (DFG-in and C-helix in)

Sorafenib

Raf

Inactive (DFG-out and C-helix in)

Sunitinib

Kit, VEGFR-2, PDGFR, Flt3

Active (DFG-in and C-helix in)

Dasatinib

Abl, PDGFRβ, Src

Active (DFG-in and C-helix in)

Lapatinib

EGFR

Inactive (DFG-in and C-helix out)
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Hence substantial information is available on the dynamics of kinases and can be
exploited for drug design.
A.2.5. Emergence of drug resistance:
The appearance of drug resistant tumors was an unwelcome addition to the already
substantial challenges to kinase drug discovery. Kinases were anticipated to be difficult
targets partly because the conservation of shape and character of the ATP binding site posed
a selectivity issue and partly because the high endogeneous concentration of ATP indicates
that inhibitors would have to be very potent to be successful as drugs. Notably, after the
first RTK inhibitors were used clinically, it became clear that various amino acid mutations,
some in the kinase domain, could lead to drug resistance. 144, 145, 167, 168 Following this
observation, addressing drug resistance has become a defining challenge of kinase drug
discovery.
Repeating patterns of mutations seem to appear at the activation loop, the P-loop,
and at the “gatekeeper” residue within the ATP binding sites.157 A “gatekeeper,” is a residue
that flanks a highly variable Hydrophobic pocket at the rear of the ATP binding site and
can act as a selectivity filter.169 Individual kinases have additional mutations that result in
alterations of ligand binding or kinase activation. Crystallographic data for complexes of
key protein-ligand pairs with mutations in Abl170-172 and EGFR162,
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has helped in

interpretation of the effect of these mutations.
Some general trends are clear. Mutations in the P-loop and activation loop can
produce active states of kinases by destabilizing the inactive forms. Hence, this can reduce
or eliminate the binding of inhibitors targeted at the inactive forms of kinases (cf. c-Kit174
and PDGFR175, 176). The effects of numerous mutations can also be rationalized by their
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direct action on ligand binding within the ATP-binding cleft or occupation of additional
accessible space in the inactive form of the kinase. Most prominent of this type of mutation
is that of the gatekeeper threonine in Bcr-Abl and c-Kit, which confer resistance to imatinib.
This has been explained as a direct loss of a critical hydrogen bond to the ligand (Figure
27b).
A.2.6. Binding of inhibitors in the RTK active site:
In this section the binding interactions of inhibitors to the ATP binding site of EGFR
and VEGFR2 are discussed to present an idea of the interaction patterns seen between the
ligand and the active site residues.

Figure 28 X-ray crystal structure of 34 bound to EGFR (PDB: 2ITT)173

Yun et al.173 reported a X-ray crystal structure of a pyrrolo[2,3-d]pyrimidine
compound 34 (AEE788)177 (Figure 28). Compound 34 displayed potent inhibition of
VEGFR and ErbB family of kinases. It has low nanomolar potency against EGFR and was
advanced to phase I clinical trials for treating relapsed glioblastoma multiforme.59 The
crystal structure indicates that the pyrrolo[2,3-d]pyrimidine core of 34 hydrogen bonds
with the hinge region, and the N3 atom interacts with the hydroxyl of Thr854. The 450

phenylethylamine moiety extends into the Hydrophobic pocket defined by Thr790,
Leu788, Lys745, and Met766. The 6-phenyl substituent is sandwiched between Leu718
above and Gly796 below. Finally the ethylpiperazine group extends towards solvent near
Asp800 and Glu804 at the edge of the active site.
Harris et al.178 reported indazolylpyrimidine 35 (Figure 29) with good potency
against VEGFR-2 (IC50 = 6.3 nM). In addition, 35 had an oral bioavailability of 85% in the
rat at a dose of 10 mg/kg. A crystal structure of 35 with VEGFR-2 indicated that the
pyrimidine N-1 and the C-2 anilino N-H making hydrogen acceptor and donor bonds with
the peptide backbone of Cys919.

Figure 29. X-ray crystal structure of 35 bound to VEGFR-2 (PDB: 3CJF)178

Figure 30. X-ray crystal structure of 36 bound to VEGFR-2 (PDB: 3CJG)178
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The N-methylated analog of 35, compound 36 (Figure 30) had an oral
bioavailability of 65%. The crystal structure of 36 with VEGFR-2 revealed the inhibitor in
a “S-shaped” conformation in contrast to 35 which exists in a “U-shaped” conformation.
The S-shaped conformation was preferred most likely to avoid an unfavorable steric
interaction between the methyl group and the pyrimidine C-5 hydrogen.

A.2.7. RTK inhibitors:
The design and synthesis of RTK inhibitors have been extensively reviewed in the
literature. The following review will cover the pyrrolo[2,3-d]pyrimidine class of RTK
inhibitors
Table 5. Pyrrolo[2,3-d]pyrimidine inhibitors of RTKs
Structure

Compound

RTK inhibitory activity

Ref

37 R=2’-Me

Whole cell assays

179

38 R=2’,5’-diOMe

41 IC50=0.25µM (VEGFR-2)

39 R=2’,4’-diCl

41 IC50=1.21µM (A431)
42 IC50=0.62µM (VEGFR-2)
42 IC50=8.92µM (PDGFR-β)
43 IC50=0.23µM (EGFR)
43 IC50=2.8µM (A431)

40 R=3’-Br

Whole cell assays

41 R=2’F,4’-Cl

37 IC50=0.3µM (EGFR)

42 R=4’-Cl

38 IC50=1.4µM (A431)

43 R=3’-CF3

39 IC50=1.6µM (A431)
40 IC50=0.03µM (CAM)

52

180

44 R1=H, R = 3’-Br

Whole cell assays

45 R1=H, R = 3’-CF3

44 IC50 = 8.5 µM (PDGFR-β)

46 R1=H, R = 3’-Br, 4’-

45 IC50 = 22.1 µM (VEGFR-2)

F

46 IC50 = 25.2 µM (VEGFR-2)

47 R1=H, R = 3’4’-

47 IC50 = 31.6 µM (VEGFR-2)

181

(C2H3N)

48 R = 4’-Br, 2’-Cl

Whole cell assays

49 R = 3’-F

48 IC50 = 0.1 µM (VEGFR-2)

50 R = 4’-iPr

48 IC50 = 16.2 µM (A431)

182

49 IC50 = 0.3 µM (VEGFR-2)
50 IC50 = 1.4 µM (VEGFR-2)

51 R1= CH3, R2=CH3,

Whole cell assays

R3=2’-CH3

51 IC50 = 1.2 µM (EGFR)

52 R1= CH3, R2=CH3,

52 IC50 = 0.5 µM (EGFR)

R3=2’,5’-diOCH3

53 IC50 = 1.3 µM (PDGFR-β)
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53 R1= CH3, R2=H,
R3=2’-CH3
Isolated enzyme assay
54

IC50 = 27 nM (EGFR)

55 R= OCH3

Potent EGFR inhibition

56 R= NHCH3

53

184-186

187, 188

57 R=NHCOCH3

Isolated enzyme assay

58 R=NHSO2CH(CH3)2

IC50 = 1-3 nM (EGFR)

187, 188

59 R=OCH3
60 R= p-NH2

Isolated enzyme assay

61 R = p-OH

IC50 = 1-5 nM (EGFR)

187, 188

62 R = p-COOH

Figure 31. Compounds used as standards in RTK inhibition assays

Gangjee et al.179 reported the design, synthesis and biological evaluation of N4(3-bromophenyl)-6-(substituted benzyl) pyrrolo[2,3-d]pyrimidines, 37–39 (Table 5) as
RTK inhibitors. These compounds were tested in human tumor cells known to over
express high levels of RTKs such as EGFR, VEGFR-1, VEGFR-2 and PDGFR-.
Compound 37 exhibited toxicity against A431 cells, which dependend on EGFR for
survival189 at values ten-fold better than standard cisplatin (Figure 31) used in this assay.
Additionally, 37 also exhibited a ten-fold better VEGFR-2 inhibition than the standard
agent semaxanib, thereby demonstrating dual kinase inhibition. The EC50 values of 38
against VEGFR-2 and PDGFR-β were four-fold better than and comparable to standard
agents semaxanib and 27 (AG1295) respectively. Inhibition of EGFR and A431 cell lines
by 39 was comparable to or five-fold better than the standard 58 (PD153035). Thus,
Gangjee et al. demonstrated that the substitution pattern in the N4-(3-bromophenyl)-6-
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(substituted benzyl) pyrrolo[2,3-d]pyrimidine scaffold strongly influences the observed
multikinase inhibition and affords potencies equivalent to or better than standard agents.
Gangjee et al.180 reported a series of N4-phenylsubstituted-6-(2phenylethylsubstituted)-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamines as a homologated
series of their previously published RTK inhibitors. 179 These compounds retained activity
against EGFR and VEGFR-2 and showed improved PDGFR-β inhibition compared to the
previous series of compounds. Compounds 40-43 are the best compounds from this
series. Compound 40 showed EGFR inhibition similar to the standard 63 used in this
assay. While the 2’F, 4’-Cl- and 4’Cl- analogs (41 and 42) did not display significant
EGFR inhibition, they were about 5- fold more active than the standard cisplatin in the
A431 cytotoxicity assay. Compound 43, the 3’-CF3 analog of 40, was 3-fold better than
semaxanib in the chicken choriallantoic membrane (CAM) assay which is a standard test
for angiogenesis.190
Gangjee et al.181 reported a series of compounds that showed variation in the
substitutions at the 2-position in order to determine the validity of their hypothesis that
the 2-NH2 group affords improved potency against RTKs by potentially providing
additional means of hydrogen bonding to the hinge region in the ATP binding site. With
the exception of 44, the 2-NH2 analogs showed better inhibition of EGFR, PDGFR- and
in whole cell inhibition assays against A431 cells. Interestingly, the 2-desamino analogs
such as 45 – 47 were more potent against VEGFR-2 than the 2-NH2 analogs. However,
the 2- desamino analogs were only micromolar inhibitors in the CAM assay and were less
potent than the standard semaxinib in these assays, proving the importance of the 2- NH2
– moiety

in this scaffold.
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Gangjee et al.182 reported eight N4-phenylsubstituted-6-(2,4-dichlorophenylmethyl)-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamines as VEGFR-2 inhibitors with
variations in the phenyl ring of the 4-anilino moiety. Compounds 48 - 50 were potent
VEGFR-2 inhibitors and were 100-fold, 40-fold and 8-fold more potent than the standard
semaxanib, respectively. Compound 48 was a potent inhibitor of A431 cells with
inhibition comparable to standard cisplatin in the assay.
In an effort to substantiate the three proposed binding modes against RTKs,
Gangjee et al.183 proposed a series of pyrrolo[2,3-d]pyrimidine analogs of three potent
lead compounds with strategically placed methyl substitutions at the N7- and/or N4positions and evaluation of the resulting analogues for RTK activity. It was hypothesized
that, depending on the preferred binding mode of the compounds in RTK, selective
methylation should lead to a loss of hydrogen bonding with the hinge region, and
consequently, should result in a decrease in activity of the compound against the
particular kinase. Additionally, if all the three proposed binding modes were viable, the
compounds with methyl groups at the N7- and N4-positions, which would lack hydrogen
bonding capabilities, should be poorly active. The biological evaluation results indicated
that dimethylation of both the N4- and N7-positions (51 and 52) afforded whole cell
EGFR inhibitors that are more cytotoxic than the standard erlotinib. In addition, monomethylation at the N4- or N7-positions (53) afforded increased PDGFR-β inhibition than
the standard sunitinib. Methylation at either the 4-N or N7 position was detrimental to
VEGFR-2 inhibition. The biological evaluation results in this study demonstrated that
methylation of the 4-NH and/or the 7-NH influences both the specificity and potency of
RTK inhibition.
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Compound 54 (CGP59326) was designed as a part of an effort to improve the
EGFR activity of 7H-pyrrolo[2,3-d]pyrimidines by using a pharmacophore model for the
ATP binding site of EGFR.184-188 It was proposed that the NH of the pyrrole ring and the
N1 of the pyrimidine ring form a bidentate hydrogen bond donor acceptor system with
Gln767 and Met769 in the hinge region of EGFR, and the substituted aniline moiety at
the C-4 position binds in the Sugar pocket and interacts with Cys773. In addition, the
substituents at the 5 and 6 positions form van der Waals interactions with the
Hydrophobic pocket not accessed by ATP. Compound 54 showed good potency and
selectivity for isolated EGFR (IC50 = 27 nM). Modifying the 4- and 6-positions of the
pyrrolo[2,3-d]pyrimidine scaffold afforded compounds with improved biological and
physicochemical properties. Variation of substituents at the 6-position including esters
(55), amides (56), were introduced in order to increase hydrophobic interactions with
residues such as Thr76 and Thr860 in the active site. These modifications resulted in
improvement of activity against EGFR (IC50 = 1-5 nM). Replacement of the mchloroanilino moiety at the 4-position by a (R)-phenylethylamino led to potent
compounds (57-59, IC50 range of 1-3 nM) with improved pharmacokinetic properties.
Similar variations at the 6-position of the pyrrolo[2,3-d]pyrimidine scaffold with p- or msubstituted aromatic rings (60 – 62) led to compounds with potent EGFR inhibition.
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A.2.8. Molecular Modeling Studies with Receptor Tyrosine Kinases
The presence of multiple high-resolution X-ray crystal structures of RTKs such as
EGFR, VEGFR-1 and VEGFR-2 complexed with various small molecule inhibitors or
peptides has enabled structure based drug-design strategies. The following section lists
selected high-resolution (< 2 Å) crystal structures in the PDB complexed with small
molecule inhibitors of EGFR (Table 6 and Figure 32) and VEGFR-2 (Table 7 and Figure
33).
A.2.8.1 EGFR Crystal Structures
There are 89 X-ray crystal structures of human EGFR currently in the PDB. The
11 high resolution (< 2 Å) crystal structures co-crystallized with small molecule
inhibitors are listed in Table 6.
Table 6: Selected X-ray crystal structures of EGFR complexed with small molecule inhibitors:
Sr.No.
1
2
3
4
6
7
8
9
10
11

PDB
3POZ
3VRP
3W33
4I22
4I24
2RGP
3W2Q
1XKK
1M17
2ITO

Resolution
1.50
1.52
1.70
1.71
1.80
2.00
2.20
2.40
2.60
3.25

Ligand
TAK-285
PTR
19B
Gefitinib
Dasitinib
HYZ
HKI-272
GW572016
Erlotinib
Iressa

Reference
97
96
26
25
25
24
91
191
192
173

A.2.8.2. VEGFR-2 Crystal Structures
There are 40 X-ray crystal structures of human EGFR currently in the PDB. The
10 high resolution (< 2 Å) crystal structures co-crystallized with small molecule
inhibitors are listed in Table 7.
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Table 7: Selected X-ray crystal structures of VEGFR-2 complexed with small molecule
inhibitors:
Sr.No.
1
2
3
4
6
7
8
9
10

PDB
3VO3
4AG8
4ASE
3VNT
3VHE
2XIR
3EWH
3BE2
1YWN

Resolution (Å)
1.52
1.95
1.83
1.64
1.55
1.50
1.60
1.75
1.71

Ligand
OKF
Axitinib
Tivozanib
OJA
42Q
PF-00337210
K11
RAJ
LIF

Reference

Figure 32. Structures of ligands co-crystallized with EGFR listed in Table 6.
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193
194
194
195
196
197
198
199
200

Figure 33. Structures of ligands co-crystallized with VEGFR-2 listed in Table 7.

A.2.9. D-QSAR Studies with Receptor Tyrosine Kinases

There is a dearth in the literature for 3D-QSAR studies on small molecule
inhibitors of RTKs.201-212A summary of selected articles from the literature is presented
here.
Wu et al.209 reported the development of CoMFA and CoMSIA models using
seventy eight 4-(1H-indazol-4-yl)phenylamino and aminopyrazolopyridine urea
derivatives to investigate how their chemical structures relate to their inhibitory activities
against KDR and to identify the key structural elements required for the rational design of
potential drug candidates of this class. Docking simulations using Surflex-dock was used
to determine probable binding conformations of all the compounds at the active site of
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KDR. CoMFA and CoMSIA models were developed based on the docking
conformations.
The CoMFA model produced statistically significant results with the crossvalidated correlation coefficient (q2) of 0.504 and the non-cross-validated correlation
coefficient (r2) of 0.913. The predictive abilities of the two models were further validated
by 14 test compounds (r2 =0.727 for CoMFA and r2 = 0.624 for CoMSIA). In addition,
the CoMFA and CoMSIA models were used to guide the design of a series of new
inhibitors of this class with predicted excellent activities.
Lu et al.206 reported the development of CoMFA and CoMSIA models from a set
of 47 compounds composed of 3-aminoindazole ureas, 7-aminopyrazolo[1,5a]pyrimidine ureas and 5-aminoquinoxaline ureas against VEGFR2. To account for the
flexibility of the molecules a pharmacophore based alignment was used to construct the
3D-QSAR models. The constructed CoMFA models (r 2 = 0.982, q2 = 0.507) were
validated by a test set of 16 compounds (r2 = 0.540).
Recently, Zhang et al. 210 reported 3D-QSAR modeling and docking studies of
arylphthalazines and 2-((1H-azol-1-yl)methyl)-N-arylbenzamides-based VEGFR2
inhibitors. Two statistically relevant 3D-QSAR models (CoMFA r 2 = 0.969; q2 = 0.671;
CoMSIA r2 = 0.936, q2 = 0.608) were developed to predict the biological activity of new
compounds. Analogs were designed using molecular fragment replacement was virtually
screened using Glide (docking) and further evaluated with CoMFA prediction, and
ADMET analysis. Fourty four novel N-(pyridin-4-ylmethyl)aniline derivatives were
developed using this approach.
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In 2009 Du et al.212 reported the CoMFA and CoMSIA analysis studies of a series
of 82 selective inhibitors of KDR with either a quinazoline, naphthalene or phenyl core
scaffold. Docking studies were performed to explore the binding mode and predict the
bioactive conformations of the 82 inhibitors in KDR. Two conformer-based alignment
strategies were employed to construct reliable 3D-QSAR models. The docked conformerbased alignment strategy gave the best 3D-QSAR models (r2 = 0.936 and 0.961; q2 =
0.546 and 0.715). The information obtained from these models were coupled with
molecular modeling studies to design 8 novel highly potent (low nanomolar), selective
inhibitors of KDR.

A.3. COLCHICINE SITE BINDING ANTI-MITOTIC AGENTS

A.3.1. Tubulin and microtubules

Figure 34. Structure of a microtubule. 213

Every nucleated cell in the human body contains two similar spherical proteins –
α and β-tubulin (Figure 34), each with a molecular weight of 50 kDa. Through a series of
events these proteins come together to form an α-β heterodimer about 8 nm in length.
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Two molecules of energy rich guanosine triphosphate (GTP) are bound to these
heterodimers. While one of these GTP molecules is tightly bound and cannot be removed
without denaturing the heterodimer, the other GTP molecule is freely exchangeable with
unbound GTP.The α-β tubulin heterodimers, at 37 °C can combine in a head-to-tail
arrangement to give a long protein fiber composed of alternating α and β-tubulin, known
as protofilaments. The protofilaments can group together to form a C-shaped protein
sheet, which then curls around to give a pipe-like structure known as a microtubule.
Microtubules typically consist of 12 or 13 protofilaments with an external diameter of
around 24 nm and internal diameter of around 15 nm. A number of proteins, known as
Microtubule Associated Proteins (MAPs), each with a mass of about 200 kDa, are
associated with microtubules. Although the exact purpose of MAPs is unclear,
microtubules form faster in their presence and the MAPs appear to protect the
microtubule from agents which induce depolymerization, namely low temperature and
Ca2+ ions.
Another key component associated with microtubules are Microtubule Organizing
Centers (MTOCs). MTOCs form a focus for microtubule growth, and all microtubules
initially begin to grow from one of these centers. A major type of MTOC in most cells is
known as the cell center or centrozome which contains two major microtubule structures
known as centrioles. It seems that the organization of microtubule growth at the MTOC
involves a third type of tubulin protein known as γ-tubulin. The presence of γ-tubulin is
vital for microtubule growth in vivo. 214 It appears that an aggregation of γ-tubulin occurs
on the surface of the MTOC, perhaps forming a ring or short cylinder and that this
aggregate acts as the site of nucleation for incoming α-β tubulin heterodimers.
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After formation, microtubules are not static. They exist in an equilibrium with
heterodimers continuously adding to one end of the microtubule [known as the “plus” (+)
end], and leaving at the other [the “minus” (–) end]. A fine balance of this equilibrium
and the resting control of the length of the microtubules is vital for numerous cellular
functions.
Microtubules are required for a number of crucial cellular functions. Amongst the
known functions are the maintenance of cell shape, cellular transport and transporting
organelles around the interior of the cell. The most crucial function of microtubules
however is the formation of the mitotic spindle which eventually makes replication
possible.
A. 3. 2. Role of microtubules in mitosis:215
One of the most complex and demanding processes undertaken by the human body
is the process of cell division. During this process, the cell must completely duplicate its
internal components including its DNA, such that it can form two identical daughter cells.

Figure 35. Different stages of mitosis 216

Once the duplication of the internal components is complete, the cell assembles
its DNA into two identical sets of chromosomes and separates them into two individual
parcels at opposite ends of the cell, ready to form the two nuclei in the daughter cells.
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Following the separation of the new nuclei, the cell is ready to split into two new
daughter cells. This ordering and relocation of the genetic material is known as mitosis.
Mitosis can be divided into five separate processes (Figure 35)
The first phase of mitosis is termed prophase. In prophase, the DNA in the
nucleus is replicated and two sets of genetic material are organized into two identical
daughter sets of chromosomes. Towards the end of prophase, the microtubules needed for
cell division begin to form and grow toward the newly formed chromosomes. The bundle
of microtubules this generates in the cellular space is known as the mitotic spindle. This
spindle grows concomitantly from two MTOCs, which begin to separate and migrate
toward opposite ends of the cell.
In the next stage, the prometaphase, the nuclear envelope rapidly disintegrates and
the microtubules attach themselves to the chromosomes at a point known as the
kinetochore, which is the center of the chromosomes.
The cell then enters metaphase. In this phase, the chromosomes gradually become
arranged in the plane between two centrozomes. After an accurate arrangement of these
chromosomes, the cell abruptly enters anaphase. The daughter chromosomes then start to
separate slowly as the microtubules depolymerize, slowly drawing and guiding the
daughter chromosomes to opposite ends of the cell.
The final phase of cell division is the telophase. During this phase, the
chromosomes reach the opposite ends of the cell and new nuclear envelopes form around
them. This completes the process of mitosis, and it only remains for the cytoplasm
surrounding the nuclei to begin to divide, in a process known as cytokinesis. The nuclei
thus become partitioned, finally dividing to give two new daughter cells. The importance

65

of microtubules in mitosis makes them an attractive target for the drug development
process.

A. 3.3. Microtubule dynamics:
The functional diversity of microtubules is dependent on their intrinsic non
equilibrium dynamic behaviors.217-226 Microtubules exhibit two types of dynamic
behaviors; one such behavior is called “dynamic instability” (Figure 36). In dynamic
instability, microtubule ends alternate between phases of growth and shortening. 218-221, 223226

Figure 36. The process of dynamic instability.213

Usually microtubules display slow growth phases and rapid shortening phases.
They also undergo a pause phase when there is no detectable growth or shortening at the
microtubule ends. The transition from a growth or a pause state to a shortening phase is
called a “catastrophe” and the transition from a shortening phase to a growth or a pause
state is called “rescue”. The transition frequencies are important for regulating
microtubule dynamics for diverse cellular tasks. 219-226
66

Figure 37. The process of treadmilling.221

Another type of dynamic behavior exhibited by microtubules is called “treadmilling”
(Figure 37). Treadmilling involves a net growth at the plus end and a net shortening at the
minus end of the microtubule.217, 223
A microtubule population may exhibit one or both of these dynamic behaviors.
The polymerization dynamics of microtubules depends on the loss or gain of a stabilizing
cap composed of either tubulin-GTP or tubulin-GDP-Pi at their ends.219, 226 The assembly
dynamics in finely regulated by several proteins including stabilizing microtubuleassociated proteins (MAPs) such as a tau, MAP1, MAP2, MAP4, and destabilizing MAPs
such as stathmin.219, 223, 226-228 Microtubule dynamics is specifically important for the
proper attachment and movement of chromosomes during various stages of the mitotic
phase.219-221 Suppression of microtubule dynamics in cells by small molecule inhibitors
block the cell division machinery at mitosis leading to cell death. Hence, the assembly
dynamics of microtubule represents a potential target for finding anticancer drugs. The
small molecule inhibitors usually imitate the action of the natural regulators of
microtubule assembly and disassembly kinetics making these agents a valuable tool for
probing the roles of microtubule dynamics in different cellular processes.
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A.3.4. Antimitotic agents:
Agents which induce cell death by inhibiting the function of microtubules are
known as antimitotics. Cancer cells are relatively sensitive to these drugs relative to
normal cells because many cancer cells divide more frequently than normal cells and thus
frequently pass through a stage of vulnerability to mitotic poisons. However it is likely
that other mechanisms, such as expression of a variety of checkpoint and apoptotic
proteins and differential uptake and retention drugs, can also distinguish the differential
responses of tumor and normal cells to antimitotics drugs.

Figure 38. Antimitotic agents.229

Antimitotics can be broadly divided into three distinct classes. The vinca alkaloids
are represented by vincristine, vinblastine, vindesine, and vinorelbine (Figure 38). These
agents bind to β-tubulin and interfere with proper mitotic spindle formation by preventing
the normal dynamics of polymerization of microtubules. Vinca alkaloids are important
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agents for the treatment of leukemias, lymphomas, small cell lung cancer, and other
cancers.221, 230 These agents are also designated as microtubule-destabilizing agents or
microtubule polymerization inhibitors or depolymerizaers.
The second class of antimitotics, taxanes, is represented by paclitaxel and
docetaxel (Figure 38). Paclitaxel binds to β-tubulin as well; however its location is
different from that of the vinca alkaloids. As determined in tubulin protofilaments in Zn
sheets, paclitaxel binds on the inside surface of the β-subunit of microtubules.231, 232
Paclitaxel induces an increase in microtubule polymerization, thereby interfering with
spindle microtubule dynamics and preventing the progression of cell division. Hence the
agents of this class are termed microtubule-stabilizing agents or polymerizing agents. The
taxanes are important for the treatment of breast, lung, ovarian, head and neck, and
bladder carcinomas among others.
The third class is typified by colchicines (Figure 38) and comprises of a diverse
collection of small molecules that bind to the colchicines binding site. Although the
nature of this binding site has not been determined with certainty, insights into
colchicines binding sites are available from homology models. 233 The agents from this
class also act by an inhibition of microtubule polymerization like the vinca alkaloids, but
along with a difference in the binding site, their depolymerization mechanism is also
different from the vinca alkaloids. The combretastatins are a class of drugs that bind to
the colchicine binding site and are in clinical trials as antitumor agents.221
The epothilones, produced by the myxobacterium Sorangium cellulosum, and
discovered in the early 1990s,234-236 are a novel class of microtubule-stabilizing agents.
These agents bind at the taxane binding site and have a mechanism of action similar to
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the taxanes. Epothilones A and B were found to have potent in vitro anticancer activity,
including activity against taxane-resistant cell lines, but their in vivo activity is modest,
owing to issues such as poor metabolic stability and unfavourable pharmacokinetics.234236

Synthesis and testing of more than 300 semisynthetic epothilone analogs with the aim

of addressing these issues led to the identification of ixabepilone.234-236 Ixabepilone has
been approved for the treatment metastatic breast cancer in 2007. 237, 238 The epothilones
are considered more superior to taxanes because their less susceptibility to multiple
mechanisms of resistance.236, 239
It has been observed that most microtubule-targeted drugs, including Vinca
alkaloids, taxanes and epothilones, also act by suppression of microtubule dynamics in
cells at concentrations that inhibit proliferation and block mitosis. 240
Microtubule targeted drugs can act by two more mechanisms. One is to inhibit the
process of angiogenesis, and the second is to shut down existing tumor vasculature by
vascular disruption.240

A. 3.5. Structure of tubulin:
A detailed description of the tubulin protein helps in the analysis of the mechanistic
aspect of drug-tubulin interaction. Electron crystallography of zinc-induced 2D crystals of
tubulin were obtained with a 6.5 Å resolution.241 The atomic model of αβ tubulin dimer
was further obtained at 3.7 Å resolution by using electron crystallography of zinc-induced
tubulin sheet. In this structure, α and β share an identical principal structure: each monomer
is composed of a core of two β sheets surrounded by α helices.
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Figure 39. X-ray crystal structure of tubulin. (PDB ID: 1JFF92)

The monomer has a compact structure and can be divided into three functional
domains: the amino-terminal domain possessing a nucleotide-binding region, an
intermediate domain where lies the taxol-binding site, and the carboxy-terminal domain
comprising the binding site for motor proteins. The model was further refined using
standard X-ray crystallography methods (Figure 39).231 This model indicates that each
monomer was composed of an N-terminal, nucleotide-binding domain, having six
parallel β-strands (S1-S6) alternating with helices (H1-H6). Loops T1-T6 connect each
strand with the strand of the next helix in binding the nucleotide. This structure provides
a detailed description of lateral contacts in zinc-sheets and the nucleotide and taxol
binding sites.
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A.3.6. Colchicine binding site on tubulin:

Figure 40: Stereoview. X-ray crystal structure of colchicine (green) bound to tubulin. (PDB:
3UT5).242 Secondary structures colored according to chain. (pink: chain A; blue: chain B). Binding
site amino acids highlighted and colored according to chain.

The colchicine site is located mostly in the β-subunit of tubulin and is bordered by
helix 7, which contains Cys β241, and helix 8. The colchicine binding site has a volume
of ~10 Å × ~10 Å × 4−5 Å and borders the α-tubulin monomer, which forms crucial
interactions at the colchicine site, notably the loop connecting sheet 5 and helix 5.242 Thr
α179 and Val α181 interact with colchicine and have also been implicated in formation of
hydrogen bonds with other colchicine site binding agents (CSAs). The molecular volume
and electrostatic properties of the colchicine site play an important role on the
conformations of colchicine site binding agents and have proved useful in elucidating the
bioactive conformations of colchicine site binding agents. 243
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A.3.7. Binding mode prediction of colchicine site agents

Figure 41:243 Stereoview. Predicted binding modes of CSAs (blue) in the colchicine binding pocket
of tubulin.

Nguyen et al.243 used docking studies to determine the binding modes of a set of 15
structurally diverse colchicine site inhibitors. These binding models were subsequently
used to construct a comprehensive, structure-based pharmacophore that was used in
combination with molecular dynamics simulations to understand binding interactions at
the colchicine site of tubulin. Figure 41243 shows the superimposition of the docked
structures of the 15 CSAs. It was observed that, despite the variations in the chemical nature
of the 15 CSAs, the CSAs occupied similar Cartesian space in the binding site. The overlaid
poses of the compounds can be bisected by two planes (Figure 42) which are roughly at 45
degrees to each other. Since the typical CSA contains a biaryl system, the relative
orientations of the two aryl chains in each molecule lie roughly along the two bisecting
planes. However, even among CSAs that lack the biaryl system, the binding architecture
was conserved.
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Figure 42:243 Stereoview. Overlay of docked poses of CSAs (blue) form roughly a 45o angle
between the bisecting planes in the colchicine binding pocket.

All 15 CSIs were found to form a hydrogen bond with the thiol group of
Cys241. In addition, a hydrogen bond was observed between 11 CSIs and the backbone
NH of Val181. Molecular modeling further indicated that hydrogen bonds could be
formed between the CSIs and backbone NH atoms of Ala250, Asp251, and Leu252
due to conformational changes in the loop or due to the presence of structured water
molecules. Thr179 was found to be involved in the formation of hydrogen bonds with 4
CSIs in their binding models.243 This publication highlighted the important residues in the
colchicine binding pocket and the key interactions with these residues. Further, the
authors utilized this data to build a 7-point pharmacophore model (three hydrogen bond
acceptors, one hydrogen bond donor, two hydrophobic centers, and one planar group) of
the binding of these CSIs in the colchicine binding site. It was observed that none of the
15 CSIs individually utilized all the 7 points, suggesting that binding affinities for each
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chemotype could be improved by appropriate chemical modifications that target the
pharmacophore point not utilized by that chemotype.

A.3.8. Targeting multidrug resistance in cancer:
The emergence of multidrug resistance (MDR) is a major concern for
contemporary cancer chemotherapy. There are three major mechanisms by which MDR
usually occurs.244 First, decreased uptake of water-soluble drugs such as folate
antagonists and nucleoside analogs which require transporters to enter cells; second,
various changes in cells that affect the capacity of cytotoxic drugs to kill cells, including
alterations in cell cycle, increased repair of DNA damage, reduced apoptosis and altered
metabolism of drugs. The third, and the major mechanism responsible for MDR, is the
increased efflux of hydrophobic cytotoxic drugs mediated by a family of energydependent transporters, known as ATP-binding cassette (ABC) transporters. ABC
transporters were discovered in 1973 by Dano et al.245 They noticed the active outward
transport of the drug daunomycin in multidrug-resistant Ehrlich ascites tumor cells.
Subsequent work indicated that the ‘reduced drug permeation’ in multidrug-resistant cells
is associated with the presence of a cell surface glycoprotein known as P-glycoprotein
(Pgp).246 Based on the presence of specific conserved sequences, Pgp was recognized to
be an ABC transporter protein.247-251
A human small-cell lung cancer cell line (H69), that shows resistance to
doxorubicin without increasing expression of Pgp was later discovered. 252 Similar to the
cells overexpressing Pgp, H69 displayed deficient combined drug accumulation and
resistance to a broad range of anticancer agents, including vinca alkaloids and
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epipodophyllotoxins.253, 254 Analysis indicated the increased expression of a novel ABC
transporter, termed multidrug resistance associated protein 1 (MRP1). 255

Figure 43. Agents reversing Pgp mediated MDR in cancer. 229, 256

Several agents have been investigated for their ability to reverse Pgp mediated
MDR. Examples include verapamil,257 cyclosporine A ,257 tariquidar258, 259 and
zosuquidar260 (Figure 43). Excellent reviews of efforts to reverse MDR inhibitory effects
have been recently published.261, 262 Although a large number of compounds possessing
diverse chemical structures and biological activities, are able to reverse MDR, there are
currently no approved reversal agents available in the clinic.263, 264 A 3.80 Å X-ray
crystal structure of Pgp has recently been reported.265 In order to address MDR, new
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agents that possess antimitotic and antitumor activities without substrate activity for Pgp
are higly coveted and would be useful antitumor agents as single agents or in
combination with other antitumor agents.

A.3.9. Antimitotic agents that also reverse tumor resistance:
The following section will provide a brief summary of 6,5-fused bicyclic agents
that act as antimitotic agents by targeting the colchicine binding pocket of tubulin.
Gangjee et al.266 reported a series of pyrrolo[2,3-d]pyrimidine antimitotics 63 –
68 (Figure 44) that are not substrates for Pgp and MRP1, and in addition, are capable of
reversing the resistance exhibited by tumors to vinblastine and vincristine.

Figure 44.266 Pyrrolo[2,3-d]pyrimidines that act as antimitotics and reverse resistance exhibited
by tumors to vinblastine and vincristine.

Compounds 63-68 were originially designed as potential RTK inhibitors. These
compounds displayed antitumor activity against a variety of tumor cells but were not
inhibitors of RTKs. In the NCI 60 cell line panel compound 63, displayed potent
inhibition (GI50 of single to two digit nanomolar) of 16 tumor cell lines. Compound 68,
the corresponding debenzylated analog of 63, showed a loss of potency of 100- to
10,000- fold against 56 tumor cell lines, suggesting that the N7-benzyl group is critical
for activity. The 2-OMe and 3-OMe analogs, 64 and 65 respectively GI50 values in the
micromolar - millimolar range against the tumor cells in culture. The 4-OMe compound
66 had GI50s similar to 65, indicating the importance of the 3- and/or 5-OMe groups. The
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unsubstituted phenyl analog 67 displayed GI50 in the millimolar or lower range for 52
tumor cells. The corresponding debenzylated analogs of 64-67 showed substantially
decreased activity against the 60 cell line panel. The buiological evaluation results from
this series indicated that a 3,4,5-triOMe substitution along with the presence of the N7benzyl moiety was important for potent inhibitory activity against tumor cells in culture.
An NCI COMPARE analysis267 was performed to elucidate the possible
mechanism of action of 63. The first five compounds whose cell type selectivity profile
showed the highest Pearson correlation coefficients (PCC)268, 269 with 63 were all wellknown antimitotic agents. Hence compound 63 was suspected to exhibit its actions
microtubule targeting agent. It was later determined from binding studies that 63 bound
to tubulin at a site different from the colchicines, Vinca, and taxane binding sites.
Compound 63 exhibited subnanomolar IC50s against both, drug sensitive (cell
lines that do not express Pgp or MRP1) as well as drug resistant tumor cell lines (cell
lines that express Pgp or MRP1)229 indicating that it is not a substrate for Pgp and MRP1.
The 2-OMe substituted compound 66 displayed best results when tested for its ability to
reverse Pgp mediated MDR to vinblastine. Compounds 64, 65 and 67 also induced a dose
dependent sensitization of the tumor cells to vinblastine. The ability of compound 63 to
display similar effect could not be determined due to its high cytotoxicity.
Gangjee et al.270 reported compounds 69 – 72 (Figure 44) as a part of a series of
compounds based on 63 that varied in the nature of substitutions on the phenyl ring of the
5-phenylethyl side chain in an attempt to optimize the antitubulin, antitumor, and
resistance reversal activities of the parent compounds. All the compounds in this series
showed two-digit micromolar IC50 values against MCF-7 cells. Compound 69 was the
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most potent compound against MCF-7 cells with an IC50 value of 15 M. Compounds 70
– 72 inhibited Pgp activity, making NCI/ADR cells more sensitive to vinblastine.
Compound 72 remarkably caused sensitization of tumor cells resistant due to both Pgp
and MRP1 and is the only known pyrrolo[2,3-d]pyrimidine analog that has native
antitumor activity and restores sensitivity of antitumor agents to tumor cells resistant to
these agents due to both Pgp and MRP1.

Figure 45.271 5,7-disubstituted-4-methyl-7H-pyrrolo[2,3-d]pyrimidin-2-amines as microtubule
inhibitors

Since the N7-benzyl moiety of 63 (Figure 44) was shown to be critical for its
antitumor activity,266 Gangjee et al.271 designed 73 – 78 (Figure 45) as a part of an effort
to optimize antitumor potential and Pgp modulatory effects. In these compounds 73 – 75
methoxy substitutions were varied on the 7-benzyl moiety while maintaining the 3,4,5triOMephenethyl substitution at C5. Compounds 76 – 78 were designed as 5-thio
analogs, with the large sulfur atom anticipated to mimic the two-carbon bridge of 73 and
its analogs. In addition, the 5-thio linker permits the side chain phenyl distance
somewhere between a one- and two-carbon-atom bridge and also cause a decrease in the
C–S–C angle (98 °) compared to a C–C–C angle (109 °), consequently altering the
orientation of the C5 phenyl ring relative to the parent scaffold.
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Compounds 73–75 with variations in the N7-benzyl moiety showed potent
inhibition (IC50 = 0.6 to 3 μM) in the cytotoxicity assay. Compound 74 was the most
potent compound in this series and was four-fold less potent than the standard compound
Taxol. In addition, 74 demonstrated a significant increase in the intracellular
accumulation of [3H] Taxol in the drug accumulation assay for determination of Pgp
activity.
The 5-thiosubstituted compounds 76–78 demonstrated micromolar cytotoxicity in
JC cells. . Compound 76 was the most potent compound in this series (IC50 = 4 μM)
Compound 77 displayed an increase in the intracellular accumulation of [ 3H] Taxol below
its IC50. Compound 78, which had a 3,4,5-triOMe substitution on the phenyl ring at the
C5 phenyl and the benzyl at the N7 position was inactive in the biological evaluation
studies.

Figure 46.50 Pyrrolo[2,3-d]pyrimidines and cyclopenta[d]pyrimidines that act as antimitotic
agents

As a part of a continued effort to develop 6,5-fused bicyclic agents that act as
antimitotic agents, Gangjee et al.50, 272 reported the synthesis and biological evaluation of
pyrrolo[2,3-d]pyrimidines (79 and 80) (Figure 46) and cyclopenta[d]pyrimidines ((±)-81
- (±)-85) (Figure 46). Compounds 79 and (±)-81.HCl displayed potent antiproliferative
activities in the nanomolar range with (±)-81.HCl displaying significantly higher potency
than 79. Mechanistic studies showed that both 79 and (±)-81.HCl cause loss of cellular
microtubules and inhibit the polymerization of purified tubulin. Additionally, both
compounds inhibit colchicine binding and were thus shown to exhibit their antimitotic
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activity by binding to the colchicine site on tubulin. Gangjee et al.273 later reported the
synthesis and evaluation of the individual R- and the S-enantiomers of 81. It was seen that
both enantiomers were potent inhibitors of cell proliferation and caused microtubule loss
in cells and mitotic arrest. Additionally, both compounds inhibited purified tubulin
assembly and the binding of [3H]colchicine to tubulin, with (S)-81 being about twice as
potent as (R)-81. However, in cytotoxicity studies against 60 tumor cell lines, (S)-81 was
10- to 88-fold more potent than (R)-81.
Gangjee et al.274 designed 82 – 85 (Figure 47) as regioisomers of the pyrrolo[2,3d]pyrimidine 79 and as as isostere of the cyclopenta[d]pyrimidine (±)-81.HCl. The
compounds in this series were designed to explore the nature and importance of
substitutions at the 2-, N4- and 6- positions and/or the aniline ring of the pyrrolo[3,2d]pyrimidine scaffold.

Figure 47.274 Pyrrolo[3,2-d]pyrimidines as antimitotic agents

Compound 85 was designed as a conformationally restricted analog of 82. The
biological evaluation studies indicated that 82 (MDA-MB-435 IC50 = 96.6 nM), was
about 2-times more potent than its lead 79 (MDA-MB-435 IC50 = 183 nM).Compound 82
(EC50 = 1.2 M), was about 5-times more potent than 79 (EC50 = 5.8 M) in the
microtubule depolymerization assay. In addition, the 4'-OMe moiety and the methyl
group attached to the nitrogen bridge both were crucial for activity. Removal of the 2-Me
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group of 82 caused a 2-fold reduction in cytotoxicity in the MDA-MB-435 cell line but
only a small loss in ability to cause microtubule disassembly in the A-10 cells. Addition
of a 6-Me group of 82 gave 84 which displayed a 3-fold improvement in activity against
MDA-MB-435 cells (IC50 = 1.2 M) and improved ability to disassemble microtubules in
the A-10 cells 5-6-fold (EC50 = 0.22 M). The conformationally restricted analog 85
showed 3-fold improved potency in the cellular assays compared to 82 and equivalent to
84. Compounds 84 and 85 showed equivalent activity against microtubule
depolymerization (EC50 = 0.22 M), but were significantly less active than the standard
combretastatin A4 (EC50 = 0.0131 M),. Compounds 84 and 85 were shown to inhibit
binding of colchicine to tubulin, thus suggesting that they likely act as an antimitotic by
binding to the colchicine site on tubulin.

A.4. COMPARITIVE MOLECULAR FIELD ANALYSIS (CoMFA)
A.4.1 Topomer CoMFA
A topomer is defined as as a molecular fragment having a single internal geometry
or ‘‘pose’’ (conformation plus position).275 Topomer CoMFA applies conventional CoMFA
methodologies to fragments attached to a central core. By definition, fragments have at
least one open valence (point of attachment to the core), which can be fixed in Cartesian
space and can be used to align other fragments. 275, 276 Topomers provide a reproducible
way of generating consistent, automatic alignments. Additionally, ligands assembled from
shape similar fragment sets tend to share biological activities. 277 Topomer CoMFA is thus
insensitive to the initial conformation of the molecules, which is a major limitation of
traditional CoMFA methodology.277 Several recent reports have shown the utility of
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topomer CoMFA in lead optimization studies278, design of novel highly active analogs of
targets such as HIV-1 integrase279, HCV NS5b polymerase,280 renin inhibitors281 and other
targets.282, 283
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B. CHEMICAL REVIEW
This section will review synthetic approaches to the following ring systems –
B. 1. Pyrido[2,3-d]pyridines
B. 2. Pyrrolo[2,3-d]pyrimidines
B. 1. Pyrido[2,3-d]pyridines
B. 1. 1. Condensation of substituted 2-amino-3-cyano pyridines with guanidine
B. 1. 2. From substituted pyridines
B. 1. 3. Miscellaneous methods
B. 2. Pyrrolo[2,3-d]pyrimidines
B. 2. 1. From substituted pyrimidines
B. 2. 2. From substituted pyrroles
B. 2. 3. Miscellaneous methods
B. 1. Pyrido[2,3-d]pyridines
B. 1. 1. Condensation of substituted 2-amino-3-cyano pyridines with guanidine
Piper et al. 284 reported the synthesis of a series of pyrido[2,3-d]pyridines as 5deaza analogues of aminopterin, MTX, folic acid and N10-methylfolic acid. The key
intermediate for the synthesis of these analogs were 2,4-diamino-5-substitutedpyrido[2,3-d]pyrimidine-6-carboxaldehydes 92a-b (Scheme 1). Intermediate 90 was
synthesized starting from condensation of malononitrile 87 with 86 to readily give the
salt 88 which, on reflux in presence of conc. HCl gave the substituted chloropyridine
intermediate 89. Reductive dechlorination of 89 afforded 90. Alternate methods285 for the
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dechlorination of 89 reported in the literature involve treatment of 89 with PdCl2 and
DMF with NEt3 as the HCl scavenger.
Scheme 1: Synthesis of pyrido[2,3-d]pyridines from substituted pyridines284

The pyrido[2,3-d]pyridine scaffolds were synthesized by condensation of
substituted pyridines 90 with guanidine.HCl under basic conditions at reflux in EtOH in
95% yield. The key intermediate 92a-b were obtained from the nitriles 90a-b by
treatment with Raney Ni in aqueous formic acid. Compounds 92a-b were reduced by
NaBH4 to the corresponding alcohols 93a-b. The 6-bromomethyl compounds 94a-b were
synthesized by bromination of 94a-b dibromotriphenylphosphorane.

Scheme 2:Synthesis of pyrido[2,3-d]pyrimidines from 2,4-dioxopyrimidine
derivitives.286
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Su et al. 286 reported the synthesis of intermediate 93a (Scheme 2) by amination
of the acetylated intermediate 99b using a method developed by Vonbruggen and
Krolikiewicz.287 The pyrido[2,3-d]pyrimidine scaffold was synthesized from the
methoxymethyl (MOM) -protected uracil 95b by condensation with guanidine.HCl.
Diazotization of the 7-NH2 group of 96 followed by reflux with conc. HCl provided the
7-chloro compound 97a which was subjected to reductive dehalogenation using Pd/C and
H2 to give 97b. Reduction of the cyano group of 97b over Raney Ni in Ac2O/AcOH
afforded the acetamide 98a in high yield.

Scheme 3: Synthesis of 6-methyl pyrido[2,3-d]pyrimidine-2,4-diamine

DeGraw et al.288 reported the synthesis of 6-methylpyrido[2,3-d]pyrimidine-2,4diamine 102 (Scheme 3) by condensation of 2-amino-5-methylnicotinonitrile 100 with
guanidine.HCl 102 under basic conditions at reflux in 56% yield.
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Scheme 4: Synthesis of 7-substituted-pyrido[2,3-d]pyrimidine-6-carbonitrile-2,4diamines

Recently, Soliman et al.289 reported the synthesis of 2,4,7-triaminopyrido[2,3d]pyrimidine-6-carbonitriles 104a-b (Scheme 4) by condensation of 2-amino-6chloropyridine-3,5-dicarbonitrile 89a284, 290 or 2-pyrrolo-6-chloropyridine-3,5dicarbonitrile 103289 with guanidine at reflux using DMF as the solvent in 76% and 66%
yields respectively.

Scheme 5: Synthesis of N6-substituted-benzylpyrido[2,3-d]pyrimidine-2,4,6-triamine

Davoll et al.291 reported N6-substituted-benzylpyrido[2,3-d]pyrimidine-2,4,6triamines 109a-b (Scheme 5) as folate antagonists and as antimalarial agents. The key
intermediate 106 was synthesized by condensation of nitropyridine compound 105 with
guanidine at reflux in EtOH in 85% yield. In situ reduction of 106 with Raney Ni afforded
the amino intermediate 107 which was condensed without isolation with benzaldehydes
108 to afford the target compounds 109a-b in 50 – 58% yield.
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Scheme 6: Synthesis of 6-(ethylthio)-5-substituted-pyrido[2,3-d]pyrimidine-2,4,7triamine

Pochat et al.292 described the synthesis of 6-(substituted thio)-5-substitutedpyrido[2,3-d]pyrimidine-2,4,7-triamines 112a-b (Scheme 6) from substituted pyridines
111a-b by condensation with guanidine under reflux in 58 – 63% yields. Intermediates
111a-b were synthesized by condensation of E-3-bromo-2-(4-substituted thio)-2butenenitriles 110293 with 2-cyanoacetamide to form an intermediate 2-pyridone
derivative and further conversion by reaction with POCl3.
Scheme 7: Synthesis of pyrido[2,3-d]pyrimidine-6-carboxaldehyde-2,4-diamine from 2cyanothioaceamide

Harrington et al.294 reported the synthesis of 92a in quantitative yields by the
hydrolysis of intermediate 115 (Scheme 7) by formic acid at room temperature.
Compound 115 was synthesized by a six-step sequence starting from 2cyanothioacetamide 113 to form the substituted pyridine intermediate 114. Compound
114 condensed with guanidine in MeOH at reflux to give 115 in 79% yield.
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B. 1. 2. From substituted pyrimidines:
Scheme 8: Synthesis of pyrido[2,3-d]pyrimidine-6-carboxaldehyde-2,4-diamine from
2,4,6-triaminopyrimidine

Temple et al.295 described the synthesis of pyrido[2,3-d]pyrimidine-6carboxaldehydes 119 (Scheme 8) and 92a from 2,4,6-triaminopyrimidine. The reaction
involved a one-pot generation of triformylmethane 117 using the method described by
Arnold, A.296 Bromoacetic acid 115 is treated by a Vilsmeier reagent, initially at 0 oC and
then at 90 oC for 10 h to give the complex 116 which is decomposed under basic
conditions to give triformylmethane 117. Analogous to condensation of 4aminopyrimidines with malonaldehyde derivitives to give pyrido[2,3-d]pyrimidines, the
reaction of 117 with 2,6-diamino-4-oxopyrimidine 118a or 2,4,6-aminopyrimidine 118b
in water at reflux afforded 119 or 92a in 82% and 33% yields respectively. The presence
of the formyl group on 92a was confirmed by condensation with 2,4dinitrophenylhydrazine to give the corresponding hydrazone. In addition, the aldehyde
moiety of 119 was oxidized to the corresponding acid 120 by potassium permanganate.
The 1HNMR of 120 prepared by this method matched the previously reported 297 1HNMR
spectra of 120 prepared by an independent route. Although the mechanism for the
condensation is unknown, it was speculated that the initial reaction occurs through the
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electrophilic attack of one formyl group of 117 with the 5-position of the pyrimidine ring
or with the 6-NH2 group on the pyrimidine to give the Schiff base followed by
cyclization of the resulting intermediate to give the pyrido[2,3-d]pyrimidine scaffold.

Scheme 9: Synthesis of 6-methyl pyrido[2,3-d]pyrimidine-2,4-diamine

Gangjee et al.298 reported the synthesis of 6-methylpyrido[2,3-d]pyrimidine-2,4diamine 102 (Scheme 9) by condensation of 2,4,6-triaminopyrimidine 118b with
methacroline 121 using piperidine acetate as a catalyst in AcOH at reflux in 57% yield.

Scheme 10: Conversion of pyrimidine-2,4,6-triamine to di-tert-butyl (6bromopyrido[2,3-d]pyrimidine-2,4-diyl)dicarbamate

Gangjee et al.299 300 described the synthesis of di-tert-butyl (6-bromopyrido[2,3d]pyrimidine-2,4-diyl)dicarbamate 124 (Scheme 10) by the condensation of freshly
prepared bromomalonaldehyde 122 with pyrimidine-2,4,6-triamine. Upon further
reaction with pivalic anhydride leads to the formation of the dipivaloylated compound
123 in 29% overall yield after silica gel chromatography. Rosowski et al.301 described the
coupling of commercially available benzyl zinc chlorides with 123 using a catalytic
amount (2.5 mol%) of 1,1-bis(diphenylphosphino)ferrocene]
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dichloropalladium(II)·CH2Cl2 in THF. The desired compounds 124 were obtained in
<40% overall yield from 123 after deprotection of the pivaloyl groups using NaOH in
MeOH and recrystallization from mixtures of aqueous DMF, mixtures of MeOH, EtOH,
and H2O, or mixtures of DMF, EtOH, and H2O.
B. 1. 3. Miscellaneous methods
Scheme 11: Synthesis of N-(4-amino-6-bromopyrido[2,3-d]pyrimidin-2-yl)pivalamide

Taylor et al.302 reported the conversion of the N-(6-bromo-4-oxo-3,4dihydropyrido[2,3-d]pyrimidin-2-yl)pivalamide 125 (Scheme 11) into N-(4-amino-6bromopyrido[2,3-d]pyrimidin-2-yl)pivalamide 127. The two-step process conversion of
the 4-oxo moiety of 125 into its triazole derivate 126 by reaction with 4H-1,2,4-triazole
using phosphorodichloridic acid as a catalyst. The triazole moiety then acts as a good
leaving group for the subsequent attack by NH3 to afford the target compound 127 in
excellent yields.

Scheme 12: Synthesis of various 4-N-substituted 7-(2-trifluoromethyl-phenyl)pyrido[2,3d]pyrimidine-2,4-diamines
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Cheung et al.303 recently published the conversion of N-(4-oxo-7-(2trifluoromethyl)phenyl) -3,4-dihydropyrido[2,3-d]pyrimidin-2-yl)pivalamide 128
(Scheme 12) into an intermediate 4-chloro derivative by reaction with POCl3 which was
subjected to reaction with various primary and secondary alkylamines under microwave
irradiation to afford various 4-N-substituted 7-(2-trifluoromethyl-phenyl)pyrido[2,3d]pyrimidine-2,4-diamines 129a-d in around 60% yield over two steps.

Scheme 13: Synthesis of (S)-2-(4-(((2,4-diaminopyrido[2,3-d]pyrimidin-6yl)methyl)amino) benzamido)pentanedioic acid

Harrington, P. J.294 described the synthesis of the classical compound 131
(Scheme 13) by the reductive alkylation of 92a using benzoyl glutamic acid and
NaBH3CN as the reducing agent. The one-step reaction involves the formation of an
intermediate Schiff base by the condensation of the aldehyde moiety of 92a and the
aniline of 130 which is reduced by NaBH3CN. The reaction however, was slow (10 days)
with poor yields (33%). Subsequent ester hydrolysis afforded the target compound 131 in
86% yield.
Scheme 14: Synthesis of 6-(thioarylmethyl)pyrido[2,3-d]pyrimidine-2,4-diamines
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Gangjee et al.80 reported the synthesis of 6-(thioarylmethyl)pyrido[2,3d]pyrimidine-2,4-diamines 133a-c by the nucleophilic displacement of the bromide of 94a
with various arylthiols using K2CO3, NEt3 or NaH as the base in 6-20% yields. All three
bases were effective at promoting the nucleophilic displacement by the thiols.
B. 2. Pyrrolo[2,3-d]pyridines
B. 2.1 From substituted pyrimidines:
Scheme 15. Synthesis of pyrrolo[2,3-d]pyrimidines from 4(alkoxycarbonylmethylamino)-6-chloro-2-methylthiopyrimidine-5-carbonitriles

Using the common intermediate 4-(alkoxycarbonylmethylamino)-6-chloro-2methylthiopyrimidine-5-carbonitriles 135a, b (Scheme 15) Tumkevicius et al.304 reported
the synthetic route for pyrrolo[2,3-d]pyrimidine-6-carboxylates 136 and 137. Reaction of
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4,6-dichloro-2-methylthiopyrimidine-5-carbonitrile 134 with methyl or ethyl esters of
glycine and sarcosine at room temperature in the presence of NEt3 provided the
corresponding 4-(alkoxycarbonylmethylamino)-6-chloro-2-methylthiopyrimidine-5carbonitriles 135a-b. The reaction of mercaptoacetic acid esters with 6-chloropyrimdine5-carbonitriles under basic conditions and subsequent cyclization has been previously
reported to afford thienopyrimidine derivatives. 305-311 It was found that compounds 135a
when heated at reflux under basic conditions afforded the pyrrolo[2,3-d]pyrimidine
derivative 136, instead of the corresponding thieno[2,3-d]pyrimidine. Displacement of
the chloride of 136 by mercaptoesters under basic conditions provided the target 137 in
80% yield.
Scheme 16. Synthesis of pyrrolo[2,3-d]pyrimidines from 6-amino-2(dimethylamino)pyrimidin-4-(3H)-one

Gangjee et al.312 reported the synthesis of 140a (Scheme 16) by the condensation
of an aqueous solution of α-chloroacetone 139a in presence of NaOAc in 70% yield. Linz
et al.313 also reported the synthesis of a series of pyrrolo[2,3-d]pyrimidines from 6amino-2-(dimethylamino)pyrimidin-4(3H)-ones 138b (Scheme 16). Compound 138b on
treatment with α-chloroacetone 139a or α-chloroacetaldehyde 139b provided the
corresponding pyrrolo[2,3-d]pyrimidines 140a or 140b in 68% and 75% yields
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respectively. This methodology has been previously used in the synthesis of several
substituted pyrrolo[2,3-d]pyrimidines 114, 179, 180, 314, 315 and has been utilized in the
synthesis of pemetrexed, which is a multitargeted antifolate.316 Secrist et al.315 reported
the generation of a furo[2,3-d]pyrimidine-2,4-diamine derivative in addition to the
pyrrolo[2,3-d]pyrimidin-4-one when this methodology was used.
Yoneda et al.317 reported the reaction of α-bromoketones with 6-amino-1,3dimethyluracil to form pyrrolo[2,3-d]pyrimidines. When DMF was used as the reaction
solvent the desired pyrrolo[2,3-d]pyrimidine product was obtained. However, when the
same reaction was repeated in acetic acid instead of DMF, a mixture of pyrrolo[2,3d]pyrimidine (major product) and furo[2,3-d]pyrimidine (minor product) was obtained.
Scheme 17. Synthesis of pyrrolo[2,3-d]pyrimidines by Paal Knorr reaction

Kidwai et al.318 reported the solid supported synthesis of a series of twelve 1,3,7triaryl-6-phenyl-2-thioxo-1,2,3,7-tetrahydropyrrolo[2,3-d]pyrimidin-4-ones 145 from
readily accessible N,N-disubstituted thiobarbaturic acids 141 using microwave conditions
by the Paal Knorr reaction (Scheme 17). Compound 141 on treatment with phenacyl
bromide 142 over basic alumina or anhydrous potassium carbonate as solid support under
microwave irradiation affords the corresponding 1,4-diketone intermediates 143 which
were cyclized with various aromatic/heteroaromatic amines 144 over acidic
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alumina/montmorillonite K-10 clay to provide the target compounds 145 in 65-88%
yields.
Scheme 18. Synthesis of 6-butyl-2,4-dimethyl-7H-pyrrolo[2,3-d]pyrimidine

Rodriguez et al.319 reported the synthesis of 6-butyl-2,4-dimethyl-7H-pyrrolo[2,3d]pyrimidine 147 (Scheme 18) by Sonogashira coupling and 5-endo-dig cyclization. The
precursor 146 was prepared by a Sonogashira coupling reaction. Compound 146 on
treatment with excess potassium tert-butoxide in polar solvent NMP undergoes 5-endodig cyclization to afford the target 147 in 61% yield.
Scheme 19: Synthesis of pyrrolo[2,3-d]pyrimidines using Fisher-Indole reaction

Taylor et al.320 synthesized methyl 4-(2-(2-amino-6-methyl-4-oxo-4,7-dihydro3H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl)benzoate 151 (Scheme 19) by a Fisher-Indole
approach. Reaction of 2-amino-6-hydrazinylpyrimidin-4(3H)-one 148 with one
equivalent of methyl 4-(4-oxopentyl)benzoate 149 in 2-methoxyethanol under reflux
afforded the requisite intermediate 150 in 84% yield. The key cyclization step was
accomplished by thermolysis of 150 in refluxing diphenyl ether under argon. This
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regioselective process provided the pyrrolo[2,3-d]pyrimidine 151 in 61% yield.
Gangjee et al.229 reported the synthesis of 7-benzyl-4-methyl-7H-pyrrolo[2,3d]pyrimidin-2-amine 156 (Scheme 20) from 2-acetylbutyrolactone 152 by a modification
of an earlier synthetic route described by Badaway et al.321 Heating 152 and guanidine
carbonate at reflux in absolute EtOH in the presence of either NEt 3 or NaOMe afforded
intermediate 153 in 57 - 69% yields.
Scheme 20. Synthesis of 7-benzyl-4-methyl-7H-pyrrolo[2,3-d]pyrimidin-2-amine

Reaction of 153 by heating with phosphorus oxychloride at reflux gave the
corresponding chloro derivative 154 which was condensed with benzylamine under basic
conditions at reflux in n-BuOH to give the tetrahydro pyrrolo[2,3-d]pyrimidine 155 in
50% yield. Oxidation of 155 with MnO2 afforded 7-benzyl-4-methyl-7H-pyrrolo[2,3d]pyrimidin-2-amine 156 in 50% yield.
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B. 2. 2. From substituted pyrroles
Scheme 21. Synthesis of pyrrolo[2,3-d]pyrimidines from 1-benzyl-2-amino-3cyanopyrroles

Traxler et al.186 reported the synthesis of a series of pyrrolo[2,3-d]pyrimidines
(Scheme 21) starting from substituted α-hydroxy ketones 158. Ketones 158 were
converted to substituted 1-benzyl-2-amino-3-cyanopyrroles 159 by treatment with
benzylamine at reflux in toluene and further condensation with malononitrile in toluene at
reflux. Cyanopyrroles 159 underwent condensation with 85% formic acid at reflux to
provide the target 160a-e.
Scheme 22. Conversion of a 2-amino pyrroles to pyrrolo[2,3-d]pyrimidines

De Rosa et al.322 reported the conversion of a 2-amino pyrroles to the
corresponding pyrrolo[2,3-d]pyrimidines 167 (Scheme 22). The 2-amino pyrroles 161 on
reaction with 2,4,6-tris(trifluoromethyl)-1,3,5-triazine 162 gives the pyrrolo[2,398

d]pyrimidine 167. According to the proposed mechanism, (Scheme 22) the initially
formed unstable intermediate 163 converts to a zwitterion intermediate 164 in presence of
base triethylamine. Compound 164 undergoes a cascade reaction to provide 165. The
cycloadduct 165 eliminates ammonia to form pyrrole 166, which undergoes a retro DielsAlder reaction to give the target pyrrolo[2,3-d]pyrimidines 167.
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C. STATEMENT OF THE PROBLEM
The present section deals with design and synthesis of inhibitors and molecular modeling
studies in the following four areas:
C.1. ANTIFOLATES
A. Selective pjDHFR inhibitors as anti-opportunistic agents and molecular modeling
studies in pjDHFR and tgDHFR homology models.
B. Development of a tgTS homology model, docking studies and topomer CoMFA
studies with bicyclic tgTS inhibitors.
C.2. RECEPTOR TYROSINE KINASE INHIBITORS
C. Inhibition of multiple receptor tyrosine kinases as potential antiangiogenic agents,
molecular modeling studies of multiple kinase inhibitors with EGFR, VEGFR2
and a PDGFR- homology model and topomer CoMFA studies with bicyclic
RTK inhibitors.
C.3. COLCHICINE SITE BINDING ANTI-MITOTIC AGENTS
D. Novel colchicine site tubulin binding agents as antimitotic agents and molecular
modeling studies of colchicine site binding agents reported in our laboratory.
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C.1. ANTIFOLATES
Selective pjDHFR inhibitors as anti-opportunistic agents and molecular modeling
studies in pjDHFR and tgDHFR homology models.
C.1.1. Selective pjDHFR inhibitors as anti-opportunistic agents
Opportunistic infections caused by Pneumocystis jirovecii can cause pneumocystic
pneumonia (PcP) in immunocompromised patients.323, 324 P. jirovecii is the most prevalent
infection in HIV-AIDS patients324 and is a growing concern in non-HIV patients.325
Current therapeutic agents for treatment of PcP include SMX (targeting DHPS) and TMP
(targeting DHFR). Although TMP-SMX is an effective first line therapy, the combination
is limited by severe toxicity.325 Additional limiting factors include lack of selectivity (TMP
or PTX), development of resistance (sulfa drug component), require co-administration of
leucovorin (with TMQ or PTX) and have shown limited utility in severe cases
(TMQ/leucovorin). Attempts to treat PcP with TMP alone either therapeutically or
prophylactically often fail. Results from studies attempting to link this failure to mutations
in pjDHFR have been inconclusive.51, 326, 327 Thus, agents that combine the potency of TMQ
or PTX and the selectivity of TMP in a single agent are highly desirable in a clinical setting.
Agents reported in the literature thus far lack these characteristics and remain a significant
challenge in the treatment of opportunistic infections. Additionally, single agents that can
target multiple opportunistic infectious agents would be highly desirable and would
significantly reduce the patient burden, increase compliance and reduce the treatment costs
by reducing the need for multiple treatment regimens.
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Figure 48. Sequence alignment of hDHFR (DYR_HUMAN) 1, pjDHFR (Q9UUP5_PNEJI)328
and pcDHFR (DYR_PNECA).329

Pneumocystis carinii (pc) had been previously misidentified as the causative agent
on pneumoscystis pneumonia in humans. Cody et al.48 reported that pcDHFR and pjDHFR
differ by around 38% in their sequence (Figure 48) with 79 residues differing overall. Of
these, 9 residues differ in the active site of pjDHFR compared to hDHFR and pcDHFR. 91
Current DHFR inhibitors such as TMP and MTX were shown to inhibit pcDHFR and
pjDHFR with different IC50s.48

C.1.1.1 Design of novel inhibitors: 2,4-Diamino-6-(arylaminomethyl)pyrido[2,3d]pyrimidines as pjDHFR inhibitors

Figure 49. Structures of 168 and 169.

Gangjee et al.74, 80, 330-334 and others44, 284, 301, 335-338 have previously reported DHFR
inhibitors of diverse chemical classes that target DHFR from opportunistic infections such
as P. carinii, P. jirovecii, and T. gondii in an attempt to design agents that can target the
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DHFR from these species potently and selectivlely over hDHFR. Gangjee et al.333 reported
a series of pyrido[2,3-d]pyrimidine compounds in which the 2,5-dichlorophenyl
substituted compound 168 (Figure 49) was the most selective inhibitor of both pcDHFR
and tgDHFR. In this series compounds with an electron withdrawing group in the side
chain phenyl ring afforded better inhibition of pcDHFR than compounds with electron
donating groups. Additionally, Cody et al.48, 91 reported that 168 displayed potent and
selective inhibition of pjDHFR (Ki pjDHFR = 2.7 nM, Ki hDHFR = 24.4 nM; 9.0 fold
selective) while showing approximately 2.3 fold selectivity for pcDHFR (Ki pcDHFR =
6.3 nM). In the same series, the 3,4,5-trichlorophenyl substituted pyrido[2,3-d]pyrimidine
169 (Figure 49) also showed good selectivity and potency against pjDHFR. Very recently
Cody et al.91 have reported the X-ray crystal structures of 168 with hDHFR and its Q35K
and Q35S/N64F variants.
While several high resolution X-ray crystal structures of pcDHFR have been
reported in the literature, there are no reported crystal structures of pjDHFR. Hence,
molecular modeling studies of 168 in pjDHFR required the generation of a homology
model.

Figure 50. Stereoview. Docked pose of 168 in the active site of the homology model for pjDHFR.
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Figure 50 shows the docked pose of 168 in the active site of a pjDHFR homology
model generated using pcDHFR as the template. In this pose the protonated N1 and 2-NH2
of 168 interact in an ionic bond with Asp32. This bidentate ionic bond with a conserved
acid residue has been observed in most DHFR crystal structures. 31, 32, 40, 53 The 4-NH2
moiety forms hydrogen bonds with the backbone of Ile10 and Ile123. The pyrido[2,3d]pyrimidine scaffold is stabilized by a pi-stacking interaction with Phe36 and with side
chain carbon atoms of Met33 and Leu25. The 2’,5’-dichlorophenyl side chain of 168
resides in a hydrophobic pocket formed by the side chains of Leu25, Thr61, Ser64, Leu65,
Pro66 and Ser69. In this model the 2’-Cl of 168 is oriented towards the side chain OH of
Thr61 (3.4 Å) and could form stabilizing Cl…O halogen bonding339 interactions. Alternate
low energy docked poses (not shown) of 168 (within 2 kcal/mol of the pose described in
Figure 50) show the formation of a hydrogen bond between the side chain NH of 168 and
Ile123 in the pocket.

Figure 51. Stereoview. Docked pose of 168 in the pjDHFR homology model (Cody et al.91)

Cody et al.91 recently reported the docked conformation (Figure 51) of 168 in a
pjDHFR homology model. With the exception of the orientation of the 2’,5’-diCl phenyl
side, the model described in Figure 50 matches the model reported by Cody et al. In their
model Cody et al.91 reported that the 5’-Cl atom is oriented toward Pro66 and Ser69. Poses
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similar to the one described by Cody et al. were also obtained within 1 kcal/mol of the
docked pose of 168 described in Figure 50 above.

Figure 52. Structures of target compounds 170 – 180

Hence compounds 170 – 180 (Figure 52) were designed to determine the effect of
the nature and position of the electron withdrawing substituents on the terminal phenyl ring
on potency and selectivity against pjDHFR.
The 2’,5’-diF substituted compound 170 was previously synthesized in the Gangjee
laboratory.340 Biological evaluation studies for 170 indicate that it displays excellent
potency (pjDHFR IC50 0.057 M) and selectivity (around 280-fold) for pjDHFR over
hDHFR. Hence, bulk synthesis of 170 was performed to enable testing in an animal model.
Docking studies performed with 170 – 180 in the pjDHFR homology model
indicate that the proposed compounds retain the key binding interactions seen in the docked
conformation of the lead 168. An example of the docking is shown in Figure 51, which
shows the docked conformation of 173 in the pjDHFR homology model.
Figure 53 shows the docked pose of the target 173 in the active site of a pjDHFR
homology model generated using pcDHFR as the template. In this pose the protonated N1
and 2-NH2 of 173 interact in an ionic bond with Asp32.
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Figure 53. Stereoview. Docked pose of 173 in the active site of the homology model for pjDHFR.

This bidentate ionic bond with a conserved acid residue has been observed in most
DHFR crystal structures. The 4-NH2 moiety forms hydrogen bonds with the backbone of
Ile10 and Ile123. The pyrido[2,3-d]pyrimidine scaffold is stabilized by a pi-stacking
interaction with Phe36 and with side chain carbon atoms of Met33 and Leu25. The 2’,6’dichlorophenyl moiety of 173 resides in the hydrophobic pocket formed by the side chains
of Leu25, Thr61, Ser64, Leu65, Pro66 and Ser69. In contrast to 168, the 2’,6’dichlorophenyl ring of 173 shows a different orientation relative to the pyrido[2,3d]pyrimidine scaffold. This is probably a reflection of the influence of the substitution
pattern on the ring and/or interaction of the halogen atoms with the amino acids in the
binding pocket and could perhaps influence the binding potency and/or selectivity of these
compounds against pjDHFR. The docked conformations of other compounds in this series
are presented in the Appendix.

106

C.1.1.2. Design of novel inhibitors: 2,4-Diamino-6-(thioarylmethyl)pyrido[2,3d]pyrimidines and 2,4-Diamino-6-(oxoarylmethyl)pyrido[2,3-d]pyrimidines as
pjDHFR inhibitors

Figure 54. Structures of compounds 181 – 185

Piper et al.341 and Queener et al.342 reported 181 (Figure 54) as a highly selective
compound against both pcDHFR and tgDHFR with selectivity ratios (vs rlDHFR) of 25.9
and 319, respectively. However 181 lacked potency against pcDHFR (9.5 mM) and
tgDHFR (0.77 mM). In addition, 181 lacked potency in cell culture, possibly due to a
combination of weak DHFR inhibition and lack of cell penetration. Gangjee et al.343 later
designed 182 – 184 (Figure 54) as 2,4-diamino-8-deaza analogues of 181. cLogP
calculations of 182 – 184 indicated that these compounds should display improved cell
penetration due to improved clogP values compared to 181. Compound 182 displayed
marginally improved potency compared to 181 against pcDHFR and tgDHFR but lacked
the selectivity of 181, thereby demonstrating the importance of N8 for selectivity. Gangjee
et al.344 later reported 185 (Figure 54) as a part of a series of analogs designed to explore
the importance of the N5 for potency and/or selectivity towards pcDHFR or tgDHFR.
Compound 185 displayed potent inhibition of pcDHFR (IC50 5.9 M, about 2-fold better
than TMP), it lacked selectivity against hDHFR (IC50 5.9 M). The inhibitory activity of
185 against pjDHFR is not known. Compound 185 is an analogue of 168, which displayed
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potent and selective inhibition of pjDHFR.

Figure 55. Structures of target compounds 186 – 191

Target compounds 186 – 191 (Figure 55) were designed as analogs of 185 to study
the influence of the nature of the linker on pjDHFR activity. Sulfur is a larger atom than
oxygen and the C-S-C bond angle is shorter (98 o) as compared to a C-O-C bond angle
(112 o). Thus replacing the sulfur atom of 185 with oxygen in 189 changes the bond angle
between the 6-position CH2 and the terminal substituted phenyl ring and could change the
orientation of the terminal phenyl ring relative to the heterocycle that could affect the
bound conformation of these molecules in the pjDHFR active site. Compound 187 and
190 were designed based on 169 which showed excellent potency and selectivity against
pjDHFR in the study reported by Cody et al.48 Compounds 188 and 191 were designed
based on the 2,5-diF containing compound 170 which has displayed excellent potency
and selectivity against pjDHFR and would serve to examine the influence of the nature of
the linker on potency and/or selectivity for pjDHFR. Docking studies were carried out for
186 – 191 with the homology model of pjDHFR in order to predict their binding modes
in the enzyme.
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Figure 56. Stereoview. Docked pose of 186 in the active site of the homology model for pjDHFR.

Figure 56 shows the docked conformation of 186 in the pjDHFR homology
model. In this pose 186 retains the key interactions of the pyrido[2,3-d]pyrimidine
scaffold with the enzyme as seen with the lead compound 168 (Figure 50). The key
difference between the docked pose of 186 compare to 168 lies in the orientation of the
2,5-dichlorophenyl moiety in the hydrophobic pocket. For 186, the chlorine atoms can
form hydrophobic interactions with the side chain atoms of Leu25, Leu65, Thr61 and
Ile123 in the binding pocket, but are not seen to interact with the hydroxyl group of
Thr61where it could form halogen bonds. 345, 346 These differences in orientation of the
terminal substituted phenyl ring of these compounds could, perhaps, influence the
interactions of these compounds in pjDHFR and could, in turn, affect their potency
and/or selectivity against pjDHFR. The docked conformations of other compounds in this
series are presented in the Appendix.
C.1.1.3. Molecular Modeling Studies with pjDHFR
C.1.1.3.1 Development of a homology model
There are no known crystal structures of pjDHFR. Hence a homology model was
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generated in order to perform modeling studies. A Basic Local Alignment Search Tool
(BLAST)347 search of the primary amino acid sequence of pjDHFR indicated high
homology (61%) between pjDHFR and pcDHFR (Figure 48). In addition, multiple high
resolution (< 2 Å) crystal structures of pcDHFR bound to various non classical antifolates
have been reported in the PDB (details of selected crystal structures in Table 1). Hence,
homology models for pjDHFR were built based on the X-ray crystal structure of
pcDHFR. Recently Cody et al.91 reported the generation of a homology model of
pjDHFR using the crystal structure of pcDHFR as a template. After validation, the
pjDHFR homology model was used for docking studies of compounds 170 – 180 (Figure
52), compounds 186 – 191 (Figure 55) and other compounds synthesized by Gangjee et
al.
C.1.1.3.2 Docking studies with 6-substituted amino-pyrido[2,3-d]pyrimidine-2,4diamines 192b-e with a pjDHFR homology model
Table 8: Structures and inhibitory concentrations (IC50, nM) of 192a72 and 192b-e348 against
pjDHFR, pcDHFR and hDHFR

Comp.
192a
192b
192c
192d
192e

R1

R2

pjDHFR pcDHFR
84
H
Me 2.2
75.5
H
H
300
2300
3,4,5-triF Me 4.1
228
3,4,5-triF H
866
8980
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hDHFR
8500
57
193
148
3070

Hu/Pj
25.6
0.6
35.4
3.5

Gangjee et al.348 described the synthesis and biological evaluation of 192b-e
(Table 8). Transposition of the 5-methyl group of PTX and TMQ to the N9-position in
pyrido[2,3-d]pyrimidine analogs improves potency as well as selectivity against pathogen
DHFR.330 Compound 192a72 exhibits 100-fold selectivity for pcDHFR over hDHFR. A
crystal structure of 192a with hDHFR showed that the N9-methyl moiety is not in
hydrophobic contact with any hydrophobic side chain of hDHFR. 349 In addition,
molecular modeling studies of 192a in pcDHFR suggested that the N9-methyl moiety of
192a interacts with both Ile123 and Ile65 of pcDHFR. These additional interactions of
the N9-methyl moiety of 192a with pcDHFR compared to the lack of similar interactions
with hDHFR could be responsible, in part, for the increased potency and selectivity of
192a for pcDHFR compared with hDHFR. Hence compounds 192b-e (Table 8) were
designed by incorporating an N9-methyl group. This methyl group was anticipated to
interact with Ile123 of pcDHFR (and also with the corresponding Ile123 of pjDHFR) and
not with the shorter Val115 in hDHFR in a similar way as that of 192b.Hence docking
studies were carried out with 192b in the pcDHFR active site (PDB: 1LY389) using
LeadIT 1.3.0.131
The N-Me compounds 192b and 192d displayed potent and selective pjDHFR
inhibitory activity.348 The corresponding N-desmethyl compounds 192c and 192e
displayed significantly less potency against pjDHFR. 348 Docking studies were performed
in the pjDHFR homology model in an attempt to provide a molecular basis for the
observed activities of 192b-e in pjDHFR and the importance of the N-Me group in 192b
and 192e.
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C.1.1.3.3. Docking studies with TMP and 168 in wild type and F36C L65P double
mutant pjDHFR models:
Table 9350: Ki values (M) against wild type pjDHFR and F36C L65P double mutant resistant
pjDHFR

Trimethoprim
168

Wild type pjDHFR (M)
3.5 x 10-8
2.7 x 10-9

F36C L65P Mutated pjDHFR (M)
1.7 x 10-5
2 x 10-8

Recent studies have demonstrated the emergence of drug-resistant forms of TMP
related to mutations in pcDHFR and pjDHFR .91, 338 One such mutation that confers
resistance in pjDHFR towards TMP is the F36C L65P double mutation. 91 DHFR
inhibitors that retain their activity or atleast show reduced sensitivity to these mutations
are, therefore, of immense interest. The results in Table 9 show that 168 only loses around
10-fold inhibitory activity in the F36C L65P double mutant as compared to the 1000-fold
loss in inhibitory activity exhibited by TMP for the same mutation. There are no crystal
structures of pjDHFR. Thus it was of interest to develop a homology model of the double
mutant form of pjDHFR in order to perform docking studies with 168 in an attempt to
provide a molecular basis for the observed activity of 168 against the double mutant
pjDHFR.

C.1.1.3.3. Docking Studies of 5-Methyl-6-(substituted thio)-thieno[2,3-d]pyrimidine2,4-diamines 193a-j with a pjDHFR homology model
Compound 193d (Table 10) was synthesized as part of a series of 5-methyl-6(substituted thio)-thieno[2,3-d]pyrimidine-2,4-diamines 193a-j (Table 10) by Gangjee et
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al.351 and displayed 0.27 M inhibition (IC50) of pjDHFR. While 193a-j were not selective
for pcDHFR over rlDHFR, compound 193f displayed 6-fold selectivity for pjDHFR over
hDHFR and about 20-fold selectivity for pjDHFR over rlDHFR. Docking studies were
hence performed for 193f to provide a possible molecular basis for the observed
activity/selectivity of 193f against pjDHFR to be utilized for the design of potent and
selective inhibitors of pjDHFR.
Table 10: Biological activities of 193a-j against pcDHFR, tgDHFR, rlDHFR, pjDHFR and
hDHFR

Compound
193a
193b
193c
193d
193e
193f
193g
193h
193i
193j
TMQ
TMP

Inhibition concentration (IC50, µM)
pcDHFR
tgDHFR
pjDHFR
rat
6.7
2.7
1.4
liver
7.3
3.2
8.6
1.9
0.63
0.88
5.2
2.4
4.9
1.7
0.25
0.33
1.63
0.282
0.27
1.64
5.9
0.99
1.8
4.9
3.4
7.1
4.4
5.1
5
10.2
2.99
3
0.042
0.01
0.00
12
2.8
180
3

Selectivity ratio (IC50/IC50)
rl/pc
rl/tg rl/pj
0.21
0.52
1.18
2.69
0.46
1.4
0.94
2.04
0.19
1.32
1
5.82 20.42
0.31
1.85
1.45
2.09
1.14
0.98
0.29
1
0.07
0.3
14
65

Inhibitory concentrations (IC50, µM) against isolated DHFRa and selectivity ratiosb of 194a-j
a

These assays were carried out at 37 °C under conditions of substrate (90 µM dihydrofolic acid)

and cofactor (119 µM NADPH) in the presence of 150 mM KCl.
rlDHFR)/(IC50 pcDHFR) and (IC50 rlDHFR)/(IC50 tgDHFR)]
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b

Selectivity Ratios [(IC50

C.1.2. Molecular Modeling Studies with tgDHFR
C.1.2.1. Development of a homology model

Figure 57. Sequence alignment of DHFR from T. gondii (DRTS_TOXGO), T. cruzi
(DRTS_TYRCR), Cryptosporidium hominis (Q5CGA3_CRYHO), Plasmodium falciparum
(A7UD81_PLAFA), Leishmania major (DRTS_LEIMA) and hDHFR (DYR_HUMAN) using
Protein BLAST (BLASTP).352

DHFR is a part of a bifunctional DHFR-TS complex in T. gondii and in other
apicomplexan parasites such as Plasmodium falciparum, P. vivae and Cryptosporidium
hominis (Ch). While X-ray crystal structures have been resolved for DHFR segment of P.
falciparum and C. hominis, when this work was initiated there were no known crystal
structures of tgDHFR. Hence a homology model was generated in order to perform
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modeling studies, to better understand the molecular reasons for potency and selectivity of
analogs and to provide a template for drug design for T. gondii inhibitors. Multiple high
resolution (< 2 Å) crystal structures of the DHFR segment of C. hominis have been reported
in the PDB. Hence, a homology model for tgDHFR was built based on the X-ray crystal
structure of ChDHFR. Very recently Pacheo Homen et al.353 reported the generation of a
homology model of tgDHFR using the crystal structure of P. vivae DHFR as a template.
After validation, the tgDHFR homology model was used for docking studies of compounds
194a-c351 (Table 11) synthesized in our laboratory.
C.1.2.2. Molecular Modeling Studies of 2-Amino-4-oxo-5-arylthio-substituted-6propyl thieno[2,3-d]pyrimidines 194a-c with a tgDHFR homology model
Table 11: Structure of 194a-c and inhibition concentration (IC50, µM) against isolated TS.351

DHFR (µM)
Human
E. colic T. gondiid
17.0
> 17 (0) 0.017
194a
> 2.6 (0) > 2.6 (0) 0.023
194b
2.2
> 25 (17) 0.02
194c
e
PMX
6.6
230
0.43
PDDFf
1.9
23
0.22
0.02
0.0088
0.033
MTX
6.8
Trimethoprim >340 (22) 0.01
Compound

DHFR selectivity (rl/tg)

b

a

1000
>113
110
15
8.6
0.6
>50

The percent inhibition was determined at a minimum of four inhibitor concentrations within 20%

of the 50% point. The standard deviations for determination of 50% points were within ± 10% of
the value given. b Kindly provided by Dr. J. H. Freisheim, Medical College of Ohio, Toledo, OH. c
Kindly provided by Dr. R. L. Blakley, St. Jude Children’s hospital, Memphis TN. d Kindly provided
by Dr. Karen Anderson, Yale Univerisy, New Haven CT. e Kindly provided by Dr. Chuan Shih, Eli
Lilly and Co. f Kindly provided by Dr. M. G. Nair, University of South Alabama.
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Compounds 194a-c (Table 11) were reported by Gangjee et al.351 as DHFR
inhibitors in an attempt to explore the effects of substitution at the 6-position of the
thieno[2,3-d]pyrimidine scaffold. DHFR inhibitory activities of 194a-c showed that these
compounds exhibit remarkable selectivities among DHFRs from different species.
Compound 194a in this series showed a 1000-fold selectivity against tgDHFR over hDHFR,
which is better than any compound known in the literature. It was therefore of interest to
perfom docking studies to elucidate the probable binding mode and the molecular reasons
for the observed selectivity for compounds in this series in order to design potent and
selective agents against tgDHFR.

Development of a tgTS homology model, docking studies and topomer CoMFA studies
with bicyclic tgTS inhibitors.
C.1.3.1. Molecular modeling studies of 2-Amino-4-oxo-5-arylthio-substituted
pyrimido[4,5-b]indoles 194d-j with T. gondii thymidylate synthase

Table 12. Inhibitory concentrations of 194a-d (IC50, µM) against TS and DHFR
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Compd
194d
194e
194f
194g
194h
194i
194j
194k
RTX
PMX
MTX

Human
0.21
2.7
0.27
1.3
0.26
0.12
1.8
0.75
0.38
9.5
29

E.
>23
coli
>27
>2.7
>25
>14
1.4
>2.6
25
5.7
76
90

TS
T.
0.012
gondii
0.13
0.027
0.13
0.1
0.1
0.65
0.23
1.8
2.8
18

Selectivity
17.5
(h/tg)
20.8
10
10
2.6
1.2
2.8
3.3
0.2
3.4
1.6

Human
>27
>32
(11%)
>27
(30%)
>30
(13%)
28
(19%)
>27
>31
>30
0.21
6.6
0.022

DHFR
E. coli
>27
>32
(20%)
27
(30%)
>30
28
(12%)
27
>31
>30
0.016
230
0.0066

T.
14
gondii
13
2.7
11
2.8
2.2
4.6
15
0.17
0.46
0.011

Compounds 194d-k (Table 12) were reported by Gangjee et al.354 as tricyclic TS
inhibitors to explore the effects of substitution at the 5-position of the pyrimido[4,5b]indole scaffold. TS inhibitory activities of 194d-k showed that these compounds were
highly potent for tgTS. Compound 194e in this series showed a 21-fold selectivity against
tgTS over hTS, which is better than standards PMX and RTX used in this study. TS is a
highly conserved enzyme across species, thus the selectivity of 194d-g was a novel an
unexpected discovery. To our knowledge these were the first and only tgTS selective and
potent inhibitors known. It was therefore of interest to perfom docking studies to elucidate
the probable binding mode and reasons for the selectivity for compounds in this series
particularly to design potent and selective tgTS inhibitors.
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C.1.4. Topomer CoMFA Analysis of Bicyclic Inhibitors of T. gondii Thymidylate
Synthase
Topomer CoMFA applies conventional CoMFA methodologies to fragments
attached to a central core. By definition, fragments have at least one open valence (point
of attachment to the core), which can be fixed in Cartesian space and can be used to align
other fragments.275, 276 Topomers provide a reproducible way of generating consistent,
automatic alignments. Additionally, ligands assembled from shape similar fragment sets
tend to share biological activities.277 Topomer CoMFA is thus insensitive to the initial
conformation of the molecules, which is a major limitation of traditional CoMFA
methodology.277

Figure 58: General structures of bicyclic non-classical pyrrolo[2,3-d]pyrimidines and thieno[2,3d]pyrimidines for topomer CoMFA analysis

Gangjee et al. have reported the synthesis and biological activities against hTS
and tgTS of > 100 bicyclic non-classical pyrrolo[2,3-d]pyrimidines312, 355-365 and
thieno[2,3-d]pyrimidines351, 359, 362, 363, 366 containing a 2-amino-4-oxo moiety (Figure 58).
Of these, 85 compounds were identified for which discrete biological activities against
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hTS and/or tgTS were reported in the literature. There are no previous literature reports of
CoMFA studies of these compounds.
While X-ray crystal structures have been resolved for non-classical inhibitors
bound to hTS, there were no crystal structures of tgTS when this work was initiated,
either in its apo form or bound to inhibitors. In the absence of structural data for tgTS, it
was of interest to develop a homology model of tgTS in order to perform docking studies
to gain an understanding of the binding modes of tgTS inhibitors. Additionally, a topomer
CoMFA analysis of the bicyclic inhbitors could be used in order derive a 3D-QSAR
model which could be used in conjunction with docking studies to gain an understanding
of the binding modes of these bicyclic compounds in tgTS and/or provide insight into the
molecular basis of selectivity of some inhibitos for tgTS over hTS in order to rationally
design potent and selective tgTS inhibitors.
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C.2. RECEPTOR TYROSINE KINASE INHIBITORS
Inhibition of multiple receptor tyrosine kinases as potential antiangiogenic agents,
molecular modeling studies of multiple kinase inhibitors with EGFR, VEGFR2 and
a PDGFR- homology model and topomer CoMFA studies with bicyclic RTK
inhibitors
C.2.1. Inhibition of multiple RTKs
Receptor tyrosine kinases play a critical role in tumor development. Antitumor
agents that inhibit tumor induced angiogenesis by the inhibition of RTKs have been
discussed in details in section A. 1. There are multiple reports in the literature regarding
the use of RTK inhibitors as monotherapy367, 368 for cancer or the use of multiple RTK
inhibitors either as single agents or in combination with other chemotherapeutic
agents.369-371
Single RTK targeting provides specificity and and reduces off-target inhibition of
other RTKs and could thus lower toxicity. However, the use of RTK inhibitors as
monotherapy has been associated with development of alternate signaling pathway(s) to
continue angiogenesis, thereby and developing resistance to specific RTK inhibitors. 150
Additionally, crosstalk has been implicated between EGFR and other growth factor
receptors involved in tumor development, aiding tumor survival. 372 It has been shown
that inhibition of VEGF signaling had no effect on the growth of large tumors because
other angiogenic factors like bFGF can substitute for VEGF. 373 Treatments targeting a
single RTK would be a less attractive option for tumor control in most patients. Thus
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there is now a paradigm shift towards targeting multiple RTKs involved in angiogenesis
rather than targeting single RTKs.Targeting multiple RTKs overcome possible resistance
and reduce alternative pathways for tumor growth. 369, 370
Since RTKs are present in endothelial cells (VEGFR, PDGFR), tumor cells
(FGFR, PDGFR), and pericyctes/ smooth muscle cells (FGFR, PDGFR), inhibition of
more than one RTK can provide synergistic effects against solid tumors. 150 Combination
therapy targeting VEGFR-2 (endothelial cell inhibition) along with PDGFR-β inhibition
(pericytes inhibition) has been shown to increase the antiangiogenic effect even in the
often intractable, late state of solid tumors. 374, 375 Thus targeting both VEGFR-2 and
PDGFR-β simultaneously is a desirable goal for antiangiogenic agents that have
cytostatic and perhaps cytotoxic activity.
C.2.2. Design and Synthesis of 2-Amino-4-substituted-6-arylmethyl-7H-pyrrolo[2,3d]pyrimidines as RTK inhibitors
Table 13: Structure and IC50 (μM) values of kinase inhibition, A 431 cytotoxicity and
inhibition of CAM assay

Comp
195
196

Ar
2-MePh
2,4- diCl
PD153035
AG 1295
SU5416
Cisplatin

EGFR
9.19±1.8
0.23 ±0.06
0.24 ±0.042

VEGFR 2
0.25 ±0.04
28.11 ±9.9

PDGFR-
>50
17 ±5.6

A431
1.21 ±0.42
2.8 ±1.1
12.6 ±2.9

CAM
1.21 ±0.23
10.8 ±3.2

19.2 ±4.2
8.2

0.032 ±0.005

6.2 ±1.6
2.43 ±0.32
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Gangjee et al.179 reported N4-(3-bromophenyl)-6-(substituted benzyl)
pyrrolo[2,3-d]pyrimidines, 195-196 (Table 13) as a part of a series of compounds that
target multiple RTKs. These compounds were tested in tumor cells known to over express
high levels of EGFR, VEGFR2 and PDGFR-. Compound 195 exhibited toxicity against
A431 cells (cell lines that depend on EGFR for survival) 376 at values 10-fold better than
the standard compound SU5416 used in this assay. In addition, 195 also demonstrated a
VEGFR-2 inhibition 10-fold better than the standard agent semaxinib. Compound 196
inhibited EGFR and A431 cell lines at concentrations which were comparable to or 5-fold
better than the standard SU5416. Thus, these compounds demonstrated multiple RTK
inhibitory potency in a single molecule. It was also determined that the potencies and/or
selectivities of compounds in this series were sensitive to the substitution patterns at
either the 4- and/or 6-positions of the pyrrolo[2,3-d]pyrimidine scaffold.

Figure 59:183 Proposed binding modes for pyrrolo[2,3-d]pyrimidine RTK inhibitors
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Figure 59183 depicts the general pharmacophore model for the binding of 196a-b
in the ATP binding pocket of RTKs. In this general pharmacophore model it was
envisioned that compounds like 195-196 could bind in Mode I where the 2-NH2, N3 and
the 4-NH groups could form hydrogen bonds to the hinge region of RTKs or in Mode II
(flipped mode, formed by rotating the compound 180o around the 2-NH2-C2 axis) where
the hinge region hydrogen bonds are formed by the 2-NH2 and pyrrole NH groups or in
Mode III (flipped mode, formed by rotating the compound 180 o around the 2-NH2-C2
axis) where the hinge region hydrogen bonds are formed by the 2-NH2, N1 and pyrrole
NH groups. These binding modes permit the 4-bromophenyl and the 6-benzyl groups to
occupy either Hydrophobic Site I or the Sugar binding pocket depending on the binding
mode. Additional binding modes where the 4- or the 6-position substituent on the
heterocycle occupy Hydrophobic Site II can be envisioned. The presence of such multiple
binding modes could explain, in part, the multiple RTK inhibition observed with 195-196
and other analogs.
C.2.2.1. Design of 2-Amino-4-substituted-6-aryl pyrrolo[2,3-d]pyrimidines
Compounds 197-210 (Figure 58) were designed based on 195-196 as the lead
compounds. These compounds contain, in place of the 4-NH linker group of 195-196, an
isosteric replacement such as S (197, 198), CH2 (201, 202) or O (205, 206). This
replacement of the linker atom with a CH2, O- or an S- linker alters the hydrogen
bonding nature of the atom (neutral or donor vs. acceptor) at the 4-position.
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Figure 60: Proposed pyrrolo[2,3-d]pyrimidine RTK inhibitors

In Mode I of the proposed binding model of 195-196 in the ATP binding site
(Figure 59), the 4-NH moiety forms hydrogen bonding with the hinge region of ATP.
Thus, replacement of the 4-NH moiety with either a CH2- or S- or O- would be expected
to affect potential hydrogen bonding in the binding pocket, influence the binding modes
of these compounds in the different RTKs and, therefore, affect the potency and/or
selectivity of these compounds against the tested RTKs.
Isosteric replacements at the 4-position also alter the bond angle between the
bromophenyl ring and the pyrrolo[2,3-d]pyrimidine scaffold (Figure 61) and can
influence the relative orientations of the bromophenyl ring and the heterocycle in the
bound conformation. Additionally, changing the bond angle would permit scanning the
binding pockets (Hydrophobic site I or the Sugar binding pocket in Figure 59) for the 4position substitution and, thereby, influence either the potency and/or selectivity of these
compounds against the tested RTKs.
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Figure 61: Comparison of C-N-C, C-S-C and C-O-C bond angles in energy minimized
conformations of 195, 197 and 205 respectively.

Compounds 199, 200, 203, 204, 207-210 (Figure 60) were designed to study the
influence of the chain length at the 4-position on potency and/or selectivity of these
compounds. Increasing the chain length of the 4-position substitution to two atoms
compared to 197, 198, 201, 202, 205, 206 and 195-196 respectively permits greater
flexibility for the bromophenyl group relative to the pyrrolo[2,3-d]pyrimidine scaffold.
This could, in turn, permit the bromophenyl group to bind deeper in the ATP binding site
(Hydrophobic site I or the Sugar binding pocket in Figure 59) and could influence the
potency and/or selectivity against the tested RTKs. Additionally, the increased chain
length of these compounds could influence the binding modes of these compounds by
influencing the binding interaction with the gatekeeper residue377, 378 in the hinge region,
and thereby influence potency and/or selectivity against RTKs.
Compounds 197-210 retain the 3’-bromophenyl substitution at the 4-position and
either the 2’-methylbenzyl or 2’,4’-dichlorobenzyl substitution at the 6-position of the
pyrrolo[2,3-d]pyrimidine scaffold from the lead compounds 195-196 in order to facilitate
comparison.
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C.2.3. Molecular Modeling Studies with RTKs
Multiple high resolution X-ray crystal structures have been reported for EGFR
(Table 6) and VEGFR2 (Table 7) bound to various inhibitors. Docking studies were
performed using X-ray crystal structures for EGFR and VEGFR2 for selected RTK
inhibitors discovered and synthesized in our laboratory for prediction of their binding
mode(s) in the kinase(s) of interest and/or explanation of observed biological activity. No
crystal structures have been reported for PDGFR-. Hence, homology models were
generated for PDGFR-for use in docking studies for prediction of binding modes of
active compounds generated in our laboratory with the aim of understanding, at a
molecular level, the interactions with the RTK to provide a template for the design of
more potent analogs. Docking studies were performed using either MOE or LeadIT.
Verficiation of the docking software was performed by redocking the crystal structure
ligand into the active site using the same methodology used for docking of the
compounds of interest and calculating the RMSD value of the best docked pose(s)
compared to the crystal structure pose. In all cases, the optimized settings provided
RMSD values of < 2 Å94 for the best docked pose of the redocked ligand compared to its
crystal structure pose.
C.2.3.1. Molecular modeling studies with proposed compounds 197-210 in EGFR
Docking studies were carried out using Flexx 3.1.2 and the proposed molecules in
the ATP binding pocket of VEGFR2 and EGFR in order to validate the hypothesis that
altering the linker moiety between the bromophenyl ring and the heterocyclic scaffold
could alter hydrogen bonding to the hinge region and/or bound conformation of the
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bromophenyl ring in the active site. As a representative example, the docked
conformations of 195, 197, 205 and 207 in EGFR (PDB: 1M17192) are discussed below
(Figures 60a-d). Docked conformations of the other proposed analogs in EGFR and
VEGFR2 are discussed in the Appendix.

Figure 62: Stereoview. Docked conformation of 195 in the ATP binding pocket of EGFR.

In its docked conformation, 195 (Figure 62) binds in the ATP binding pocket of
EGFR with the pyrrolo[2,3-d]pyrimidine occupying the adenine binding site in the
pocket. Three hydrogen bonds are formed between the 2-NH2, N3 and 4-NH moieties of
195 with hinge region amino acids Gln767 and Met769. This binding mode is analogous
to a flipped version of proposed binding mode I (Figure 59). In the docked pose, the
positions of the 4- and the 6- substitutions have been interchanged compared to proposed
binding mode I. In this orientation, the bromophenyl moiety of 195 binds in Hydrophobic
region II and interacts with the side chains of Pro770 and Phe771. The 6-(2’methylbenzyl) moiety is oriented towards the back of the pocket and interacts with the
side chain atoms of Leu694, Thr830 and Asp831 in the pocket. The docked score of 195
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was -24.78 kJ/mol.
The docked conformation of 197 (Figure 63) shows the compound in a flipped
mode (analogous to binding mode II, Figure 59) compared to the docked conformation of
195, in order to maintain the three hydrogen bonds between the compound (2-NH2, N1
and the pyrrole NH moieties) and the hinge region amino acids. This change in the
docked conformation also causes an exchange in the placement of the 4- and 6-position
substitutions of 197 compared to 195. The docked score of 197 was - 24.78 kJ/mol,
comparable to 195.

Figure 63: Stereoview. Docked conformation of 197 in the ATP binding pocket of EGFR

In contrast, 205 docks similar to the lead compound 195 in the ATP binding site of
EGFR. However, the replacement of the 4-NH of 195 with an O-linker causes the loss of
a hydrogen bond with the hinge region. This loss of a hydrogen bond is reflected in the
lower docked score of 205 in EGFR (- 21.526 kJ/mol) compared to 195.
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Figure 64: Stereoview. Docked conformation of 205 in the ATP binding pocket of EGFR.

Figure 65: Stereoview. Docked conformation of 207 in the ATP binding pocket of EGFR.

The docked conformation of 207 in the EGFR pocket is similar to the docked
pose of 197 (Figure 63) with the 2-NH2, N1 and pyrrole NH moieties forming hydrogen
bonds with the hinge region amino acids (Gln767, Met769 and side chain OH of Thr766).
In addition, due to the longer 4-OCH2- linker, the bromophenyl moiety binds deeper in
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the hydrophobic pocket where it can form additional interactions with Phe699. The
docking score of 207 was - 30.154 kJ/mol, significantly better than the docked score of
205 and better than the docked score of the lead 195.
Similar results were seen with the docked conformations of the other proposed
analogs (Appendix 1). The docking studies indicate that the docked conformations and
the docking scores of the proposed compounds are sensitive to the nature of the linker.
These differences could perhaps influence the kinase potency and/or selectivity of
compounds in this series and provides justification for the synthesis and evaluation.
C.2.3.2. Development of a PDGFR- homology model.
Compound 196 and other analogs reported by Gangjee et al. 183, 379-382 show
potent inhibition of PDGFR-. It was therefore of interest to perform docking studies in
an attempt to elucidate the probable binding mode of these compounds in PDGFR-. At
the time of initiation of molecular modeling studies against PDGFR- there were no
reported crystal structures of PDGFR-. In 2010 Shim et al.342 reported the 2.3 Å X-ray
crystal structure of a complex of PDGF- with the first three Ig domains of PDGFRThere are no reported crystal structures of PDGFR- with inhibitors bound to the ATP
binding site.
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Figure 66: Sequence alignment of PDGFR- (P09619), FLT3 (PDB: 1PKG), FLT-3 kinase (PDB:
1RJB), LCK (PDB: 1QPD) and FGFR (PDB: 1FGI)

The 1106 amino acid sequence PDGFR- has been reported. (Uniprot ID:
P09619). A BLASTP search using MOE 2007.09 383 indicated that the kinase domain
amino acid sequence (amino acids 600-962) shows high sequence similarity with chain A
of the c-KIT kinase complex (FLT3) (PDB: 1PKG384), chain A of FLT-3 kinase (PDB:
1RJB347, E-value: 1e-88), chain A of the lymphocyte-specific kinase LCK (PDB:
1QPD385) and chain A of Fibroblast Growth Factor Receptor (PDB: 1FGI386) as shown in
the sequence alignment file above (Figure 66). Thus, a homology model was generated
using MOE 2007.09 and validated for performing docking studies with PDGFR-
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C.2.3.3. Docking Studies with N4-(3-bromophenyl)-7-(substituted benzyl)-7Hpyrrolo[2,3-d]pyrimidine-2,4-diamines as potential multiple RTK inhibitors.

Figure 67. N4-(3-bromophenyl)-7-(substituted benzyl)-7H-pyrrolo[2,3-d]pyrimidine-2,4diamines 211a-k as potential multiple RTK inhibitors.

Compounds 211a-k (Figure 67) were reported by Gangjee et al.380 as analogs
obtained by transposition of the 6-position substitutions of lead compounds 195, 196 and
196c-k to the 7-position of the pyrrolo[2,3-d]pyrimidine scaffold. A general
pharmacophore model with five predicted binding modes for compounds 211a-k was
proposed (Figure 68) that would enable inhibition of an increased spectrum of RTKs
compared to the previously reported387 parent 6-benzyl substituted series.
In binding mode I, the N4-(3-bromophenyl) is accommodated in Hydrophobic
region I. The 7-benzyl group interacts with the Sugar binding pocket. Three hydrogen
bonds can be made with the hinge region via the 2-NH2, N3 and 4-NH groups. In binding
mode 2, the interactions in the hinge region and Hydrophobic region I are conserved. The
7-benzyl group in this mode lies in Hydrophobic region II. A 180 ° rotation of the C2–
NH2 bond in binding mode 1 produces an orientation of the molecule as depicted in
binding mode 3. In this mode, the 7-benzyl group is accommodated in Hydrophobic
region I, and the 3-bromoaniline lies in the Sugar binding pocket.
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Figure 68. 380 General pharmacophore model of pyrrolo[2,3-d]pyrimidines with five potential
binding modes.

Three hydrogen bonds in the hinge region are formed. The N7-nitrogen is
proposed to interact with the hinge region carbonyl via a water molecule bridge. Rotating
the molecule in binding mode 1 by 180 ° along the hydrogen bond formed between the
N3 of the molecule (hydrogen bond acceptor) and the NH at the hinge region (hydrogen
bond donor), results in binding mode 4. In this mode, the 3-bromoaniline is placed in
Hydrophobic region II and the 7-benzyl group lies in Hydrophobic region I. Three
hydrogen bonds with the hinge region are conserved. Rotating the molecule in binding
mode 3 by 180 ° along the hydrogen bond formed between the N3 of the molecule
(hydrogen bond acceptor) and the NH at the hinge region (hydrogen bond donor), results
in binding mode 5. In this mode, the 3-bromoaniline is accommodated in Hydrophobic
region I while the N7 benzyl interacts with Hydrophobic region II. While three hydrogen
bonds are proposed in the hinge region, the N7 nitrogen presumably interacts with the
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hinge carbonyl via a water molecule bridge.
Molecular modeling studies were carried out for 211c (Figure 67) and its
corresponding 6-position substituted lead compound 196c (Figure 67) in VEGFR2,
EGFR and a homology model of PDGFR- as an example to determine if the binding
modes proposed in Figure 68 could be observed in silico and to determine the binding
mode preference, if any, of compounds with substitutions at the 6- and the 7-position of
the pyrrolo[2,3-d]pyrimidine scaffold.
C.2.3.4. Molecular modeling studies of 2-amino-4-m-bromoanilino-6-arylmethyl-7Hpyrrolo[2,3-d]pyrimidines as tyrosine kinase inhibitors

Figure 69.183 Structures of lead compounds (195, 212a-b) and analogues (212c-k)
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Figure 70:183 Proposed binding modes for pyrrolo[2,3-d]pyrimidine RTK inhibitors

Gangjee et al.183 reported the synthesis and biological evaluation against selected
RTKs of a series of 2-amino-4-m-bromoanilino-6-benzyl pyrrolo[2,3-d]pyrimidines 212ck (Figure 69) as analogs of lead compounds 195 and 212a-b.387 As proposed in the
general pharmacophore model in Figure 70, compounds such as 195 and 212a-b could
adopt multiple binding modes in the ATP binding site of RTKs. It was envisioned that
these hypothetical binding modes could be substantiated by the deliberate introduction of
methyl groups at strategic positions on the scaffold. Thus, analogs of the three most
potent previously reported lead compounds 195, 212a-b were designed by introduction of
methyl groups at either the 4-N (212c-e) or N7 (212f-h) or both the 4-N and N7-positions
(212i-k). Thus if the compounds adpopted either Mode I and/or Mode II (Figure 70) for
binding and the 4-NH was necessary for binding, compounds 212c, 212e-f, 212h-i and
212k should be poorly active. However, if the compounds bound in Mode III (Figure 70)
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and the N7-H was necessary for binding, compounds 212d-e, 212g-h, 212j-k should be
poorly active. If however, all three modes were possible, only compounds 212e, 212h and
212k should be poorly active since they would be unable to form H -bonds at both the 4N and N7 positions. In addition, methylation at the N7- and/or the 4-N could also
influence the conformation of the 4- and/or 6-substituent relative to the pyrrolo[2,3-d]
pyrimidine scaffold and could also, in part, influence the potency and selectivity of the
methylated compounds compared with the parent compounds. 183
Table 14.183 IC50 values (µM) of kinase inhibition, A431 cytotoxicity, and inhibition of the CAM
assay of 195, 212a-k.
Compound

EGFR

195
212a
212b
212c
212d
212e
212f
212g
212h
212i
212j
212k
58
212l
Semaxanib
Cisplatin
Erlotinib
Sunitinib

1.67
9.19
12.62
53.1
>200
253.6
31.2
12.8
1.2
143.5
>200
0.5
0.23

VEGFR-

PDGFR-

A431

CAM

2
>50
0.25
0.62
89.2
>200
>200
>200
116.3
>200
>200
>200
>200

β
>50
>50
8.92
>500
2.8
71.7
34.8
>500
>500
1.3
348.0
>500

Cytotoxicity
31.8
1.21
>50
45.7
27.9
50.9
>500
204.3
226.3
197.4
35.6
94.1

angiogenesis
ND
1.21
1.32
1.56
6.22
2.6
0.93
3.0
1.6
0.83
3.3
2.05

3.75
12.9
10.6
1.2
172.1

124.7
18.9

83.1
12.2

0.04
18.2
29.1
1.3

The results from the biological evaluation of 212c-k along with standard
compounds 58, 212l (SU4312, Figure 69), semaxanib, cisplatin, erlotinib and sunitinib
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are shown in Table 14. 183 These results indicate that methylation of the 4-NH and/or the
7-NH influences both the specificity and potency of RTK inhibition. Dimethylation of
both the 4-N and N7 positions afforded improved whole cell EGFR inhibition compared
to clinically used erlotinib. Mono methylation at the 4-N or N7 position led to improved
whole cell PDGFR- cytotoxicity compared to clinically used sunitinib. Thus docking
studies were performed with 212c-k in EGFR, VEGFR-2 and the PDGFR-β homology
model to explain the molecular basis of the observed RTK inhibition.
C.2.3.5. Molecular Modeling Studies of 5- Substituted Pyrimido[4,5-b]indoles in a
PDGFR-Homology Model

Figure 71.379 Design and structures of pyrimido[4,5-b]indoles 213b-c.

Gangjee et al.379 reported 213b-c (Figure 71) as agents with combination
chemotherapy potential in a single molecule. Compounds 213b-c were designed as agents
with RTK, TS and as antitumor agents. Tricyclic compounds like 213a have been
reported388 in the literature as potent RTK inhibitors. 388 In a general RTK model (Figure
71)179, 389-391 the 2-NH2, N3 and 4-anilino nitrogen of 213a form hydrogen bonds with the
hinge region. In addition, the 4-anilino moiety lies in Hydrophobic region 1, and the
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tricyclic scaffold binds in the purine binding pocket of ATP.186, 388 It was envisioned that
transposing the phenyl ring from the 4-position of 213a to the 5-position of the tricyclic
scaffold in 213b-c retains its binding to Hydrophobic region 1 and simultaneously allows
hydrogen bonds with the hinge region. Thus compounds 213b-c were expected to
maintain RTK inhibitory activity. In addition, moving the phenyl ring from the 4- to the
5-position reveals a 2,4-diaminopyrimidine motif on the tricyclic scaffold that has
shown379 to be highly conducive for DHFR and/or TS inhibition.

Table 15.379 IC50 Values (µM) of kinase inhibition and A431 cytotoxicity assay of 213b-c.
Compd
213b
213c
PD153035
Semaxinib
DMBI
Cisplatin

EGFR
VEGFR-2
15.07 ± 3.1 22.6 ± 4.5
10.41 ± 1.2 56.3 ± 7.1
0.23 ± 0.05
12.9 ± 2.9

PDGFR-β
2.8 ± 0.42
40.3 ± 5.1

A431 Cytotoxicity
49.2 ± 4.7
14.1 ± 2.0

3.75 ± 0.31
10.6 ± 3.5

The kinase inhibitory activities of 213b-c are shown in Table 15. It was seen that
213b-c were potent inhibitors of VEGFR-2 and PDGFR-β with RTK inhibitory activities
comparable or better than the standards (except 213c for PDGFR-β). Thus docking
studies were performed with 213b in the PDGFR-β homology model to explain the
molecular basis of its potent PDGFR-β inhibition.
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C.2.4. Topomer CoMFA Analysis of Bicyclic Inhibitors of Multiple Receptor
Tyrosine Kinases

Figure 72. General structures of pyrrolo[2,3-d]pyrimine and furo[2,3-d]pyrimidine based RTK
inhibitors

Gangjee et al. have previously reported the design, synthesis and biological
evaluation of a series of RTK inhibitors based on either a pyrrolo[2,3-d]pyrimidine182, 183,
379, 380, 387, 392-394

or a furo[2,3-d]pyrimidine395, 396 scaffold (Figure 72). Since the objective

of the development of these compounds was multiple RTK inhibition in a single molecule,
a general pharmacophore model of the ATP binding site was used in the design of the
compounds rather than a specific crystal structure of the ATP binding site of an RTK. 379,
380, 387

Gangjee et al.183 also reported molecular modeling studies to support multiple

potential binding modes for these compounds in the ATP binding site of RTKs, which
would enable multiple RTK inhibition.
A topomer CoMFA analysis of bicyclic pyrrolo[2,3-d]pyrimine and furo[2,3d]pyrimidine based RTK inhibitors has not been previously reported. There are no
literature reports of CoMFA/ topomer CoMFA analysis of single molecules with multiple
RTK potential to determine structural features that are condusive to multiple RTK
inhibitory potential.
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A topomer CoMFA analysis of a compound set results in the development of 3-D
steric and electrostatic maps. Thus, analysis of the pyrrolo[2,3-d]pyrimine and furo[2,3d]pyrimidine RTK inhibitors would afford steric and electrostatic maps for individual
kinases (EGFR, VEGFR2 and PDGFR-) against which the compounds were tested.
Since all the pyrrolo[2,3-d]pyrimine and furo[2,3-d]pyrimidine RTK inhibitors included
in this study were designed as ATP-site kinase binders, comparison of the electrostatic
and steric maps should reveal areas of similarity between the maps (common
pharmacophore element) which could be used to identify regions in the molecules that
contribute to multiple kinase inhibition and further drug design of molecules with
multiple RTK inhibitory potential.
On the other hand, identification of the differences between the 3-D steric and
electrostatic maps of the different kinases were anticipated to help identify structural
features in the molecules which could be explored to enhance selectivity for a kinase or
selected kinases.

C.3.COLCHICINE SITE BINDING ANTI-MITOTIC AGENTS
Novel colchicine site tubulin binding agents as antimitotic agents and molecular
modeling studies of colchicine site binding agents reported by Gangjee et al.
C.3.1. Design of 2-amino-4-substituted-5-thioaryl-6-methyl-7-substituted
pyrrolo[2,3-d]pyrimidines as colchicine site binding agents
Microtubules play a vital role in mitosis and cell division and are a particularly
attractive target for drug development, particularly as anticancer agents. Antimitotic agents
such as paclitaxel, vincristine and vinblastine among others have been successfully used
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clinically in the treatment of various cancers. However, the utility of such agents are often
limited by the emergence of resistant cell lines. 397 Drug resistance to antimitotic agents is
primarily caused by overexpression of Pgp and MRP1, which are unidirectional efflux
pumps that transport drug molecules from the inside of the cells to the exterior. Both vinca
alkaloids and paclitaxel are substrates of Pgp, leading to a reduction in their concentration
in the cancer cells, thereby leading to resistance. Methods to overcome these resistance
mechanisms include co-administration of agents that target the efflux pumps or the use of
compounds that are not substrates of these pumps, such as epothilones. 234-237, 239 A novel
mechanism for targeting resistant cells, discovered by Gangjee et al.,

266

was the

development of cytotoxic agents which reverse drug resistance.
Compounds 214a-d were discovered by Gangjee et al.

266

and displayed excellent

antimitotic properties and reversed drug resistance, by restoring tumor cell sensitivity to
other anitmitotics to which the tumor cells had become resistant.

Figure 73. Structures of pyrrolo[2,3-d]pyrimines 214a-e.

Compound 214a (Figure 73) was the most potent compound in this series in the
NCI-60 preclinical tumor cell line panel and inhibited tumor cells 7 to 10 fold better than
214b (Figure 73).

However, 214b demonstrated effective reversal of Pgp-mediated

resistance to vinblastine in the NCI/ADR cell lines. 266 Other analogs in this series showed
reduced effectiveness in both inhibition of tumor cells and reversal of drug resistance to
141

vinblastine. Additionally, while 214a,b and other analogs in this series did not reverse the
MRP1 mediated resistance to vincristine in MCF7/VP cells, they themselves were not
substrates for MRP1. In 214a-d, removal of the N7-benzyl group led to poor antimitotic
activity. Efforts to determine the binding site of these compounds266 indicated that the
compounds did not bind to the known binding sites on tubulin (vinca, colchicine or the
taxol binding site) and probably bind to a novel site on tubulin. 266 Further optimization of
the phenethyl side chain270 by nine analogs with di-, tri- or tetra-methoxy or chloro
substitutions on the phenyl ring led to compounds that showed improved cytotoxicity
against the resistant tumor cells, NCI/ADR and MCF-7/VP, in culture. This study by
Gangjee et al.266 led to the discovery of 214e (Figure 73) which reversed both Pgpmediated as well as MRP1-mediated resistance to clinically used antimitotic agents while
simultaneously displaying antimitotic mediated antitumor activity.270

Figure 74. Structures of pyrrolo[2,3-d]pyrimines 215.

Methyl

3-[(3’,4’,5’-trimethoxyphenyl)thio]-5-methoxy-1H-indole-2-carboxylate

215 was reported by De Martino et al.398 as the most active compound in a series of
arylthioindoles that displayed excellent inhibitory activity against tubulin polymerization
and of the growth of MCF-7 human breast carcinoma cells. Compound 215 was the most
potent derivative, (IC50 2.0 M) and was 1.6 times more active than colchicine, equipotent
as combretastatin A-4 (CSA4) and showed potent inhibition of the growth of MCF-7 cells
(IC50 13 nM). Preliminary SAR studies indicated that introduction of the 2142

methoxycarbonyl function on the indole scaffold improved potency by 2-fold. Oxidation
of the sulfur atom to the sulfone led to inactive compounds. The 3’,4’,5’-trimethoxyphenyl
group attached to the sulfur atom provided the best activity. Introduction of the methoxy
group at the 5-position of indole led to a 7-fold improvement in the inhibition of tubulin
polymerization activity of 215 compared to the 5-H compound. It was also reported that
tubulin polymerization was less sensitive to substitutions at the 5-position. The proposed
binding mode398 of 215 in the colchicine binding site of tubulin (Figure 75) shows that the
trimethoxy ring of 215 interacts with Cys241 and adopts a conformation similar to the Cring of DAMA-colchicine. Additionally, the indole NH was proposed to interact with the
backbone carbonyl of Thr179 in the active site.

Figure 75. Superimposition of the proposed binding mode of 215 (green) with DAMA-colchicine
(yellow) in the colchicine binding site.398

Figure 75a. Structures of target compounds 216a-h and 217a-h.

Compounds 216a-h retain design elements from 214a, the most potent compound
in that series and introduce design elements from 215. The larger sulfur atom in the 5-S
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linker in 216a-h mimics the ethyl linker in 214a. Additionally, trimethoxyphenyl ring in
216a-h is conformationally more restricted as compared to the flexibility afforded by the
2-atom linker to which the corresponding trimethoxyphenethyl ring in 214a is attached.
Additional conformation restriction on the trimethoxyphenyl ring is afforded by the
presence of the 6-Me group in 216a-h, which is absent in 214a and its analogs. Varying the
nature of substituent on the 4-position of 216a-h explores the influence of substitutions at
this position on the biological activity. Thus, 4-OH (216a, 216e) and 4-NH2 (216d, 216h)
groups could form hydrogen bonds in the binding site. Compounds with a 4-H group (216c,
216g) would provide information about the importance of substitutions at the 4-position of
these molecules. The 4-Cl compounds (216b, 216f) mimic the 4-Me group of 214a. The
pyrrole NH in 216a-d mimics the indole NH in 215. Compounds 217a-h vary in the nature
of the aryl group linked to the sulfur atom. The electron poor 4-pyridyl group is in contrast
to the electron rich trimethoxyphenyl ring in 216a and 216a-h. In addition, the protonatable
pyridyl group could aid in increasing the water solubility of these compounds and the
formation of acid salts.

C.3.2. Molecular Modeling Studies in the Colchicine Binding Site of Tubulin.

Figure 76. Structures of tubulin inhibitors 218a,b and 219a-e.
Table 16.50

IC50 values for inhibition of proliferation of MDA-MB-435 cells and EC50s for
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cellular microtubule loss.
Cmpd
218a
218b
(±)-219a•HCl
(±)-219b
(±)-219c•HCl
(±)-219d•HCl
(±)-219e•HCl

IC50±SD (MDA-MB-435)
183 ± 3.4 nM
>10 µM
17.0 ± 0.7 nM
>10 µM
153 ± 11.1 nM
ND
2.7 ± 0.3 µM

EC50 for microtubule depolymerization
5.8 µM
> 40 µM
56 nM
> 40 µM
3.0 µM
> 40 µM
> 40 µM

Compounds 218a, b (Figure 76) and (±)-219a·HCl (Figure 76) were originally
designed by Gangjee et al.50, 394 as a part of a series of RTK inhibitors based on the general
structure A (Figure 76) to determine the binding modes of these compounds in RTK.
Compounds 218a, b and (±)-219a·HCl did not show RTK inhibition (evaluated against
EGFR, VEGFR-1 VEGFR-2 and PDGFR-β),269 but in the preclinical screening program of
the National Cancer Institute in its 60 tumor cell line panel, 218a inhibited the proliferation
of most of the 60 cancer cell lines with a GI50 < 500 nM and (±)-219a·HCl inhibited the
proliferation of the majority of the 60 cell lines with GI50 <30 nM.272, 399 A COMPARE
analysis267, 269 indicated that the mechanism of action of these compounds could involve
binding to tubulin. Further biological evaluation of 218a and (±)-219a·HCl50 showed
dramatic reorganization of the interphase microtubule network and caused formation of
aberrant mitotic spindles and mitotic accumulation when measured by flow cytometry,
similar to the effects of colchicine and Combretastatin A-4 phosphate (CA4P). In further
mechanistic studies, 218a and (±)-219a•HCl was shown to inhibit the polymerization of
purified bovine brain tubulin about as well as CA4P and inhibited [3H]colchicine binding
to the protein.50
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To determine the structural requirements for the 4´-OMe and N4-Me moieties for
activity, compounds 218b and (±)-219b-(±)-219e were synthesized. The results from the
biological evaluation (Table 16) indicated that a methyl substitution on the 4-aniline N is
critical for activity in both scaffolds.

In addition, the 4´-OMe moiety is important for

potent activity. Transposition of the methoxy group from the 4´-position to either the 3'- (in
(±)-219c·HCl) or 2´- (in (±)-219d·HCl), was detrimental to activity.

The critical

importance of N-Me and 4’-OMe for inhibitory activity of these compounds remains
unexplained. Hence, docking studies were hence performed with 218a and 219a to predict
their bound conformations and binding interactions with residues in the colchicine binding
site of tubulin.
A 3.5 Å X-ray crystal structure of the colchicine binding site of tubulin bound to
DAMA-colchicine (Figure 75, PDB: 1SA0)232 has been resolved. It was of further interest
to determine if the predicted bound conformation of 218a and (±)-219a could explain the
observed SAR for microtubule depolymerization for the compounds in this series. Docking
studies of other compounds reported by the Gangjee laboratory were similarly performed
and are reported in the Appendix
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D. CHEMICAL DISCUSSION

D.1. ANTIFOLATES
D.1.1. Synthesis of novel pjDHFR inhibitors
D.1.1.1. Synthesis of novel 2,4-diamino-6-(arylaminomethyl)pyrido[2,3-d]pyrimidines
Scheme 23: Synthesis of target compounds 171 – 173

The syntheses of target compounds 171 – 173 (Scheme 23) were performed using
methods described by Gangjee et al.333 and involved the reductive amination of the key
intermediate 2,4-diaminopyrido[2,3-d]pyrimidine-6-carbonitrile 91a with the
appropriately substituted aniline. Intermediate 91a was prepared, in turn, by a method
previously reported by Piper et al.284 and modified by Gangjee et al.400 Condensation of
triethyl orthoformate with malononitrile using pyridine as a solvent followed by
treatment with concentrated HCl at 80 °C afforded the cyclized intermediate 2-amino-6chloropyridine-3,5-dicarbonitrile 89a in 24% yield over two steps. Reductive
dechlorination of 89a in the presence of 5% palladium on barium carbonate with
hydrogen at 50 psi afforded 2-aminopyridine-3,5-dicarbonitrile 90a. Cyclization of 90a
with guanidine afforded the key bicyclic intermediate 91a in 36% yield. Reductive
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amination with the appropriate aniline in a Paar hydrogenation apparatus in presence of
Raney nickel and hydrogen at atmospheric pressure afforded compounds 171-173. The
poor yields of the reaction could be accounted for by the electron withdrawing nature of
the anilines and/or steric hinderance due to the presence of ortho-substitution on the
aniline and is consistent with similar results previously reported (3 – 16% yields) by
Gangjee et al.333 Chromatographic separation of the target compounds presented
significant challenges due to the presence of tailing impurities (Rf ~ 0.15 – 0.22) near the
product (Rf ~ 0.25 – 0.28 using 5:1:0.1 CHCl3: MeOH: NH4OH as the solvent system)
necessitating repeated column separation. Additionally, several target compounds in this
series tend to stick to the silica gel leading to band widening during separation, resulting
in fractions with mixtures of compounds and a reduction in the reaction yield. Attempts
to reduce sticking of the compound to the silica gel column by using basic alumina as the
stationary phase or neutralization of the slight acidic nature of silica gel by packing the
column with a 1% NH4OH solution in CHCl3 were unsuccessful.
Scheme 24: Modified synthesis of 170, 174 – 179

The long synthetic route (Scheme 23) and the tedious isolation of the
intermediates and the target compounds prompted a search for alternate routes to access
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these compounds. It was envisioned that 2,4-diaminopyrido[2,3-d]pyrimidine-6carbaldehyde 92a could be used as the reductive amination partner with the substituted
anilines to afford the target compounds. Intermediate 92a is also presumably formed in
situ during the reductive amination of 91a295 (Scheme 23) and reacts with the substituted
aniline present in solution to afford the desired compounds. Thus, the direct synthesis of
92a could avoid an additional in situ hydrolysis step necessary for the reaction to proceed
in Scheme 23.
The synthesis of 92a was performed using methods described by Temple et al.295
and involves the condensation of triformylmethane 117 with 2,4,6-triaminopyrimidine
118b under mild conditions. The synthesis of triformylmethane 117 was carried out using
a method initially reported by Arnold et al.401 and involved the reaction of bromoacetic
acid 115 with an N,N-DMF-POCl3 complex resulting in the formation of an intermediate
quaternary salt 116 which underwent hydrolysis in presence of base (NaOH) to afford 117
which was used without purification. Literature methods 295, 401 of purification of 117
involve formation of an intermediate diperchlorate salt which can be recrystallized from
acetonitrile. Neutralization of the diperchlorate salt with 4N NaOH and subsequent
sublimation of the isolated crude material affords pure 117.
A modified procedure reported by Buděšínský et al.402 was utilized for the
synthesis of pure 117. The procedure involves the formation of the bisperbromide 116a as
the intermediate. Compound 116a was synthesized by the reaction of bromoacetic acid
with N,N-DMF and POCl3, decomposition of the reaction mixture using ice and
precipitation of the orange colored salt using an aqueous mixture of bromine and sodium
bromide. The crude salt was purified by dissolving it in acetonitrile, filtration and
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reprecipitation by addition of 1,2-dichloroethane. Triformylmethane 117 was synthesized
from the salt 116a by addition of sodium metabisulfite to a cooled suspension of 116a in
water followed by basification with NaOH, neutralization with conc. HCl and extraction
with CH2Cl2 in 64% yield over four steps.
Reaction295 of crude 117 with 2,4,6-triaminopyrimidine 118b to afford 92a
proceeds with comparable efficiency (36 – 42% yield) with both, pure and crude 117.
Hence, reactions carried out for the bulk synthesis of the key intermediate 92a were
performed using crude 117. Compound 92a was then treated with appropriate anilines
under reductive amination conditions333, 403 to provide the target compounds 170, 174 –
179 in 4 – 9% yields. Though the isolated yield of the target compounds was comparable
to the method described in Scheme 23, the modified reaction sequence led to a reduction
in the number of steps in the reaction sequence, reduced isolation of intermediates, and
thus greatly improved the ease of access of the target compounds.

D.1.1.2. Bulk synthesis of lead compound 170
Scheme 25: Synthesis of lead compound 170 from 91a

Compound 170 was initially synthesized from 91a utilizing the method described
in Scheme 23, analogous to the method described for the synthesis of 171 – 173. This
method involved a long reaction sequence, tedious chromatographic separation and poor
yields. Hence it was necessary to find an alternate synthetic route to access 170. Initial
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attempts to synthesize 170 in bulk were carried out using methods described in Scheme
24 using reductive amination of 92a with 2,5-difluoroaniline 220 in a Paar hydrogenator
using 15 psi hydrogen as the reductant as shown in Scheme 25. Extending the reaction
time to 48 or 72 h did not significantly improve the yield of 170 and led to increased
formation of polar impurities, presumably (2,4-diamino-pyrido[2,3-d]pyrimidin-6yl)methanol formed by the reduction of the intermediate aldehyde 92a prior to the
formation of the Schiff base intermediate by reaction with 2,5-difluoroaniline. Similarly,
increasing the pressure of hydrogen in the Paar hydrogenation vessel to 35 or 50 psi to
shorten the reaction time led to increased formation of (2,4-diaminopyrido[2,3d]pyrimidin-6-yl)methanol with no improvement in the yield of the desired target
compound.
Scheme 26: Synthesis of 170 from 92a

1
2
3
4
5
6

H2 Pressure
15 psi
35 psi
50 psi
50 psi
15 psi
15 psi

Time
24 h
8h
4h
8h
48 h
72 h

Yield
10%
8%
3%
9%
11%
10%

In an attempt to improve the yield of 170, reductive amination was attempted
using the aldehyde compound 92a and 2,5-difluoroaniline 220 using a Paar hydrogenator
under varying H2 pressure and reaction time (Scheme 26). Reactions were carried out
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using 0.5 mmol 92a and 1 mmol of 220. There was no significant improvement in yield
over those obtained in Scheme 25. Increasing the pressure of H2 to 35 psi (entry 2) led to
a reduction in reaction time to 8 h. Increasing the reaction time at 35 psi of H 2 led to
significant increase in the polar side products. Increasing the H 2 pressure to 50 psi
(entries 3 and 4) did not increase the yield of 170 but caused increased polar side
products. Increasing the reaction time at 15 psi of H2 to 48 h or 72 h did not improve the
yields.
Synthesis of 170 using stepwise reductive amination
Abdel-Magid et al404 state that “A reductive amination reaction is described as a
direct reaction when the carbonyl compound and the amine are mixed with the proper
reducing agent without prior formation of the intermediate imine or iminium salt. A
stepwise or indirect reaction involves the preformation of the intermediate imine
followed by reduction in a separate step.” A stepwise reductive amination was utilized in
an attempt to improve reaction yields. A variety of reducing agents have been reported in
the literature including sodium borohydride, sodium cyanoborohydride, sodium
triacetoxyborohydride, borane-pyridine complex, borohydride exchange resin,
Ti(OiPr)4/NaBH3CN and NaBH4/Mg(ClO4)2.405 Based on literature reports,406, 407 it was
anticipated that the use of a reducing agent should afford 170 in a stepwise manner from
the intermediate imine resulting from the reaction of 92a and 220 (Scheme 26). A
stepwise reductive amination approach would have the added advantage of ease of
scalability, enables the reaction to be performed safely under normal laboratory
conditions without the use of specialized hardware such as the Paar hydrogenator, and
avoids the use of high pressure hydrogen gas and avoids the use of toxic, expensive and
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pyrophoric metals such as Raney Ni.

Scheme 27: Optimization of reductive amination conditions

1
2
3
4
5
6
7
8

Reductant
NaBH4
NaBH4
NaBH3CN
Na(CH3COO)3BH
Na(CH3COO)3BH
Na(CF3COO)3BH
Na(CH3COO)3BH
Na(CH3COO)3BH

Eq. of reductant
1.5
1.5
1.5
1.5
1.5
1.5
3
5

Time
12 h
24 h
12 h
12 h
24 h
24 h
24 h
24 h

Result
Trace amounts
Multiple close spots on TLC
7%
11%
12%
6%
14%
12%

A series of reactions carried out to optimize the reducing agent for the reaction is
described in Scheme 27 above. One of the most commonly employed reducing agents
for reductive amination is sodium borohydride. The reaction was performed by stirring a
mixture of 92a and 220 in glacial AcOH for 12h at room temperature to permit formation
of the intermediate imine, addition of the reducing agent and continued stirring for an
additional 12 – 24 h. The use of 1.5 equivalents of NaBH4 as the reducing agent led to the
formation of trace amounts of 170 on TLC after 12 h. Increasing the reaction time to 24 h
led to the formation of multiple close spots on TLC which could not be separated using
silica gel chromatography under gravity or flash chromatography.
Sodium cyanoborohydride is a milder reducing agent than NaBH 4 and has been
successfully employed in reductive amination procedures due to its stability in acidic
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conditions (~ pH 3). It is soluble in polar solvents such as MeOH and shows different
selectivities at different pH values. At low pH (~ 3) NaBH3CN reduces aldehydes and
ketons effectively and at higher pH (~ 6) it reduces imines more effectively than
aldehydes.404, 407 Hence, NaBH3CN was attempted as a reducing agent. This reaction
(entry 4, 7% yield) showed improved yields compared to NaBH 4 and provided the
impetus for a further scan of reducing agents. The reaction with sodium
triacetoxyborohydride (entries 5 and 6, 11-12% yield) showed better yields compared to
reactions with NaBH4 or NaBH3CN. Reactions with sodium trifluoroacetoxyborohydride
(entry 7, 6% yield) showed poorer yields compared to Na(CH3COO)3BH . Increasing the
amount of Na(CH3COO)3BH to 3- or 5-equivalents led to marginal improvement in yield.
It was seen that the best yields were obtained by the use of 3 equivalents of
Na(CH3COO)3BH with a reaction time of 24 h at room temperature.

The formation of large amounts of polar baseline impurities relative to the desired
compound spot (TLC), presumably due to the competing reduction of the aldehyde
group344 of 170 indicated that the rate limiting step could be the formation of the
intermediate imine. The reversible addition of the aldehyde 92a and 220 leads to the
formation of a hydroxylamine addition product, which undergoes dehydration to form an
iminium ion which is the target of the reductant. (Figure 77).

Figure 77: Reductive amination mechanism
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Thus, removal of water from the reaction was anticipated to aid in the formation
of the iminium intermediate and could help in improving yields. Activated 4 Å molecular
sieves have been used to scavenge water in reductive amination reactions. 405-407

Scheme 28: Optimized reaction conditions for synthesis of 170

Addition of 4 Å molecular sieves to the reaction (Scheme 28) led to improved
yields (18%). The optimized reaction conditions involved addition of 3 eq. of
Na(CH3COO)3BH in divided portions 170. Although the reaction in Scheme 28 was
much cleaner, the presence of trailing impurities necessitated multiple column
chromatographic separations. Separations were aided by the use of Combiflash separation
(12g or 24g Teledyne Isco columns, CHCl3 : MeOH, 0 – 15% gradient elution).
A total of 750 mg of 170 was synthesized for biological evaluation studies using
this methodology.

D.1.1.2. Synthesis of novel 2,4-diamino-6-[(arylthio)methyl]pyrido[2,3-d]pyrimidines

The synthesis of 2,4-diamino-6-[(arylthio)methyl]pyrido[2,3-d]pyrimidine
compounds 186 - 188 (Scheme 29) was performed from the key bromo intermediate 94a
using methods described by Gangjee et al.344 The aldehyde intermediate 94a was
obtained by the hydrolysis of the nitrile group of 91a using Raney Ni and formic acid at
reflux 344 or by using methods295 described in Scheme 24.
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Scheme 29: Synthesis of 2,4-diamino-6-[(arylthio)methyl]pyrido[2,3-d]pyrimidines 186 - 188

1
2
3
4
5
6
7

R
2’,5’-diCl
2’,5’-diCl
2’,5’-diCl
3’,4’,5’-triCl
3’,4’,5’-triCl
2’5’-diF
2’,5’-diF

Base
K2CO3
NEt3
NaH
NEt3
NaH
NaH
NEt3

Result
Trace amount
4%
10%
8%
6%
6%
7%

Reduction of the aldehyde group of 91a using NaBH4 in MeOH afforded the
alcohol 92a which was brominated using HBr/AcOH in AcOH to give the bromo
intermediate 93a. Nucleophilic displacement of the bromo group of 93a with appropriate
arylthiols using either sodium hydride, potassium carbonate or triethylamine as the base
and N,N-dimethylacetamide as the solvent afforded the target compounds 186 and 187.
The use of K2CO3 as the base afforded trace amounts of compound while the use of either
NEt3 or NaH afforded compounds 186 - 188 in 6-10% yields.
Compounds 189 and 190 were synthesized by the nucleophilic displacement of
the bromo intermediate 94a using either K2CO3, NEt3 or NaH as the base and N, Ndimethylacetamide or N, N-dimethylformamide as the solvent (Scheme 30). Improved
reaction yields were observed when NaH was used as the base compared to K2CO3 or
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NEt3. The reaction involved stirring the phenol with the base at 0 oC to form the
phenoxide anion followed by dropwise addition of 94a dissolved in the solvent. The
reaction was then allowed to warm to rt and stirred for 3-5 days. The reaction was
monitored by TLC and was quenched when multiple side products began to appear in the
reaction mixture.

D.1.1.3. Synthesis of novel 2,4-diamino-6-[(aryloxo)methyl]pyrido[2,3-d]pyrimidines
Scheme 30: Synthesis of 2,4-diamino-6-[(aryloxo)methyl]pyrido[2,3-d]pyrimidines 189 - 191

1
2
3
4
5
6
7
8
9

R
2’,5’-diCl
2’,5’-diCl
2’,5’-diCl
3,4,5-triCl
3’,4’,5’-triCl
3’,4’,5’-triCl
2’5’-diF
2’,5’-diF
2’,5’-diF

Base
K2CO3
NEt3
NaH
K2CO3
NEt3
NaH
K2CO3
NEt3
NaH

Result
8%
4%
12%
6%
8%
11%
complex mixture
complex mixture
complex mixture

D.1.1.4. Docking studies with pyrido[2,3-d]pyrimidines in pcDHFR and pjDHFR
D.1.1.4.1. Docking Studies with pcDHFR
Protein and ligand preparation prior to docking:
Docking studies were performed for 192a using the 1.90 Å crystal structure of
pcDHFR (PDB: 1LY389) complexed with 2,4-diamino-6-[N-(2',5'-dimethoxybenzyl)-N157

methylamino] quinazoline, (COQ, Figure 20). The active site was defined by a sphere of
6.5 Å near the ligand. Protein preparation prior to docking was performed using the LigX
functionality in MOE 2008.10.408 LigX is a graphical interface and collection of
procedures for conducting interactive ligand modification and energy minimization in the
active site of a flexible receptor. In LigX calculations, the receptor atoms far from the
ligand are constrained and not allowed to move while receptor atoms in the active site of
the protein are allowed to move but are subject to tether restraints that discourage gross
movement. The procedure was performed with the default settings. The process of
protein preparation using LigX involves addition of hydrogen atoms according to the
ionization state of the atoms of the molecule/protein loaded. The heavy atoms are then
fixed and a brief energy minimization is carried out to refine the positions of the added
hydrogen atoms. The receptor atoms are then tethered during geometry optimization so
that they do not deviate too much from their initial coordinates and then energy
minimized using the Amber99 forcefield. Ligands used for docking were sketched in
MOE, minimized and exported as an SDF file.

Docking:
Docking of ligands into the pcDHFR active site was performed using LeadIT
1.3.0.409 Polar hydrogen atoms of amino acids with a polar side chain (Asn23, Ser24,
Tyr35, Thr61, Ser64, Tyr129 and Thr144) were not constrained, thereby permitting free
rotation. Base placement of fragments for docking was carried out using triangle
matching. Default parameters were used for scoring and clash handling. The maximum
number of solutions per iteration and the maximum number of solution per fragmentation
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were set to 500. Ten poses were obtained per molecule. Docking processes were repeated
to ensure reproducibility of the docked conformations. The docked poses were exported
to MOE 2008.10, rescored using the affinity dG scoring system, refined using the
forcefield system and rescored using London dG scoring system. The binding poses were
also visualized using the ligplot utility in MOE and the Poseview utility in LeadIT 1.3.0.

Validation of docking software:
The crystal structure of the inhibitor, 2,4-diamino-6-[N-(2',5'-dimethoxybenzyl)N-methylamino]quinazoline from PDB: 1LY3, was sketched, prepared and docked into
the pcDHFR active site as described above. The best docked pose displayed and RMSD
of 1.072 Å compared to the crystal structure ligand, thereby validating LeadIT 1.3.0 for
our docking purposes. Docking studies with 192b were performed similarly.

Docking studies with N6-methyl-N6-phenylpyrido[2,3-d]pyrimidine-2,4,6triamine, 192b, in pcDHFR
Docking studies of 192b in the pcDHFR active site (PDB: 1LY3) were performed
using LeadIT 1.3.0. Figure 78 shows the best scoring pose of 192b in the pcDHFR active
site. In this pose, the protonated N1 and 2-NH2 of 192a interact in an ionic bond with
Glu32. This bidentate ionic bond with a conserved acid residue has been observed in
most DHFR crystal structures.22, 31, 32, 53 The 4-NH2 moiety forms hydrogen bonds with
the backbone of Ile10 and Ile123.
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Figure 78: Stereoview. Docked pose of 192b in pcDHFR binding pocket (PDB: 1LY389).

The pyrido[2,3-d]pyrimidine scaffold is stabilized by a pi-stacking interaction
with Phe36 and with side chain carbon atoms of Met33 and Leu25. The N9-methyl group
of 192b was 3.94 Å from the terminal methyl group of Ile123 of pcDHFR. In hDHFR,
the corresponding Val115, being shorter by one carbon, may not interact with the N9methyl group. This was expected to improve selectivity as well as potency of these
compounds against pcDHFR (and pjDHFR) over hDHFR. In addition the N9-methyl
group of 192b was 3.8 Å away from side chain Ile65 in pcDHFR, and could improve
potency by hydrophobic interactions. The N9-methyl group also restricts the number of
possible conformations of the side chain phenyl group compared to the N9-H, thus
perhaps increasing selectivity.332 The docked score of 192b in pcDHFR was -42.416
kJ/mol. Thus docking studies corroborate the proposed interactions of the N9-methyl
group in pcDHFR and lend credence to the importance of the N9-group in the design of
selective inhibitors of pcDHFR (and pjDHFR) over hDHFR as previously observed by
Gangjee et al. 332
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D.1.1.4.2. Homology model of pjDHFR
There is currently no known crystal structure of pjDHFR. Thus, a homology
model was hence built to evaluate the binding of 192b-e in pjDHFR. The 206 amino acid
sequence of the folate domain was obtained from the UniProt database (ID:
Q9UUP5_PNEJI [Q9UUP5]). A BLAST search for the pjDHFR sequence showed high
sequence identity with pcDHFR, (61% sequence identity). The BLAST search was
carried out on the Uniprot website (www.uniprot.org) using default settings (Threshold:
10; Matrix: Auto; Gapped Hits: Yes).
Alignment of the sequences was performed using clustalw program as
implemented on the Uniprot website. The sequence alignment between pjDHFR and
pcDHFR (Figure 46) shows a high degree of similarity between the two sequences and
makes pcDHFR a valid template for model generation.

Homology model building: MOE 2008.10
The primary pjDHFR FASTA sequence was loaded into MOE 2008.10. Template
identification was performed using the BLASTP module implemented in MOE 2008.10
using the default settings and indicated that the pcDHFR crystal structure (PDB: 2FZI 44)
shares high homology with pjDHFR (E value: 1e -65). The E-value is an estimate of the
likelihood of the score arising due to chance, with low E-values preferred over higher
values. Thus, the high sequence identity between pjDHFR and pcDHFR (61%) and the
availability of high quality crystal structures of pcDHFR in the PDB makes it a valid
template for building the pjDHFR homology models. The homology model was built
with MOE 2008.10 using the 1.60Å crystal structure of pcDHFR as a template (PDB:
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2FZI, chain A). Sequence alignment was performed using MOE_Align using the ‘actual
secondary structure’ option in MOE.

Model validation:
The model returned from the software was evaluated using structure assessment
tools (Ramachandran plot, Protein Structure Analysis (ProSA), 410, 411 Procheck,412
Anolea,413 Gromos,414 and QMEAN415) as implemented on the Swiss-Model website.416

Figure 79: Ramachandran plot and Procheck analysis of the pjDHFR homology model generated
using MOE 2008.10

a) Ramachandran plot (Figure 79): A Ramachandran plot generated for the
pjDHFR model showed that, with the exception of Asp2, all the residues have
acceptable geometries. Since Asp2 is distant from the active site, and was not
expected to influence the docking studies, modeling studies were performed
without any additional refinements.
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b) Procheck412 (Figure 79): A Procheck analysis of the model indicated 87.5% of
residues in the most favored regions, 11.5% residues in additional allowed
regions, 1% in the generously allowed regions and 0% residues in the disallowed
region.

pjDHFR Model

Template: 2FZI

Overall z-score: -10.71

Overall z-score: -10.74

Figure 80: ProSA analysis of the pjDHFR homology model generated using MOE 2008.10.

c) Protein Structure Analysis (ProSA):410, 411 ProSA calculates an overall quality
score (z-score) for a specific input structure. A plot of local quality scores points
to problematic parts of the model. The z-score estimates the overall model quality
(Figure 80). The Z-score of the input model is plotted along with the z-scores of
all experimentally determined protein chains in PDB. In this plot, groups of
structures from different sources (X-ray, NMR) are distinguished by different
colors (Figure 80). ProSA can be used to check whether the z-score of the input
model is within the range of scores typically found for native proteins of similar
size with a score outside a range characteristic for native proteins indicating
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probable structural errors. The ProSA analysis of the pjDHFR model fell within
the range of z-scores of experimentally determined structures.

Details of validation including Anolea,413 Gromos,414 and QMEAN415 are provided in the
experimental secion. The results from these studies confirmed the validity of the pjDHFR
model for docking studies.

Active site definition and docking to the pjDHFR model
The pjDHFR homology model prepared in MOE was superimposed on the X-ray
crystal structure of pcDHFR (PDB: 2FZI, chain A) and NADPH and DH3 (2,4-diamino5-[3',4'-dimethoxy-5'-(5-carboxyl-1-pentynyl)]benzyl pyrimidine), the co-crystallized
ligand in 2FZI, were added to the model. The active site was defined by a sphere of 6.5 Å
near the ligand. Docking of ligands to the pjDHFR model was performed using LeadIT
1.3.0. as described below.

Validation of the docking system
The pjDHFR structure was obtained by means of homology modeling using
pcDHFR as template. Hence, the validation of LeadIT 1.3.0 as suitable docking systems
for pjDHFR was carried out by redocking the native ligand in the X-ray crystal structure
of pcDHFR (PDB: 2FZI,44chain A). The protein was prepared as mentioned above. The
ligand was built and minimized in MOE. The docking procedure in LeadIT 1.3.0 was
constrained to the active site of the protein. Polar hydrogen atoms of amino acids with a
polar side chain (Ser37, Thr61, Ser64, Ser69, Tyr129, Thr144) were not constrained,
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thereby permitting free rotation. Base placement of fragments for docking was carried out
using triangle matching. Default parameters were used for scoring and clash handling.
The maximum number of solutions per iteration and the maximum number of solution
per fragmentation were set to 500. Ten poses were obtained per molecule. Docking
processes were repeated to ensure reproducibility of the docked conformations. The best
docked pose of the ligand had an RMSD of 0.941 compared to the crystal structure. Thus,
LeadIT 1.3.0 was validated for docking studies with the proposed analogs.

Homology model building using automated servers:

Figure 81: Ribbon rendition of the superimposition of pjDHFR homology models generated
using MOE 2008.10 (red), Swiss-Model417-419 (green), Phyre2420 (yellow) and CPHmodel 3.0421
(blue). RMSD between models = 0.955 Å. The model generated using MOE 2008.10 was used
for docking studies described below.
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In addition to the model generated using MOE, additional homology models were
generated using automated homology modeling servers to validate the model from MOE.
Model generation using the automated servers was performed by submitting the pjDHFR
amino acid sequence to the servers (Swiss-Model417-419, Phyre2420 and CPHmodel 3.0421).
The process was carried out using the respective default settings for all three servers. The
homology models returned from the three servers was overlaid with the model built using
MOE 2008.10 (Figure 81). All the four homology models show good overlap with
RMSD between models of 0.955 Å.

D.1.1.4.3. Docking studies with the pjDHFR homology model
D.1.1.4.3.1. Docking studies with N6-methyl-N6-(3,4,5-trifluorophenyl)pyrido[2,3d]pyrimidine-2,4,6-triamine, 192d, in pjDHFR
Docking studies were performed for 192b-e (Table 8) using LeadIT 1.3.0. The
docked pose of 192d, which displays the highest selectivity (35-fold, Table 8) is
described here. The docking procedure was identical to that described above for the
validation of the software. The binding poses were visualized using the ligplot utility in
MOE 2008.10 and the Poseview utility in LeadIT 1.3.0.
Figure 82 shows the best docked pose of 192d (white) in the folate binding site of
the pjDHFR model. In this pose the protonated N1 and 2-NH2 of 192d interact in an
ionic bond with Asp32. This bidentate ionic bond with a conserved acid residue has been
observed in most DHFR crystal structures. The 4-NH2 moiety forms hydrogen bonds
with the backbone of Ile10. The pyrido[2,3-d]pyrimidine scaffold is stabilized by a pistacking interaction with Phe36 and with side chain carbon atoms of Met33 (not shown)
and Leu25.
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Figure 82: Stereoview. Docked pose of 192d in the pjDHFR homology model.

Figure 83: Stereoview. N-Me of 192d interacts with Ile123 (pjDHFR model, red) but not as well
with Val115 (superimposed hDHFR422, green)

The 3’-F of 192d interacts with the hydroxyl moiety of Ser64. The N9-Me moiety
of 192d is oriented towards the hydrophobic pocket formed by Ile123, Leu72 and Leu65
and interacts specifically with Ile123. The docking score of 192d was -8.594 kcal/mol for
pjDHFR compared with -8.412 kcal/mol for hDHFR. With the exception of the trifluoro
groups, 192b makes similar binding with pjDHFR as compared to 192d. It was of interest
to explain the potency and selectivity of 192b and 192d (compared to 192c and 192e
respectively) for pjDHFR. From the IC50 values in Table 8 for the two pairs 192b and
192c; and 192d and 192e it is evident that the N9-Me moiety makes about a 300- and a
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200-fold difference in potency for pjDHFR respectively, indicating that the N-Me group
must contribute significantly to the increased potency. There are two important
consequences of adding the Me group on the N9. The first one is the interaction of the
N9-Me with Ile123 in pjDHFR (Figure 83). This interaction would not exist for the N9-H
analogs, 192c and 192e from modeling studies. The second is that the N9-Me restricts the
available low energy conformations (50 conformations, calculated using Sybyl X 1.2423)
the molecule can adopt compared with the unhindered N9-H (94 conformations,
calculated using Sybyl X 1.2). Thus it is perhaps easier for 192b and 192d to adopt the
bound conformation than it is for 192c and 192e and results, in part, to the increased IC50
of 192b and 192d over 192c and 192e. In addition to potency, the selectivity of 192b and
192d for pjDHFR over hDHFR are superior to that of 192c and 192e. Thus, the N-Me
moiety must also play a significant role in the high selectivity of 192b and 192d for
pjDHFR over hDHFR compared to 192c and 192e. In pjDHFR the N9-Me moiety is 3.67
Å away from the longer Ile123 compared to hDHFR where it is 4.64 Å away from the
shorter Val115. These superimpositions of the docked structure of 192d in the pjDHFR
homology model and hDHFR crystal structure (Figure 82) and the highly productive
interaction of the N9-Me with Ile123 at 3.67 Å and the lack of productive interaction of
the N9-Me with the shorter Val115 of hDHFR also provides, in part, a molecular
explanation of the pjDHFR selectivity of 192d over hDHFR. Thus the docking study
validates the structural rationale for selectivity of 192b and 192d.
Conformational analysis
Low energy conformers of 192b-e were generated using the Systematic Search
option in Sybyl X 1.3423 using 5 o increments.
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D.1.1.4.4. Docking studies of 168 in the F36C L65P double mutant pjDHFR
homology model
D.1.1.4.4.1. Generation of F36C L65P double mutant pjDHFR model
The F36C L65P double mutant pjDHFR model was generated from the pjDHFR
model used in the docking studies of 192b-e. using the ‘mutate’ option in MOE 2010.10.
The resultant double mutant model was minimized using the Amber99 forcefield. The
protein geometry was verified using Ramachandran plots to ensure absence of outliers in
the putative active site of the protein. Docking studies were carried out using TMP and
168 in the wild type and mutated pjDHFR homology models. Preparation of the ligands
and the docking studies were performed as described earlier.
D.1.1.4.4.2. Docking of TMP in the pjDHFR model

Figure 84: Stereoview. Docked pose of TMP in the pjDHFR homology model.

Figure 84 shows the best docked pose of TMP (white) in the folate binding site of
the pjDHFR model. In this pose the protonated N1 and 2-NH2 of TMP interact in an
ionic bond with Asp32. The 4-NH2 group of TMP can form a hydrogen bond with the
backbone of Gly124. The pyrimidine scaffold is stabilized by a pi-stacking interaction
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with Phe36 and with side chain carbon atoms of Met33. The 3’,4’,5’-methoxyphenyl
moiety of TMP can form hydrophobic interactions with the side chain atoms of Leu25,
Ser64, and Leu65. The docking scores of TMP were -5.832 kcal/mol with MOE 2010.10
and -23.023 kJ/mol with LeadIT 2.0.1.
D.1.1.4.4.3. Docking of TMP in the F36C L65P double mutant pjDHFR model

Figure 85: Stereoview. Docked structure of TMP in the F36C L65P double mutant pjDHFR
homology model.

Figure 85 shows the best docked pose of TMP (white) in the folate binding site of
the F36C L65P double mutant pjDHFR active site model. This docked pose maintains
ionic bond between the protonated N1 and 2-NH2 of TMP and Asp32 as is seen in the
docked pose of TMP in the unmutated enzyme model (Figure 84). The 4-NH2 group of
TMP can form a hydrogen bond with the backbone of Ile10. Mutation of Phe36 with
Cys36 causes a loss of the stacking interactions seen in the unmutated enzyme and could
explain, in part, the loss of activity of TMP against the mutated enzyme. The 3’,4’,5’methoxyphenyl moiety of TMP can form hydrophobic interactions with the side chain
atoms of Leu25, Ser69, and Pro65. The docking scores of TMP were -4.555 kcal/mol
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with MOE 2010.10 and -16.367 kJ/mol with LeadIT 2.0.1.

D.1.1.4.4.4. Docking of 168 in the pjDHFR model
The docked pose of 168 (Figure 86) retains the ionic bond with Asp32 as is seen
for TMP. The bicyclic scaffold of 168 is stabilized by a pi-stacking interaction with
Phe36 and with side chain carbon atoms of Met33 and Leu25. The aryl side chain of 168
can form hydrophobic interactions with the side chain atoms of Leu25, Thr61, Ser64, and
Leu65 and Pro66. The docking score of 168 was -6.491 kcal/mol with MOE 2010.10 and
-24.638 kJ/mol with LeadIT 2.0.1.

Figure 86: Stereoview. Docked structure of 168 in the pjDHFR homology model.

D.1.1.4.4.5. Docking of 168 in the F36C L65P double mutant pjDHFR model
Figure 87 shows the best docked pose of 168 (white) in the folate binding site of
the double mutant pjDHFR active site model.The best docked pose of 168 in the folate
binding site of the F36C L65P double mutant pjDHFR active site model retains the ionic
bond of the bicyclic scaffold with Asp32. The bicyclic scaffold is placed deeper into the
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binding pocket which permits the formation of a hydrogen bond with the side chain
hydroxy moiety of Thr144.

Figure 87: Stereoview. Docked structure of 168 in the double mutant pjDHFR homology model.
pjDHFR homology model.

This additional hydrogen bond, which is not observed in the docked pose of 168
in the non-mutated enzyme, could offset the loss of stacking interactions between the
bicyclic scaffold and Phe65 in the non-mutated enzyme. Additional hydrophobic
interactions between the scaffold and the side chain carbon atoms of Leu25, Met33 and
Cys36 help to stabilize the docked pose of 168. This additional hydrophobic stabilization
is less likely with the monocyclic pyrimidine scaffold of TMP in the mutated enzyme.
The aryl side chain 168 maintains hydrophobic interactions with the side chain atoms of
Leu25, Thr61, Ser64, and Leu65 and Pro66 as is seen with in the docked pose with the
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non-mutated enzyme. Thus, a combination of an additional hydrogen bond and
maintenance of hydrophobic interactions of the bicyclic scaffold and the aryl side chain
provides, in part, a molecular explanation for the maintenance of potency of 168 against
the F36C L65P double mutant pjDHFR. The docking score of 168 was -6.026 kcal/mol
with MOE 2010.10 and -23.155 kJ/mol with LeadIT 2.0.1.
Docking of 192d in the F36C L65P double mutant pjDHFR model

Figure 88: Stereoview. Docked structure of 192d in the double mutant pjDHFR homology model.

Figure 88 shows the best docked pose of 192d in the folate binding site of the
F36C L65P double mutant pjDHFR active site model. In this pose the protonated N1 of
192d forms the ionic bond with Asp32 while the 2-NH2 group forms a hydrogen bond
with the side chain hydroxy of Thr144. The pyrido[2,3-d]pyrimidine scaffold forms
hydrophobic interactions with the side chain carbon atoms of Leu25, Met33 and Cys36.
The 3’,4’,5’-trifluorophenyl side chain of 192d is oriented similar to the docked
conformation of 192d in the non-mutated enzyme (Figure 86) and forms hydrophobic
interactions with Leu25,Thr61 (not shown) Pro65 and Pro66. The docking score of 192d
was -8.145 kcal/mol with MOE 2010.10 and -30.969 with LeadIT 2.0.1.
Table 17: Docking scores for the best docked pose of TMP and 168
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Trimethoprim
168

Wild type pjDHFR
LeadIT 2.0.1
MOE 2010.10
-23.023
-5.832
-24.638
-6.491

F36C L65P Mutated pjDHFR
LeadIT 2.0.1
MOE 2010.10
-16.367
-4.555
-23.155
-6.026

The homology model of pjDHFR and its mutated resistant form (F36C, L65P)
could thus be used in docking studies to explain the significant loss of activity of TMP
compared to 168 on the basis of the loss of the stacking interaction of Phe36 with the
single pyrimidine ring of trimethoprim. Compound 168 has a bicyclic system and is able
to compensate for most of the loss of this interaction in the mutated resistant pjDHFR via
to a combination of a reinforced ionic bond between the protonated N1 and N8 nitrogens
and Asp32, an additional hydrogen bond and maintenance of hydrophobic interactions of
the bicyclic scaffold and the aryl side chain moiety. This is not possible with the
monocyclic TMP docked into the resistant mutant pjDHFR. There is good correlation
between the docking scores of 168 and TMP using both LeadIT 2.0.1 and MOE 2010.10
and their biological activities against wild type and double mutant pjDHFR. This further
validates the homology models generated in this study.

D.1.1.4.5. Docking studies with 5-Methyl-6-thioaryl-thieno[2,3-d]pyrimidines in
pjDHFR
Figure 89 shows the best docked pose of 193f (Table 10) in the folate binding site
of the pjDHFR model. In this pose the protonated N1 and 2-NH2 of 193f interact in an
ionic bond with Asp32. This bidentate ionic bond with a conserved acid residue has been
observed in most DHFR crystal structures. High scoring docked poses where a single
bond between the 2-NH2 of 193f and Asp32 were observed, but were not considered in
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these molecular modeling studies because such bindings deviate from the bidentate bond
that is generally observed for 2,4-diamino substituted antifolates binding to a variety of
DHFRs in their crystal structure.422

Figure 89. Stereoview. Docked pose of 193f (white) in the pjDHFR active site model.

The 4-NH2 moiety forms hydrogen bonds with the backbone of Ile10 and Val123.
The thieno[2,3-d]pyrimidine scaffold is stabilized by a pi-stacking interaction with Phe36
and with the side chain carbon atoms of Ile10, Leu25 and Met33. The 5-Me moiety of
193f is oriented towards a small hydrophobic pocket formed by Ile123, Leu72 and
Leu65. The 3’-OMe forms a hydrogen bond with the backbone amide of Leu25. The
3’,4’-dimethoxyphenyl side chain of 193f is stabilized by hydrophobic interactions with
the side chain of Leu25, Met33 and Leu65. This orientation of the 3’,4’-dimethoxyphenyl
side chain affords severe steric clashes with Phe31 in hDHFR (Figure 90). This forces a
change in the docked conformation of the 3’,4’-dimethoxyphenyl side chain in hDHFR
that is detrimental to binding and translates to the lower overall docked score of 193f in
hDHFR (-6.132 kcal/mol) compared to pjDHFR (-6.663 kcal/mol). This docked score
difference is reflected in the 19-fold selectivity of 193f for pjDHFR. Figure 90 shows the
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steric clash of the Ar side chain with Phe31 (hDHFR) superimposed on Met33 (pjDHFR)
where there is no hinderance.

Figure 90. Stereoview. Steric clash of phenyl side chain of 193f with Phe31 in hDHFR

D.1.2.Molecular modeling studies with tgDHFR
D.1.2.1 tgDHFR homology model
When this work was initiated there was no known crystal structure of tgDHFR. A
homology model was hence built for evaluating the binding of 194a-c (Table 11) in
tgDHFR. The amino acid sequence of the dihydrofolate domain of the bifunctional
enzyme was obtained from the Uniprot database (ID:DRTS_TOXGO [Q07422]).

Homology model building with automated comparative protein modeling servers
The amino acid sequence for tgDHFR (amino acids 1-300) obtained from the Uniprot
website was submitted to four automated comparative protein modeling servers (SwissModel417-419, M4T Server424, 3D-Jigsaw425 and Proteus2426). Modeling was performed in
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the automated mode. The crystal structure templates used by the modeling servers for the
generation of the models were bifunctional DHFR-TS crystal structures from T. cruzi
(PDB:2H2Q427, Swiss-Model, M4T Server, 3D-Jigsaw; 33% sequence identity) and P.
falciparum (PDB:1J3I92, Proteus2, 31% sequence identity). Ramachandran plots were
generated for all the homology models returned. The models returned by the servers
showed an average of four outlying amino acid residues. All the observed outlying amino
acid residues were distant (>8 Å away) from the putative folate binding pocket and were
not expected to influence the docking results.

Homology model building with MOE 2009.10
A homology model was also built using MOE 2009.10 428 using the crystal
structure of the bifunctional DHFR-TS from T. cruzi (PDB: 2H2Q, chain A) as the
template. Sequence alignment was performed using MOE_Align using the ‘actual
secondary structure’ option in MOE. The final homology model returned by the program
was subjected to further energy minimization using Amber99 as the forcefield and a 0.5
RMS gradient. A Ramachandran plot of the model showed the presence of seven outlying
residues (Phe29, Ala125, Glu136, Tyr138, Asp186, Ile229 and Lys231). The outlying
amino acids were locally energy minimized using the Amber99 forcefield. The model
was imported into Sybyl X and refined using the Fix Bumps functionality available
within Sybyl X.

D.1.2.2. Docking studies with the tgDHFR homology model.
Active site definition
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The models returned were superposed with P. falciparum DHFR (PDB:1J3I) and
the crystal structure ligand (6,6-dimethyl-1-[3-(2,4,5-trichlorophenoxy)propoxy]- 1,6dihydro-1,3,5-triazine-2,4-diamine, WR99210)92 and NADPH were added to the model.
Protein preparation prior to docking was performed using the LigX functionality in MOE
2009.10. LigX is a graphical interface and collection of procedures for conducting
interactive ligand modification and energy minimization in the active site of a flexible
receptor. In LigX calculations, the receptor atoms far from the ligand are constrained and
not allowed to move while receptor atoms in the active site of the protein are allowed to
move but are subject to tether restraints that discourage gross movement. The procedure
was performed with the default settings. The process of protein preparation using LigX
involves addition of hydrogen atoms according to the ionization state of the atoms of the
molecule/protein loaded. The heavy atoms are then fixed and a brief energy minimization
is carried out to refine the positions of the added hydrogen atoms. The receptor atoms are
then tethered during geometry optimization so that they do not deviate too much from
their initial coordinates and then energy minimized using the Amber99 forcefield.
Ligands were built using the molecule builder function in MOE and were energy
minimized to their local minima using the MMF94X forcefield to a constant of 0.05
kcal/mol. Ligands were docked into the active site of the prepared protein using the
docking suite as implemented in Flexx 3.1.2. The active site was defined by a sphere of
6.5 Å near the WR99210 ligand. The docking was performed using Alpha triangle base
placement method. Around 50 poses were returned for each compound at the end of each
docking run. The docked poses were imported into MOE 2009.10 and manually
examined in the binding pocket to ensure quality of docking and to confirm absence of
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steric clashes with the amino acid residues of the binding pocket. The docked poses were
scored using the affinity dG scoring system refined using the forcefield system and
rescored using London dG scoring system implemented in MOE. The binding poses were
also visualized using the ligplot utility as in MOE.
Validation of the docking system
Validation of Flexx429 as a suitable docking system was carried out using two
docking studies. In the first study, the X-ray crystal structure of P. falciparum DHFR
(1J3I92) was used for docking WR99210, the native ligand in the crystal structure. The
protein was prepared as mentioned above. The ligand was built and minimized in MOE.
Docking was carried out with Flexx as described above. The best docked pose of
WR99210 had an RMSD of 1.1782 Å compared to the crystal structure ligand. The
docked pose of WR99210 maintained all the contacts exhibited by the crystal structure
ligand. The best docked pose of WR99210 had a score of -6.291 kcal/mol.
Docking studies with compounds 194a-b
Compounds 194a-b (Table 11) were docked into the tgDHFR model as
representative examples for compounds in this series using Flexx as described above. The
docked poses were scored in MOE and ranked on the basis of the scores. The best docked
poses of 194a-b showed high consistency in terms of the conformation of the ligands in
the active site (Figure 92, and the protein-ligand contacts made as a result of the
orientation. The best docked pose of 194a had a score of -6.861 kcal/mol while the best
docked pose of 194b had a score of -6.742 kcal/mol. The slight difference in the scores of
the two compounds reflects the observed difference in the tgDHFR inhibitory potencies
of the two compounds.
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Figure 91. Stereoview. Superimposition of docked pose of 194a (green) and 194b (purple) in the
active site of the tgDHFR model showing similar docked conformations.

Figure 92 shows the docked pose of 194a in the folate binding site of the tgDHFR
model. In this pose, the 2-NH2 and N3 moieties of 194a interact with Asp31. The
thieno[2,3-d]pyrimidine ring pi-stacks with Phe35 further stabilizing this pose. The 1naphthyl ring of 194a is placed in the hydrophobic pocket formed by Phe32, Phe91, Leu23
and Met87. The naphthyl ring forms pi-stacking interactions with Phe32.

Figure 92. Stereoview. Docked pose of 194a (green) in the active site of the tgDHFR model
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Figure 93. Stereoview. . Superimposition of 194a (white) on the furo[2,3-d]pyrimidine ligand (blue)
in hDHFR. (PDB: 3K45359). The naphthyl ring of 194a (space fill) shows steric clashes with
molecular surface near Ile60 and Leu67 (represented in dots) suggesting poor inhibition of hDHFR
as observed for 194a.

Importantly, the 1-naphthyl moiety is involved in a cation-pi interaction430 with the
protonated Arg89 stabilizing the docked conformation. The propyl side chain forms
hydrophobic interactions with Met79, Met87 and Val151. The propyl side chain also aids
in orienting the naphthyl ring correctly in the hydrophobic pocket and its interactions with
Arg89. Docking of 194a-b in hDHFR (PDB id: 3K45359) resulted in docked poses outside
the folate binding site. Superimposition of the thieno[2,3-d]pyrimidine ring of 194a on the
furo[2,3-d]pyrimidine ring of the bound ligand in 3K45 indicated steric clashes with the
side chain of Ile60 and Leu67 in hDHFR (Figure 93), which could explain, in part, the
decreased activity of 194a-b against hDHFR.
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D.1.3. Molecular modeling studies with T. gondii thymidylate synthase

D.1.3.1. Development of a tgTS homology model:
When this work was initiated there was known crystal structure of tgTS, hence a
homology model was built using the automated comparative protein modeling server
SWISSMODEL416-419 and using MOE 2010.10431 for evaluating the binding of 194d-k
(Table 12) in tgTS. Docking studies were performed using LeadIT 2.1.0131 and Sybyl-X
1.2.423

Homology model building
tgTS is a part of a bifunctional DHFR-TS enzyme, as is seen with the TS domains
of other apicomplexan parasites. The sequence for the TS portion (Uniprot id: Q07422,
amino acids 322 – 610) was obtained from the Uniprot website. Modeling using the
Swissmodel server416 was done using the automated mode.
An alternate model was generated using the homology model module of MOE
2010.10. Two models using the bifunctional DHFR-TS crystal structures of Trypanosoma
cruzi (PDB: 2H2Q)432 or wild type Plasmodium falciparum (PDB: 1J3I)92 were generated
using the homology builder module as implemented in MOE.
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Sequence alignment:

Figure 94. Sequence alignment of T. cruzi TS (DRTS_TRYCR),433 pcTS (TYSY_PNECA),434 tgTS
(DRTS_TOXGO),435 and hTS (TYSY_HUMAN)436 using Clustal W.437
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The resulting models were minimized using Amber99 forcefield. Superimposition of the
resulting models indicated high overall similarities and a C-RMSD of 0.855 Å (Figure 95).

Figure 95. Ribbon diagram of the superimposition of homology models generated using T. cruzi
(blue), T. cruzi (brown) and swissmodel (magenta) showing good overlap of the models. CRMSD: 0.855 Å

Model validation:
The model returned from the software was evaluated using structure assessment
tools (Ramachandran plot, ProSA, 410,

411

Procheck,412 Anolea,413 Gromos,414 and

QMEAN415) as implemented on the Swissmodel server.416
a) Ramachandran plot (Figure 96): A Ramachandran plot generated for the
pjDHFR model showed that, with the exception of Glu580, all the residues have
acceptable geometries. Since Glu580 is distant from the active site, and is not
expected to influence the docking studies, modeling studies were performed
without any additional refinements.
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Figure 96: Ramachandran plot and Procheck analysis of the tgTS homology model generated using
MOE 2008.10

b) Procheck412 (Figure 96): A Procheck analysis of the model indicated 85.9% of
residues in the most favored regions, 13.7% residues in additional allowed
regions, 0% in the generously allowed regions and 0.4% (1 residue, Glu 580) in
the disallowed region.
tgTS Model; Z-score = -8.30

Template: 1J3I; Z-score = -7.45

Figure 97: ProSA analysis of the tgTS homology model generated using MOE 2008.10

c) ProSA:410, 411 ProSA calculates an overall quality score (z-score) for a specific
input structure for comparison with the z-scores of all experimentally determined
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protein chains in PDB. ProSA can be used to check whether the z-score of the
input model is within the range of scores typically found for native proteins of
similar size with a score outside a range characteristic for native proteins
indicating probable structural errors. The ProSA analysis of the tgTS model
(Figure 97) is comparable to the score of the template (PDB: 1J3I) and fell within
acceptable limits for z-scores.
d) Details of validation including Anolea,413 Gromos,414 and QMEAN415 are
provided in the experimental secion. The results from these studies confirmed the
validity of the tgTS model for docking studies.

D.1.3.2. Docking studies with the tgTS homology model
Active site definition and docking to the tgTS model
The tgTS homology model prepared in MOE was homology aligned and
superimposed on the X-ray crystal structure of tcTS (PDB: 2H2Q427) containing NADP,
DUMP and DH3 (2,4-diamino-5-[3',4'-dimethoxy-5'-(5-carboxyl- 1-pentynyl)]benzyl
pyrimidine), the co-crystallized ligand in 2H2Q, were added to the model. The active site
was defined by a sphere of 6.5 Å near the ligand. Protein preparation prior to docking
was performed using the LigX functionality in MOE 2010.10. The procedure was
performed with the default settings. The process of protein preparation using LigX
involves addition of hydrogen atoms according to the ionization state of the atoms of the
molecule/protein loaded. The heavy atoms are then fixed and a brief energy minimization
is carried out to refine the positions of the added hydrogen atoms. The receptor atoms are
then tethered during geometry optimization so that they do not deviate too much from
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their initial coordinates and then energy minimized using the Amber99 forcefield.
Ligands used for docking were sketched in MOE, minimized and exported as an SDF
file.
Docking of ligands to the tgTS model were performed using LeadIT 1.3.0 131 and
MOE 2010.10.431 The docking procedure in LeadIT 1.3.0 was constrained to the active
site of the protein. Polar hydrogen atoms of amino acids with a polar side chain were not
constrained, thereby permitting free rotation. Base placement of fragments for docking
was carried out using triangle matching. Default parameters were used for scoring and
clash handling. The maximum number of solutions per iteration and the maximum
number of solution per fragmentation were set to 500. Ten poses were obtained per
molecule. Docking processes were repeated to ensure reproducibility of the docked
conformations. The docked poses were exported to MOE 2010.10, rescored using the
affinity dG scoring system, refined using the forcefield system and rescored using
London dG scoring system. The binding poses were also visualized using the ligplot
utility in MOE and the Poseview utility in LeadIT 1.3.0.
Ligands were docked into the active site of the prepared protein using the docking
suite as implemented in MOE. The docking was restricted to the active site pocket
residues using the Alpha triangle placement method. Refinement of the docked poses was
carried out using the Forcefield refinement scheme and scored using the Affinity dG
scoring system. Around 30 poses were returned for each compound at the end of each
docking run. The docked poses were examined in the binding pocket to confirm absence
of steric clashes with the amino acid residues of the binding pocket. The docked poses
were scored using the affinity dG scoring system, refined using the forcefield system and
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rescored using London dG scoring system. The binding poses were also visualized using
the ligplot utility in MOE.

Validation of the docking system
The tgTS structure was obtained by means of homology modeling using tcTS as
template. Hence, the validation of LeadIT and MOE as suitable docking systems for tgTS
were carried out by redocking the native ligand in the X-ray crystal structure of tcTS (PDB:
2H2Q). The protein was prepared as mentioned above. The ligand was built and minimized
in MOE. Docking was carried out with LeadIT and MOE as described above. The best
docked pose of the ligand had an RMSD of 0.941 Å in LeadIT and 1.036 Å in MOE
compared to the crystal structure. Thus, LeadIT and MOE were validated and were chosen
for docking studies with the proposed analogs.

D.1.3.3. Molecular modeling studies of 2-Amino-4-oxo-5-arylthio-substituted
pyrimido[2,3-d]indoles 194d-j with T. gondii thymidylate synthase

D.1.3.3.1. Docking of 194e in the tgTS homology model
Figure 98 shows the best docked pose of 194e (white) in the binding site of the
tgTS model. In this pose N3 forms a hydrogen bond with Asp553. The pyrido[4,5b]indole scaffold is stabilized by hydrophobic interactions with Ile402, Trp403, Asn406,
Leu486, Leu516, Met608 and Ala609. The 2-naphthyl moiety of 194e forms hydrophobic
interactions with Phe374, Ile402, Leu516 and Phe520. Specifically, the second ring of the
2-naphthyl moiety forms hydrophobic interactions with Phe374. This additional
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interaction of 194e and the 1-naphthyl analog 194f with tgTS Phe374 compared to a lack
of similar interaction of the phenyl analog 194d (Figure 88) explains, in part, the 10-fold
improved potency of 194e and 5-fold for 194f for tgTS over 194d. The docking score of
194e was -25.942 kJ/mol.

Figure 98. Stereoview. Docked pose of 194e (white) in the tgTS homology model
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Figure 99. Stereoview. Docked pose of 194e (white) in hTS (PDB: 1JU6438)

Figure 100. Stereoview. Docked pose of 194d (white) in the tgTS active site homology model.

The 5-thiophenyl ring of 194d does not extend far enough in the binding pocket to
interact with Phe374 (Figure 100). The amino acid corresponding to Phe374 in hTS is
Phe80 and is found to be oriented away from the binding pocket in the hTS crystal
structure (PDB: 1JU6438) (Figure 99), and would not interact with the 2-naphthyl moiety
of 194e in its docked pose (Figure 99) and provides, in part, an explanation for the
significant selectivity of 194e for tgTS over hTS (Table 12). There are indications in the
literature439 that this region of Phe374 coincides with Ala287 of the C. hominis TS
structure and is a region previously identified440, 441 as a possible target for species
selective drug design.
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D.1.3.3.2. X-ray crystal structure of 194d in tgTS

Figure 101. Ribbon depiction of the superimposition of the docked pose of 194d in the tgTS
homology model (white) and the X-ray crystal structure (red, PDB: 4KY4)354 of 194d in tgTS.
C RMSD = 0.68 Å

The X-ray crystal structure of 194d in tgTS was recently published. (PDB:
4KY4)354 Superimposition of the docked pose of 194d in the tgTS homology model and
its X-ray crystal structure (Figure 101) showed remarkable similarity between the
predicted and the crystal structure of tgTS. (C RMSD = 0.68 Å). Further, the predicted
bound conformation of 194d and its crystallized conformation show strong similarities,
serving to validate the docking software and docking protocol for future use in designing
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inhibitors that target tgTS. The crystal structure pose of 194d shows all binding
interactions seen in its predicted binding pose. A closer look at the binding pocket
(Figure 102) shows that, with the exception of Phe374 and Arg603 (not shown), the
predicted conformation of the binding pocket residues matches their crystal structure
conformation. As predicted, Phe374 does not interact with 194d.

Figure 102. Superimposition of the docked conformation of 194d in the tgTS homology model
(white) and its X-ray crystal structure (red, PDB: 4KY4)354 in the tgTS binding pocket.

D.1.3.3.3. Docking of compound 194f in the tgTS homology model
Figure 103 shows the docked pose of 194f in the tgTS active site model. The
docked pose of 194f is similar to the docked pose of 194e (Figure 98) and retains
interactions described for 194e in its docked pose. The docking score of 194f was 22.996 kJ/mol. The X-ray crystal structure of 194f was recently published (PDB:
4KYA).354 Superimposition of the docked conformation of 194f in the tgTS homology
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model and its X-ray crystal structure 354 (Figure 103) in the tgTS binding pocket shows
that the predicted interactions of the tricyclic scaffold of 194f are maintained. However,
the crystal structure conformation of the 1’-naphthyl moiety of 194f is rotated by about
115o relative to the predicted conformation of the 1’-naphthyl moiety. This occurs,
presumably, due to the alternate position of the side chains of Phe374 and Arg603in the
crystal structure compared to their predicted side chain conformations in the homology
model. The predicted and actual conformation of the backbone residues of Phe374 and
Arg603 closely match. It is interesting to note that the predicted relative distance
between the side chains of Arg603 and Phe374 is similar to that seen in the homology
model of the active site. (Figure 105)

Figure 103. Stereoview. Docked pose of 194f (white) in the tgTS active site homology model.
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Figure 104. Stereoview. Superimposition of the docked conformation of 194f in the tgTS
homology model (white) and its X-ray crystal structure (red, PDB: 4KY4).354

Figure 105. Stereoview. Difference in the predicted (white) and crystal structure (red) 354
conformations of the 1’-naphthyl of 194f and the side chains of Phe374 and Arg603 in tgTS.
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The strong correlation between the predicted and bound conformations of 194e
and 194f provides validation for the utility of the docking software and protocols used in
this study for design of future analogs against tgTS.

D.1.3.4.Topomer CoMFA analysis of bicyclic inhibitors of hTS and tgTS
The advantages of using topomer CoMFA over traditional CoMFA are described
above in the Biochemical Review section. Importantly, topomer CoMFA methods are
sensitive only to the aligned 3D topomer fragments, and do not have any receptor
requirements. Hence, it was used for the 3D QSAR analysis of tgTS or hTS inhibitors
previously reported in our laboratory to elucidate steric and/or electronic features that
lead to potent activity against either hTS or tgTS. Since the compounds used in this study
for generating the Topomer CoMFA model share a bicyclic 6-5 (pyrrolo[2,3-d]pyrimidine
or a thieno[2,3-d]pyrimidine) core, the differences in biological activity against hTS or
tgTS probably originate from differences in the substitutions on the bicyclic core.
Topomer CoMFA calculations were performed using Sybyl X 1.2 5 on a Windows
platform.

D.1.3.4.1. Data Set for Topomer CoMFA Analysis
Gangjee et al. 312, 355-365 have reported the synthesis and biological activities
against hTS and tgTS of >100 bicyclic non-classical pyrrolo[2,3-d]pyrimidines and
thieno[2,3-d]pyrimidines containing a 2-amino-4-oxo moiety (Figure 58). Of these, 85
compounds were identified for which discrete biological activities against hTS and/or
tgTS were reported in the literature. There are no previous literature reports of these
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compounds in CoMFA studies. The molecules were sketched in MOE 2009.10428 and
energy minimized using the MMFF94X forcefield to a constant of 0.05 kcal/mol. The
molecules were imported into a Sybyl database followed by addition of Gasteiger-Huckel
charges. The biological activities were added to the table and were converted to the
corresponding log values for use in the model generation. The compounds showed an
approximate 3 log unit range in their activities against hTS or tgTS. Approximately 20%
of these compounds were used for generation of a test set while the rest of the molecules
were used in the training set.

D.1.3.4.2. Fragmentation for Topomer CoMFA Generation.
The pyrrolo[2,3-d]pyrimidine and thieno[2,3-d]pyrimidine inhibitors used in this
study vary in the nature of the substituents on either the 5- or the 6- position. Hence,
three different methods were used to fragment the these inhibitors: Fragmentation using
the ‘Split in two’ option at either the 5- or the 6- positions (Figure 2 A, B) and
fragmentation involving a common bicyclic scaffold (Figure 2 C) with two substituents
(R1, R2) attached at the 5- and 6- positions respectively of the scaffold. The resulting
fragments were stored in separate Sybyl tables.

Model Generation: Topomer CoMFA models were generated using the biological
evaluation data for hTS and tgTS for each of the three sets generated by the above
fragmentation schemes.
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Figure 106B. Method B

Figure 106A. Method A

Figure 106C. Method C

Figure 106: Fragmentation methods for compounds used in this study: (A) Split in two –
substitutions at the 5-position. (B) Split in two – substitutions at the 6-position. (C) Two
substitutions (R1, blue and R2, red) on the core scaffold (green)

D.1.3.4.3. Topomer CoMFA Models:
The Topomer CoMFA descriptors derived above were used as explanatory
variables, and the pIC50 values were used as the target variable in PLS regression
analyses to derive 3D QSAR models using the implementation in the SYBYL package.
The conventional correlation coefficient r 2 and its standard error (r2 stderr), the crossvalidated r2 (q2) and its standard error, (q2 stderr) were subsequently computed for the
final models. Additionally, the Y-intercept value for the PLS analysis (intercept) was
returned by the program. Adding the R-group contributions to this value gives the

predicted activity value.
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D.1.3.4.4. Statistical data for analysis of tgTS inhibitors
Table 18a: Topomer CoMFA Statistics – tgTS
Method A Method B Method C
Conventional r
0.942
0.772
0.907
2
r std. err.
0.23
0.38
0.28
2
2
Cross-validated r (q )
0.778
0.648
0.814
2
q std. err.
0.44
0.47
0.4
Intercept
4.19
5.25
6.4
Opt. no. components
8
4
2
2

The training set for generation of a Topomer CoMFA model had a total of 65
compounds and the test set contained 20 compounds. A total of three models were
generated using Topomer CoMFA using the fragment databases generated by Methods A C. The key statistical parameters associated with these models are shown in Table 18a.
The CoMFA model generated by splitting the molecule into two (Method A) afforded
slightly better conventional and cross-validated r2 values compared to the models
generated by the other two methods. Figure 107.

Figure 107. CoMFA predictions for the training set of tgTS inhibitors using Method A

All three models showed satisfactory cross-validated r2 values (q2 > 0.5) and were
used to predict the activities of the test set and showed good predictive abilities. The
199

CoMFA predictions for the training set for Method A is shown in
D.1.3.4.5. Statistical data for analysis of hTS inhibitors
Table 18b: Topomer CoMFA Statistics – hTS
Method A Method B Method C
Conventional r
0.909
0.786
0.91
2
r std. err.
0.25
0.38
0.38
2
2
Cross-validated r (q )
0.759
0.652
0.647
2
q std. err.
0.4
0.49
0.28
Intercept
4.63
5.58
4.58
Opt. no. components
7
5
6
2

A total of three Topomer CoMFA models were generated, as in the previous case,
using the fragment databases generated by Methods A - C. The key statistical parameters
associated with these models are shown in Table 18b. The CoMFA models generated by
splitting the molecule into two (Method A) and by considering two substitutions on the
core afforded comparable conventional and cross-validated r2 values compared to the
model generated by method B. All three models showed satisfactory cross-validated r2
values (q2 > 0.5). The CoMFA predictions for the training set for Method C is shown in
Figure 108.

Figure 108. CoMFA predictions for the training set of tgTS inhibitors using Method C
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D.1.3.4.6. Using the topomer CoMFA model to explain tgTS SAR
The The Stdev*coefficient contour maps generated using the CoMFA model
generated using method A (described above) can be used to provide a possible
explanation for the observed gain in potency for tgTS activity between two inhibitors
from a series of thieno[2,3-d]pyrimidine inihibitors442 shown below.

Figure 109. Structures and biological activities of 221a-b.

Figure 110. Topomer COMFA maps representing steric and electrostatic contributions for 221a
(left) and 221b (right). Steric maps: green – steric bulk favored, yellow - steric bulk disfavored;
Electrostatic maps: red – negative charge favored, blue – positive charge favored.

The synthesis and biological evaluation of 221a-b (Figure 109) was described by
Gangjee et al.442 Figure 110 represent StDev*Coeff maps that represent steric and
electrostatic contributions of the substitutions and shows where variability in the
molecule’s fields can explain differences in the activities of the molecules. In these maps,
the regions in green favor steric bulk while regions in yellow disfavor steric bulk. The
regions in red and blue represent electrostatic contributions with regions in blue favoring
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positive charge while red regions favor negative charge. As can be seen in Figure 110
(left), the phenyl substitutions in 221a do not reach the large hydrophobic region in green
where the addition of bulk is favorable. This region is occupied by the naphthyl ring of
221b (Figure 110, right) and can perhaps explain the increase in potency of 221b as
compared to 221a.

D.1.3.4.7. Using the topomer CoMFA model to explain tgTS selectivity:

Figure 111. Structures and biological activities of 222a-b against tgTS and hTS.

The synthesis and biological evaluation of 222a-b (Figure 111) was described by
Gangjee et al.358 The 1-naphthyl substituted 222b compound displays a 10-fold
selectivity for tgTS over hTS and shows a 4-fold increased activity over the phenyl
substituted compound 222a. Figures 96a-b display the Topomer COMFA maps
representing steric and electrostatic contributions for 222 in the hTS and tgTS models
respectively.
These maps suggest that the region where the 5-thioaryl substituent binds in hTS and tgTS
differs in its ability to tolerate bulk. Subsequently, the 5-naphthtyl substituent of 222 is able
to access the larger region in green in tgTS (steric bulk favored) over the yellow region
(steric bulk disfavored) in hTS.
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Figure 112. Topomer COMFA maps representing steric and electrostatic contributions for 222b in
the hTS model. Steric maps: green – steric bulk favored, yellow - steric bulk disfavored;
Electrostatic maps: red – negative charge favored, blue – positive charge favored.

Figure 113. Topomer COMFA maps representing steric and electrostatic contributions for 222b in
the tgTS model. Steric maps: green – steric bulk favored, yellow - steric bulk disfavored;
Electrostatic maps: red – negative charge favored, blue – positive charge favored.

This can explain, in part, the higher potency of 222 for tgTS over hTS. Similar
findings (Figure 114-115) were also seen in case of the StDev*Coeff maps for 194a-b
(Table 12), thereby providing further evidence that supports the validity of the topomer
CoMFA models generated.
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Figure 114. Topomer COMFA maps representing steric and electrostatic contributions for 222a in
the tgTS model. Steric maps: green – steric bulk favored, yellow – steric bulk disfavored;
Electrostatic maps: red – negative charge favored, blue – positive charge favored.

Figure 115. Topomer COMFA maps representing steric and electrostatic contributions for 222b in
the tgTS model. Steric maps: green – steric bulk favored, yellow - steric bulk disfavored;
Electrostatic maps: red – negative charge favored, blue – positive charge favored.
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D.1.3.4.8. Comparing Docking Studies with the Topomer CoMFA Model
Docking studies were performed with 222b in the tgTS homology model to
ascertain if a molecular basis could be found to explain the observed SAR. In addition,
docking studies could be used to determine which amino acids in the tgTS active site, if
any, are responsible for the interactions predicted by the topomer CoMFA model.
Docking studies were performed using LeadIT 2.1.0 using the procedures described for
194 in the tgTS homology model above.
Figure 116 shows the best docked pose of 222b (white) in the binding site of the
tgTS model. In this pose the N3 forms a hydrogen bond with Asp513. The thieno[2,3d]pyrimidine scaffold is stabilized by hydrophobic interactions with Ile402, Trp403,
Asn406, Leu486 and Leu516, Met608 and Ala609. The 2-naphthyl moiety forms
hydrophobic interactions with Ile402, Leu516 and Phe520.

Figure 116. Stereoview. Docked pose of 222b (white) in the active site of the tgTS homology
model.

Additional hydrophobic interactions afforded by the second ring in the 2-naphthyl
205

moiety with Phe520 could explain, in part, the 4-fold gain in potency of 222b compared to
222a. There are indications in the literature439 that this region of Phe374/Phe520 coincides
with Ala287 of C. hominis TS structure and is a region previously identified440, 441 as a
possible target for species selective drug design.
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D.2.RECEPTOR TYROSINE KINASE INHIBITORS
D.2.1. Synthesis of 2-Amino-4-substituted-6-arylmethyl-7H-pyrrolo[2,3d]pyrimidines as RTK inhibitors
Scheme 31: Synthesis of 2-amino-4-substituted-6-arylmethyl-7H-pyrrolo[2,3-d]pyrimidines 197210

Scheme 31 shows the route utilized in the synthesis of target compounds 197 –
210. The target compounds were synthesized by a nucleophilic displacement of the
chloro group of the key intermediate 230a-b387 with the corresponding bromothiols,
phenols or amines 231 under basic conditions using isopropanol or butanol as the solvent
under reflux conditions. The key intermediates 230a-b were synthesized using literature
methods reported by Gangjee et al. 387 The corresponding substituted phenyl acetic acids
223a-b were heated with SOCl2 at reflux to afford the acid chlorides 224a-b which were
used without purification. Treating the acid chlorides 224a-b with freshly prepared
diazomethane387 afforded the α-diazoketones 225a-b which were further treated with a
48% aqueous HBr solution to afford the -bromomethyl benzyl ketones 226a-b which
were used without purification. Etheral diazomethane was prepared under basic
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conditions using literature methods387 from N-nitroso-N-methyl urea or N-methyl-Nnitroso-p-toluenesulfonamide (Diazald). Since N-nitroso-N-methyl urea has been reported
to be toxic, carcinogenic and a potent mutagen,443 large scale preparation (5-10 mmol
scale) of ethereal diazomethane was carried out using Diazald. Condensation of 226a-b
with 2,6-diamino-4-oxo-pyrimidine 231afforded the desired 2-amino-4-oxo-6-substituted
benzyl pyrrolo[2,3-d]pyrimidines 228a-b in 54-60% yields. Pivaloyl protection of the 2NH2 group gave compounds 229a-b. Treatment of 229a-b with POCl3 at reflux afforded
the key 2-amino-4-chloro-6-substituted benzyl pyrrolo[2,3-d]pyrimidines 230a-b.
Significantly improved yields (65-76%) were obtained on chlorination of the pivaloyl
protected 2-amino-4-oxo-6-substituted benzyl pyrrolo[2,3-d]pyrimidines 229a-b
compared to the unprotected compounds 228a-b as has been previously reported.387 The
protected compounds showed significantly improved solubility in organic solvents such
as CHCl3 and MeOH which improved their purification using normal phase column
chromatography compared to the unprotected analogs.
Scheme 32: Synthesis of target compounds 197-200

The synthesis of 197-202 by nucleophilic displacement of the chloro group of
230a-b by the thiol moiety of 231 is shown in Scheme 32. Different bases such as NEt 3,
K2CO3, Cs2CO3 and tBuOK were used in order to deprotonate the thiol for the
nucleophilic displacement. The reactions were carried out with 2 eq. of base. The best
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yields were obtained on using K2CO3 as the base for 3-bromobenzene thiol (entries 1-7)
and using tBuOK as the base for (3-bromophenyl)methanethiol (entries 8-15).

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15

Comp.
197
198
197
198
197
198
198
197
199
199
199
200
200
199
200

Ar
2-MePh
2,4- diClPh
2-MePh
2,4- diClPh
2-MePh
2,4- diClPh
2,4- diClPh
2-MePh
2-MePh
2-MePh
2-MePh
2,4- diClPh
2,4- diClPh
2-MePh
2,4- diClPh

X
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S

n Time (h)
0
4
0
4
0
4
0
24
0
4
0
4
0
24
1
4
1
24
1
4
1
24
1
4
1
4
1
4
1
4

Base
K2CO3
K2CO3
Cs2CO3
Cs2CO3
NEt3
NEt3
NEt3
NEt3
NEt3
tBuOK
tBuOK
K2CO3
K2CO3
K2CO3
tBuOK

Solvent Yield (%)
iPrOH
34
iPrOH
30
iPrOH
12
iPrOH
22
iPrOH
12
iPrOH
Trace
iPrOH
8
iPrOH
N/A
iPrOH
Trace
nBuOH
21
nBuOH
24
iPrOH
5
nBuOH
15
iPrOH
6
nBuOH
25

The choice of base was based on literature precedence. 390, 391 Increasing the
reaction time led to modest improvements in yields in some cases (eg. entries 10, 11).
Changing the solvent from iPrOH to nBuOH permitted increasing the reaction
temperature and facilitated improved yields. Conducting the reaction under microwave
conditions did not lead to an appreciable improvement in yields. Similar yields were
obtained when the pivoloyl protected 4-chloro compounds were treated with the
corresponding thiols under basic conditions. Deprotection of the pivaloyl group occured
by heating the intermediates with 15% KOH in 1,4-dioxane for 12 h.387 Compounds 205
– 210 (Scheme 33) were synthesized using nucleophilic displacement of the 4-Cl of 230a
or 230b similar to the synthesis of 197 – 200 described above.
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Scheme 33: Synthesis of target compounds 205-210
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Comp.
205
206
205
206
207
207
207
208
207
208
209
209
209
209
209
210

Ar
2-MePh
2,4- diClPh
2-MePh
2,4- diClPh
2-MePh
2-MePh
2-MePh
2,4- diClPh
2-MePh
2,4- diClPh
2-MePh
2-MePh
2-MePh
2-MePh
2-MePh
2,4- diClPh
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O 0
24
O 0
24
O 0
24
O 0
24
O 1
4
O 1
12
O 1
24
O 1
24
O 1
24
O 1
24
NH 1
4
NH 1
24
NH 1
24
NH 1
24
NH 1
24
NH 1
24
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K2CO3
K2CO3
Cs2CO3
Cs2CO3
K2CO3
K2CO3
tBuOK
tBuOK
tBuOK
tBuOK
NEt3
K2CO3
K2CO3

Solvent Yield (%)
iPrOH
18
iPrOH
22
iPrOH
Trace
iPrOH
Trace
iPrOH
N/A
iPrOH
N/A
iPrOH
Trace
iPrOH
Trace
nBuOH
11
nBuOH
10
iPrOH
N/A
iPrOH
N/A
nBuOH
N/A
nBuOH
Trace
iPrOH
8
iPrOH
13

Scheme 34: Attempted synthesis of 203-204

Attempts to synthesize the one-carbon linked compounds 203-204 using a Wittig
reaction390 (Scheme 34) afforded a complex, inseparable mixture of compounds.
Repeating the reaction using benzaldehyde as a model system also failed to provide the 4benzyl substituted analogs. The reaction failed to proceed as expected when it was carried
210

out using the dipivaloyl protected analog of 230a. In order to rule out complications in
the reaction due to the deprotonation of the acidic pyrrole NH of 230a-b, the
corresponding N-7 benzyl protected analog (234) of 230a380 was synthesized (Scheme
35) in 22% yield.
Scheme 35: Synthesis of target compound 234

Attempts to repeat the Wittig reaction described in Scheme 34 provided a
complex mixture of compounds which were not separable using normal phase
chromatography or flash chromatography. Increasing the reaction time from 6 to 24 h led
to an increase in the number of spots on TLC. Changing the reaction solvent to DMF did
not change the proportion of the side products.
Scheme 36: Attempted synthesis of target compound 235

Attempts to synthesize the two-carbon linked analogs 235 and 236 using Suzuki
coupling390 of either 230a or its N7-benzyl protected analog 234 with stryrylboronic acid
as the coupling partner (Scheme 36) did not afford the desired compounds. Increasing the
reaction time from 12 to 24 h or 48 h led to increasing side products which could not be
separated using column chromatography.
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D.2.2. Molecular modeling studies with RTKs
D.2.2.1 Homology model of PDGFR-

Figure 117. DISOPRED analysis of PDGFR-kinase domain amino acid sequence.

There is currently no known crystal structure of PDGFR-. A homology model
was hence built for performing molecular modeling studies. The amino acid sequence
(amino acids 600 – 962) of the PDGFR- kinase domain was obtained from the Uniprot
database (Uniprot ID:PGFRB_HUMAN [P09619]). A BLASTP search implemented in
MOE 2007.09383 indicated that chain A of the 2.90 Å c-KIT kinase complex (PDB:
1PKG384, chain A) shows high sequence similarity with PDGFR- (E-value: 1e -58). A
homology model was then built using MOE 2007.09 and the structure of c-KIT kinase
complex (PDB: 1PKG, chain A) as the template.
As has been reported earlier in the literature, 339 a DISOPRED 2.0444 analysis of
the PDGFR-amino acid sequence was performed to predict the ordered and disordered
regions. The results from this analysis (Figure 117) predicted amino acids 700 – 792 were
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disordered.

Figure 118. Superimposition of the PDGFR- homology model (brown) with the c-KIT crystal
structure (magenta). The disordered amino acids of PDGFR do not superimpose with the crystal
structure.

The disordered amino acids were accounted for during the model building step by
using the ‘actual secondary structure’ option in MOE 2007.09. Using literature methods,
i.e. truncation of the disordered region, provided models similar to that seen with the
models generated using the ‘actual secondary structure’ option in MOE 2007.09. The
final homology model returned by the program was subjected to further energy
minimization using Amber99 as the forcefield and a 0.5 RMS gradient. Figure 118 shows
the superimposition of the PDGFR- homology model with the c-KIT crystal structure
template.
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Model validation:
The model generated using MOE 2007.09 was evaluated using structure
assessment tools (Ramachandran plot, Protein Structure Analysis (ProSA), 410, 411
Anolea,413 Gromos,414 and QMEAN415) as implemented on the Swiss-Model website.416

Figure 119. Ramachandran plot of the PDGFR- homology model.

a) Ramachandran plot (Figure 119): A Ramachandran plot of the model showed
the presence of six outlying residues (Glu563, Ser 623, Val722, Asp776, Thr790
and Glu911). Initial efforts to resolve the structure of the outlying residues by
tethered energy minimization steps led to the generation of different outlying
residues. A tethered global energy minimization for the protein did not resolve the
outlying residues. Attempts to use different software such as Sybyl X to prepare
the protein did not give satisfactory results. Since these residues are not in the
proximity of the purpoted ATP binding site and are tethered during the docking
process, they are not expected to influence the docked conformations of the
compound. Hence, the model was used without further refinement.
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b) Protein Structure Analysis (ProSA):410, 411 ProSA calculates an overall quality
score (z-score) for a specific input structure for comparison with the z-scores of
all experimentally determined protein chains in PDB. The ProSA analysis of the
PDGFR- model (Figure 120) is comparable to the score of the template (PDB:
1PKG, chain A) and fell within acceptable limits for z-scores.
Template: 1PKG; Z-score = -6.30

PDGFR Model; Z-score = -7.09

Figure 120. ProSA analysis of the PDGFR- homology model.

Docking studies were performed using the docking suite of MOE 2007.09. After
addition of hydrogen atoms, the protein was then “prepared” using the LigX function in
MOE. LigX is a graphical interface and collection of procedures for conducting
interactive ligand modification and energy minimization in the active site of a flexible
receptor. In LigX calculations, the receptor atoms far from the ligand are constrained and
not allowed to move while receptor atoms in the active site of the protein are allowed to
move but are subject to tether restraints that discourage gross movement. The procedure
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was performed with the default settings. Ligands were built using the molecule builder
function in MOE and were energy minimized to its local minima using the MMF94X
forcefield to a constant of 0.05 kcal/mol.
Ligands were docked into the active site of the prepared protein using the docking
suite as implemented in MOE. The docking was restricted to the active site pocket
residues using Alpha triangle placement method. Refinement of the docked poses was
carried out using the Forcefield refinement scheme and scored using Affinity dG scoring
system. About 30 poses were returned for each compound at the end of each docking
run. The docked poses were manually examined in the binding pocket to ensure quality of
docking and to confirm absence of steric clashes with the amino acid residues of the
binding pocket. The binding poses were also visualized using the ligplot utility as
implemented in MOE 2007.09.

D.2.2.2. Docking Studies with N4-(3-bromophenyl)-7-(substituted benzyl)-7Hpyrrolo[2,3-d]-pyrimidine-2,4-diamines as potential multiple RTK inhibitors.
Table 19.380 IC50 values (µM) of kinase inhibition and the A431 cytotoxicity assay of 195, 196a-k
and 211a-k.
Compd
195
#
196
196c
196d
196e
196f
196g
196h
196i
196j
196k

PDGFR-β
>50
inhibition
17.0±5.6
>50
>50
8.92±1.6
>50
>50
>50
>50
>50
14.7±3.4

VEGFR-2
0.25±0.04
inhibition
28.11±9.9
5.58±0.69
8.28±0.69
0.62±0.21
>50
>50
5.08±0.83
>50
5.97±0.78
9.42±1.9
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VEGFR-1
>50
inhibition
>50
26.8±4.1
42.7±6.1
31.1±5.8
>50
>50
19.2±4.3
15.2±2.9
>50
>50

EGFR
9.19±1.8
inhibition
0.23±0.06
4.31±1.75
17.42±3.9
12.62±3.3
1.67±0.3
19.77±5.6
>50
1.24±0.21
6.16±1.2
>50

A431
1.21±0.42
cytotoxicity
2.8±1.1
>50
28.6±5.1
>50
31.8±6.3
33.5±6.2
>50
33.2±5.9
23.5±5.2
42.1±18.5

Compd
211a
#
211b
211c
211d
211e
211f
211g
211h
211i
211j
211k

PDGFR-β
159.6±26.3
inhibition
34.2±4.4
1.5±0.21
>500
>500
229.6±37.1
129.3±21.1
212.4±16.2
129.1±20.5
1.8±0.29

VEGFR-2
113.4±17
inhibition
>200
17.9±2.4
65.3±7.9
>200
23.8±3.0
64.5±7.8
14.9±2.1
22.9±2.9
22.9±10.7
25.7±4.6

VEGFR-1
129.3±20.4
inhibition
138.1±24.2
126.3±19.1
79.9±8.4
>200
99.3±10.3
118.6±11.4
150±22.1
50.8±6.2
>200
156.5±25

EGFR
113.3±18.9
inhibition
>200
>200
99.9±18.6
69.2±6
166.4±20.6
>200
>200
>200
>200
>200

A431
15.7±2.8
cytotoxicity
15.3±1.9
88.4±10.2
16.1±2.2
40.6
50.4±5.9
19.2±3.0
36.3±4.9
20.4±3.5
13.3±20.5
39.0±6.8

Table 19380 shows the results from the biological evaluation studies for 195, 196,
196c-k and 211a-c (Figure 69) against selected RTKs. Molecular modeling studies were
performed for 196c and its corresponding analogue 211c as representative examples from
this set.

Figure 121.380 Stereoview. Superimposition of docked poses of 196c (red) and 211c (white) in the
ATP binding site of VEGFR2. (PDB: 1YWN)

Molecular modeling studies380 were carried out using Flexx 3.1.2445 and MOE
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2008.10408 in VEGFR2 (pdb code 1YWN)200 and a homology model of PDGFR 
Figures 121 and 122 depict the docked poses of 196c (Figure 67) and its regioisomer
211c (Figure 73) as a representative study in VEGFR2 and the homology model of
PDGFR Figure 121 shows the superimposition of the best scored docked poses of 196c
(red) and 211c (white) in the ATP binding site of VEGFR-2. The binding site of ATP
competitive inhibitors in RTKs consists of a hinge region, two hydrophobic binding sites
(Hydrophobic Region I and II) and a Sugar binding pocket (Figure 121) as described
previously.179, 186, 390, 447 Compounds 196c and 211c adopt different docked conformations
in the active site. The pyrrolo[2,3-d]pyrimidine ring of 196c occupies the adenine binding
portion of the ATP binding site. The 2-NH2 moiety forms a hydrogen bond with the
backbone carobonyl oxygen of Glu915 in the hinge region while the N3 and 4-anilino
NH are involved in hydrogen bonds with the backbone of Cys917 in the hinge region.
Additional hydrophobic interactions of the pyrrolo[2,3-d]pyrimidine ring with Leu1033
(not labeled) can stabilize the docked pose. In this pose, the N7-benzylic substitution
extends towards Hydrophobic region I and is involved in interactions with Val846,
Ala864, Val897 and Val914. The N7-benzylic substitution also interacts with the side
chain carbon atoms of Glu883 and Cys1043. The N4-(3-bromophenyl) is extended
towards Hydrophobic region II and interacts with the side chains of Phe916, Leu838(not
shown) and Leu1033 (not shown).
In contrast, the pyrrolo[2,3-d]pyrimidine scaffold of 196c docks380 in a flipped
conformation compared to 211c described above that permits the formation of three
hydrogen bonds with the hinge region (Figure 3). The 2-NH2, N1 and pyrrole NH of 196c
form hydrogen bonds with the backbone of Glu915 and Cys917. Additionally, the

218

pyrrolo[2,3-d]pyrimidine scaffold forms hydrophobic interactions with Leu838 (not
shown), Val846, Ala864, Val897 and Leu1033 (not shown). This pose causes the N4-(3bromophenyl) moiety to bind in Hydrophobic region I where it interacts with Val846,
Ala864, Leu887, Val897, Val912 and Val914. Additional hydrophobic interactions with
the side chain carbon atoms of Lys866 and Glu883 stabilize this docked pose. The 6benzylic substitution extends towards Hydrophobic region II and forms interactions with
Leu838 (not shown), side chain atoms of Phe916, Cys917, Lys918 and Gly920 (not
shown). Thus, molecular modeling and docking studies suggest that the 7-benzylic
substitution forces 211c to adopt a binding mode different from that docked for the 6benzylic compound 196c in VEGFR2.

Figure 122.380 Stereo view. Docked pose of 196c (red) and 211c (white) in the putative
binding site of the PDGFRhomology model
There is no reported crystal structure of PDGFRβ bound to a ligand. Hence a
homology model of PDGFRβ was built using the structure of c-KIT kinase complex
(PDB: 1PKG) as a template.379 Docking studies380 were performed with 196c and 211c as
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described above for VEGFR-2. Compound 104 binds to the ATP binding site of
PDGFR with the pyrrolo[2,3-d]pyrimidine portion occupying the adenine binding site
(Figure 122). Three hydrogen bonds with the hinge region are maintained in this binding
mode. The aniline NH hydrogen bonds with the backbone of Cys684 while the N3 and 2NH2 moieties form hydrogen bonds with Glu682. This pose causes the bromophenyl
moiety to bind in Hydrophobic region I and form hydrophobic interactions with Val614,
Ala632 (not shown), Val665 and Leu833 (not shown) and with the side chain carbon
atoms of Lys634 andThr681. The N7-benzyl substituent lies in the Sugar binding pocket
and interacts with Leu606 (not shown), Val614, Val615 (not shown) and Ala848. The
best scored pose of 196e binds similar to the binding pose seen with 196c in PDGFRβ.
The 6-benzylic substituent of 196e accesses the same region accessed by the 7-benzylic
substituent of 211e, however in a different conformation as shown in Figure 122. It was
interesting to note that alternate binding modes380 of 211e that scored 1-2 kcal/mol higher
than the best docked pose indicate different bound conformations of the 7-benzylic
substituent (Figure 123). In the alternate binding mode, the 7-benzylic substituent
accesses Hydrophobic region II instead of the sugar binding pocket as is seen in the
bound conformation in Figure 123 where it interacts with Phe916 and Leu938 (not
shown). Compound 196e, which has a 6-benzylic substituent cannot access Hydrophobic
region II in the poses seen in Figures 103 and 104. These binding modes suggested that
the presence of multiple docked poses could lead to differences in the activity and/or
selectivity of these compounds against different kinases as compared to the parent
compounds 195 and 196.
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Figure 123.380 Stereoview. Superimposition of the best scored pose (white) and alternate docked
pose (blue) of 211e in the putative binding site of PDGFR

D.2.2.3. Molecular modeling studies of 2-Amino-4-m-bromoanilino-6-arylmethyl7H-pyrrolo[2,3-d]pyrimidines as Tyrosine Kinase Inhibitors
D.2.2.3.1. Docking studies in EGFR.

Figure 124.183 Stereoview. Overlay of docked poses of 195 (red), 212a (white) and 212b (blue) in
EGFR active site (PDB: 1M17).
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Figure 125.183 Ligand interaction plots of docked poses of 195 (red), 212a (white) and 212b
(blue) in EGFR active site

Compounds 212c-k were evaluated for activity against cells overexpressing
EGFR, VEGFR-2 or PDGFR-Table 14).183 Molecular modeling studies were
performed with the lead compounds 195, 212a-b and their corresponding analogues
212c-k in an attempt to provide a molecular basis for the observed SAR for these
compounds.
In an attempt to explain the activity for 212c-k against EGFR in the whole cell
assay, docking studies were performed183 using Flexx 3.1.2 and the X-ray crystal
structure of the 4-anilinoquinazoline inhibitor erlotinib in EGFR (PDB ID: 1M17).192
Multiple low energy binding modes were seen for all the docked compounds. The
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binding modes presented in Figure 124 for 195, 212a-b were observed to be within 2
kcal/mol of the lowest energy pose and permits comparison between the proposed
binding modes of the three molecules. All the molecules form hydrogen bonds with the
hinge region using the 2-NH2 moiety. Hinge region hydrogen bonds with the 4-NH is
observed for 195 and 212b but not 212a. Additional hydrogen bonding using the N3nitrogen is seen for 195 and 212a but not for 212b. This explains, in part, the greater
potency of 195 against EGFR compared with 212a and 212b. The anilino rings of the
three compounds reside in Hydrophobic site II and can interact with Leu694, Leu768 and
Pro770. The 6-benzyl moieties of the molecules extend into the Sugar binding pocket and
interact with Leu694, Phe699 and Val702. The altered conformations of the side chain
benzyl ring in 212a due to the 2'-Me and in 212b due to the 2'-,5'- diOMe cause the
benzyl ring to extend away from Val702, reducing the extent of hydrophobic interaction
of these molecules. Ligand interaction plots for 195, 212a-b are shown in Figure 125.183
Docked poses183 of the 4-N methylated compound 212c in EGFR show the loss of
hydrogen bonding to the backbone of Met769 afforded by the 4-NH group in the lead
compound 195 (Figures 126 and 127). Additionally,212c is oriented farther from the
hinge region as compared to 195 to accommodate the 4-N methyl group. This results in
the loss of a hydrogen bond of the N3-nitrogen with the backbone NH of Met769.
Additional binding interactions afforded by other portions of 212c are similar to those
seen in the docked pose of 195. This loss in H-bonding of the N3 in 212c could explain,
in part, its reduction in whole cell activity against EGFR as compared to 195 which lacks
the 4-N methyl group.183
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Figure 126.183 Stereoview. Overlay of docked poses of 195 (red) and 212c (white) in EGFR
active site.

A

B

Figure 127. 183 (A) Ligand interaction plots of docked pose of 212c in the EGFR active site. (B)
Overlay of ligand interaction plots of docked poses of 212c (red) and 195 (green) in the EGFR
active site. Generated using MOE 2009.10
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Figure 128. 183 Stereoview. Overlay of docked poses of 212k (red) and 212b (white) in EGFR
active site

B

A

Figure 129. 183 (A) Ligand interaction plots of docked pose of 212k in the EGFR active site. (B)
Overlay of ligand interaction plots of docked poses of 212k (red) and 212b (green) in the EGFR
active site.

When comparing the N4, N7-dimethylated compounds 212e, 212h and 212k, it
was noted183 that the whole cell activity of the compounds increase with increasing size of
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the substitution on the 6-benzyl ring. Docking studies with 212k (Figures 128 and 129)
indicated that this compound adopts a binding mode different from that seen with the
docked poses of 195, 212a-b. In the docked pose of 212k (Figure 128), the 2-NH2 moiety
is involved in the lone hinge region hydrogen bond. The N4 and N7-methyl groups alter
the conformation of the molecule and cause the aniline portion to bind to Hydrophobic
site I. The 2',5'-dimethoxybenzyl side chain accesses the Sugar binding pocket and is
placed in a hydrophobic site formed by Leu694, Phe699 and Val702. The 2',5'-dimethoxy
moieties provide additional hydrogen bonds with Thr766 and Lys721. The
conformational change due to N4, N7-dimethylation and additional interactions due to
the nature and orientation of the benzyl side chain could be expected to compensate for
the loss of hydrogen bonding by either the N4 or N7 nitrogen atom and contribute to the
increased potency of 212k against EGFR in whole cell assays compared with 212b.
All the mono- and di-methylated derivatives were comparatively inactive against
VEGFR-2 in whole cell assays suggesting that, for VEGFR-2 inhibition in whole cells,
both the N4- and N7- protons are important for binding and necessary for activity.
Whether this reflects space requirements or hydrogen bond donor ability at the N4and/or N7-positions is not clear.183

D.2.2.3.2. Docking studies in PDGFR-β
The 4-N-methyl compound, 212i, was the most potent analogue in this series and
was about 7-fold more potent than its lead analogue 212b in the PDGFR-β whole cell
assay. Molecular modeling studies183 were performed using Flexx 3.1.2 with the
homology model of PDGFR- as described above in an attempt to explain the increased
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activity of 212i compared with 212b in the whole cell assays for PDGFR-.

Figure 130.183 Stereoview. Docked pose of 212b (white) in PDGFR- homology model.

Figure 131.183 Stereoview. Overlay of docked poses of 212i (red) and 212b (white) in PDGFR-
homology model.
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A

B

Figure 132.183 (A) Ligand interaction plots of docked pose of 212b in the PDGFR- model.
(B) Overlay of ligand interaction plots of docked poses of 212b (red) and 212i (green) in the
PDGFR- model.

Figure 130 shows the best docked pose of 212b within 2 kcal/mol of the lowest
energy pose in the purpoted ATP binding site of the PDGFR-homology model. In this
pose183 the pyrrolo[2,3-d]pyrimidine ring of 212b rests in the Adenine binding region and
forms hydrogen bonds with Glu682 and Cys684 in the hinge region via the N1-, 2-NH2
and N7- nitrogen atoms. These interactions serve to anchor the molecule and permit the
anilino moiety to bind in Hydrophobic site I where it can interact with Ala848, Val614
and Leu606. The 2'-OMe substituent forms a hydrogen bond with the backbone of
Asp688. The docked pose of 212i in the homology model (Figure 131) also maintains
these interactions seen in the docked pose of 212b. In addition, 212i, which is methylated
at the N4, binds in a mode which orients the aniline ring deeper in Hydrophobic Site I.
The bromophenyl residues can form hydrophobic interactions with Val614, Leu606,
Val665 (not shown), Phe845 and Ala848 and the side chain of Lys634. Additionally, the
methyl group on the N4 can form hydrophobic interactions with Val614 and Ala848 and
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provide additional stabilization of the pose. Together, these interactions could account, in
part, for the improvement in activity of 212i over the lead compound 212b. Figure 132
shows the ligand interaction plots183 for 212b and 212i in the active site of the PDGFR-
homology model.
Molecular modeling studies thus indicate the presence of multiple low energy
binding modes for these molecules and explain, in part, the potent activities of 212f, 212i
and 212k. 183 Thus, while general activity trends can be observed, it would be challenging
to predict the preferred binding modes for these compounds in receptor tyrosine kinases
on the basis of molecular modeling and docking studies.

D.2.2.4. Molecular Modeling Studies of 5- Substituted Pyrimido[4,5-b]indoles in a PDGFRHomology Model

Figure 133.379 Stereoview of the docked pose of 213b in the putative PDGFR-β active site
model.
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Results from the biological evaluation studies of tricyclic compounds 213b-c
against cells overexpressing EGFR, VEGFR-2 or PDGFR-are shown in Table 15.379
Molecular modeling studies were carried out using Flexx 3.1.2 445 and MOE 2008.10408 in
VEGFR2 (PDB: 1YWN)200 and a homology model of PDGFR-β379 to explain the
molecular basis of its potent PDGFR-β inhibition.
Docking studies were performed using the energy minimized structure of 213b in
a homology model of PDGFR-β.379 The homology model of PDGFR-β was generated as
described above. Figure 133 depicts the best docked pose of 213b in the homology model
of PDGFR-β. In this figure, the 2- and 4- NH2 groups of 213b form hydrogen bonds with
the backbone residues of the hinge region (Tyr683, Cys684). Additionally, the 5-S-Ph is
involved in a cation-pi interaction (10-15 kcal/mol stabilization) with the protonated
Arg604. Figure 133 thus provides a working model for binding to PDGFR-β.

D.2.3. CoMFA analysis of pyrrolo[2,3-d]pyrimidines and furo[2,3-d]pyrimidines as
multiple receptor tyrosine kinase inhibitors
The use of traditional CoMFA methods is time-consuming and is very sensitive to
the initial preparatory steps of molecular alignment and conformer selection. 448 The
dearth of crystal structures of EGFR and VEGFR2 bound to ligands which bear close
structural similarity to the molecules of our interest make the selection of the active or
“receptor bound conformation” for alignment of our compounds challenging.
Additionally, there are no reported crystal structures for PDGFR-bound to ligands, thus
severely limiting the applicability of conventional CoMFA methods for this analysis.
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Topomer CoMFA423 minimizes the preparation needed for 3D QSAR analysis
through an entirely objective and consistent set of alignment rules. Topomer CoMFA
generates a 3D QSAR by: (a) splitting the molecules into fragments; (b) topomerically
aligning each fragment; (c) calculating steric and electrostatic field descriptor values for
the topomerically aligned fragments; and (d) creating a CoMFA table with the field
descriptor values. The correlation among the molecules can then be analyzed using steric
and electrostatic contour displays. Since Topomer CoMFA methods are sensitive only to
the aligned 3D topomer fragments, and do not have any receptor requirements, it was
used for the 3D QSAR analysis of our RTK inhibitors. Since the compounds used for
generating the Topomer CoMFA model share either a pyrrolo[2,3-d]pyrimidine or a
furo[2,3-d]pyrimidine scaffold, the differences in activity probably originate from the
differing portions of the structures. i. e., the nature of the substitution on the scaffold.
Topomer CoMFA calculations were performed using Sybyl X 1.1.1423 on a Windows
platform.

D.2.3.1. Data Set and Biological Activity.
Gangjee et al. have previously reported the design and synthesis and biological
evaluation of a series of RTK inhibitors based on either a pyrrolo[2,3-d]pyrimidine182, 183,
379, 380, 387, 392-394

or a furo[2,3-d]pyrimidine395, 396 scaffold (Figure 72). The molecules

used in the model generation were sketched using the molecule builder in MOE
2009.10428 and energy minimized using the MMFF94x forcefield to a constant of 0.05
kcal/mol. The molecules were imported into a Sybyl database followed by addition of
Gasteiger-Huckel charges. The biological activities were added to the table and were
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converted to the corresponding log values for use in the model generation. The
compounds showed an approximately 3 log unit range in their activities against EGFR,
VEGFR2 and PDGFR-. Approximately 20% of these compounds were used for
generation of a test set while the rest of the molecules were used in the training set.
D.2.3.2. Alignment of compounds:
The energy minimized structures of the 60 compounds (structures and CoMFA
data presented in the attached excel sheet) were aligned using MOE 2009.10 using the
flexible align option in MOE in the default settings. The resultant aligned structures are
shown in Figure 134.

Figure 134: Results from the flexible alignment of the 60 compounds using MOE 2009.10

Fragmentation for Topomer CoMFA Generation.
The pyrrolo[2,3-d]pyrimidine inhibitors used in this study vary in the nature of the
substituents on either the 4- or the 6- position. Three different methods were used to
fragment the pyrrolo[2,3-d]pyrimidine inhibitors: Fragmentation using the ‘Split in two’
option at either the 4- or the 6- positions (Figures 113 A, B) and fragmentation involving a
common pyrrolo[2,3-d]pyrimidine scaffold (Figure 135 C) with two substituents (R1, R2)
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attached at the 4- and 6- positions respectively of the scaffold. Since the reported furo[2,3d]pyrimidine inhibitors used in this study varied only in the nature of the substituents on
the 5- position of the scaffold, the molecules, only the ‘Split in two’ option was used in the
generation of fragments for the furo[2,3-d]pyrimidines. (Figure 135 D). The resulting
fragments were stored in separate Sybyl tables.

Method A

Method B

Method C

Method D
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Figure 135: Fragmentation methods for pyrrolo[2,3-d]pyrimidines (A – C) and furo[2,3d]pyrimidines (D). (A, B, D) – two fragments. R1: blue, R2: red. (C) – Two substitutions (R1,
blue and R2, red) on the core scaffold (green).

D.2.3.3. Model Generation: Topomer CoMFA models were generated using the biological
evaluation data for EGFR, VEGFR2 and PDGFR- for each of the four fragment sets
generated by the above fragmentation schemes.

D.2.3.4. Results:
The Topomer CoMFA descriptors derived above were used as explanatory variables,
and the pIC50 values were used as the target variable in PLS regression analyses to derive
3D QSAR models using the implementation in the SYBYL package. The conventional
correlation coefficient r2 and its standard error (r2 stderr), the cross-validated r2 (q2) and its
standard error, (q2 stderr) were subsequently computed for the final models. Additionally,
Y-intercept value for the PLS analysis (intercept) was returned by the program. Adding the
R-group contributions to this value gives the predicted activity value.

D.2.3.4.1. Statistical data for analysis of pyrrolo[2,3-d]pyrimidines
The training set for generation of a Topomer CoMFA model had a total of 48
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compounds and the test set contained 12 compounds. A total of nine models were generated
using Topomer CoMFA using the fragment databases generated for the pyrrolo[2,3d]pyrimidine scaffold by Methods A - C. The key statistical parameters associated with
these models are shown in Tables 20 - 22. In general, for the pyrrolo[2,3-d]pyrimidine
scaffold, CoMFA models generated by splitting the molecule into two (Tables 20 and 21)
afforded slightly better conventional and cross-validated r2 values compared to the models
generated by considering two substitution positions on the pyrrolo[2,3-d]pyrimidine
scaffold. (Table 22) In all nine cases, the models which showed satisfactory cross-validated
r2 values (q2 > 0.5) were used to predict the activities of the test set and showed good
predictive abilities.
Table 20: Model generated from fragments using Method A

2

Conventional r
r2 stderr
Cross-validated r2 (q2)
q2 stderr
Intercept
Opt. no. components

EGFR
0.895
0.422
0.529
0.47
4.62
6

Kinase
VEGFR2 PDGFR-
0.794
0.819
0.354
0.447
0.552
0.468
0.332
0.387
4.48
3.6
5
4

All three models returned from the analysis of fragments developed by Method A
(Table 20) showed good conventional r2 values. Satisfactory cross-validated r2 values (q2 >
0.5) were obtained for models generated for EGFR and VEGFR2.
Table 21: Model generated from fragments using Method B

Conventional r2
r2 stderr
Cross-validated r2 (q2)

EGFR
0.834
0.38
0.58
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Kinase
VEGFR2 PDGFR-
0.954
0.611
0.411
0.243
0.504
0.41

q2 stderr
Intercept
Opt. no. components

0.293
5.04
4

0.317
4.06
4

0.329
4.02
3

Models returned from the analysis of fragments developed by Method B (Table
21) showed good conventional r2 values for EGFR and VEGFR2 but not PDGFR-.
Satisfactory cross-validated r2 values (q2 > 0.5) were obtained for models generated for
EGFR and VEGFR2.
Models returned from the analysis of fragments developed by Method C (Table
22) showed r2 values lower than those obtained by Methods A and B. However,
satisfactory cross-validated r2 values (q2 > 0.5) were obtained for models generated for
EGFR and VEGFR2.
Table 22: Model generated from fragments using Method C

Conventional r2
r2 stderr
Cross-validated r2 (q2)
q2 stderr
Intercept
Opt. no. components

EGFR
0.755
0.223
0.521
0.233
4.1
3

Kinase
VEGFR2 PDGFR-
0.715
0.682
0.281
0.326
0.50
0.322
0.29
0.42
4.5
4.1
3
4

EGFR: Method A, which generated the fragment database by splitting the molecule in
two at the 4-position of the pyrrolo[2,3-d]pyrimidine scaffold afforded the best
conventional r2 (0.895, Table 20) and also gave a satisfactory internal cross-validated q2
at 0.529 (Optimum number of components, ONC = 6).
VEGFR2: Method B, which generated the fragment database by splitting the molecule in
two at the 6-position of the pyrrolo[2,3-d]pyrimidine scaffold afforded the best
conventional r2 (0.954, Table 21) and also gave a satisfactory internal cross-validated q2
236

at 0.504 (ONC = 4).
PDGFR-: The model obtained by Method A provided the best conventional r 2 (0.819,
Table 20). All the three models generated failed to provide a satisfactory internal crossvalidated q2 > 0.5 with the best q2 value of 0.468 returned by Method A (Table 22).
D.2.3.4.2. Statistical data for analysis of furo[2,3-d]pyrimidines
All three kinase models generated for the furo[2,3-d]pyrimidine scaffold showed
conventional r2 values lower than those returned for the corresponding kinases for the
pyrrolo[2,3-d]pyrimidine scaffold. The graph of the actual vs. predicted activities indicated
8 – 10 outlying molecules. Removal of the outlying molecules improved the conventional
r2 values but did not significantly improve the cross-validated r2 values.
Table 23: Model generated from fragments using Method D

Conventional r2
r2 stderr
Cross-validated r2 (q2)
q2 stderr
Intercept
Opt. no. components

EGFR
0.799
0.454
0.489
0.36
4.12
5

Kinase
VEGFR2 PDGFR-
0.715
0.688
0.39
0.402
0.446
0.387
0.36
0.294
4.08
3.64
4
4

An analysis of the biological activities indicated that a bias towards less active
compounds in the database could account, in part, for the failure of the method to provide
satisfactory q2 values. Refinement of the model will be performed after the biological
evaluation results of molecules with further variations at different locations of this
scaffold are obtained.
The Stdev*coefficient Contour Maps
The CoMFA model which provided the best results for the three kinases tested for
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the pyrrolo[2,3-d]pyrimidine scaffold were used to construct the stdev*coefficient
contour maps for the most active fragments (R1, shown on top in each figure and R2,
shown below R1 in each figure) for each kinase. (Figures 114 - 116). In the CoMFA steric
field, the green (sterically favorable) and yellow (sterically unfavorable) contours
represent 80% and 20% level contributions, respectively. The CoMFA electrostatic
contour map for kinase inhibitory activity is depicted alongside the steric contour map.
The red (negative charge favorable) and blue (negative charge unfavorable) contours in
the CoMFA electrostatic field represent 80% and 20% level contributions, respectively.
An analysis of the Stdev*coefficient contour maps indicates similarities and
differences between the steric and electrostatic requirements at the R 1 and R2 positions
among the three kinases. These observed similarities and differences at a fragment level
could be explored for the generation of new analogs with multiple kinase inhibition.

Thus, topomer CoMFA analysis models that correlate the 3D chemical structures
of 60 pyrrolo[2,3-d]- pyrimidines and 49 furo[2,3-d]pyrimidines synthesized in our
laboratory and their inhibitory potencies for EGFR, VEGFR2 and PDGFR- were
developed.

Fragments were generated from the molecules by either splitting the molecule
into two for both scaffolds or by considering substitutions at the 4- or 6- positions of the
pyrrolo[2,3-d]pyrimidine scaffold. Models generated for the pyrrolo[2,3-d]pyrimidines
showed good conventional r2 values and satisfactory cross-validated r2 (q2) values. The
models generated for furo[2,3-d]pyrimidines showed reasonable conventional r 2 values
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but not q2 values.

Comparison of the topomer CoMFA maps for pyrrolo[2,3-d]pyrimidines (Figure
136 – 138) show differences in the steric and/or electronic requirements among the three
RTKs. These differences could be used, in conjuction with other medicinal chemistry
techniques and docking studies to modulate the selectivity and/or potency of designed
small molecule inhibitors with multiple RTK inhibitory potential against the three RTKs.

Figure 136. Stdev*coefficient contour maps for EGFR
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Figure 137. Stdev*coefficient contour maps for VEGFR2
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Figure 138. Stdev*coefficient contour maps for PDGFR

D.3.COLCHICINE SITE BINDING ANTI-MITOTIC AGENTS
D.3.1. Synthesis of novel 2-amino-4-substituted-5-thioaryl-6-methyl-7-substituted
pyrrolo[2,3-d]pyrimidines as colchicine site binding agents
Scheme 37: Synthesis of compound 236

The common synthetic intermediate 3,4,5-trimethoxybenzene thiol 236 was
synthesized by a Sandmeyer reaction using reported literature methods449 as shown in
Scheme 37. 3,4,5-Trimethoxyaniline 237 was diazotized using NaNO2 in a 10% HCl
solution at 0 oC. The diazonium salt was treated with potassium ethyl xanthate at 65 oC to
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afford the xanthate salt 238 which was purified using chromatography (silica gel, 10%
EtOAc in hexanes). Basic hydrolysis of the xanthate 238 afforded the desired thiol 236 in
88% yield.
Scheme 38 shows the synthetic route used for 216a-c, 216f-g. 2-Amino-4-oxo-6methyl pyrrolo[2,3-d]pyrimidine 140a was synthesized according to the literature
procedure reported by Gangjee et al.,312 shown previously in Scheme 16. Compound
140a was subjected to oxidative thiolation103, 312, 450, 451 with 3,4,5-trimethoxybenzene
thiol 236 in the presence of iodine at reflux using a 5:1 mixture of EtOH and H2O as the
solvent to afford compound 216a in 26% yield. The absence of the 5-H proton peak and
presence of the corresponding aromatic and methoxy peaks in the 1H NMR confirmed
that the substitution had occurred as anticipated.
Scheme 38: Synthesis of compounds 216a-c, 216f-g, 217a-c, 217f-g
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Chlorination357 of 216a by treatment with POCl3 at reflux in presence of N,Ndimethylaniline afforded the chloro compound 216b in 26% yield. Chlorination was
confirmed by 1H NMR by the disappearance of the lactam NH peak at  10.46 and
deshielding of the other proton peaks. Reductive dehalogenation of 216b using 10%
palladium on activated carbon and hydrogen at atomospheric pressure afforded 216c.
Reductive dehalogenation was confirmed by 1H NMR by the appearance of an additional
peak at  8.46 corresponding to the 4-H. Conditions attempted to optimize the conversion
of 216b to 216c are listed in Scheme 39 below. Deprotonation of the pyrrole NH of 216b
with NaH and subsequent reaction with benzyl bromide380 gave the target compound 216f
in 12% yield. Reductive dehalogenation of 216f using conditions identical to that used for
the synthesis of 216c afforded the N7-benzyl protected target compound 217g in 29%
yield. The 4-pyridylthiol substituted compounds 217a-c and 217f-g were synthesized
using a similar process as described for the synthesis of 217a-c and 217f-g above. 2Amino-6-methyl-5-(pyridin-4-ylthio)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one
217a was synthesized according to the procedure reported by Gangjee et al.355
Scheme 39. Optimization of reaction conditions for conversion of 216b to 216c
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Catalyst
1
2
3
3
4
5
6
7

10% Pd/C
10% Pd/C
10% Pd/C
10% Pd/C with 2 drops NH3 in MeOH
10% Pd/C
10% Pd/C
30% Pd/C
30% Pd/C

H2 pressure Time (h) Yield (%)
15 psi
4
15
15 psi
12
25
15 psi
24
40
15 psi
24
40
35 psi
12
50
50 psi
6
40
15 psi
12
28
15 psi
24
40

Reductive dehalogenation of 216b to 216c was carried out using H2 in a Paar
hydrogenation apparatus in presence of Pd/C as a catalyst. Initial attempts were carried
out using 10% Pd/C at atmospheric pressure for 4 h led to partial conversion of 216b to
216c and a 15% isolated yield of 216c. Increasing the reaction time improved the reaction
yield. Complete conversion of 216b required recharging the reaction vessel with an
additional equivalent of the catalyst after 12 h. Increasing the H2 pressure to 35 or 50 psi
did not lead to a significant increase in the yield of 216c. Using 30% Pd/C as the catalyst
gave similar yields as using 10% Pd/C as the catalyst. Addition of 2 drops of a solution of
ammonia in methanol to the reaction mixture and recharging the catalyst after 12 h
provided the best yield of 55% for the conversion of 216b to 216c.
Scheme 40: Synthesis of target compounds 216d and 216h

Compounds 216d and 216h were synthesized from compounds 216b and 216d
respectively by the nucleophilic displacement of the chloro groups by ammonia in a
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sealed vessel reaction.357 The presence of an additional amino peak at  5.22 in the 1H
NMR confirmed that the displacement had taken place.
Scheme 41: Synthesis of target compounds 217a-h

Synthesis of target compounds 217a-h from the common synthon 140a is shown
in Scheme 40. Oxidative thiolation312 of 140a with commercially available thiol 236a in
presence of I2 in an EtOH:H2O (5:1) mixture at reflux afforded the 5-substituted target
compound 217a in 34% yield. Chlorination of the 4-oxo moiety of 217a was carried out
by heating a mixture of 217a in POCl3 at reflux in presence of N,N-dimethylaniline to
afford target compound 217b in 30% yield. Abstraction of pyrrole NH proton with NaH
and subsequent nucleophilic displacement 380 with benzyl bromide afforded the target
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compound 217f in 14% yield. While reductive dechlorination of 217b in a Paar
hydrogenation apparatus with hydrogen at 15 psi afforded target compound 216c in 30%
yield, attempts to synthesize target compound 217g from the corresponding chloro
compound 216f afforded a complex mixture which could not be separated using gravity
or flash chromatography. Attempts to increase the ratio of Pd/C from 1 eq. to 2 or 3 eq.
increasing reaction time or performing the hydrogenation at higher pressure (35 or 50 psi)
did not afford a cleaner reaction, presumably due to debenzylation of 217g under the
reaction conditions. Compound 217d was synthesized from 217b by the nucleophilic
displacement of the 4-Cl of 216b by ammonia in a sealed vessel reaction, similar to the
synthesis of 216b (Scheme 41).

D.3.2. Molecular Modeling Studies in the Colchicine Binding Site of Tubulin.
In an attempt to provide a molecular basis of the remarkable activity of the N-Me
analogs 218a and (±)-219a (Figure 76) and the inactivity of the N-desmethyl analogs
218b and (±)-219b (Figure 76), we have modeled compounds 218a – 219e (Figure 76)
into the colchicine binding site.50, 399 The X-ray crystal structure of tubulin at 3.58Å
resolution was obtained from the protein database (PDB ID 1SA0).232 This crystal
structure contains the dimers of tubulin complexed with N-deacetyl-N-(2mercaptoacetyl)colchicine (DAMA colchicine), a close structural analog of colchicine.
The binding of colchicine to the tubulin dimer has been described in the literature. 243, 452,
453

Colchine binds to  tubulin at its interface with  tubulin. The colchicine site has

dimensions of ~10 Å x ~10 Å x ~4-5 Å and is composed of strands S8 and S9, loop T7
and helices H7 and H8 from the  subunit and loop T5 from the  subunit of tubulin.232
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Thr179 and Val181 in the -tubulin subunit form hydrogen bonds with colchicine.
Additionally, Cys41 forms a hydrogen bond with the oxygen atom of the 3-OMe in the
A-ring of colchicine. Additional hydrophobic stabilization is afforded by side chain atoms
of Val181 and Met259. The carbonyl group of the A-ring also H-bonds with Lys352.
Docking studies50 were performed using the docking suite of MOE 2008.10.
Details of the docking protocol used are provided in the experimental section. Multiple
low-energy conformations (within 1kcal/mol of the best pose) were obtained on docking
(R)-219a and other analogs.

D.3.2.1. Docking of (R)- and (S)-219a in the colchicine binding site of tubulin.
Docking of (R)-219a in the colchicine binding site of tubulin.

The multiple docked poses can be explained by the large volume of the active site
(10 Å x 10 Å x 4-5 Å).232 Figure 139 shows the docked conformation of (R)-219a which
was selected as a working model for the docking of compounds 218a,b and 219a-e on the
basis of their structural similarity to the bound conformation of DAMA-colchicine. The
pose in Figure 139 for (R)-219a was ranked 4th in the results and had a score (-6.838
kcal/mol) within 1 kcal/mol of the best scored pose. 50, 399
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Figure 139:50, 399 Stereoview. Docked pose of (R)-219a (white) overlaid with DAMA colchicine
(red) in the colchicine binding site of tubulin.

Comparison of the docked conformation of (R)-219a50, 399 and the crystal structure
conformation of DAMA colchicine shows overlap of the 4’-OMe phenyl group of (R)219a with the tri-OMe containing A-ring of DAMA colchicine (Figure 139). In this pose
the 4’-OMe of (R)- 219a overlaps with the 3’-OMe group in the A ring of DAMA
colchicine. Similar interactions of -OMe groups with Cys241, as observed in Figure
139, have been reported in the literature.243 The conformation of (R)-219a depicted in
Figure 139 permits the formation of a hydrogen bond between Cys241 and the oxygen
atom of the 4’-OMe of (R)-219a as is observed with the 3’-OMe group of DAMA
colchicine in its X-ray crystal structure with tubulin. The phenyl ring of (R)-219a mimics
the A ring of colchicine and is involved in hydrophobic interactions with amino acids
from -tubulin (Leu248, Ala250, Leu255, Ala316). Additionally, the methyl group
from 4’-OMe could also interact with the side chain of Ile378 and/or with the side chain
of Val318.

248

The N-Me group of (R)-219a occupies a region in space in proximity to the C5
and C6 atoms of the B-ring of DAMA-colchicine. In this orientation the N-Me group is
involved in hydrophobic interactions with the side chain C atoms of Lys254 and
Ala250. An additional hydrophobic interaction between the N-Me moiety of (R)-219a
and the side chain C-atom of Leu248 also occurs due to the flexible nature of the protein
(measured distance between N-Me and side chain C of Leu248 is 4.21Å). These
interactions could assist in stabilization of the docked conformation of (R)-219a and
could partly explain the remarkable difference in activity of the N-desmethyl analog, (R)219b, of 219a which would lack these additional interactions (Figure 140). The N-Me
also aids in maintaining the relative conformations of the cyclopenta[d]pyrimidine and
the phenyl rings of R-219a. While similar docked poses were observed for 219b, the
docked poses of compounds with the N-Me group consistently scored higher (~1
kcal/mol) than those of compounds that lacked the N-Me group.50

The cyclopenta[d]pyrimidine of (R)-219a ring partially overlaps with the C-ring
of DAMA colchicine and is stabilized by hydrophobic interactions with side chains C
atoms of Leu255, Asn258 and Lys252. The C7 of (R)-219a overlaps the C9 carbonyl
C of DAMA colchicine. The C2 methyl group of (R)-219a is involved in a hydrophobic
interaction with Ala180 (4.35Å) while the C6-methyl group of (R)-219a is involved in
hydrophobic interactions with Val181 and Ala316. There was no significant difference
in the binding poses and the docked scores of (R)-219a (-6.838 kcal/mol) and (S)-219a (6.945 kcal/mol) due to the difference in the chirality of the C6-Me group (Figure 141).
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Figure 140:50 Stereoview. Superimposition of the docked poses of (R)-219a (white) and 219b
(magenta) in the colchicine binding site of tubulin.

Figure 141:50 Stereoview. Superimposition of the docked poses of (R)-219a (white), (S)-219a
(cyan) and DAMA colchicine (red) in the colchicine binding site of tubulin.

While this work was in progress a series of quinazolines454-457 and thieno[3,2d]pyrimidines458 as potent apoptosis inducers were published. These reports suggest a
similar function for the N-methyl moiety, but do not provide details about the binding
modes of the quinazolines and/or thieno[3,2-d]pyrimidines.
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Molecular modeling suggests that the binding interactions afforded by the 4’OMe group on the anilino ring also plays an important part in dictating the potency of
these compounds against tubulin. Deletion or moving the 4’-OMe moiety results in a
significant loss of activity. However, molecular modeling does not provide a reason(s) for
the loss of potency of (±)-219d compared to (±)-219a. We speculate that the loss of
potency could be explained either by the loss of interactions by the 4’-OMe moiety of
219a and/or the additional conformational restriction of the anilino ring by a combination
of N-methylation and the 2’-OMe moiety of 219d on the phenyl ring or both.50, 400

Figure 142:50 Stereoview. Docking mode of (R)-219a (white) overlaid with docked poses of 15
ligands243 (blue) in the colchicine binding site of tubulin.

Comparison of the binding mode of compounds (R)-219a to the reported binding
modes243 of 15 known tubulin inhibitors that bind to the colchicine site were carried out.
As an example, (R)-219a retains the key binding interactions exhibited by the known
tubulin inhibitors and is in a conformation consistent with those for the reported
compounds (Figure 142).
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D.3.2.1. Molecular dynamics calculations
While there was no significant difference in the binding poses and docked scores
of (R)-219a (-6.838 kcal/mol) and (S)-219a (-6.945 kcal/mol) due to the chirality of the
C6-Me group in the initial docking study, the biological evaluation studies of the two
isomers (Table 23) indicated that (S)-219a showed higher potency towards tubulin in
vitro assays. It was therefore of interest to perform molecular dynamics studies in order
to further probe the reasons for the difference in activities between the two enantiomers.

Table 23:459 Biological activities of (R)-219a and (S)-219a
Cmpd

(R,S)(S)-1•HCl
1•HCl
(R)-1•HCl
Paclitaxel
CA4

IC50 ± SD (nM)
SKOV3
SKOV-3
MDR-134.5 ± 1.4
60.9 ± 4.4
16.4 ± 1.6
62.66/6
± 6.7
85.9 ± 4.5
119.8 ±
2.95 ± 0.07
4,875 ±
11.3
6.05 ± 0.61
22.0
± 6.9
153

a

Rr

HeLa

1.8
3.8
1.4
1,622
3.6

37.3 ± 4.1
19.0 ± 0.9
92.9 ± 5.6
13.8 ± 0.13
4.09 ± 0.05

IC50 ± SD (nM)
WTβIII
23.9 ± 1.7
13.3 ± 0.5
67.7 ± 1.3
9/05 ± 51.1
4.02 ± 0.26

Figure 143. Stereo view. Superimposition of the final docked conformations of (R)-219a (blue)
and (S)-219a (white) in the colchicine site of tubulin.
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Rrb
0.6
0.7
0.7
6.6
0.98

Subjecting the docked poses of (R)-219a and S-219a to an unconstrained
molecular dynamics protocol in MOE 2010.10 (heating the system from 0o to 300o K
followed by equilibration, production for 500 ps and cooling to 0o K) revealed differences
in the final conformations of docked poses of the R- and S-enantiomers in the colchicine
site as shown in Figure 143. Compound S-219a is bound in a more favorable
conformation in the colchicine binding pocket as compared to R-219a, which permits the
formation of hydrophobic interactions between C2-Me and Leu248, and C6-Me and
Leu255 for S-219a. The corresponding C2- and C6-Me moieties of R-219a do not form
these hydrophobic interactions with Leu248 and Leu255 respectively. These
hydrophobic interactions could explain, in part, the improvement in the IC 50 value of S219a compared to R-219a against isolated tubulin. Prediction of the binding energies of
the docked conformations of R-219a and S-219a using the Hyde module in LeadIT
2.0.1460 indicated a greater contribution of the C6-Me group of the S-enantiomer (-6.5
kJ/mol) towards the total binding energy (-28 kJ/mol) of S-219a as compared to the
corresponding C6-Me moiety of R-219a (-5.1 kJ/mol) towards the total binding energy of
R-219a (-25kJ/mol).
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E. SUMMARY
The results from this work are reported into two sections listed below: synthesis of bicyclic
heterocyclic molecules and molecular modeling studies.
Synthesis of bicyclic heterocyclic molecules:
Following structural classes of compounds have been designed, synthesized and studied as
inhibitors of pjDHFR, RTKs and tubulin:
4. 2,4-Diamino-6-(substituted-arylmethyl)pyrido[2,3-d]pyrimidines
5. 4-((3-bromophenyl)linked)-6-(substituted-benzyl)-7H-pyrrolo[2,3-d]pyrimidin-2amines
6. 6-methyl-5-((substitutedphenyl)thio)-7H-pyrrolo[2,3-d]pyrimidin-2-amines
From these projects a total of thirty five new compounds (excluding intermediates) were
synthesized and characterized and were submitted for various biological assays. Results
from these biological evaluation studies will be presented in due course. These
compounds are as follows:
1. 170 6-(((2,5-difluorophenyl)amino)methyl)pyrido[2,3-d]pyrimidine-2,4-diamine
2. 171 6-(((2,4,6-trichlorophenyl)amino)methyl)pyrido[2,3-d]pyrimidine-2,4diamine
3. 172 6-(((2,3,4-trichlorophenyl)amino)methyl)pyrido[2,3-d]pyrimidine-2,4diamine
4. 173 6-(((2,6-dichlorophenyl)amino)methyl)pyrido[2,3-d]pyrimidine-2,4-diamine
5. 174 6-(((3,5-dichlorophenyl)amino)methyl)pyrido[2,3-d]pyrimidine-2,4-diamine
6. 175 6-(((3,4-dichlorophenyl)amino)methyl)pyrido[2,3-d]pyrimidine-2,4-diamine
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7. 176 6-(((3,4,6-trichlorophenyl)amino)methyl)pyrido[2,3-d]pyrimidine-2,4diamine
8. 177 6-(((2,4,5-trichlorophenyl)amino)methyl)pyrido[2,3-d]pyrimidine-2,4diamine
9. 178 6-(((2,3-dichlorophenyl)amino)methyl)pyrido[2,3-d]pyrimidine-2,4-diamine
10. 179 6-(((2,5-dibromophenyl)amino)methyl)pyrido[2,3-d]pyrimidine-2,4-diamine
11. 180 6-(((2,6-dinitrophenyl)amino)methyl)pyrido[2,3-d]pyrimidine-2,4-diamine
12. 186 6-(((2,5-dichlorophenyl)thio)methyl)pyrido[2,3-d]pyrimidine-2,4-diamine
13. 187 6-(((3,4,5-trichlorophenyl)thio)methyl)pyrido[2,3-d]pyrimidine-2,4-diamine
14. 188 6-(((2,5-difluorophenyl)thio)methyl)pyrido[2,3-d]pyrimidine-2,4-diamine
15. 189 6-((2,5-dichlorophenoxy)methyl)pyrido[2,3-d]pyrimidine-2,4-diamine
16. 190 6-((3,4,5-trichlorophenoxy)methyl)pyrido[2,3-d]pyrimidine-2,4-diamine
17. 191 6-((2,5-difluorophenoxy)methyl)pyrido[2,3-d]pyrimidine-2,4-diamine
18. 197 4-((3-bromophenyl)thio)-6-(2-methylbenzyl)-7H-pyrrolo[2,3-d]pyrimidin-2amine
19. 198 4-((3-bromophenyl)thio)-6-(2,4-dichlorobenzyl)-7H-pyrrolo[2,3-d]pyrimidin2-amine
20. 199 4-((3-bromobenzyl)thio)-6-(2-methylbenzyl)-7H-pyrrolo[2,3-d]pyrimidin-2amine
21. 200 4-((3-bromobenzyl)thio)-6-(2,4-dichlorobenzyl)-7H-pyrrolo[2,3-d]pyrimidin2-amine
22. 205 4-(3-bromophenoxy)-6-(2-methylbenzyl)-7H-pyrrolo[2,3-d]pyrimidin-2amine
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23. 206 4-(3-bromophenoxy)-6-(2,4-dichlorobenzyl)-7H-pyrrolo[2,3-d]pyrimidin-2amine
24. 207 4-((3-bromobenzyl)oxy)-6-(2-methylbenzyl)-7H-pyrrolo[2,3-d]pyrimidin-2amine
25. 208 4-((3-bromobenzyl)oxy)-6-(2,4-dichlorobenzyl)-7H-pyrrolo[2,3-d]pyrimidin2-amine
26. 209 N4-(3-bromobenzyl)-6-(2-methylbenzyl)-7H-pyrrolo[2,3-d]pyrimidine-2,4diamine
27. 210 N4-(3-bromobenzyl)-6-(2,4-dichlorobenzyl)-7H-pyrrolo[2,3-d]pyrimidine2,4-diamine
28. 216a 2-Amino-6-methyl-5-((3,4,5-trimethoxyphenyl)thio)-3,7-dihydro-4Hpyrrolo[2,3-d]pyrimidin-4-one
29. 216b 4-chloro-6-methyl-5-((3,4,5-trimethoxyphenyl)thio)-7H-pyrrolo[2,3d]pyrimidin-2-amine
30. 216c 6-methyl-5-((3,4,5-trimethoxyphenyl)thio)-7H-pyrrolo[2,3-d]pyrimidin-2amine
31. 216d 6-methyl-5-((3,4,5-trimethoxyphenyl)thio)-7H-pyrrolo[2,3-d]pyrimidine2,4-diamine
32. 216e 2-amino-7-benzyl-6-methyl-5-((3,4,5-trimethoxyphenyl)thio)-3,7-dihydro4H-pyrrolo[2,3-d]pyrimidin-4-one
33. 216f 7-benzyl-4-chloro-6-methyl-5-((3,4,5-trimethoxyphenyl)thio)-7Hpyrrolo[2,3-d]pyrimidin-2-amine

256

34. 216g 7-benzyl-6-methyl-5-((3,4,5-trimethoxyphenyl)thio)-7H-pyrrolo[2,3d]pyrimidin-2-amine
35. 216h 7-benzyl-6-methyl-5-((3,4,5-trimethoxyphenyl)thio)-7H-pyrrolo[2,3d]pyrimidine-2,4-diamine

In addition, bulk synthesis of the potent lead compound 170 (750 mg) was carried out to
facilitate in vivo evaluation.
During the bulk synthesis of 170, the following synthetic improvements were
achieved successfully including:
1. Use of a scalable alternate route to synthesize the advanced intermediate 92a
(Scheme 24) in one pot. This intermediate was used without purification without
significantly affecting the yield or purity of the reductive amination step needed
for synthesis of 170.
2. Use of mild reductive amination in presence of molecular sieves improved the
yield of 170 from 7% to 18% and reduced the amounts of side products generated
which are challenging to separate. Use of benchtop reductive amination instead of
reductive amination using a Paar-hydrogenation vessel is easily scalable, permits
parallel synthesis of multiple analogs from the common intermediate 92a, and
eliminates the use of hydrogen gas for reduction.

Docking Studies
Docking studies were performed using LeadIT, MOE, Sybyl or Flexx for the target
compounds listed above and for other compounds reported by Gangjee et al. against the
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following targets:
5. Dihydrofolate reductase: human, P. carinii, P. jirovecii and T. gondii.
6. Thymidylate synthase: human and T. gondii.
7. Receptor tyrosine kinases: VEGFR2, EGFR and PDGFR-
8. Colchicine binding site of tublulin.

There are no reported crystal structures for pjDHFR and PDGFR- At the time this
work was initiated there were no reported crystal structures for tgDHFR and tgTS. Hence
homology models were generated for these targets using MOE and validated using tools
available from the Swissmodel website in order to perform molecular modeling studies.
Models generated using MOE were validated by comparison with homology models
generated independently using various automated homology modeling servers available
online. The X-ray crystal structures of tgTS complexed with 194d and 194f were very
recently published. The tgTS homology model generated in this study and employed to
design novel agents shows remarkable similarity with the recently published X-ray crystal
structures (C RMSD = 0.68-0.72 Å). (Figure 101) At the time this work was initiated,
there were no previously reported homology models against pjDHFR. A novel homology
model was generated for the F36C L65P double mutant form of pjDHFR, which is resistant
to standard therapeutic agents such as TMP.

Docking studies were performed to provide a molecular basis for the observed activity
of target compounds against DHFR, RTKs or tubulin. Results from these studies support
structure-based and ligand-based medicinal chemistry efforts in order to improve potency
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and/or selectivity of analogs of the docked compounds against these targets. Key findings
from the docking studies against selected targets are listed below:
1. pjDHFR homology model: Docking studies of 192d (Figure 83) against pjDHFR
suggest that the interaction of N-Me of 192d Ile123 in pjDHFR but not with
Val115 in hDHFR, and conformational restriction of the terminal aniline moiety
by the N-Me group could explain, in part, the 300-fold improvement in potency of
192d against pjDHFR compared to the des-methyl compound 192e.
Docking studies suggest that steric clash with the larger Phe31 in hDHFR
compared to the smaller Met33 in pjDHFR (Figure 90) explain, in part, the 19fold selectivity of 193f for pjDHFR over hDHFR
2. F36C L65P double mutant pjDHFR homology model: Docking studies were
used to explain, in part, the 10-fold loss of potency of 168 against F36C L65P
double mutant pjDHFR and the 1000-fold loss of potency of standard TMP
against F36C L65P double mutant pjDHFR compared to wild-type pjDHFR.
3. tgDHFR homology model: Docking studies of 194a-b (Figure 91) in the
tgDHFR homology model suggest that the bulky naphthyl moiety in these
compounds is better accommodated in the larger binding pocket of tgDHFR
instead of the smaller pocket in hDHFR, and explains, in part, the the decreased
activity of 194a-b against hDHFR.
4. tgTS homology model: Docking studies of 194d-j in the tgTS homology model
suggest that additional interaction of the second ring of the 2-naphthyl moiety of
194e and the 1-naphthyl analog 194f with tgTS Phe374 compared to a lack of
similar interaction of the phenyl analog 194d (Figure 88) explains, in part, the 10-
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fold improved potency of 194e and 5-fold for 194f for tgTS over 194d.
Comparison of the predicted docked pose (Figure 102) and the recently published
X-ray crystal structure of 194e in tgTS show that the key interactions predicted by
the docking studies are maintained. This provides validation for the utility of the
docking software and protocols used in this study for design of analogs of these
compounds against tgTS.
5. RTKs: Results from docking studies of three series of bicyclic and tricyclic
inhibitors against VEGFR2, EGFR and PDGFR- homology model suggest that
the target compounds can have multiple distinct low-energy binding poses in the
ATP-binding pocket of these RTKs. In some cases the docking studies could
explain, in part, the observed activity of the target compounds against RTKs.
Findings from these docking studies provide validation for the original design
hypothesis by Gangjee et al. of multiple binding modes of a single agent as a
means of achieving multiple kinase inhibition in a single molecule. However, the
presence of multiple distinct binding modes reduces the predictive utility of these
models for novel compounds against the target RTKs.
6. Colchicine binding site of tubulin: Results from docking studies suggest that the
cyclopenta[d]pyrimidines (R)-219and (S)-219 and other compounds in the series
bind in the colchicine binding site of tubulin with the 4-methoxyphenyl moiety of
219 mimicking the A-ring of the crystal structure ligand DAMA-colchicine and
the cyclopenta[d]-pyrimidine scaffold mimicking the C-ring of DAMAcolchicine. The N4-Me mimicks the C5-C6 bridge of DAMA-colchicine and
helps maintain the relative orientation of the cyclopenta[d]pyrimidine scaffold
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and the 4-methoxyphenyl moiety. The 4’-OMe moiety of 219 overlaps the 3-OMe
of DAMA-colchicine. These findings explain, in part, the molecular basis of the
importance of both, the N-Me and 4’-OMe moieties in compounds of this series.

Topomer CoMFA models:
1. tgTS and hTS: Topomer CoMFA provides a useful method for generating 3DQSAR models that are insensitive to the initial structural alignment between
molecules used for model generation. Topomer CoMFA models were developed
for tgTS and hTS using a set of 85 bicyclic non-classical pyrrolo[2,3d]pyrimidines and thieno[2,3-d]pyrimidines using their tgTS and/or hTS
inhibitory data reported by Gangjee et al. The resultant tgTS topomer CoMFA
maps representing steric and electronic contributions could be used to explain the
potency difference between compounds 221a and 221b. Comparison of topomer
tgTS and hTS CoMFA maps show that the tgTS model is more tolerant to bulk
compared to the hTS model, and could explain, in part, the 10-fold tgTS
selectivity of 222a and 222b over hTS. The tgTS topomer CoMFA model was
further validated by docking 222b in a tgTS homology model and identifying
Phe374/Phe520 as residues which could interact with the bulky naphthyl ring of
222b.
2. RTKs: Topomer CoMFA models were developed for a set of 60 RTK inhibitors
with either a pyrrolo[2,3-d]pyrimidine or a furo[2,3-d]pyrimidine scaffold by
using their whole-cell inhibitory data against EGFR, VEGFR2 and PDGFR-.
Statistically significant models (q2 > 0.3) were developed for the pyrrolo[2,3-
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d]pyrimidine dataset but could not be developed for the furo[2,3-d]pyrimidine
dataset, possibly due to the low number of furo[2,3-d]pyrimidines for which
biological data could be obtained. Comparing the topomer CoMFA maps for
pyrrolo[2,3-d]pyrimidines show differences in the steric and/or electronic
requirements among the three RTKs, and could be used, in conjuction with other
medicinal chemistry approaches, to modulate the selectivity and/or potency of
inhibitors with multiple RTK inhibitory potential.

Drug design efforts that involve virtual library screening using these topomer CoMFA
models in conjunction with traditional medicinal chemistry techniques and docking are
currently underway.
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F. EXPERIMENTAL
Melting points were determined on a Mel-Temp II melting point apparatus with
FLUKE 51 K/J thermocouple and are uncorrected. Nuclear magnetic resonance spectra
for proton (1H) were recorded on a Bruker 300MHz spectrometer or Bruker 400MHz
spectrometer. The chemical shift values were expressed in ppm (parts per million)
relative to tetramethylsilane as internal standard; s = singlet, d = double, t = triplet, q =
quartet, m = multiplet, br = broad singlet. Nuclear magnetic resonance spectra for carbon
(13C NMR) were recorded on a Bruker 400MHz NMR spectrometer. The relative
integrals of peak areas agreed with those expected for the assigned structures. Highresolution mass spectra (HRMS) were recorded on a MICROMASS AUTOSPEC (EBE
Geometry) double focusing mass spectrometer (Electron Impact – EI) or Waters Q-TOF
(quadrupole/time-of-flight tandem instrument) mass spectrometer (Electro-Spray
Ionization – ESI). Thin-layer chromatography (TLC) was performed on WHATMAN
UV254 silica gel plates with a fluorescent indicator, and the spots were visualized under
254 and/or 365 nm illumination. Proportions of solvents used for TLC were by volume.
Column chromatography was performed on 230-400 mesh silica gel purchased from
ThermoFisher Scientific. All evaporations were carried out under reduced pressure using
a rotary evaporator. Analytical samples were dried under reduced pressure (0.2 mmHg) in
an Chem-Dry drying apparatus over P2O5 at 50-80 oC. Elemental analysis was performed
by Altlantic Microlabs, Norcross, GA. Element compositions are within  0.4% of
calculated values. Fractional moles of water or organic solvents frequently found in some
analytical samples could not be prevented despite 24-48 h of drying under reduced
pressure (0.1 torr) and were confirmed where possible by their presence in the 1H NMR
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spectra. All solvents and chemicals were purchased from Strem Chemicals Inc., SigmaAldrich Chemical Co. or Fisher Scientific. All of the chemicals and the solvents were
used as received.

Synthesis of 6-((substituted-phenylamino)methyl)pyrido[2,3-d]pyrimidine-2,4diamines
General procedure for synthesis of 170 – 173
Compounds 170 – 173 (Scheme 23) were synthesized using literature methods333
from the common synthons 91a or 92a and the corresponding anilines. Compounds
91a333 or 92a284 were synthesized according to literature methods. To a solution of the
substituted aniline in 70−80% acetic acid were added 91a and Raney Ni. The mixture
was hydrogenated in a Parr hydrogenation apparatus at atmospheric pressure and room
temperature for 6 h. TLC analysis using solvent A (5:1:0.1 CHCl3:MeOH:NH4OH) or
solvent B (6:1 CHCl3:MeOH) showed the disappearance of the starting material and the
appearance of a product spot along with a spot for the alcohol which resulted from an
over-reduction of the nitrile 91a or aldehyde 92a. The mixture was treated with Norit®
and filtered through Celite®. To the acidic filtrate was added 1−3 g of silica gel, and the
solvent was evaporated to afford a silica gel plug. Alternatively, the acidic filtrate was
evaporated and the residue dissolved in 50 mL of warm ethanol. The solution was
adjusted to pH 8 using 1 N Na2CO3 and the resulting crude precipitate filtered. The crude
product was stirred in hot methanol and filtered, to the filtrate was added 1−3 g of silica
gel, and the solvent was evaporated to afford a silica gel plug. The resulting plug was
applied to a 2.2 × 24 cm silica gel column and eluted with solvent C
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(6:1:0.1CHCl3:MeOH;NH4OH) or solvent D (5:1 CHCl3:MeOH). Fractions containing
pure product (TLC) were pooled and evaporated to afford analytically pure compounds
170−191.

6-(((2,5-Difluorophenyl)amino)methyl)pyrido[2,3-d]pyrimidine-2,4-diamine (170)
Compound 170 was synthesized from intermediate 91a (0.50 g, 2.64 mmol), 2,5fluoroaniline (0.68 g, 5.2 mmol), and Raney Ni (2.0 g) in 100 mL of 80% acetic acid for
48 h and purified by column chromatography using solvent D to afford a yellow solid
(0.07 g, 9%): mp > 232 °C dec; TLC Rf 0.2 in solvent D; 1H NMR (DMSO-d6) δ 4.38
(d, 2 H, CH2), 6.26−6.33 (m, 3 H, 2-NH2 and NH, exch.), 6.58 (m, 2 H, 2‘,4‘-H), 7.26 (t,
1 H 3‘-H), 7.49 (br, 2 H, 4-NH2, exch), 8.49 (s, 1 H, 5-H), 8.58 (d, 1 H, 7-H). HR-MS:
C14H12F2N6: calcd. mass 302.1092, found mass 302.1091.

6-(((2,4,6-Trichlorophenyl)amino)methyl)pyrido[2,3-d]pyrimidine-2,4-diamine (171)
Compound 171 was synthesized from intermediate 91a (0.25 g, 1.3 mmol), 2,4,6trichloroaniline (0.52 g, 2.6 mmol), and Raney Ni (1.0 g) in 100 mL of 80% acetic acid
for 48 h and purified by column chromatography using solvent D to afford a brown solid
(0.02 g, 5%): mp > 240 °C dec; TLC Rf 0.2 in solvent D; 1H NMR (DMSO-d6) δ 4.35
(d, 2 H, CH2), 6.26−6.33 (m, 3 H, 2-NH2 and NH, exch.), 7.26 (d, 2 H 3‘,5’-H), 7.49 (br,
2 H, 4-NH2, exch), 8.49 (s, 1 H, 5-H), 8.58 (d, 1 H, 7-H). HR-MS: C14H11N6Cl3: calcd.
mass 368.0111, found mass 368.0106.

6-(((2,3,4-Trichlorophenyl)amino)methyl)pyrido[2,3-d]pyrimidine-2,4-diamine (172)
Compound 172 was synthesized from intermediate 91a (0.25 g, 1.3 mmol), 2,3,4266

trichloroaniline (0.52 g, 2.6 mmol), and Raney Ni (1.0 g) in 100 mL of 80% acetic acid
for 48 h and purified by column chromatography using solvent D to afford a brown solid
(0.01 g, 3%): mp > 240 °C dec; TLC Rf 0.2 in solvent D; 1H NMR (DMSO-d6) δ 4.38
(d, 2 H, CH2), 6.33−6.36 (m, 3 H, 2-NH2 and NH, exch.), 6.41 (d, 1 H 6’-H), 7.09 (d, 1 H
5’-H), 7.46 (br, 2 H, 4-NH2, exch), 8.49 (s, 1 H, 5-H), 8.56 (d, 1 H, 7-H). HR-MS:
C14H11N6Cl3: calcd. mass 368.0111, found mass 368.0121.

6-(((2,6-Dichlorophenyl)amino)methyl)pyrido[2,3-d]pyrimidine-2,4-diamine (173)
Compound 173 was synthesized from intermediate 91a (0.25 g, 1.32 mmol), 2,6dichloroaniline (0.42 g, 2.6 mmol), and Raney Ni (1.0 g) in 100 mL of 80% acetic acid
for 48 h and purified by column chromatography using solvent B to afford a yellow solid
(0.02 g, 4%): mp > 230 °C dec; TLC Rf 0.25 in solvent A; 1H NMR (DMSO-d6) δ 4.38
(d, 2 H, CH2), 6.26−6.33 (m, 3 H, 2-NH2 and NH, exch.), 6.89 (m, 1 H, 2‘,4‘-H), 7.317.33 (m, 2 H 3‘, 5’-H), 7.49 (br, 2 H, 4-NH2, exch), 8.36 (s, 1 H, 5-H), 8.63 (d, 1 H, 7-H).
HR-MS: C14H12N6Cl2: calcd. mass 334.0500, found mass 334.0488.

6-(((3,5-Dichlorophenyl)amino)methyl)pyrido[2,3-d]pyrimidine-2,4-diamine (174)
Compound 174 was synthesized from intermediate 92a (0.25 g, 1.32 mmol), 3,5dichloroaniline (0.44 g, 2.6 mmol), and Raney Ni (1.0 g) in 100 mL of 80% acetic acid
for 48 h and purified by column chromatography using solvent B to afford a yellow solid
(0.035 g, 7%): mp > 236 °C dec; TLC Rf 0.2 in solvent A; 1H NMR (DMSO-d6) δ 4.37
(d, 2 H, CH2), 6.26−6.33 (m, 3 H, 2-NH2 and NH, exch.), 6.89 (m, 1 H, 2‘,4‘-H), 7.287.33 (m, 1 H 4’-H), 7.59 (br, 2 H, 4-NH2, exch), 8.36 (s, 1 H, 5-H), 8.63 (d, 1 H, 7-H).
HR-MS: C14H12N6Cl2: calcd. mass 334.0500, found mass 334.0512.
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6-(((3,4-Dichlorophenyl)amino)methyl)pyrido[2,3-d]pyrimidine-2,4-diamine (175)
Compound 175 was synthesized from intermediate 92a (0.25 g, 1.32 mmol), 3,4dichloroaniline (0.44 g, 2.6 mmol), and Raney Ni (1.0 g) in 100 mL of 80% acetic acid
for 48 h and purified by column chromatography using solvent B to afford a yellow solid
(0.03 g, 6%): mp > 235 °C dec; TLC Rf 0.23 in solvent A; 1H NMR (DMSO-d6) δ 4.36
(d, 2 H, CH2), 6.28−6.31 (m, 3 H, 2-NH2 and NH, exch.), 6.90 (m, 1 H, 6‘-H), 7.28-7.33
(m, 2 H 4’, 5’-H), 7.56 (br, 2 H, 4-NH2, exch), 8.34 (s, 1 H, 5-H), 8.61 (d, 1 H, 7-H). HRMS: C14H12N6Cl2: calcd. mass 334.0500, found mass 334.0502.

6-(((3,4,6-Trichlorophenyl)amino)methyl)pyrido[2,3-d]pyrimidine-2,4-diamine (176)
Compound 176 was synthesized from intermediate 92a (0.25 g, 1.32 mmol), 3,4dichloroaniline (0.44 g, 2.6 mmol), and Raney Ni (1.0 g) in 100 mL of 80% acetic acid
for 48 h and purified by column chromatography using solvent B to afford a brown solid
(0.03 g, 6%): mp > 265 °C dec; TLC Rf 0.23 in solvent A; 1H NMR (DMSO-d6) δ 4.26
(d, 2 H, CH2), 6.31 (br, 2 H, 2-NH2, exch.), 6.78 – 6.83 (m, 2 H, 6‘-H, NH exch.), 7.47 (s,
1 H 5’-H), 7.56 (br, 2 H, 4-NH2, exch), 8.30 (s, 1 H, 5-H), 8.58 (d, 1 H, 7-H). HR-MS:
C14H11N6Cl3: calcd. mass 368.0111, found mass 368.0116.

6-(((2,4,5-Trichlorophenyl)amino)methyl)pyrido[2,3-d]pyrimidine-2,4diamine (177)
Compound 177 was synthesized from intermediate 92a (0.25 g, 1.32
mmol), 3,4-dichloroaniline (0.44 g, 2.6 mmol), and Raney Ni (1.0 g) in 100 mL of
80% acetic acid for 48 h and purified by column chromatography using solvent B
268

to afford a brown solid (0.03 g, 6%): mp > 265 °C dec; TLC Rf 0.23 in solvent A;
1

H NMR (DMSO-d6) δ 4.26 (d, 2 H, CH2), 6.31 (br, 2 H, 2-NH2, exch.), 6.78 –

6.83 (m, 2 H, 6‘-H, NH exch.), 7.47 (s, 1 H 5’-H), 7.56 (br, 2 H, 4-NH2, exch),
8.30 (s, 1 H, 5-H), 8.58 (d, 1 H, 7-H). HR-MS: C14H11N6Cl3: calcd. mass
368.0111, found mass 368.0112.

6-(((2,3-Dichlorophenyl)amino)methyl)pyrido[2,3-d]pyrimidine-2,4-diamine (178)
Compound 178 was synthesized from intermediate 92a (0.25 g, 1.32 mmol), 3,4dichloroaniline (0.44 g, 2.6 mmol), and Raney Ni (1.0 g) in 100 mL of 80% acetic acid
for 48 h and purified by column chromatography using solvent A to afford a yellow solid
(0.03 g, 6%): mp > 233 °C dec; TLC Rf 0.23 in solvent D; 1H NMR (DMSO-d6) δ 4.36
(d, 2 H, CH2), 6.28−6.31 (m, 3 H, 2-NH2 and NH, exch.), 6.90 (m, 1 H, 6‘-H), 7.28-7.33
(m, 2 H 4’, 5’-H), 7.56 (br, 2 H, 4-NH2, exch), 8.34 (s, 1 H, 5-H), 8.61 (d, 1 H, 7-H). HRMS: C14H12N6Cl2: calcd. mass 334.0500, found mass 334.0505.

6-(((2,5-Dibromophenyl)amino)methyl)pyrido[2,3-d]pyrimidine-2,4-diamine (179)
Compound 179 was synthesized from intermediate 92a (0.25 g, 1.32 mmol), 3,4dichloroaniline (0.44 g, 2.6 mmol), and Raney Ni (1.0 g) in 100 mL of 80% acetic acid
for 48 h and purified by column chromatography using solvent A to afford a yellow solid
(0.03 g, 6%): mp > 233 °C dec; TLC Rf 0.23 in solvent D; 1H NMR (DMSO-d6) δ 4.37
(d, 2 H, CH2), 6.26−6.33 (m, 3 H, 2-NH2 and NH, exch), 6.56 (m, 2 H, 2‘,4‘-H), 7.24 (t, 1
H 3‘-H), 7.49 (br, 2 H, 4-NH2, exch), 8.49 (s, 1 H, 5-H), 8.58 (d, 1 H, 7-H). HR-MS:
C14H12N6Br2: calcd. mass 421.9490, found mass 421.9501.
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6-(((2,6-dinitrophenyl)amino)methyl)pyrido[2,3-d]pyrimidine-2,4-diamine (180)
Compound 180 was synthesized from intermediate 92a (0.25 g, 1.32 mmol), 3,4dichloroaniline (0.44 g, 2.6 mmol), and Raney Ni (1.0 g) in 100 mL of 80% acetic acid
for 48 h and purified by column chromatography using solvent A to afford a yellow solid
(0.03 g, 6%): mp > 233 °C dec; TLC Rf 0.23 in solvent D; 1H NMR (DMSO-d6) δ 4.37
(d, 2 H, CH2), 6.26−6.33 (m, 3 H, 2-NH2 and NH, exch), 6.56 (m, 2 H, 2‘,4‘-H), 7.24 (t, 1
H 3‘-H), 7.49 (br, 2 H, 4-NH2, exch), 8.49 (s, 1 H, 5-H), 8.58 (d, 1 H, 7-H). HR-MS:
C14H12N6O4 calcd. mass 356.0982, found mass 356.0969.

General procedure for bulk synthesis of 170
A mixture of intermediate 92a (0.50 g, 2.64 mmol) and 2,5-fluoroaniline (0.68 g,
5.2 mmol) in 20 mL of 80% acetic acid was stirred for 12 h in presence of activated 4 Å
molecular sieves. Sodium triacetoxyborohydride (1.68 g, 7.93 mmol) was added in
divided portions to the mixture, with the first half being added at 12 h and the other at 24
h after initiation of the reaction. The reaction was monitored by TLC (5:1 CHCl3:MeOH).
At the end of the reaction, the solution was filtered by filter paper to remove the
molecular sieves and concentrated in vacuo. To the concentrated acidified solution was
added silica gel (1 – 3 g) and a plug was formed by evaporation. The resulting plug was
applied to a 2.2 × 24 cm silica gel column and eluted with solvent C (6:1:0.1CHCl3:
MeOH;NH4OH). Fractions containing pure product (TLC) were pooled and evaporated to
afford analytically pure 170 as yellow solid (0.13 g, 14%): mp > 232 °C dec; TLC Rf 0.2
in solvent D; 1H NMR (DMSO-d6) δ 4.38 (d, 2 H, CH2), 6.26−6.33 (m, 3 H, 2-NH2 and
NH, exch.), 6.58 (m, 2 H, 2‘,4‘-H), 7.26 (t, 1 H 3‘-H), 7.49 (br, 2 H, 4-NH2, exch), 8.49
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(s, 1 H, 5-H), 8.58 (d, 1 H, 7-H).
General procedure for the synthesis of compounds 186-191.
Compounds 186 – 191 were synthesized from intermediate 94a. Intermediate 94a was
synthesized from 91a using literature methods.344 To a cooled solution (0–5 °C) of the
appropriate arylthiol dissolved in N,N-dimethyl acetamide or N,N-dimethyl formamide
was added sodium hydride, triethyl amine or potassium carbonate. The solution was
stirred under nitrogen for 15 min before intermediate 94a was added. The reaction was
allowed to warm to room temperature and stirred for 24 h under nitrogen. The desired
product precipitated out of solution. The yellow solid was filtered and washed with water,
ethanol and ether. Thin layer chromatographic analyses were performed in two solvent
systems using solvent A (5:1:0.1 CHCl3:MeOH:NH4OH) or solvent B (6:1
CHCl3:MeOH). The crude precipitate was re-dissolved in warm N,N-dimethylformamide
and 1 g of silica gel added to this solution and the solvent was evaporated to afford a plug
of silica gel for column chromatographic purification. The crude product silica gel plug
was loaded onto a silica gel column and eluted with solvent D (5:1 CHCl3:MeOH).
Fractions shown by thin layer chromatography to contain pure product were pooled and
evaporated to afford a light yellow solid. The solid was washed with water, ethanol and
ether. All solids were dried in vacuum with the aid of phosphorous pentoxide.

6-(((2,5-dichlorophenyl)thio)methyl)pyrido[2,3-d]pyrimidine-2,4-diamine (186)
Compound 186 was synthesized from intermediate 94a (0.25 g, 1 mmol) and 2,5dichlorobenzenethiol (0.21 g, 1.2 mmol) using NaH (0.035 g, 1.5 mmol) as the base in 10
mL of N,N-dimethyl formamide as the solvent using the general method described above
and purified by column chromatography using solvent D. Compound 186 was obtained as
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a yellow solid (0.03 g, 10%): mp > 243 °C dec; TLC Rf 0.56 in solvent A; 1H NMR
(DMSO-d6) δ 4.39 (s, 2 H, CH2), 6.68 (s, 2 H, 2-NH2 exch.), 6.56 (m, 2 H, 2‘,4‘-H),
7.24-7.49 (m, 3 H 3‘,4’,5’-H), 7.84 (br, 2 H, 4-NH2, exch), 8.49 (s, 1 H, 5-H), 8.68 (d, 1
H, 7-H). HR-MS: C14H11Cl2N5S: calcd. mass 351.0112, found mass 351.0108.

6-(((3,4,5-trichlorophenyl)thio)methyl)pyrido[2,3-d]pyrimidine-2,4-diamine (187)
Compound 187 was synthesized from intermediate 94a (0.25 g, 1 mmol) and 3,4,5trichlorobenzenethiol (0.25 g, 1.2 mmol) using NaH (0.035 g, 1.5 mmol) as the base in 10
mL of N,N-dimethyl formamide as the solvent using the general method described above
and purified by column chromatography using solvent D. Compound 187 was obtained as
a yellow solid (0.03 g, 10%): mp > 246 °C dec; TLC Rf 0.59 in solvent A; 1H NMR
(DMSO-d6) δ 4.22 (d, 2 H, CH2), 6.31 (br, 2 H, 2-NH2 exch.), 6.78-6.82 (m, 2 H, 2‘,6‘-H ),
7.49 (br, 2 H 4-NH2 exch.), 8.30 (d, 1 H, 5-H), 8.58 (d, 1 H, 7-H) HR-MS: C14H10Cl3N5S:
calcd. mass 384.9722, found mass 384.9716.

6-(((2,5-difluorophenyl)thio)methyl)pyrido[2,3-d]pyrimidine-2,4-diamine (188)
Compound 188 was synthesized from intermediate 94a (0.25 g, 1 mmol) and 2,5difluorobenzenethiol (0.15 g, 1.2 mmol) using NaH (0.035 g, 1.5 mmol) as the base in 10
mL of N,N-dimethyl formamide as the solvent using the general method described above
and purified by column chromatography using solvent D. Compound 188 was obtained as
a yellow solid (0.03 g, 10%): mp > 240°C dec; TLC Rf 0.23 in solvent D; 1H NMR
(DMSO-d6) δ 4.37 (d, 2 H, CH2), 6.28 (br, 2 H, 2-NH2 exch.), 6.56 (m, 2 H, 2‘,4‘-H), 7.24
(t, 1 H 3‘-H), 7.49 (br, 2 H, 4-NH2, exch), 8.49 (s, 1 H, 5-H), 8.58 (d, 1 H, 7-H). HR-MS:
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C14H11F2N5S: calcd. mass 319.0703, found mass 319.0711.

6-((2,5-dichlorophenoxy)methyl)pyrido[2,3-d]pyrimidine-2,4-diamine (189)
Compound 189 was synthesized from intermediate 94a (0.25 g, 1 mmol) and 2,5dichlorophenol (0.25 g, 1.2 mmol) using K2CO3 (0.2 g, 1.5 mmol) as the base in 10 mL
of N,N-dimethyl formamide as the solvent using the general method described above and
purified by column chromatography using solvent D. Compound 189 was obtained as a
light yellow solid (0.026 g, 8%): mp > 230 °C dec; TLC Rf 0.23 in solvent D; 1H NMR
(DMSO-d6) δ 4.37 (d, 2 H, CH2), 6.26 (br, 2 H, 2-NH2 exch), 6.56 (m, 2 H, 2‘,4‘-H),
7.24 (t, 1 H 3‘-H), 7.49 (br, 2 H, 4-NH2, exch), 8.49 (s, 1 H, 5-H), 8.58 (d, 1 H, 7-H).
HR-MS: C14H11Cl2N5O: calcd. mass 335.0341, found mass 335.0344.

6-((3,4,5-trichlorophenoxy)methyl)pyrido[2,3-d]pyrimidine-2,4-diamine (190)
Compound 190 was synthesized from intermediate 94a (0.25 g, 1 mmol) and
3,4,5-trichlorophenol (0.23 g, 1.2 mmol) using NaH (0.035 g, 1.5 mmol) as the base in 10
mL of N,N-dimethyl formamide as the solvent using the general method described above
and purified by column chromatography using solvent D. Compound 190 was obtained as
a yellow solid (0.038 g, 11%): mp > 236 °C dec; TLC Rf 0.23 in solvent D; 1H NMR
(DMSO-d6) δ 4.23 (d, 2 H, CH2), 6.34 (br, 2 H, 2-NH2 exch.), 6.78-6.83 (m, 2 H, 2‘,6‘H), 7.50 (br, 2 H 4-NH2 exch.), 8.31 (d, 1 H, 5-H), 8.58 (d, 1 H, 7-H) HR-MS:
C14H10Cl3N5O: calcd. mass 368.9951, found mass 368.9960.
General Procedure for the Synthesis of 228a,b
Compounds 228a,b were synthesized using reported literature methods. 387 A
solution of substituted phenyl acetic acids (5 mmol) in 5 mL of dry toluene and 5 mL of
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thionyl chloride was heated at reflux for 1 h and the colorless solution was evaporated in
vacuo. The resulting acid chloride was dissolved in 10 mL of ether and added dropwise
with stirring to 30 mL of ethereal diazomethane (about 13 mmol, made from 20 mmol of
N-nitroso-N-methyl urea)461 at 0–5 °C. The yellow solution was allowed to stand at room
temperature for 1 h, then 5 mL of 47.5% aqueous HBr was added drop wise to the
solution and the yellow mixture was heated at 70–80 °C (oil bath) for 1 h. The reaction
was cooled to room temperature and the ether layer was separated, washed with water (10
mL), saturated NaHCO3 aqueous solution (10 mL) and water (10 mL) and dried
(anhydrous Na2SO4). The solution was evaporated to afford the α-bromomethyl benzyl
ketones 226a-b which were used in the next step without further purification.
The α-bromomethyl benzyl ketones 226a-b was placed in a 50-mL flask with an
equivalent amount of 2,6-diaminopyrimidin-4-one 227 and 5 mL dry DMF was added to
form a clear solution. The mixture was stirred at room temperature for 3 days. After 1 day
the reaction mixture darkened and at the third day of the reaction, a solid could be
precipitated out in some cases. To the reaction mixture was added 1 g of silica gel and the
solvent was evaporated in vacuo to afford a dry plug. This plug was placed on the top of
45×150 mm silica gel column and eluted with CHCl3/MeOH (gradient elution, 2%
MeOH in CHCl3, and 5% MeOH in CHCl3). Fractions containing the product (TLC)
were pooled and evaporated to afford the pure 2-amino-4-oxo-6-substituted benzyl
pyrrolo[2,3-d]pyrimidines 228a-b.

2-Amino-4-oxo-6-(2-methylbenzyl)-pyrrolo[2,3-d]pyrimidine 228a
1-bromo-3-(2-methylphenyl)-acetone 226a was obtained from 2methylphenylacetic acid (0.75 g, 5 mmol)using the general procedure described above as
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a yellow oil (0.64 g, 56%). Rf : 0.55 (Hexane/EtOAc, 3:1). 1H NMR (CDCl3): δ 2.25 (s,
3H, CH3), 3.85 (s, 2H, CH2), 3.95 (s, 2H, CH2), 7.10–7.22 (m, 4H, Ph–H).
Using the general procedure described above, compound 226a (1 g, 4.2 mmol)
reacted with an equivalent amount of 2,6-diaminopyrimidin-4-one 227 to afford
compound 228a (400 mg, 51%) as a yellow solid. Mp: 287 °C. (Lit. 387 290 °C) TLC Rf
0.56 (CHCl3/CH3OH, 5:1). 1H NMR (DMSO-d6): δ 2.32 (s, 3H, CH3), 3.90 (s, 2H, CH2),
5.85 (s, 1H, C5-CH), 6.03 (s, 2H, NH2, exch.), 7.14–7.28 (m, 4H, Ar–H), 10.10 (s, 1H,
NH, exch.), 10.94 (s, 1H, NH).

2-Amino-4-oxo-6-(2,4-dichlorobenzyl)-pyrrolo[2,3-d]pyrimidine 228b
1-bromo-3-(2,4-dichlorophenyl)-acetone 226b was obtained from 2,4dichlorophenylacetic acid (1.02 g, 5 mmol),using the general procedure described above
as a white solid (0.68 g, 50%). Mp: 71–73 °C. (Lit.387 70 – 73 °C). TLC Rf0.60
(Hexane/EtOAc, 3:1). 1H NMR (CDCl3): δ 3.95 (s, 2H, CH2), 4.05 (s, 2H, CH2), 7.20–
7.45 (m, 3H, Ar–H).
Using the general procedure described above, compound 226b (700 mg, 2.5 mmol) was
reacted with an equivalent amount of 2,6-diaminopyrimidin-4-one 227 to afford the
compound 228b (430 mg, 43%) as a yellow solid. Mp: 265 °C. TLC Rf 0.51
(CHCl3/CH3OH, 5:1). 1H NMR (DMSO-d6): δ 3.94 (s, 2H, CH2), 5.85 (s, 1H, C5-CH),
7.25–7.60 (m, 3H, Ar–H), 8.24 (s, br., 2H, NH2, exch.), 10.60 (s, 1H, NH, exch.), 11.20
(s, 1H, NH, exch.).
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General procedure for the synthesis of compounds 230a-b
2-Amino-4-oxo-6-substitued-pyrrolo[2,3-d]pyrimidines 228a or 228b (about 1
mmol), 5 mL of POCl3 and 0.1 mL of PhNMe2 were placed in a 50-mL round-bottom
flask. The mixture was heated to reflux and kept stirring for 4 h. After evaporation of the
excess of POCl3, crushed ice was added to the mixture. The reaction mixture was
neutralized with NH3·H2O (pH 7, tested with a pH paper), and extracted with
CHCl3 (3×50 mL). The organic phase was combined and dried with Na2SO4.
Concentration of the chloroform layer afforded a brown solid that was re-dissolved in
chloroform (2–3 mL) and was placed to the top of a 15×150 mm column and eluted with
0.1% methanol in chloroform. Alternatively, a silica gel plug was formed using around
500mg of silica gel and was placed on top of the column for chromatography. Fractions
containing the product were pooled and evaporated to afford pure 2-amino-4-chloro-6substitued-pyrrolo[2,3-d]pyrimidine 230a-b.

2-Amino-4-chloro-6-(2-methylbenzyl)-pyrrolo[2,3-d]pyrimidine 230a
Compound 230a was synthesized from 2-amino-4-oxo-6-(2-methylbenzyl)-pyrrolo[2,3d]pyrimidine 228a (200 mg, 0.78 mmol) using the general procedure described above to
afford 230a 64 mg (29%) as a light yellow solid. Mp: 250-252 °C (Lit.387 250 °C).
TLC Rf 0.53 (CHCl3/CH3OH, 10:1). 1H NMR (DMSO-d6): δ 3.91 (s, 2H, CH2), 5.69 (s,
1H, C5-CH), 6.42 (s, 2H, NH2), 7.13–7.16 (m, 4H, Ar–H), 11.46 (s, 1H, NH).
2-Amino-4-chloro-6-(2,4-dichlorobenzyl)-pyrrolo[2,3-d]pyrimidine 35b
Compound 230b was synthesized from 2-amino-4-oxo-6-(2,4-dichlorobenzyl)pyrrolo[2,3-d]pyrimidine 228b (300 mg, 0.97 mmol) using the general procedure
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described above to afford 107 mg (32%) of 230b as a light yellow solid. Mp: >250 °C
(Lit.387 >255 °C) . TLC Rf 0.5 (CHCl3/CH3OH, 10:1). 1H NMR (DMSO-d6): δ 4.17 (s,
2H, CH2), 5.82 (s, 1H, C5-CH), 6.48 (s, 2H, NH2), 7.33–7.66 (m, 3H, Ar–H), 11.53 (s,
1H, NH).
General method for synthesis of 197-200, 205-210
Compounds 197-200, 205-210 were synthesized from the nucleophilic
displacement of the 4-chloro moiety of intermediates 230a-b. Intermediates 230a-b were
synthesized using literature methods.462 To a cooled solution (0–5 °C) of 3bromobenzenethiol, 3-bromophenol, (3-bromophenyl)methanethiol, (3bromophenyl)methanol or (3-bromophenyl)methanamine in iPrOH or nBuOH was added
2 eq. of base (sodium hydride, triethyl amine or potassium carbonate). The solution was
stirred under nitrogen for 30 min before intermediate 230a or 230b was added. The
reaction was allowed to warm to room temperature and stirred for 24 h under nitrogen. To
the solution was added 1-3 g of silica gel was added to the mixture concentrated in vacuo
to afford a plug of silica gel for column chromatographic purification. Thin layer
chromatographic analyses were performed in two solvent systems using solvent A
(5:1:0.1 CHCl3:MeOH:NH4OH) or solvent B (10:1 CHCl3:MeOH). The crude product
silica gel plug was loaded onto a silica gel column and eluted with solvent D (5:1
CHCl3:MeOH). Fractions shown by thin layer chromatography to contain pure product
were pooled and evaporated to afford a solid. The solid was washed with water, ethanol
and ether. All solids were dried in vacuum with the aid of phosphorous pentoxide.
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4-((3-bromophenyl)thio)-6-(2-methylbenzyl)-7H-pyrrolo[2,3-d]pyrimidin-2-amine
(197 )
Compound 197 was synthesized from intermediate 230a (0.2 g, 0.75 mmol) and
3-bromobenzenethiol (0.27 g, 1.5 mmol) using K2 CO3 (0.2 g, 1.5 mmol) as the base in 10
mL of iPrOH as the solvent using the general method described above and purified by
column chromatography using solvent D. Compound 189 was obtained (11 mg, 18%) as
an off white solid. Mp: 241–243 °C. TLC Rf 0.49 (CHCl3/CH3OH, 10:1). 1H NMR
(DMSO-d6): δ 2.27 (s, 3H, CH3), 3.89 (s, 2H, CH2), 4.36 (s, 2H, CH2) 5.72 (s, 2H, NH2
exch.), 5.98 (s, 1H, C5-CH), 7.04–7.20 (m, 6H, Ar–H), 7.99–8.09 (m, 2H, Ar–H), 8.88 (s,
1H, NH, exch.), 10.91 (s, 1H, NH, exch.) Anal. (C20H17N4BrS): Cal. C: 56.48, H: 4.03, N:
13.17. Found C: 56.45, H: 3.98, N: 13.13.

((3-bromophenyl)thio)-6-(2,4-dichlorobenzyl)-7H-pyrrolo[2,3-d]pyrimidin-2-amine
(198)
Compound 198 was synthesized from intermediate 230b (0.2 g, 0.75 mmol) and
3-bromobenzenethiol (0.27 g, 1.5 mmol) using K2 CO3 (0.2 g, 1.5 mmol) as the base in 10
mL of iPrOH as the solvent using the general method described above and purified by
column chromatography using solvent D. Compound 198 was obtained (11 mg, 18%) as
an off white solid. Mp: 237–239 °C. TLC Rf 0.49 (CHCl3/CH3OH, 10:1). 1H NMR
(DMSO-d6): δ 2.27 (s, 3H, CH3), 3.89 (s, 2H, CH2), 5.73 (s, 2H, NH2), 5.98 (s, 1H, C5CH), 7.04–7.20 (m, 6H, Ar–H), 7.99–8.09 (m, 2H, Ar–H), 8.87 (s, 1H, NH), 10.91 (s, 1H,
NH). Anal. (C20H17N4BrS): Cal. C: 56.48, H: 4.03, N: 13.17. Found C: 56.45, H: 3.98, N:
13.13.
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4-((3-bromobenzyl)thio)-6-(2-methylbenzyl)-7H-pyrrolo[2,3-d]pyrimidin-2-amine
(199)
Compound 199 was synthesized from intermediate 230a (0.2 g, 0.75 mmol) and
3-bromobenzenethiol (0.29 g, 1.5 mmol) using tBuOK (0.16 g, 1.5 mmol) as the base in
10 mL of iPrOH as the solvent using the general method described above and purified by
column chromatography using solvent D. Compound 189 was obtained (62 mg, 24%) as
an off white solid. Mp: 226–228 °C. TLC Rf 0.52 (CHCl3/CH3OH, 10:1). 1H NMR
(DMSO-d6): δ 2.29 (s, 3H, CH3), 3.85 (s, 2H, CH2), 5.72 (s, 2H, NH2), 5.91 (s, 1H, C5CH), 7.08–7.35 (m, 6H, Ar–H), 7.94–8.03 (m, 2H, Ar–H), 10.93 (s, 1H, NH). Anal.
(C21H19N4BrS): Cal. C: 57.41, H: 4.03, N: 12.75. Found C: 57.45, H: 4.28, N: 12.71.

4-((3-bromobenzyl)thio)-6-(2,4-dichlorobenzyl)-7H-pyrrolo[2,3-d]pyrimidin-2-amine
(200)
Compound 200 was synthesized from intermediate 230b (0.2 g, 0.6 mmol) and 3bromobenzenethiol (0.25 g, 1.2 mmol) using tBuOK (0.14 g, 1.2 mmol) as the base in 10
mL of nBuOH as the solvent using the general method described above and purified by
column chromatography using solvent D. Compound 189 was obtained (44 mg, 15%) as
an off white solid. Mp: 231–233 °C. TLC Rf 0.52 (CHCl3/CH3OH, 10:1). 1H NMR
(DMSO-d6): δ 3.96 (s, 2H, CH2), 5.91 (s, 2H, NH2 exch), 6.04 (s, 1H, C5-CH), 7.08–7.45
(m, 5H, Ar–H), 7.91–8.02 (m, 2H, Ar–H), 11.03 (s, 1H, NH). Anal. (C20H15N4Cl2BrS
0.35H2O): Cal. C: 48.60, H: 3.06, N: 11.34. Found C: 47.88, H: 3.04, N: 11.12.
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4-(3-bromophenoxy)-6-(2-methylbenzyl)-7H-pyrrolo[2,3-d]pyrimidin-2-amine (205)
Compound 205 was synthesized from intermediate 230a (0.2 g, 0.75 mmol) and
3-3-bromophenol (0.17 g, 1.5 mmol) using K2CO3 (0.16 g, 1.5 mmol) as the base in 10
mL of iPrOH as the solvent using the general method described above and purified by
column chromatography using solvent D. Compound 205 was obtained (66 mg, 22%) as
an off white solid. Mp: > 239 °C dec. TLC Rf 0.49 (CHCl3/CH3OH, 10:1). 1H NMR
(DMSO-d6): 1H NMR (DMSO-d6): δ 2.26 (s, 3H, CH3), 3.84 (s, 2H, CH2), 5.72 (s, 2H,
NH2), 5.99 (s, 1H, C5-CH), 6.85–7.14 (m, 6H, Ar–H), 7.94–8.03 (m, 2H, Ar–H), 10.93
(s, 1H, NH). Anal. (C20H17N4BrO): Cal. C: 58.69, H: 4.19, N: 13.69. Found C: 58.88, H:
4.03, N: 13.55.

4-(3-bromophenoxy)-6-(2,4-dichlorobenzyl)-7H-pyrrolo[2,3-d]pyrimidin-2-amine
(206)
Compound 206 was synthesized from intermediate 230b (0.2 g, 0.75 mmol) and
3-3-bromophenol (0.21 g, 1.5 mmol) using K2CO3 (0.14 g, 1.5 mmol) as the base in 10
mL of nBuOH as the solvent using the general method described above and purified by
column chromatography using solvent D. Compound 205 was obtained (66 mg, 22%) as
an off white solid. Mp: > 240 °C dec. TLC Rf 0.49 (CHCl3/CH3OH, 10:1). 1H NMR
(DMSO-d6): δ 4.00 (s, 2H, CH2), 5.84 (s, 2H, NH2 exch.), 6.02 (s, 1H, C5-CH), 7.09–
7.63 (m, 5H, Ar–H), 8.04–8.22 (m, 2H, Ar–H), 10.99 (s, 1H, NH exch.). Anal.
(C19H13N4BrCl2O 0.15H2O): Cal. C: 49.17, H: 2.82, N: 12.07. Found C: 48.67, H: 2.63,
N: 11.76.
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4-((3-bromobenzyl)oxy)-6-(2-methylbenzyl)-7H-pyrrolo[2,3-d]pyrimidin-2-amine
(207)
Compound 207 was synthesized from intermediate 230a (0.2 g, 0.75 mmol) and
3-3-(3-bromophenyl)methanol (0.27 g, 1.5 mmol) using tBuOK (0.16 g, 1.5 mmol) as the
base in 10 mL of nBuOH as the solvent using the general method described above and
purified by column chromatography using solvent D. Compound 207 was obtained (32
mg, 11%) as an off white solid. Mp: 228–231 °C. TLC Rf 0.49 (CHCl3/CH3OH, 10:1). 1H
NMR (DMSO-d6): δ 2.35 (s, 3H, CH3), 3.88 (s, 2H, CH2), 4.42 (s, 2H, CH2) 5.74 (s, 2H,
NH2 exch.), 6.01 (s, 1H, C5-CH), 7.05–7.43 (m, 6H, Ar–H), 8.00–8.10 (m, 2H, Ar–H),
8.91 (s, 1H, NH, exch.), 10.94 (s, 1H, NH, exch.) Anal. (C21H19N4BrO 0.35MeOH): Cal.
C: 59.58, H: 4.52, N: 13.24. Found C: 58.77, H: 6.64, N: 12.76.
4-((3-bromobenzyl)oxy)-6-(2,4-dichlorobenzyl)-7H-pyrrolo[2,3-d]pyrimidin-2-amine
(208)
Compound 208 was synthesized from intermediate 230b (0.2 g, 0.61 mmol) and
3-3-(3-bromophenyl)methanol (0.23 g, 1.2 mmol) using tBuOK (0.14 g, 1.2 mmol) as the
base in 10 mL of nBuOH as the solvent using the general method described above and
purified by column chromatography using solvent D. Compound 207 was obtained (32
mg, 11%) as an off white solid. Mp: 240–242 °C. TLC Rf 0.49 (CHCl3/CH3OH, 10:1). 1H
NMR (DMSO-d6): δ 4.02 (s, 2H, CH2), 4.59 (s, 2H, CH2) 5.76 (s, 2H, NH2 exch.), 6.02
(s, 1H, C5-CH), 7.12–7.78 (m, 5H, Ar–H), 7.98–8.06 (m, 2H, Ar–H), 10.98 (s, 1H, NH,
exch.) Anal. (C20H15N4BrCl2O 0.05H2O): Cal. C: 50.24, H: 3.16, N: 11.72. Found C:
50.11, H: 3.02, N: 11.34.
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N4-(3-bromobenzyl)-6-(2-methylbenzyl)-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine
(209)
Compound 209 was synthesized from intermediate 230a (0.2 g, 0.75 mmol) and
(3-bromophenyl)methanamine (0.27 g, 1.5 mmol) using tBuOK (0.16 g, 1.5 mmol) as the
base in 10 mL of nBuOH as the solvent using the general method described above and
purified by column chromatography using solvent D. Compound 209 was obtained (23
mg, 8%) as an off white solid. Mp: 218–221 °C. TLC Rf 0.49 (CHCl3/CH3OH, 10:1). 1H
NMR (DMSO-d6): δ 2.27 (s, 3H, CH3), 3.89 (s, 2H, CH2), 4.36 (s, 2H, CH2) 5.72 (s, 2H,
NH2 exch.), 5.98 (s, 1H, C5-CH), 7.04–7.20 (m, 6H, Ar–H), 7.99–8.09 (m, 2H, Ar–H),
8.88 (s, 1H, NH, exch.), 10.91 (s, 1H, NH, exch.) HRMS (C21H20N5Br 0.35MeOH):
calcd. mass 421.0902, found mass 421.0960.
N4-(3-bromobenzyl)-6-(2,4-dichlorobenzyl)-7H-pyrrolo[2,3-d]pyrimidine-2,4diamine (210)
Compound 209 was synthesized from intermediate 230b (0.2 g, 0.6 mmol) and
(3-bromophenyl)methanamine (0.22 g, 1.2 mmol) using tBuOK (0.14 g, 1.2 mmol) as the
base in 10 mL of nBuOH as the solvent using the general method described above and
purified by column chromatography using solvent D. Compound 209 was obtained (40
mg, 13%) as an off white solid. Mp: 224–227 °C. TLC Rf 0.49 (CHCl3/CH3OH, 10:1).
1

H NMR (DMSO-d6): δ 4.01 (s, 2H, CH2), 4.62 (s, 2H, CH2) 5.81 (s, 2H, NH2 exch.),

6.04 (s, 1H, C5-CH), 7.05–7.64 (m, 5H, Ar–H), 8.00–8.09 (m, 2H, Ar–H), 8.91 (s, 1H,
NH, exch), 10.98 (s, 1H, NH, exch.). HRMS (C21H20N5Br 0.35MeOH): calcd. mass
474.1870, found mass 474.1902.
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2-Amino-6-methyl-3,4-dihydro-4-oxo-7H-pyrrolo[2,3-d]pyrimidine (140a).
Compound 140a was synthesized using literature methods.312 A suspension of
2,6-diamino-4-hydroxypyrimidine (1.26 g, 10 mmol) in 25 mL of water containing
sodium acetate (0.82 g, 10 mmol) was heated to 100 °C until it formed a clear solution.
Chloroacetone (0.79 mL, 10 mmol) was added to this solution in one lot, following which
a precipitate began to form within 10 min. The reaction mixture was heated with stirring
at 100 °C for an additional 4 h, cooled to 0 °C, and filtered to afford 1.05 g (63%) of
140a as a slight pink colored solid: mp  260 °C (lit.312  260 °C); TLC Rf 0.37
(CHCl3/MeOH, 4:1); 1H NMR (DMSO-d6) δ 2.14 (s, 3H, 6-CH3), 5.83 (s, 1H, 5-CH),
5.98 (bs, 2H, 2-NH2), 10.15 (bs, 1H, 7-NH), 10.78 (bs, 1H, 3-NH).

3,4,5-Trimethoxybenzenethiol (236).
Compound 236 was synthesized from xanthate 238 using literature methods.449
Xanthate 238 was synthesized from 3,4,5-trimethoxyaniline 237. Aniline 237 (0.97 g,
5.44 mmol) was dissolved in MeOH (10 mL) and 10% aqueous HCl and was then cooled
to 0 °C. A solution of sodium nitrite (0.5 g, 7.25 mmol) in H 2O (20 mL) was added
dropwise over 1 h. The reaction mixture was stirred at 0 °C for an additional 15 min at
which time the solution was added to a solution of potassium ethyl xanthate (1.73 g, 10.8
mmol) in H2O (50 mL) at 65 °C. After the mixture was stirred for 15 min, the reaction
was cooled to 25 °C. The resulting mixture was extracted with EtOAc (3 × 20 mL) and
the combined organic extracts were washed with brine (20 mL), dried (Na 2SO4), and
concentrated in vacuo. Flash column chromatography of the residue (silica gel, 10%
EtOAc in hexanes) afforded xanthate 238 (0.72 g, 51%). Rf 0.36 (EtOAc: hexanes 1:5);
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1

H NMR (CDCl3) δ 6.72 (s, 2 H, ArH), 4.60 (q, 2 H, OCH2), 3.86 (s, 3 H, OCH3), 3.84 (s,

6 H, OCH3), 1.33 (t, 3 H, CH3)

A solution of xanthate 238 (0.7 g, 2.43 mmol) in 1N NaOH (20 mL) was heated
under reflux for 8 h. The solution was concentrated under vacuum, water (75 mL) was
added, and the solution was extracted with ether (3 × 25 mL). The ether extracts were
discarded. The aqueous layer was cooled in an ice bath and acidified to pH 1-2 with 6N
H2SO4. The oil that separated was extracted with ether (3 × 25 mL). The ether layer was
washed with water (3 × 25 mL) and dried over anhydrous Na2SO4. Ether was removed
under vacuum to afford a crude oil that contained 236, and was used without further
purification.

General procedure for synthesis of 216a, 217a

To a solution of 140a (2.0 mmol) in a mixture of ethanol/water (2:1, 90 mL) was
added the appropriate thiophenol (4.0 mmol) and the reaction mixture was heated to 100110 °C. At this point, I2 (4.0 mmol) was added and the heating was continued with
stirring for a total of 3 hours. To this mixture was added excess Na2S2O7 and
concentrated under reduced pressure. To the resulting residue was added some silica gel
and MeOH and the solution was evaporated to dryness to afford a plug which was loaded
on top of a column and eluted with a gradient of 1-5% MeOH in CHCl3. Fractions
containing the desired spot (TLC) were pooled and evaporated to dryness. The resulting
residue was recrystallized from MeOH, filtered and dried to obtain the desired
compound.
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2-Amino-6-methyl-5-((3,4,5-trimethoxyphenyl)thio)-3,7-dihydro-4H-pyrrolo[2,3d]pyrimidin-4-one (216a).

Compound 140a (0.330g, 2 mmol) was reacted with 236 (0.8 g, 4 mmol) in
presence of I2 (1 g, 4 mmol) using the method described above to afford 216a (194 mg,
26%) as an off-white solid. Mp  240 °C dec.; TLC Rf 0.44 (CHCl3/MeOH, 5:1, with 2
drops of NH4OH); 1H NMR (DMSO-d6) δ 2.19 (s, 3H, 6-CH3), 3.82 (s, 3H, OCH3), 3.84
(s, 6H, OCH3) 6.15 (bs, 2H, 2-NH2 exch.), δ 6.53 (s, 2H, C6H4), 10.46 (s, 1H, 3-NH),
11.48 (s, 1 H, 7-NH). Anal. (C16H18N4O4S 0.1H2O) C, H, N: Cal. C: 53.03, H: 5.01, N:
15.46. Found C: 52.61, H: 4.88, N: 15.34.

2-Amino-6-methyl-5-(pyridin-4-ylthio)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4one (217a).

Compound 140a (0.330g, 2 mmol) was reacted with pyridine-4-thiol 239 (0.45 g,
4 mmol) in presence of I2 (1 g, 4 mmol) using the method described above to afford 217a
(94 mg, 16%) as a brown solid. mp 242 °C (lit.355 >250 oC, dec.); TLC Rf 0.27
(CHCl3/MeOH, 5:1, with 2 drops of NH4OH); 1H NMR (DMSO-d6) δ 2.17 (s, 3 H, 6CH3), 6.14 (s, 2 H, 2-NH2 exch.), 6.93 (d, 2 H, 3'-, 5'-CH,), 8.26 (d, 2 H, 2'-, 6'-CH,),
10.46 (s, 1 H, 3-NH exch.), 11.53 (s, 1 H, 7-NH exch.).
General method for synthesis of 216b and 217b
2-Amino-4-oxo-6-substitued-pyrrolo[2,3-d]pyrimidine 216a or 217a (about 1 mmol), 5
mL of POCl3 and 0.1 mL of PhNMe2 were placed in a 50-mL round-bottom flask. The
mixture was heated to reflux and kept stirring for 4 h. After evaporation of the excess of
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POCl3, ice-cold water was added and the reaction mixture was neutralized with
NH3·H2O. The precipitated solid was collected by filtered, and the filtrate was extracted
with CHCl3 (3×50 mL). The organic phase was combined and dried (Na2SO4).
Concentration of the chloroform afforded additional solid compounds. The solids thus
obtained were dissolved in methanol, then 1 g silica gel was added and removed the
solvent in vacuo to afford a dry plug. The plug was placed on the top of a 15×150 mm
column and eluted with 2% methanol in chloroform. Fractions containing the product
were pooled and evaporated to afford pure 216b or 217b respectively.

4-Chloro-6-methyl-5-((3,4,5-trimethoxyphenyl)thio)-7H-pyrrolo[2,3-d]pyrimidin-2amine (216b)

Reaction of 216a (0.36 g, 1 mmol) with 5 mL POCl3 in presence 0.1 mL of PhNMe2
using the method described afforded 216b (53 mg, 18%) as a brown solid. mp 250 °C,
dec.; TLC Rf 0.51 (CHCl3/MeOH, 5:1, with 2 drops of NH4OH) 1H NMR (DMSO-d6) δ
2.19 (s, 3H, 6-CH3), 3.78 (s, 3H, OCH3), 3.83 (s, 6H, OCH3) 6.15 (bs, 2H, 2-NH2, exch.),
δ 6.53 (s, 2H, C6H4), 11.84 (s, 1 H, 7-NH, exch.). Anal. (C16H17ClN4O3S 0.1MeOH) C,
H, N: Cal. C: 50.46, H: 4.50, N: 14.71. Found C: 50.83, H: 4.34, N: 14.12.
4-Chloro-6-methyl-5-(pyridin-4-ylthio)-7H-pyrrolo[2,3-d]pyrimidin-2-amine (217b)

Reaction of 217a (0.27 g, 1 mmol) with 5 mL POCl3 in presence 0.1 mL of PhNMe2
using the method described afforded 217b (35 mg, 12%) above as a tan solid. mp
250 °C, dec.; TLC Rf 0.36 (CHCl3/MeOH, 5:1, with 2 drops of NH4OH); 1H NMR
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(DMSO-d6) δ 2.17 (s, 3 H, 6-CH3), 6.21 (s, 2 H, 2-NH2 exch.), 6.94 (d, 2 H, 3'-, 5'-CH,),
8.24 (d, 2 H, 2'-, 6'-CH,), 11.53 (s, 1 H, 7-NH exch.).
6-methyl-5-((3,4,5-trimethoxyphenyl)thio)-7H-pyrrolo[2,3-d]pyrimidin-2-amine
(216c)

To a solution of 216b (150 mg, 0.4 mmol) was in 20 mL MeOH in a Paar hydrogenation
vessel was added 10% Pd/C (500 mg) and the mixture subjected to hydrogenation at 15
psi of hydrogen. The reaction was continued till the appearance of a new spot (TLC) and
consumption of the starting material spot. The reaction was stopped and the mixture
filtered through celite to remove Pd/C. The celite was washed with MeOH (2 x 20 mL)
and the washing combined with the filtrate. To this, 1 g of silica gel was added and the
solvent removed in vacuo to afford a silica gel plug. This plug was placed on the top of a
15×150 mm column and eluted with 2% methanol in chloroform. Fractions containing
the product were pooled and evaporated to afford pure 216c (73 mg, 55%) as a light
brown solid. Mp  238 °C, dec.; TLC Rf 0.4 (CHCl3/MeOH, 5:1, with 2 drops of
NH4OH) 1H NMR (DMSO-d6) δ 2.19 (s, 3H, 6-CH3), 3.78 (s, 3H, OCH3), 3.83 (s, 6H,
OCH3) 6.19 (bs, 2H, 2-NH2, exch.), 6.53 (s, 2H, C6H4), 8.46 (s, 1H, 4-H), 11.82 (s, 1 H,
7-NH, exch.). Anal. (C16H18N4O3S) C, H, N: Cal. C: 55.48, H: 5.24, N: 16.17. Found C:
55.82, H: 5.14, N: 16.16.
6-Methyl-5-((3,4,5-trimethoxyphenyl)thio)-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine
(216d)
To a Parr bomb apparatus was added 10 ml methanol and cooled in a dry iceacetone bath. To this solution was added ammonia gas for 30 minutes along with
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continuous stirring. Compound 216b (100 mg, 0.26 mmol) was added to this saturated
solution of ammonia in methanol following which the bomb was tightly sealed and
placed in an oil bath at 135 ° C with continuous stirring for 48 hours. At this point tlc
indicated the disappearance of the starting material and formation of one major spot at Rf
0.41 CHCl3/MeOH 5:1). The reaction was stopped at this point and the solution
transferred to a 100 ml round bottom flask. The excess ammonia was allowed to
evaporate and 2 grams of silica gel was added to this solution following which the
methanol was evaporated and the plug obtained. This plug was placed on the top of a
15×150 mm column and eluted with 2% methanol in chloroform. Fractions containing
the product were pooled and evaporated to afford pure 216d (58mg, 62%) of as an offwhite solid. mp 243-246 °C; TLC Rf 0.38 (CHCl3/MeOH, 5:1, with 2 drops of NH4OH)
1

H NMR (DMSO-d6) δ 2.17 (s, 3H, 6-CH3), 3.78 (s, 3H, OCH3), 3.84 (s, 6H, OCH3) 5.22

(bs, 2H, 4-NH2, exch.) 6.20 (bs, 2H, 2-NH2, exch.), δ 6.53 (s, 2H, C6H4), 10.44 (s, 1 H, 7NH, exch.) HRMS (C16H19N5O3S) : calcd. mass 361.1209, found mass 361.1212.

2-Amino-7-benzyl-6-methyl-5-((3,4,5-trimethoxyphenyl)thio)-3,7-dihydro-4Hpyrrolo[2,3-d]pyrimidin-4-one (216e)
To a round bottomed flask was added 216a (100 mg, 0.4 mmol) and dissolved in
5 ml of DMF. The solution was cooled to 0 °C and sodium hydride (10 mg, 0.4 mmol)
was added. After stirring at 0 °C for 1 hour, benzylbromide (81 mg, 0.48 mmol) was
added. The reaction was continued at rt till the appearance of a new spot (TLC) after
which the reaction was quenched with water. The water phase was extracted with
chloroform. The organic phase was dried over sodium sulfate and evaporated under
reduced pressure. The residue was dissolved in methylene chloride, 250 mg silica gel was
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added to the solution which was then evaporated to dryness to form a plug. The silica gel
plug obtained was loaded onto a silica gel column and eluted with 1% methanol in
chloroform. Fractions corresponding to the product (TLC) were pooled and evaporated to
dryness under reduced pressure to afford 216e (16 mg, 12%) as a light brown solid. mp
250 °C, dec.; TLC Rf 0.5 (CHCl3/MeOH, 5:1, with 2 drops of NH4OH) Mp  240 °C
dec.; TLC Rf 0.48 (CHCl3/MeOH, 5:1, with 2 drops of NH4OH); 1H NMR (DMSO-d6) δ
2.19 (s, 3H, 6-CH3), 3.82 (s, 3H, OCH3), 3.84 (s, 6H, OCH3) 5.30 (s, 2H CH2) 6.15 (bs,
2H, 2-NH2 exch.), 6.53 (s, 2H, C6H4), 7.22–7.31 (m, 4H, C6H5) 7.49–7.51 (m, 1H, C6H5),
10.46 (s, 1H, 3-NH exch). HR-MS: C23H24N4O4S: calcd. mass 452.1518, found mass
452.1511.

7-benzyl-4-chloro-6-methyl-5-((3,4,5-trimethoxyphenyl)thio)-7H-pyrrolo[2,3d]pyrimidin-2-amine (216f)
Compound 216b when reacted with benzyl bromide using conditions described
for the synthesis of 216e afforded 216f (16 mg, 12%) as a light brown solid. mp 250 °C,
dec.; TLC Rf 0.55 (CHCl3/MeOH, 5:1, with 2 drops of NH4OH) 1H NMR (DMSO-d6) δ
2.19 (s, 3H, 6-CH3), 3.82 (s, 3H, OCH3), 3.84 (s, 6H, OCH3) 5.30 (s, 2H CH2) 6.19 (bs,
2H, 2-NH2 exch.), 6.53 (s, 2H, C6H4), 7.26–7.33 (m, 4H, C6H5) 7.48–7.51 (m, 1H, C6H5).
HR-MS: C23H23ClN4O3S: calcd. mass 470.1179, found mass 470.1160.
7-benzyl-6-methyl-5-((3,4,5-trimethoxyphenyl)thio)-7H-pyrrolo[2,3-d]pyrimidin-2amine (216g)
Treatment of 216f with 10% Pd/C and hydrogen at 15 psi using a Paar
hydrogenator and conditions used for the synthesis of 216e afforded 216f (16 mg, 12%)
289

as a light brown solid. mp 240 °C, dec.; TLC Rf 0.4 (CHCl3/MeOH, 5:1, with 2 drops of
NH4OH) 1H NMR (DMSO-d6) δ 2.21 (s, 3H, 6-CH3), 3.81 (s, 3H, OCH3), 3.83 (s, 6H,
OCH3) 5.28 (s, 2H CH2) 5.86 (s, 1H 4-H) 6.19 (bs, 2H, 2-NH2 exch.), 6.53 (s, 2H, C6H4),
7.26–7.33 (m, 4H, C6H5) 7.48–7.51 (m, 1H, C6H5). HR-MS: C23H24N4O3S: calcd. mass
436.1569, found mass 436.1560.
7-benzyl-6-methyl-5-((3,4,5-trimethoxyphenyl)thio)-7H-pyrrolo[2,3-d]pyrimidine2,4-diamine (216h)
Treatment of 216g with a saturated solution of ammonia in methanol in a paar
bomb apparatus and conditions used for the synthesis of 216d afforded 216f (16 mg,
12%) as a light brown solid. mp 250 °C, dec.; TLC Rf 0.6 (CHCl3/MeOH, 5:1, with 2
drops of NH4OH) 1H NMR (DMSO-d6) δ 2.19 (s, 3 H, 6-CH3), 3.65 (s, 6 H, OCH3), 3.79
(s, 3 H, OCH3), 5.30 (s, 2H, CH2) 6.19 (bs, 2 H, 2-NH2), 6.56 (d, 1 H, 5‘-CH). 7.22–7.31
(m, 4H, Ar–H) 7.49–7.51 (m, 2H, Ar–H). HR-MS: C23H25N5O3S: calcd. mass 451.1678,
found mass 451.1680.
Validation of homology models:
In addition to Ramachandran plots, Procheck and ProSA analysis, the following
model validation tests were carried out for the three homology models generated.
1. pjDHFR homology model
Errat2 analysis:416 The program works by analyzing the statistics of non-bonded
interactions between different atom types. A single output plot is produced that gives the
value of the error function vs. position of a 9-residue sliding window and can be compared
with statistics from highly refined structures to give confidence limits.
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Figure E1. Errat2 analysis of the pjDHFR homology model
QMEAN

Figure E2. Comparison of the overall Qmean score of the pjDHFR homology model with PDB
structures

291

Figure E3. Comparison of the overall Qmean score of the pjDHFR homology model with PDB
structures

QMEAN416 is a composite scoring function which is able to derive both global (i.e. for
the entire structure) and local (i.e. per residue) error estimates based on a single model.
tgDHFR homology model analysis
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Figure E4: ANOLEA analysis of the tgDHFR homology model

ANOLEA evaluation:
The atomic empirical mean force potential ANOLEA416 is used to assess packing
quality of the models. The program performs energy calculations on a protein chain,
evaluating the "Non- Local Environment" (NLE) of each heavy atom in the molecule.
The y-axis of the plot represents the energy for each amino acid of the protein chain.
Negative energy values (in green) represent favourable energy environment whereas
positive values (in red) unfavourable energy environment for a given amino acid. Energy
minimization was performed to minimize the unfavorable energy regions of the model.
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Figure E5: Z-score analysis of the bond angles, backbone length and dihedral angles of the
tgDHFR homology model.

Z-score analysis416 of the the bond angles, backbone length and dihedral angles of
the tgDHFR homology model indicate that the values lie within acceptable range.
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APPENDIX 1
Validation of docking software and docking studies with compounds listed in the
statement of the problem with pjDHFR, tgDHFR, tgTS and RTKs (EGFR and VEGFR2)

Docking studies with pyrido[2,3-d]pyrimidines in pcDHFR
Validation of LeadIT 1.3.0 for docking in pcDHFR:

Figure A1. Stereoview. Superimposition of best docked pose (white) and the crystal structure (red)
of the native crystal structure ligand of pcDHFR (PDB: 1LY3).

Figure A1 shows the best docked pose (white) of 2,4-diamino-6-[N-(2',5'dimethoxybenzyl)-N-methylamino] quinazoline superimposed on its crystal structure in
pcDHFR (PDB: 1LY3). The docking studies were performed using LeadIT 1.3.0 using
methods described in the Chemical Discussion section above. As seen in Figure A1, the
best docked pose retains the key interactions seen in the crystal structure ligand and has an
RMSD of 1.07 Å compared to the crystal structure ligand, thereby validating LeadIT 1.3.0
for docking purposes.
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Docking studies with a pjDHFR homology model
Docking studies with target compounds 170 – 180 in pjDHFR
Docking studies with 171:

Figure A2. Stereoview. Docked pose of 171 in the active site of the pjDHFR homology model.

Figure A2 shows the docked pose of the target 171 in the active site of a pjDHFR
homology model generated using pcDHFR as the template. Compound 171 adopts a
flipped conformation in the binding pocket as compared to the docked post of 173 (Figure
55). In its docked pose, the N3 and 4-NH2 of 171 interact with Asp32. The 2-NH2 moiety
forms hydrogen bonds with the backbone of Ala143 and Thr144. Additional hydrogen
bonding is afforded between the pyridine N of 171 and the side chain OH of Tyr129 and
between the side chain NH of 171 and the backbone carbonyl of Ile123. The pyrido[2,3d]pyrimidine scaffold is stabilized by a pi-stacking interaction with Phe36 and with side
chain carbon atoms of Met33 and Leu25. The 2,4’,6’-trichlorophenyl moiety of 171 resides
in the hydrophobic pocket formed by the side chains of Leu25, Thr61, Ser64, Leu65, Pro66
and Ser69. The docked score of 171 was -26.67 kJ/mol.
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Docking studies with 172:

Figure A3. Stereoview. Docked pose of 172 in the active site of the pjDHFR homology model.

Figure A3 shows the docked pose of compound 172 in the active site of a pjDHFR
homology model generated using pcDHFR as the template. Compound 172 binds in an
orientation similar to that seen in the docked pose of 171 (Figure A2) above. . The docked
score of 172 was -28.68 kJ/mol.
Docking studies with 174:

Figure A4. Stereoview. Docked pose of 174 in the active site of the pjDHFR homology model.
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Figure A4 shows the docked pose of compound 174 in the active site of a pjDHFR
homology model generated using pcDHFR as the template. Compound 174 binds in an
orientation similar to that seen in the docked pose of 171 (Figure A2) above. The docked
score of 174 was -29.97 kJ/mol.
Docking studies with 175:

Figure A5. Stereoview. Docked pose of 175 in the active site of the pjDHFR homology model.

Figure A5 shows the docked pose of compound 175 in the active site of a pjDHFR
homology model generated using pcDHFR as the template. Compound 175 binds in an
orientation similar to that seen in the docked pose of 171 (Figure A2) above. The docked
score of 175 was -27.95 kJ/mol.
Docking studies with 176:
Figure A6 shows the docked pose of compound 176 in the active site of a pjDHFR
homology model generated using pcDHFR as the template. Compound 176 binds in an
orientation similar to that seen in the docked pose of 171 (Figure A2) above. The docked
score of 176 was -28.27 kJ/mol.
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Figure A6. Stereoview. Docked pose of 176 in the active site of the pjDHFR homology model.

Docking studies with 177:

Figure A7. Stereoview. Docked pose of 177 in the active site of the pjDHFR homology model.

Figure A7 shows the docked pose of compound 177 in the active site of a pjDHFR
homology model generated using pcDHFR as the template. Compound 177 binds in an
orientation similar to that seen in the docked pose of 171 (Figure A2) above. The docked
score of 177 was -28.26 kJ/mol.
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Docking studies with 178:

Figure A8. Docked pose of 178 in the active site of the pjDHFR homology model.

Figure A8 shows the docked pose of compound 178 in the active site of a pjDHFR
homology model generated using pcDHFR as the template. Compound 178 binds in an
orientation similar to that seen in the docked pose of 171 (Figure A2) above. The docked
score of 178 was -28.74 kJ/mol.
Docking studies with 180:

Figure A9. Stereoview. Docked pose of 180 in the active site of the pjDHFR homology model.
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Figure A9 shows the docked pose of compound 180 in the active site of a pjDHFR
homology model generated using pcDHFR as the template. Compound 180 binds in an
orientation similar to that seen in the docked pose of 173 (Figure 53). The docked pose
indicates that the side chain NH could form an intramolecular hydrogen bond with the 2’NO2 moiety of 180 which can influence the bound conformation of 180 in the pocket. The
docked score of 180 was -28.28 kJ/mol.

Molecular modeling studies with 2,4-diamino-6-(thioarylmethyl)pyrido[2,3d]pyrimidines and 2,4-Diamino-6-(oxoarylmethyl)pyrido[2,3-d]pyrimidines as
pjDHFR inhibitors
Docking studies with 187:

Figure A10. Stereoview. Docked pose of 187 in the active site of the pjDHFR homology model.

Figure A10 shows the docked pose of compound 187 in the active site of a pjDHFR
homology model generated using pcDHFR as the template. Compound 187 binds in an
orientation similar to that seen in the docked pose of 173 (Figure 53). The docked score of
187 was -23.56 kJ/mol.
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Docking studies with 188:

Figure A11. Stereoview. Docked pose of 188 in the active site of the pjDHFR homology model.

Figure A11 shows the docked pose of compound 188 in the active site of a pjDHFR
homology model generated using pcDHFR as the template. Compound 188 binds in an
orientation similar to that seen in the docked pose of 173 (Figure 53). The docked score of
188 was -25.15 kJ/mol.
Docking studies with 189:

Figure A12. Stereoview. Docked pose of 189 in the active site of the pjDHFR homology model.

Figure A12 shows the docked pose of compound 189 in the active site of a pjDHFR
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homology model generated using pcDHFR as the template. Compound 189 binds in an
orientation similar to that seen in the docked pose of 173 (Figure 53). The docked score of
189 was -25.8030 kJ/mol.
Docking studies with 190:

Figure A13. Stereoview. Docked pose of 190 in the active site of the homology model for pjDHFR.

Figure A13 shows the docked pose of compound 190 in the active site of a pjDHFR
homology model generated using pcDHFR as the template. Compound 190 binds in an
orientation similar to that seen in the docked pose of 173 (Figure 53). The docked score of
190 was -24.0010 kJ/mol.
Docking studies with 191:
Figure A14 shows the docked pose of compound 191 in the active site of a pjDHFR
homology model generated using pcDHFR as the template. Compound 191 binds in an
orientation similar to that seen in the docked pose of 173 (Figure 53). The docked score of
191 was -25.90 kJ/mol.
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Figure A14. Docked pose of 191 in the active site of the homology model for pjDHFR.

Molecular modeling studies with the tgDHFR homology model
Validation of Flexx 3.1.2 for docking:

Figure A15. Stereoview. Superimposition of best docked pose (white) and the crystal structure (red)
of the native crystal structure ligand of pfDHFR (PDB: 1J3I).

Figure A15 shows the best docked pose (white) of 6,6-dimethyl-1-[3-(2,4,5trichlorophenoxy)propoxy]-

1,6-dihydro-1,3,5-triazine-2,4-diamine

(WR99210)

superimposed on its crystal structure in pfDHFR (PDB: 1J3I). The docking studies were
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performed using Flexx 3.1.2 using methods described in the Chemical Discussion section.
As seen in Figure 13, the best docked pose retains the key interactions and the overall
bound conformation of WR99210 as seen in the crystal structure and has an RMSD of 1.18
Å compared to the crystal structure ligand, thereby validating Flexx 3.1.2 for docking
purposes.

Docking Studies of 2-Amino-4-oxo-5-arylthio-substituted-6-propyl thieno[2,3d]pyrimidines 194c with a tgDHFR homology model

Figure A16. Docked pose of 194c in the active site of the pjDHFR homology model.

Figure A16 shows the docked pose of compound 194c in the active site of a
pjDHFR homology model generated using pcDHFR as the template. Compound 194c
binds in an orientation similar to that seen in the docked pose of 194a and 194b (Figure
92). The 3,4-diCl phenyl moiety in 194c resides in the binding site occupied by the
naphthyl moieties of 194a-b. The 3,4-diCl phenyl moiety similarly shows steric clashes
with hDHFR. This can explain, in part, the selectivity of 194c towards tgDHFR over
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hDHFR. The docked score of 194c was -6.71 kcal/mol, similar to the docking score of
194b.

Molecular modeling studies of 2-Amino-4-oxo-5-arylthio-substituted pyrimido[4,5b]indoles 194d-j with T. gondii thymidylate synthase
Docking of 194g in the tgTS homology model

Figure A17. Stereoview. Docked pose of 194g in the active site of the tgTS homology model

Figure A17 shows the docked pose of 194d (white) in the folate binding site of the
tgDHFR homology model. This docked pose is similar to the docked pose of 194a in tgTS
(Figure82a). The docked score of 194d was -6.80 kcal/mol, similar to the docking score of
194b.
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Molecular modeling studies of 2-Amino-4-oxo-5-arylthio-substituted pyrimido[2,3d]indoles 194d-j with T. gondii dihydrofolate reductase
Docking of 194d in the tgDHFR homology model
Figure A18 shows the docked pose of 194d (white) in the folate binding site of the
tgDHFR homology model. The 2-NH2 and N3 moieties of 194d form hydrogen bonds with
Asp31. The benzene ring in the pyrimido[4,5-b]indole scaffold of 194d affords pi-stacking
interactions with Phe35 and additional hydrophobic interactions with Val151. In addition,
the 6-S-side chain helps to orient the naphthyl moiety of 194d into the hydrophobic pocket.

Figure A18. Stereoview. Docked pose of 194d in the active site of the tgDHFR homology model

The naphthyl side chain of 194d maintains the cation-pi interaction with Arg89 (or
Lys90) and the pi-stacking interaction with Phe32 as is seen with the side chain of 194a.
Docking of 194d into the active site of hDHFR (PDB: 3K45) did not yield docked poses
within the active site. Superimposition of the pyrimidine ring of 194d on the pyrimidine
ring of the bound furo[2,3-d]pyrimidine ligand in 3K45 indicated steric clashes with the
side chain of Ile60 and Leu67 in hDHFR, which could explain the decreased activity of
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194d (Table 12) against hDHFR and hence its selectivity for tgDHFR.
Molecular modeling studies in RTKs
Validation of Flexx 3.1.2 for docking studies with EGFR

Figure A19. Stereoview. Superimposition of best docked pose (white) and the crystal structure (red)
of the native crystal structure ligand of EGFR (PDB:1M17).

Figure A19 shows the best docked pose (white) of erlotinib ([6,7-bis(2-methoxyethoxy)quinazoline-4-yl]-(3-ethynylphenyl)amine) superimposed on its crystal structure in
EGFR (PDB: 1M17). The docking studies were performed using Flexx 3.1.2 using methods
described in the Chemical Discussion section. As seen in Figure A19, the best docked pose
retains the key interactions and the overall bound conformation of erlotinib as seen in the
crystal structure and has an RMSD of 0.91 Å compared to the crystal structure ligand,
thereby validating Flexx 3.1.2 for docking purposes.
Validation of Flexx 3.1.2 for docking studies with VEGFR2
Figure A20 shows the best docked pose (white) of the furo[2,3-d]pyrimidine ligand
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superimposed on its crystal structure in VEGFR2 (PDB: 1YWN). The docking studies were
performed using Flexx 3.1.2 using methods described in the Chemical Discussion section.
As seen in Figure A19, the best docked pose retains the key interactions and the overall
bound conformation of erlotinib as seen in the crystal structure and has an RMSD of 0.91
Å compared to the crystal structure ligand, thereby validating Flexx 3.1.2 for docking
purposes.

Figure A20. Stereoview. Superimposition of best docked pose (white) and the crystal structure (red)
of the furo[2,3-d]pyrimidine ligand of VEGFR2 (PDB:1YWN).

Docking studies with lead 196, and target compounds 196 and 200 in EGFR
Docking studies with target compounds 197 – 210 in EGFR were performed using
the same settings as those used for lead compounds 195 and 196.
Docking studies with lead compound 196 in EGFR
Figure A21 shows the docked pose of the lead compound 196 (white) in ATP
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binding site of EGFR (PDB: 1M17). This docked pose is similar to the docked pose of 195
in EGFR (Figure 62). The docked score of 196 was -20.43 kJ/mol, similar to the docking
score of 195.

Figure A21. Stereoview. Docked pose of 196 in the ATP binding site of EGFR. (PDB: 1M17)

Figure A22. Stereoview. Docked pose of 200 in the ATP binding site of EGFR. (PDB: 1M17)

Figure A22 shows the docked pose of the lead compound 200 (white) in ATP
binding site of EGFR (PDB: 1M17). This docked pose is similar to the docked pose of 197
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in EGFR (Figure 63). The docked score of 200 was -22.74 kJ/mol, similar to the score of
195.
Docking studies with leads 195, 196, and target compounds 197 and 210 in VEGFR2
Docking studies with target compounds 197 – 210 in VEGFR2 were performed
using the same settings as those used for validation of the docking software. The docked
poses of target compounds 197 and 210 are depicted here as illustrative examples.

Docking studies with lead compound 195 in VEGFR2

Figure A23. Stereoview. Superimposition of best docked pose (white) of 195 in VEGFR2
(PDB:1YWN).200

Docking studies with lead compound 196 in VEGFR2
Figures A23 and A24 shows two low enegey docked poses of the lead compound
195 (within 1 kcal of each other) VEGFR2 (PDB: 1YWN). In both docked poses, 195
binds in the ATP binding site of VEGFR2 and forms three hydrogen bonds with the
hinge region residues (Glu915 and Cys917).
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Figure A24. Stereoview. Superimposition of best docked pose (white) of 196 in VEGFR2
(PDB:1YWN).200

In pose 1 (Figure A23), 195 forms hydrogen bonds with the hinge region using
the 2-NH2, N3- and the 4-anilino nitrogen atoms (analogous to the proposed Binding
mode 2 in Figure 68) . In contrast, 195 binds analogous to the proposed Binding mode 5
(Figure 68) in Figure A24 and forms hydrogen bonds with the hinge region with its 2NH2, N3 and pyrrole NH atoms. The 2’-MePh moiety of 195 binds in the Hydrophobic
site 2 of VEGFR2 while the aniline moiety binds in the sugar binding pocket. In pose 2
(Figure A24), 195 binds with the 2’-MePh extending towards the sugar binding pocket
and the aniline moiety binding toward Hydrophobic binding site 1. These alternate lowenergy binding poses provide a molecular basis of the proposed design idea of multiple
binding poses in a single agent. The docking score of 195 in pose 1 was -21.60 kJ/mol
while the docking score in pose 2 was -22.80 kJ/mol.
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Docking studies with target compound 197 in VEGFR2

Figure A25. Stereoview. Superimposition of best docked pose (white) of 197 in VEGFR2
(PDB:1YWN).200

Figure A25 shows the docked pose of the target compound 197 in VEGFR2. The
docked pose of 197 is similar to that seen in the docked pose of lead 195 in Figure A25.
The docked score of 197 in VEGFR2 was -18.74 kJ/mol, lower than that of 195.
Docking studies with target compound 210 in VEGFR2

Figure A26. Stereoview. Superimposition of best docked pose (white) of 197 in VEGFR2
(PDB:1YWN).200
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Figure A26 shows the docked pose of the target compound 197 in VEGFR2. The
docked pose of 197 is similar to that seen in the docked pose of lead 195 in Figure A25.
The docked score of 197 in VEGFR2 was -22.61 kJ/mol, comparable to the docked score
of 195 in VEGFR2.
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APPENDIX 2
Molecular modeling: docking studies of 223d with GARFTase and AICARFTase

Figure A27. Structures of 223a-g

Compounds 223a, c-e were reported by Gangjee et al.463 Based on the cellular
metabolic data, 223d was seen to inhibit both GARFTase (IC50 = 29.7 ± 10.6nM) and
AICARFTase in KB cells. Thus molecular modeling studies were performed with 223d
in human GARFTase (PDB ID: 1NJS)464 and human AICARFTase (PDB ID: 1PL0)465 to
determine the molecular basis of the potent activity of 223d against these enzymes.
Molecular modeling of compound 223d was performed using LeadIT 1.3.0 and the
results were visualized using MOE 2011.10. LeadIT 1.3.0 was validated for docking by
redocking the native crystal structure ligands 10-CF3CO-DDACTHF (223f) 464 for human
GARFTase and (BW2315U89, BW2315, 223g) 465 for AICARFTase into their respective
crystal structures afforded docked poses with RMSD ~ 1Å.
Figure A28 shows the docked pose of 223d in the human GARFTase active site.
The cofactor binding pocket of GARFTase is located at the interface between the Nterminal mononucleotide binding domain and the C-terminal half of the structure. The
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binding site for the folate cofactor moiety consists of three parts: the pteridine binding
cleft, the benzoylglutamate region, and the formyl transfer region.

Figure A28. Stereoview. Overlay of the docked pose of 223d (blue) with 10-CF3CO-DDACTHF
(red) in human GARFTase (PDB ID: 1NJS). 464

Figure A29. Stereoview. Overlay of the docked pose of 223d (blue) with 223g (red) in human
AICARFTase (PDB ID: 1PL0).

The docked pose shows the pyrrolo[2,3-d]pyrimidine scaffold of 223d to be
buried deep in the active site and to occupy the same location as the diaminopyrimidone
348

ring in the native crystal structure ligand (10-CF3CO-DDACTHF). This orientation of the
scaffold permits the 2-amino moiety to form hydrogen bonds to the backbone of Glu141
and Ser93. The N1 nitrogen interacts with the backbone of Leu92 to form a hydrogen
bond. The 4-oxo moiety forms a hydrogen bond with Asp144 and forms water-mediated
hydrogen bonds with Asp142 and Ala140 (not shown).
The molecule is oriented in a manner which aids the N7 nitrogen to form a
hydrogen bond with Arg90. The pyrrolo[2,3-d]pyrimidine scaffold resides in a
hydrophobic pocket formed by Leu85, Ile91 (not shown), Leu92, Val97, and the folate
binding loop residues 141-146. The flexible 4-atom side chain helps to orient the benzoyl
moiety of compound 223d into the benzoylglutamate region of the protein. The amide
NH of the glutamate side chain forms a hydrogen bond with Met89. The α-carboxylic
acid of the glutamate side chain interacts with Arg64 and additionally interacts with the
backbone of Ile91. The γ-carboxylic acid can form a water-mediated hydrogen bond with
Arg90. The interaction of the flexible glutamate side chain is very similar to the
interaction network observed for the glutamate side chain of 10-CF3CO-DDACTHF.
Figure A29 shows the overlay of the docked poses of 223d (blue) with the crystal
structure ligand 223f (red) (a potent inhibitor) in human AICARFTase (PDB ID: 1PL0).
The pyrrolo[2,3-d]pyrimidine scaffold of 223d occupies the same location as the
dihydroquinazoline scaffold of 223f. Analogous to 223f the 2-NH2 and N3 nitrogens of
223d interact with Asp546 while the 4-oxo moiety forms a hydrogen bond with the side
chain of Asn547. The N7-nitrogen of 223d forms a hydrogen bond with the backbone of
Met312. The pyrrolo[2,3-d]pyrimidine scaffold of 223d forms hydrophobic interactions
with Met312, Phe315, Ile452, Pro543 and Phe544. The aryl glutamate section of 223d is
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oriented similar to the phenyl glutamate side chain of 223f.
These docking results predict that 223d should bind and inhibit the two folatedependent purine biosynthetic enzymes (GARFTase and AICARFTase) and were entirely
consistent with the results of the in situ metabolic assays (not shown).
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